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Abstract
Faecal immunochemical tests to triage patients with lower
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Background: Colorectal cancer (CRC) is the third most common cancer in the UK. Presenting symptoms
that can be associated with CRC usually have another explanation. Faecal immunochemical tests (FITs)
detect blood that is not visible to the naked eye and may help to select patients who are likely to benefit
from further investigation.
Objectives: To assess the effectiveness of FITs [OC-Sensor (Eiken Chemical Co./MAST Diagnostics, Tokyo,
Japan), HM-JACKarc (Kyowa Medex/Alpha Laboratories Ltd, Tokyo, Japan), FOB Gold (Sentinel/Sysmex,
Sentinel Diagnostics, Milan, Italy), RIDASCREEN Hb or RIDASCREEN Hb/Hp complex (R-Biopharm,
Darmstadt, Germany)] for primary care triage of people with low-risk symptoms.
Methods: Twenty-four resources were searched to March 2016. Review methods followed published
guidelines. Summary estimates were calculated using a bivariate model or a random-effects logistic
regression model. The cost-effectiveness analysis considered long-term costs and quality-adjusted life-years
(QALYs) that were associated with different faecal occult blood tests and direct colonoscopy referral.
Modelling comprised a diagnostic decision model, a Markov model for long-term costs and QALYs that
were associated with CRC treatment and progression, and a Markov model for QALYs that were
associated with no CRC.
Results: We included 10 studies. Using a single sample and 10 µg Hb/g faeces threshold, sensitivity
estimates for OC-Sensor [92.1%, 95% confidence interval (CI) 86.9% to 95.3%] and HM-JACKarc
(100%, 95% CI 71.5% to 100%) indicated that both may be useful to rule out CRC. Specificity estimates
were 85.8% (95% CI 78.3% to 91.0%) and 76.6% (95% CI 72.6% to 80.3%). Triage using FITs
could rule out CRC and avoid colonoscopy in approximately 75% of symptomatic patients. Data from
our systematic review suggest that 22.5–93% of patients with a positive FIT and no CRC have other
significant bowel pathologies. The results of the base-case analysis suggested minimal difference in QALYs
between all of the strategies; no triage (referral straight to colonoscopy) is the most expensive. Faecal
immunochemical testing was cost-effective (cheaper and more, or only slightly less, effective) compared
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with no triage. Faecal immunochemical testing was more effective and costly than guaiac faecal occult
blood testing, but remained cost-effective at a threshold incremental cost-effectiveness ratio of £30,000.
The results of scenario analyses did not differ substantively from the base-case. Results were better for
faecal immunochemical testing when accuracy of the guaiac faecal occult blood test (gFOBT) was based on
studies that were more representative of the correct population.
Limitations: Only one included study evaluated faecal immunochemical testing in primary care; however,
all of the other studies evaluated faecal immunochemical testing at the point of referral. Further, validation
data for the Faecal haemoglobin, Age and Sex Test (FAST) score, which includes faecal immunochemical
testing, showed no significant difference in performance between primary and secondary care. There were
insufficient data to adequately assess FOB Gold, RIDASCREEN Hb or RIDASCREEN Hb/Hp complex. No
study compared FIT assays, or FIT assays versus gFOBT; all of the data included in this assessment refer to
the clinical effectiveness of individual FIT methods and not their comparative effectiveness.
Conclusions: Faecal immunochemical testing is likely to be a clinically effective and cost-effective strategy
for triaging people who are presenting, in primary care settings, with lower abdominal symptoms and who
are at low risk for CRC. Further research is required to confirm the effectiveness of faecal immunochemical
testing in primary care practice and to compare the performance of different FIT assays.
Study registration: This study is registered as PROSPERO CRD42016037723.
Funding: The National Institute for Health Research Health Technology Assessment programme.
ABSTRACT
NIHR Journals Library www.journalslibrary.nihr.ac.uk
vi
Contents
List of tables xi
List of figures xxi
Glossary xxiii
List of abbreviations xxv
Plain English summary xxvii
Scientific summary xxix
Chapter 1 Objective 1
Note 1
Chapter 2 Background and definition of the decision problem(s) 3
Population 3
Intervention technologies 4
Units for faecal immunochemical tests for haemoglobin 5
OC-Sensor 5
HM-JACKarc system 7
FOB Gold 7
RIDASCREEN haemoglobin/haptoglobin complex 7
Potential advantages of faecal immunochemical testing 7
Comparator 8
Care pathway 8
Testing for occult blood in faeces in patients presenting to primary care settings 8
Further testing following a positive test result for occult blood in faeces 9
Treatment of colorectal cancer 9
Chapter 3 Assessment of clinical effectiveness 11
Systematic review methods 11
Search strategy 11
Inclusion and exclusion criteria 12
Inclusion screening and data extraction 12
Quality assessment 13
Methods of analysis/synthesis 14
Results of the assessment of clinical effectiveness assessment 14
Overview of included studies 15
Study quality 17
Diagnostic performance of the OC-Sensor faecal immunochemical test assay 21
Diagnostic performance of the HM-JACKarc faecal immunochemical test assay 33
Diagnostic performance of the FOB Gold faecal immunochemical test assay 40
Diagnostic performance of the RIDASCREEN faecal immunochemical test assay 44
Comparative diagnostic accuracy of different faecal immunochemical test assays and
guaiac faecal occult blood testing 44
Selection of test strategies for inclusion in cost-effectiveness modelling 44
DOI: 10.3310/hta21330 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 33
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Westwood et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
vii
Chapter 4 Assessment of cost-effectiveness 45
Review of economic analyses of faecal immunochemical tests 45
Methods 45
Results 46
Model structure and methodology 51
Diagnostic model structure 51
Colorectal cancer Markov model structure 52
Healthy population Markov model 52
Model parameters 54
Overview of main model assumptions 67
Model analyses 69
Scenario analyses 69
Results of cost-effectiveness analyses 71
Base-case analysis 71
Sensitivity analysis 75
Scenario analysis 79
Chapter 5 Discussion 91
Statement of principal findings 91
Clinical effectiveness 91
Cost-effectiveness 93
Strengths and limitations of assessment 94
Clinical effectiveness 94
Cost-effectiveness 96
Uncertainties 100
Clinical effectiveness 100
Cost-effectiveness 102
Chapter 6 Conclusions 103
Implications for service provision 103
Suggested research priorities 103
Acknowledgements 105
References 107
Appendix 1 Literature search strategies 119
Appendix 2 Data extraction tables 153
Appendix 3 Assessments of study quality 161
Appendix 4 Excluded studies 181
Appendix 5 Excluded studies (cost-effectiveness review) 195
Appendix 6 Questionnaire and information sent to clinical experts 197
Appendix 7 Equations used to estimates probabilities in the diagnostic
(decision tree) model 201
Appendix 8 Annual survival/mortality rates included in the colorectal cancer
Markov model 205
CONTENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
viii
Appendix 9 Annual mortality rates included in the healthy population
Markov model 209
Appendix 10 Technical details about parameter estimation 211
Appendix 11 Results (full incremental and intervention versus comparator) of
base case and scenario analyses 213
Appendix 12 National Institute for Health and Care Excellence guidance relevant
to colorectal cancer 233
DOI: 10.3310/hta21330 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 33
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Westwood et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
ix

List of tables
TABLE 1 Overview of Quantitative Faecal Immunochemical Tests (information
supplied to NICE by test manufacturers) 6
TABLE 2 Inclusion criteria 13
TABLE 3 Details of included studies 16
TABLE 4 The QUADAS-2 results for studies of FIT assays 18
TABLE 5 The PROBAST results for studies reporting the development and
validation of risk scores that included faecal immunochemical testing 20
TABLE 6 Accuracy of OC-Sensor for the detection of CRC using a single faecal sample 23
TABLE 7 Sensitivity of OC-Sensor for determining the stage and location of CRC
using a single faecal sample 26
TABLE 8 Accuracy of OC-Sensor for the detection of advanced neoplasia
(CRC or HRA) using a single faecal sample 27
TABLE 9 Accuracy of OC-Sensor for the detection of other/composite target
conditions using a single faecal sample 30
TABLE 10 Acceptability of faecal immunochemical testing using OC-Sensor 32
TABLE 11 Accuracy of HM-JACKarc for the detection of CRC using a single
faecal sample 34
TABLE 12 Accuracy of HM-JACKarc for the detection of advanced neoplasia
(CRC or high-/higher-risk adenoma) using a single faecal sample 35
TABLE 13 Effects of multiple sampling on the accuracy of HM-JACKarc for the
detection of advanced neoplasia (CRC or HRA) 37
TABLE 14 Effects of participant sex on the accuracy of HM-JACKarc for the
detection of advanced neoplasia (CRC or HRA) using a single faecal sample 38
TABLE 15 Accuracy of HM-JACKarc for the detection of other/composite target
conditions using a single faecal sample 39
TABLE 16 Acceptability of faecal immunochemical testing using HM-JACKarc 39
TABLE 17 Accuracy of FOB Gold for the detection of CRC using a single faecal sample 41
TABLE 18 Accuracy of FOB Gold for the detection of advanced neoplasia
(CRC or HRA) using single and double sampling regimens 42
TABLE 19 Accuracy of FOB Gold for the detection of other/composite target
conditions using a single faecal sample 43
DOI: 10.3310/hta21330 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 33
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Westwood et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xi
TABLE 20 Inclusion criteria for cost-effectiveness studies 46
TABLE 21 Summary of included full papers 47
TABLE 22 Quality assessment of studies, using the Drummond checklist 48
TABLE 23 Sensitivity and specificity for OC-Sensor, HM-JACKarc and gFOBT,
base case 55
TABLE 24 The PPV and NPV for OC-Sensor, HM-JACKarc and gFOBT, base case 55
TABLE 25 Percentage of test negative patients who remain symptomatic
(and undergo colonoscopy) or get a second test, per expert 56
TABLE 26 Probability that CRC is present for symptomatic patients after negative
FIT/gFOBT for OC-Sensor, HM-JACKarc and gFOBT, base case 57
TABLE 27 Probabilities at decision nodes in the diagnostic model 57
TABLE 28 Percentage of test positive patients who are referred to colonoscopy
vs. CTC, per expert 58
TABLE 29 Probability of experiencing adverse events due to colonoscopy 59
TABLE 30 Estimated resource use 60
TABLE 31 Comparison of gFOBT cost estimates 61
TABLE 32 Costs of faecal immunochemical testing 61
TABLE 33 Comparison of FIT cost estimates 62
TABLE 34 Costs included in the diagnostic model 63
TABLE 35 Number of cases (percentage) per stage at diagnosis of patients with CRC 64
TABLE 36 Probability of progression for undiagnosed CRC 64
TABLE 37 Number of cases (percentage) per stage at ‘initial’, ‘delayed 6 months’
and ‘delayed 1 year’ diagnosis of patients with CRC 65
TABLE 38 Five-year relative survival of patients with CRC diagnosed between
1996 and 2002, England (NCIN) 65
TABLE 39 Yearly CRC survival per Dukes’ stage, England (NCIN) 65
TABLE 40 Lifetime CRC costs included in the model 66
TABLE 41 Utilities included in the CRC Markov model 66
TABLE 42 Age-specific utilities based on the general UK population that was
included in the healthy population Markov model 67
LIST OF TABLES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xii
TABLE 43 Main model assumptions 67
TABLE 44 Scenario settings for accuracy of faecal immunochemical testing/guaiac
faecal occult blood testing 70
TABLE 45 Lifetime results for all of the strategies in the base-case scenario
(deterministic) 71
TABLE 46 Lifetime results for intervention vs. comparator in the base-case
scenario (deterministic) 72
TABLE 47 Breakdown of lifetime results for all of the strategies in the base-case
scenario (deterministic) 73
TABLE 48 Lifetime results for all of the strategies in the base-case scenario
(probabilistic) 75
TABLE 49 Lifetime results for intervention vs. comparator in the base-case
scenario (probabilistic) 76
TABLE 50 Lifetime results for all of the strategies in the scenario of FIT threshold
of ≥ 20 µg Hb/g faeces (deterministic) 81
TABLE 51 Lifetime results for intervention vs. comparator: FIT threshold of
≥ 20 µg Hb/g faeces (deterministic) 81
TABLE 52 Lifetime results for intervention vs. comparator, prevalence 3%
(deterministic) 84
TABLE 53 Lifetime results for intervention vs. comparator, prevalence 5.4%
(deterministic) 84
TABLE 54 Lifetime results for intervention vs. comparator, initial distribution
from a study in our systematic review (deterministic) 85
TABLE 55 Lifetime results for intervention vs. comparator, initial distribution by
clinical experts (deterministic) 86
TABLE 56 Lifetime results for intervention vs. comparator, 1-year delayed
diagnosis (deterministic) 86
TABLE 57 Lifetime results for all of the strategies: scenario – without CRC
progression (deterministic) 86
TABLE 58 Lifetime results for intervention vs. comparator: scenario – without
CRC progression (deterministic) 87
TABLE 59 Lifetime results for all of the strategies: scenario – double probability
of persisting in symptoms after negative test result (deterministic) 88
TABLE 60 Lifetime results for all of the strategies: scenario – half probability of
persisting in symptoms after negative test result (deterministic) 88
DOI: 10.3310/hta21330 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 33
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Westwood et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xiii
TABLE 61 Lifetime results for all of the strategies: scenario – high mortality
associated to colonoscopy (deterministic) 89
TABLE 62 Lifetime results for all of the strategies: scenario – no adverse events
associated to colonoscopy (deterministic) 89
TABLE 63 Lifetime results for all of the strategies: scenario – all patients referred
to colonoscopy, as opposed to CTC (deterministic) 90
TABLE 64 Lifetime results for all of the strategies: scenario – FIT-/gFOBT-negative
patients who persist in symptoms get a second test (deterministic) 90
TABLE 65 Baseline study details 153
TABLE 66 Index test and reference standard details 157
TABLE 67 Details of excluded studies with rationale for exclusion 182
TABLE 68 Details of studies excluded from the cost-effectiveness review 196
TABLE 69 Predicted 15-year CRC survival probability by Dukes’ stage used in NG12 205
TABLE 70 Annual CRC mortality estimates and the parameters of beta
distributions used in the PSA 206
TABLE 71 Annual mortality rate, by age, used in the healthy population
Markov model 209
TABLE 72 Lifetime results for all of the strategies in the base-case scenario
(deterministic) 213
TABLE 73 Lifetime results for intervention vs. comparator in the base-case
scenario (deterministic) 213
TABLE 74 Lifetime results for all of the strategies in the base-case scenario
(probabilistic) 213
TABLE 75 Lifetime results for intervention vs. comparator in the base-case
scenario (probabilistic) 214
TABLE 76 Lifetime results for all of the strategies in the scenario that a
proportion of patients receives a second FIT/gFOBT: results for all of the
strategies (deterministic) 214
TABLE 77 Lifetime results for intervention vs. comparator in the scenario that a
proportion of patients receives a second FIT/gFOBT: results for all of the
strategies (deterministic) 214
TABLE 78 Lifetime results for all of the strategies in the scenario that a
proportion of patients receives a second FIT/gFOBT: results for all of the
strategies (probabilistic) 214
LIST OF TABLES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xiv
TABLE 79 Lifetime results for intervention vs. comparator in the scenario that a
proportion of patients receives a second FIT/gFOBT: results for all of the
strategies (probabilistic) 215
TABLE 80 Lifetime results for all of the strategies in the scenario that prevalence
of CRC is asymmetric (deterministic) 215
TABLE 81 Lifetime results for intervention vs. comparator in the scenario that
prevalence of CRC is asymmetric (deterministic) 215
TABLE 82 Lifetime results for all of the strategies in the scenario that prevalence
of CRC is asymmetric (probabilistic) 215
TABLE 83 Lifetime results for all of the strategies in the scenario that prevalence
of CRC is asymmetric (probabilistic) 216
TABLE 84 Lifetime results all of the strategies in the scenario in which FOB Gold
is included (deterministic) 216
TABLE 85 Lifetime results intervention vs. comparator in scenario in which FOB
Gold is included (deterministic) 216
TABLE 86 Lifetime results for all of the strategies in the scenario in which FOB
Gold is included (probabilistic) 216
TABLE 87 Lifetime results for intervention vs. comparator in the scenario in
which FOB Gold is included (probabilistic) 217
TABLE 88 Lifetime results for all of the strategies in the scenario with increased
mortality due to colonoscopy (deterministic) 217
TABLE 89 Lifetime results for intervention vs. comparator in the scenario with
increased mortality due to colonoscopy: intervention vs. comparator (deterministic) 217
TABLE 90 Lifetime results for all of the strategies in the scenario with increased
mortality due to colonoscopy (probabilistic) 217
TABLE 91 Lifetime results for intervention vs. comparator in the scenario with
increased mortality due to colonoscopy (probabilistic) 218
TABLE 92 Lifetime results for all of the strategies in the scenario in which the
diagnosis was delayed with 1 year (deterministic) 218
TABLE 93 Lifetime results for intervention vs. comparator in the scenario in
which the diagnosis was delayed with 1 year (deterministic) 218
TABLE 94 Lifetime results for all of the strategies in the scenario in which the
diagnosis was delayed with 1 year (probabilistic) 218
TABLE 95 Lifetime results for intervention vs. comparator in the scenario in
which the diagnosis was delayed with 1 year (probabilistic) 219
DOI: 10.3310/hta21330 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 33
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Westwood et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xv
TABLE 96 Lifetime results for all of the strategies in the scenario that the FIT
threshold was set to ≥ 20µg Hb/g faeces (deterministic) 219
TABLE 97 Lifetime results for intervention vs. comparator in the scenario that
the FIT threshold was set to ≥ 20 µg Hb/g faeces (deterministic) 219
TABLE 98 Lifetime results for all of the strategies in the scenario that the FIT
threshold was set to ≥ 20µg Hb/g faeces (probabilistic) 219
TABLE 99 Lifetime results for intervention vs. comparator in the scenario that
the FIT threshold was set to ≥ 20µgHb/g faeces (probabilistic) 220
TABLE 100 Lifetime results for all of the strategies in the scenario for which
accuracy data for faecal occult blood testing are taken from Bjerregaard et al.
(deterministic) 220
TABLE 101 Lifetime results for intervention vs. comparator in the scenario for
which accuracy data for faecal occult blood testing are taken from Bjerregaard
et al. (deterministic) 220
TABLE 102 Lifetime results for all of the strategies in the scenario for which
accuracy data for faecal occult blood testing are taken from Bjerregaard et al.
(probabilistic) 220
TABLE 103 Lifetime results for intervention vs. comparator in the scenario for
which accuracy data for faecal occult blood testing are taken from Bjerregaard
et al. (probabilistic) 221
TABLE 104 Lifetime results for all of the strategies in the scenario for which
accuracy data for faecal occult blood testing are taken from Niv and Sperber
(deterministic) 221
TABLE 105 Lifetime results for intervention vs. comparator in the scenario for
which accuracy data for faecal occult blood testing are taken from Niv and
Sperber (deterministic) 221
TABLE 106 Lifetime results for all of the strategies in the scenario for which
accuracy data for faecal occult blood testing are taken from Niv and Sperber
(probabilistic) 221
TABLE 107 Lifetime results for intervention vs. comparator in the scenario for
which accuracy data for faecal occult blood testing are taken from Niv and
Sperber (probabilistic) 222
TABLE 108 Lifetime results for all of the strategies in the scenario for which the
distribution of the Dukes’ stages is based on Cubiella et al. (deterministic) 222
TABLE 109 Lifetime results for intervention vs. comparator in the scenario for
which the distribution of the Dukes’ stages is based on Cubiella et al.
(deterministic) 222
TABLE 110 Lifetime results for all of the strategies in the scenario for which the
distribution of the Dukes’ stages is based on Cubiella et al. (probabilistic) 222
LIST OF TABLES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xvi
TABLE 111 Lifetime results for intervention vs. comparator in the scenario for
which the distribution of the Dukes’ stages is based on Cubiella et al.
(probabilistic) 223
TABLE 112 Lifetime results for all of the strategies in the scenario for which the
distribution of the Dukes’ stages is based on expert opinion (deterministic) 223
TABLE 113 Lifetime results for all intervention vs. comparator in the scenario for
which the distribution of the Dukes’ stages is based on expert opinion
(deterministic) 223
TABLE 114 Lifetime results for all of the strategies in the scenario for which the
distribution of the Dukes’ stages is based on expert opinion (probabilistic) 223
TABLE 115 Lifetime results for intervention vs. comparator in the scenario for
which the distribution of the Dukes’ stages is based on expert opinion
(probabilistic) 224
TABLE 116 Lifetime results: scenario with no adverse events associated to
colonoscopy – results for all of the strategies (deterministic) 224
TABLE 117 Lifetime results: scenario with no adverse events associated to
colonoscopy – intervention vs. comparator (deterministic) 224
TABLE 118 Lifetime results: scenario with no adverse events associated to
colonoscopy – results for all of the strategies (probabilistic) 224
TABLE 119 Lifetime results: scenario with no adverse events associated to
colonoscopy – intervention vs. comparator (probabilistic) 225
TABLE 120 Lifetime results: scenario without CRC progression – results for all of
the strategies (deterministic) 225
TABLE 121 Lifetime results: scenario without CRC progression – intervention vs.
comparator (deterministic) 225
TABLE 122 Lifetime results: scenario without CRC progression – results for all of
the strategies (probabilistic) 225
TABLE 123 Lifetime results: scenario without CRC progression: intervention vs.
comparator (probabilistic) 226
TABLE 124 Lifetime results: scenario for which all patients referred to
colonoscopy as opposed to CTC – results for all of the strategies (deterministic) 226
TABLE 125 Lifetime results: scenario for which all patients referred to
colonoscopy as opposed to CTC – intervention vs. comparator (deterministic) 226
TABLE 126 Lifetime results: scenario all patients referred to colonoscopy as
opposed to CTC – results for all of the strategies (probabilistic) 226
TABLE 127 Lifetime results: scenario all patients referred to colonoscopy as
opposed to CTC – intervention vs. comparator (probabilistic) 227
DOI: 10.3310/hta21330 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 33
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Westwood et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xvii
TABLE 128 Lifetime results: scenario for OC threshold – results for all of the
strategies (deterministic) 227
TABLE 129 Lifetime results: scenario for OC threshold – intervention vs.
comparator (deterministic) 227
TABLE 130 Lifetime results: scenario for OC threshold – results for all of the
strategies (probabilistic) 227
TABLE 131 Lifetime results: scenario for OC threshold – intervention vs.
comparator (probabilistic) 227
TABLE 132 Lifetime results: scenario double probability of persisting in
symptoms after negative test result – results for all of the strategies
(deterministic) 228
TABLE 133 Lifetime results: scenario double probability of persisting in
symptoms after negative test result – intervention vs. comparator (deterministic) 228
TABLE 134 Lifetime results: scenario double probability of persisting in
symptoms after negative test result – results for all of the strategies
(probabilistic) 228
TABLE 135 Lifetime results: scenario double probability of persisting in
symptoms after negative test result – intervention vs. comparator (probabilistic) 228
TABLE 136 Lifetime results: scenario half probability of persisting in symptoms
after negative test result – results for all of the strategies (deterministic) 229
TABLE 137 Lifetime results: scenario half probability of persisting in symptoms
after negative test result – intervention vs. comparator (deterministic) 229
TABLE 138 Lifetime results: scenario half probability of persisting in symptoms
after negative test result – results for all of the strategies (probabilistic) 229
TABLE 139 Lifetime results: scenario half probability of persisting in symptoms
after negative test result – intervention vs. comparator (probabilistic) 229
TABLE 140 Lifetime results: prevalence 3% – results for all of the strategies
(deterministic) 230
TABLE 141 Lifetime results: prevalence 3% – intervention vs. comparator
(deterministic) 230
TABLE 142 Lifetime results: prevalence 3% – results for all of the strategies
(probabilistic) 230
TABLE 143 Lifetime results: prevalence 3% – intervention vs. comparator
(probabilistic) 230
TABLE 144 Lifetime results: prevalence 5.4% – results for all of the strategies
(deterministic) 231
LIST OF TABLES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xviii
TABLE 145 Lifetime results: prevalence 5.4% – intervention vs. comparator
(deterministic) 231
TABLE 146 Lifetime results: prevalence 5.4% – results for all of the strategies
(probabilistic) 231
TABLE 147 Lifetime results: prevalence 5.4% – intervention vs. comparator
(probabilistic) 231
DOI: 10.3310/hta21330 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 33
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Westwood et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xix

List of figures
FIGURE 1 Flow of studies through the review process 15
FIGURE 2 Summary of QUADAS-2 results for studies of FIT assays 19
FIGURE 3 (Confidential information has been removed.) 25
FIGURE 4 (Confidential information has been removed.) 25
FIGURE 5 Testing outcomes for a hypothetical cohort of 1000 patients using
OC-Sensor at (a) the 10 µg Hb/g faeces threshold; and (b) any detectable Hb,
for the target condition CRC 25
FIGURE 6 Receiver operating characteristic space plot for the OC-Sensor assay
using different thresholds for the target condition of advanced neoplasia
(CRC or HRA) 28
FIGURE 7 Testing outcomes for a hypothetical cohort of 1000 patients using
OC-Sensor at (a) any detectable Hb, for the target condition of advanced
neoplasia (CRC or HRA); and (b) the 10 µg Hb/g faeces threshold 29
FIGURE 8 Testing outcomes for a hypothetical cohort of 1000 patients using
HM-JACKarc: the 10 µg Hb/g faeces threshold, for the target condition of CRC 35
FIGURE 9 Receiver operating characteristic space plot for the HM-JACKarc assay
using different thresholds for the target condition of advanced neoplasia
(CRC or HRA) 36
FIGURE 10 Testing outcomes for a hypothetical cohort of 1000 patients using
HM-JACKarc: the 10 µg Hb/g faeces threshold for the target condition of
advanced neoplasia (CRC or HRA) 37
FIGURE 11 (Confidential information has been removed.) 41
FIGURE 12 Diagnostic decision-analytic model 53
FIGURE 13 Colorectal cancer Markov model 54
FIGURE 14 Healthy population Markov model 54
FIGURE 15 Cost-effectiveness plane with PSA outcomes for all of the strategies in
the base-case scenario 76
FIGURE 16 Cost-effectiveness acceptability curves for all of the strategies in the
base-case scenario 76
FIGURE 17 Cost-effectiveness plane with PSA outcomes for intervention vs.
comparator in the base-case scenario 77
DOI: 10.3310/hta21330 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 33
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Westwood et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xxi
FIGURE 18 Cost-effectiveness acceptability curves for intervention vs. comparator
in the base-case scenario 78
FIGURE 19 Cost-effectiveness acceptability curves for all of the strategies:
alternative gFOBT accuracy estimates 79
FIGURE 20 Cost-effectiveness acceptability curves for intervention vs. gFOBT,
alternative gFOBT accuracy estimates 80
FIGURE 21 Cost-effectiveness acceptability curves for OC-Sensor vs. gFOBT:
scenario – any detectable Hb 81
FIGURE 22 Cost-effectiveness acceptability curves for all of the strategies:
FIT threshold of ≥ 20 µg Hb/g faeces 82
FIGURE 23 Cost-effectiveness acceptability curves for intervention vs. gFOBT:
FIT threshold of ≥ 20 µg Hb/g faeces 83
FIGURE 24 Cost-effectiveness acceptability curves for all of the strategies in the
scenario including FOB Gold 83
FIGURE 25 Cost-effectiveness acceptability curves for FOB Gold vs. comparator in
the scenario including FOB Gold 84
FIGURE 26 Cost-effectiveness acceptability curves for all of the strategies:
scenario – without CRC progression 87
FIGURE 27 Cost-effectiveness acceptability curves for intervention against gFOBT
in the scenario without CRC progression 88
LIST OF FIGURES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xxii
Glossary
Adenoma A benign tumour of the epithelial tissue that, over time, may transform to become malignant.
Colonoscopy Endoscopic examination of the large intestine and distal small intestine with a charge-coupled
device camera or a fibre-optic camera.
Colorectal cancer Cancer of the colon or rectum (large intestine).
Computed tomography colonography A medical imaging procedure using X-rays to produce two- and
three-dimensional images of the colon and distal small intestine.
Cost-effectiveness analysis An economic analysis that converts effects into health terms and describes
the costs for additional health gain.
Decision modelling A mathematical construct that allows the comparison of the relationship between
costs and outcomes of alternative health-care interventions.
Faecal immunochemical test An immunochemical method of detecting blood in the faeces, which
specifically detects the globin moiety of human haemoglobin.
Faecal occult blood Blood in the faeces that is not visibly apparent.
False negative Incorrect negative test result – number of diseased persons with a negative test result.
False positive Incorrect positive test result – number of non-diseased persons with a positive test result.
Guaiac faecal occult blood test A chemical method of detecting blood in the faeces that utilises the
pseudo-peroxidase activity of haem to detect the haem complex.
Incremental cost-effectiveness ratio The difference in the mean costs of two interventions in the
population of interest divided by the difference in the mean outcomes in the population of interest.
Index test The test whose performance is being evaluated.
Inflammatory bowel disease A group of inflammatory diseases of the colon and small intestine
(e.g. Crohn’s disease, ulcerative colitis).
Markov model An analytic method that is particularly suited to modelling repeated events or the
progression of a chronic disease over time.
Meta-analysis Statistical techniques used to combine the results of two or more studies and obtain a
combined estimate of effect.
Meta-regression Statistical technique used to explore the relationship between study characteristics and
study results.
Negative predictive value The probability of non-disease among persons with a negative test result.
Opportunity costs The cost of forgone outcomes that could have been achieved through alternative
investments.
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Positive predictive value The probability of disease among persons with a positive test result.
Probabilistic sensitivity analysis A method of quantifying the uncertainty in a mathematical model,
such as a cost-effectiveness model.
Publication bias Bias arising from the preferential publication of studies with statistically
significant results.
Quality of life An individual’s emotional, social and physical well-being and their ability to perform the
ordinary tasks of living.
Quality-adjusted life-year A measure of health gain, used in economic evaluations, in which survival
duration is weighted or adjusted by the patient’s quality of life during the survival period.
Receiver operating characteristic curve A graph that illustrates the trade-offs between sensitivity and
specificity that result from varying the diagnostic threshold.
Reference standard The best currently available method for diagnosing the target condition. The index
test is compared against this to allow calculation of estimates of accuracy.
Regression analysis A statistical method for estimating relationships among variables.
Sensitivity Proportion of people with the target disorder who have a positive test result.
Specificity Proportion of people without the target disorder who have a negative test result.
True negative Correct negative test result – number of non-diseased persons with a negative test result.
True positive Correct positive test result – number of diseased persons with a positive test result.
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Plain English summary
Bowel (colorectal) cancer is the third most common cancer in the UK. Symptoms, such as anaemia,abdominal pain and altered bowel habit, can be early warnings of bowel cancer, but these symptoms
usually have another explanation. In order to be sure whether or not someone has bowel cancer, hospital
tests, such as colonoscopy, are needed. Because colonoscopy can be unpleasant and carries a small risk
of heavy bleeding or tearing of the bowel, it is important to find tests that can help to select people who
really need to have colonoscopy, that is, those who are more likely to have bowel cancer and other serious
lower gastrointestinal disease, including inflammatory bowel disease.
The faecal immunochemical test (FIT) for haemoglobin detects blood in the faeces that is not visible to the
naked eye.
This report looks at whether or not faecal immunochemical testing should be offered to people reporting
bowel symptoms to their doctor who are considered to be at low risk of having bowel cancer.
We included 10 studies that looked at how well the results of faecal immunochemical testing can predict
whether or not bowel cancer is found when a person has a colonoscopy examination. Research indicates
that a negative FIT result could be used to reliably determine that a person does not have bowel cancer in
around three-quarters of people with low-risk bowel symptoms. Using faecal immunochemical testing
could therefore reduce the number of people who do not have bowel cancer undergoing ‘unnecessary’
colonoscopy. Although most people who have a positive FIT result and low-risk bowel symptoms do not
have bowel cancer, other bowel diseases are often found when these people are sent for colonoscopy
examination.
Because there has been no research comparing different brands of FITs, we cannot know whether or not
any one test is better than another.
DOI: 10.3310/hta21330 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 33
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Westwood et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xxvii

Scientific summary
Background
The primary indication for this assessment is the use of tests for the presence of occult blood in the faeces
as a triage step in the investigation of people presenting in primary care settings with lower abdominal
symptoms, in whom investigation for possible colorectal cancer (CRC) is being considered.
Quantitative faecal immunochemical tests (FITs) use antibodies that specifically recognise the globin of
human haemoglobin (Hb) to determine the amount of Hb that is present in a faecal sample. Four FIT
assays for Hb [OC-Sensor (Eiken Chemical Co./MAST Diagnostics, Tokyo, Japan), HM-JACKarc (Kyowa
Medex/Alpha Laboratories Ltd, Tokyo, Japan), FOB Gold (Sentinel/Sysmex, Sentinel Diagnostics, Milan,
Italy), RIDASCREEN Hb, R-Biopharm, Darmstadt, Germany)] and one FIT assay for human Hb–haptoglobin
(Hp) complex (RIDASCREEN Hb/Hp complex, R-Biopharm) are currently available for use in the UK NHS
in England and Wales. Quantitative FIT assays the estimation of quantities of blood that are not detectable
by normal visual inspection.
Faecal immunochemical testing has been approved for the Scottish Bowel Screening Programme and
has recently been approved for use in the NHS Bowel Cancer Screening Programme in England. This
assessment considers the clinical effectiveness and cost-effectiveness of FIT assays, used at various
thresholds, in symptomatic populations.
Objectives
To assess the clinical effectiveness and cost-effectiveness of testing for the presence of occult blood in
faeces, using quantitative faecal immunochemical testing, as a triage test, for people presenting, in primary
care settings, with lower abdominal symptoms and who are at low risk for CRC.
Methods
Assessment of clinical effectiveness
Thirteen databases, including MEDLINE and EMBASE, research registers and conference proceedings were
searched to March 2016. Search results were screened for relevance independently by two reviewers.
Full-text inclusion assessment, data extraction and quality assessment were conducted by one reviewer and
checked by a second. Study quality was assessed using QUADAS-2 and PROBAST (Prediction model study
Risk Of Bias Assessment Tool). The bivariate/hierarchical summary receiver operating characteristic (HSROC)
model was used to estimate summary sensitivity and specificity with 95% confidence intervals (CIs) and
prediction regions around the summary points, and to derive HSROC curves for meta-analyses involving
four or more studies. For meta-analyses with fewer than four studies, we estimated separate pooled
estimates of sensitivity and specificity, using random-effects logistic regression. Analyses were conducted
separately for each FIT assay, threshold and target condition {CRC, advanced neoplasia [CRC or high-risk
adenoma (HRA)] or significant bowel disease (CRC or HRA or inflammatory bowel disease)} for which data
were available.
Assessment of cost-effectiveness
A de novo health economic model was developed to explore the cost-effectiveness of using faecal
immunochemical testing for Hb as a triage step in the investigation of symptomatic people presenting in
primary care who are at low risk of CRC. The cost-effectiveness of faecal immunochemical testing was
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compared with guaiac faecal occult blood tests (gFOBTs) and no triage (referral straight to colonoscopy).
The model consists of three parts: a decision model reflecting the diagnosis of colorectal cancer; a Markov
state-transition model to estimate long-term costs and the effects [life-years (LYs) and quality-adjusted
life-years (QALYs)] associated with the treatment and progression of CRC; and a Markov state-transition
model to estimate the LYs and QALYs associated with those who do not have CRC. The following
strategies were included in the main economic analysis:
l triage using OC-Sensor at a threshold of 10 µg Hb/g faeces
l triage using HM-JACKarc at a threshold of 10 µg Hb/g faeces
l triage using guaiac faecal occult blood testing
l no triage (referral straight to colonoscopy).
The model was largely based on that used in the National Institute for Health and Care Excellence (NICE)
guideline [National Collaborating Centre for Cancer. Suspected Cancer: Recognition and Referral. NG12.
London: NCC-C; 2015. URL: www.nice.org.uk/guidance/ng12/evidence/full-guidance-74333341 (accessed
13 January 2016)], but with diagnostic accuracy data coming from the systematic review that was used
to inform the assessment of effectiveness. When available, data were obtained from the most recent
published sources, although expert opinion was required to inform some parameters. Any differences
in costs between the tests in patients without CRC were assumed to occur only in the first year. Any
differences in life expectancy between tests for patients without CRC were assumed to be due only to
difference in mortality due to colonoscopy/computed tomography colonography (CTC). A negative FIT
or gFOBT results in a watchful waiting strategy, in which a colonoscopy/CTC will be performed when
symptoms persist, which is assumed to occur with all patients with CRC. All of the unit cost data on faecal
immunochemical testing were obtained from manufacturers where supplied.
The uncertainty about the model input parameters and the potential impact on the model results were
explored by scenario, one-way deterministic and probabilistic sensitivity analyses.
Results
Assessment of clinical effectiveness
Ten studies (25 publications and two unpublished manuscripts) were included in the systematic review.
The main potential sources of bias in the included studies related to patient spectrum and patient flow
(numbers of patients who did not return a FIT sample or who were subsequently excluded). All of the
included studies had concerns about the applicability of the population, as no study reported data for a
population that exactly matched that defined in the scope for this assessment.
When faecal immunochemical testing was based on a single faecal sample and a threshold of 10 µg Hb/g
faeces, sensitivity estimates indicated that a negative result using either OC-Sensor and HM-JACKarc may
be considered adequate to rule out CRC; the summary estimate of sensitivity for OC-Sensor was 92.1%
(95% CI 86.9% to 95.3%), based on four studies, and the only study of HM-JACKarc to assess the
10 µg Hb/g faeces threshold reported a sensitivity of 100% (95% CI 71.5% to 100%). The corresponding
specificity estimates were 85.8% (95% CI 78.3% to 91.0%) and 76.6% (95% CI 72.6% to 80.3%),
respectively. (Confidential information has been removed.)
Where a lower diagnostic threshold was considered, that is, the target condition included HRA as well as
CRC, the rule-out performance of all FIT methods was reduced. For faecal immunochemical testing based
on a single faecal sample and a threshold of 10 µg Hb/g faeces, the sensitivity estimates indicated that
neither a negative OC-Sensor nor a negative HM-JACKarc FIT would be likely to be considered to have
adequate rule-out performance; the summary estimate of sensitivity for OC-Sensor was 62.9% (95% CI
55.9% to 69.4%), based on three studies, and the estimate of sensitivity for HM-JACKarc was 70.0%
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(95% CI 50.6% to 85.3%), based on one study. The corresponding specificity estimates were 84.6%
(95% CI 82.8% to 86.2%) and 77.8% (95% CI 73.8% to 81.4%), respectively.
Triage using faecal immunochemical testing at thresholds of around 10 µg Hb/g faeces has the potential to
correctly rule out CRC and avoid colonoscopy in approximately 75% of symptomatic patients. In addition,
the relatively high proportion of FIT false positives (FPs) that are observed when the target condition is CRC
may be mitigated by the detection of other bowel pathologies in these patients. Based on data from the
studies included in our systematic review, between 22.5% and 93% of patients with a positive FIT and no
CRC will have other significant bowel pathologies.
No studies were identified which assessed the diagnostic performance of RIDASCREEN Hb or RIDASCREEN
Hb/Hp complex in symptomatic patients.
No studies were identified which directly compared the performance of different FIT assays, or which
compared one or more FIT assays with a gFOBT method.
Assessment of cost-effectiveness
The results of the base-case analysis suggested that the difference in QALYs between all of the strategies
included in this assessment is minimal and that the no-triage strategy (referral straight to colonoscopy)
is the most expensive. Overall, faecal immunochemical testing was cost-effective when compared with no
triage. This was either because the latter was dominated (less effective and more costly) or because faecal
immunochemical testing was slightly less effective, but cheaper, than no triage. In this case the cost savings
could be said to ‘outweigh’ the slight loss in QALYs. When the comparator was guaiac faecal occult blood
testing, the cost-effectiveness results showed that faecal immunochemical testing was more effective and
more costly than guaiac faecal occult blood testing, but the incremental cost-effectiveness ratios (ICERs)
obtained were below the common threshold ICER of £30,000 and thus faecal immunochemical testing
remained cost-effective.
The results of the different scenario analyses did not differ substantively from the base-case results. The
scenarios for which the accuracy estimates for guaiac faecal occult blood testing were based on studies
that were considered more representative of the population of this diagnostic assessment were more
favourable than the base-case with regard to faecal immunochemical testing. In only two scenarios would
faecal immunochemical testing not be considered cost-effective because the ICER exceeded the £30,000
threshold. The highest ICER was obtained when OC-Sensor was compared with guaiac faecal occult blood
testing when a threshold of any detectable Hb was assumed for faecal immunochemical testing (£65,192).
This was expected, as reducing the threshold for FIT results in the test being less effective in avoiding
colonoscopies, that is, this threshold is associated with the highest number of FPs. When HM-JACKarc was
compared with guaiac faecal occult blood testing in the scenario with high mortality due to colonoscopy
the ICER was £45,271.
Conclusions
Implications for service provision
There is evidence to suggest that triage using faecal immunochemical testing, when used at a threshold
of 10 µg Hb/g faeces for OC-Sensor or HM-JACKarc, may be sufficient to rule out CRC in symptomatic
patients. In addition, the relatively high proportion of FIT FPs observed when the target condition is CRC
may be mitigated by the potential to diagnose other bowel pathologies in these patients. There was
insufficient evidence to adequately assess the diagnostic performance of FOB Gold, RIDASCREEN Hb or
RIDASCREEN Hb/Hp complex in symptomatic patients. Similarly, there was no direct evidence about the
comparative performance of different FIT assays, or faecal immunochemical testing versus guaiac faecal
occult blood testing.
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The base-case cost-effectiveness results suggested that the difference in QALYs between all of the
strategies included in this assessment is minimal and that the no-triage strategy (referral to colonoscopy)
is the most expensive. Overall, faecal immunochemical testing was cost-effective when compared against
no triage or guaiac faecal occult blood testing. The results of the different scenario analyses did not differ
substantially from the base-case results. However, the scenarios for which the accuracy estimates for
guaiac faecal occult blood testing were based on studies that were considered more representative of the
population of this diagnostic assessment were more favourable than the base-case scenario with regard to
faecal immunochemical testing. The results of our analysis suggest that faecal immunochemical testing
could provide a cost-effective (cost-saving) triage option for patients whose symptoms are not considered
high risk for CRC.
Suggested research priorities
New studies are needed to fully evaluate the performance of faecal immunochemical testing in the setting
(primary care) and population (symptomatic patients who are at low risk of CRC, as defined in NG12)
specified in the scope for this assessment. Further research (diagnostic cohort studies or multivariable
prediction modelling studies) is needed to fully explore possible variation in the performance of faecal
immunochemical testing in relevant subgroups (e.g. age and sex) and explore the possible advantages of
using faecal immunochemical testing as part of a risk score. Studies that can fully explore the potential
benefits of faecal immunochemical testing in symptomatic patients, including those relating to diagnoses
other than CRC, are also likely to be informative. This issue may be particularly important in younger
patients, where the prevalence of CRC is lowest and other diagnoses are more likely.
Study registration
This study is registered as PROSPERO CRD42016037723.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Objective
The overall objective of this project is to summarise the evidence on the clinical effectiveness andcost-effectiveness of using quantitative faecal immunochemical tests (FITs) as a triage test for people
presenting, in primary care settings, with lower abdominal symptoms, who are at low risk for colorectal
cancer (CRC) according to the criteria defined in the 2015 National Institute for Health and Care Excellence
(NICE) guideline (NG12).1 Use of occult blood testing in the faeces has been recently recommended for this
population; this assessment will consider the clinical effectiveness and cost-effectiveness of quantitative
faecal immunochemical testing as a replacement for guaiac testing. The following research questions have
been defined to address the review objective:
l What is the clinical effectiveness of faecal immunochemical testing compared with guaiac faecal occult
blood testing or no triage, for achieving appropriate referral for further investigation within the 2-week
suspected cancer referral target?
l What is the comparative accuracy of different quantitative FIT assays and guaiac faecal occult blood
testing, for which CRC determined by colonoscopy (the reference standard method) is the target
condition?
l What is the diagnostic accuracy of different quantitative FIT assays, where CRC determined by colonoscopy
(the reference standard method) is the target condition?
l What is the cost-effectiveness of using faecal immunochemical testing for the presence of occult blood as
a triage step in the investigation of symptomatic patients for suspected CRC compared with the recent
recommendation of guaiac faecal occult blood testing and no triage (referral straight to colonoscopy)?
Note
This report contains reference to confidential information provided as part of the NICE appraisal process.
This information has been removed from the report and the results, discussions and conclusions of the
report do not include the confidential information. These sections are clearly marked in the report.
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Chapter 2 Background and definition of the
decision problem(s)
Population
The primary indication for this assessment is the use of tests for the presence of occult blood in the faeces
as a triage step in the investigation of people presenting in primary care settings, with lower abdominal
symptoms in whom investigation for possible CRC is being considered. NICE guidance on suspected
cancer: recognition and referral (NG121) recommends the use of guaiac testing for occult blood in the
faeces as a triage step before referral for secondary care investigations, in specified symptomatic patient
groups – people aged:
l ≥ 50 years, who have unexplained abdominal pain or weight loss
l < 60 years, who have changes in their bowel habit or iron-deficiency anaemia
l ≥ 60 years, who have anaemia in the absence of iron deficiency.
This assessment will consider the clinical effectiveness and cost-effectiveness of using quantitative
faecal immunochemical testing for haemoglobin (Hb) as a triage test. The clinical effectiveness and
cost-effectiveness of triage testing using faecal immunochemical testing will be considered for all people
presenting, in primary care settings, with lower abdominal symptoms who require investigation for possible
CRC, not limited to the specific groups detailed in NG12.1
Colorectal cancer is the third most common cancer in the UK population overall and in people aged
≥ 50 years, after breast cancer and lung cancer for females and prostate cancer and lung cancer for males.
The most common cancers differ for younger age groups. The Office for National Statistics (ONS) cancer
registration data for 2013 showed approximately 35,000 new cases of CRC in England (18,839 males
and 14,926 females).2 The incidence of CRC was 87 cases per 100,000 males and 52 cases per 100,000
females; the age-standardised incidence rate was 54.4% higher in males than in females and has
increased for both males and females over the last 10 years.2 CRC accounted for approximately 11.5% of
all new cancers diagnosed in 2013 (12.6% in males and 10.4% in females) and increasing with age to
14.2% of cancers in males aged ≥ 80 years and 15.2% in females aged ≥ 80 years.2 The age-standardised
1-year survival rates for men and women who were diagnosed with CRC between 2009 and 2013, and
followed up to 2014, were 77.5% and 75.8%, respectively.3 The corresponding 5-year survival rates were
58.5% and 58.2%, respectively.3 Survival rates for CRC have not changed substantively since the previous
data collection period (2008–12).
The UK NHS Bowel Cancer Screening Programme in England currently utilises guaiac faecal occult
blood testing, but faecal immunochemical testing has been recently recommended by the UK National
Screening Committee, has been piloted for national roll-out and recommended by European Commission
guidelines.4,5 However, studies assessing the effectiveness of faecal immunochemical testing or comparing
the performance of faecal immunochemical testing and guaiac faecal occult blood testing in asymptomatic
population-based screening for CRC will not be included in this assessment. This is because the prevalence
of CRC is likely to be higher in a population with even relatively low-risk symptoms than in the general
population without symptoms that are eligible for screening, and faecal immunochemical testing used for
screening applications will generally use higher cut-off faecal Hb concentrations than would be used for
triage of people with symptoms. The cost-effectiveness modelling used to inform NG121 based its estimate
of the prevalence of CRC in a low-risk population on the positive predictive value (PPV) of symptoms in
22 studies that were identified as relevant.6 The PPV of altered bowel habit in men and women aged
< 60 years ranged from 0.01 to 15.7, and the base-case analysis used a CRC prevalence estimate that was
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at the lower end of this range (1.5%).6 By comparison, estimating the prevalence of CRC in the general
population of England, based on ONS cancer registration and population data, gives approximately
0.065% for the whole population and 0.226% for the screening-eligible age group (60–74 years), that is,
those who were most likely to match the population included in screening studies. Furthermore, it has
been shown that differences in disease prevalence can affect estimates of test performance; data from
23 meta-analyses, which covered a wide range of clinical conditions, showed changes in sensitivity and
specificity estimates of between 0% and 40% from the lowest to the highest prevalence.7 In relation
to faecal immunochemical testing, a recent meta-analysis of 19 studies conducted in average-risk,
asymptomatic screening populations reported summary estimates of sensitivity and specificity for CRC of
79% [95% confidence interval (CI) 69% to 86%] and 94% (95% CI 92% to 95%), respectively; however,
this analysis pooled data for eight different FIT assays.8
The 2015 National Bowel Cancer Audit Report9 stated that, of all patients diagnosed with CRC in 2014,
55% were diagnosed following a general practitioner (GP) referral and 9% (20% of those in the eligible
age range for screening, 60–74 years) were diagnosed through the NHS Bowel Cancer Screening
Programme; however, 20% were diagnosed only following an emergency presentation (referral source
data were missing for 16% of patients).9 Treatment with curative intent was possible for more of those
patients who were diagnosed through screening (90%) and following GP referral (70%) than those who
were presenting as an emergency admission (52%).9 Work to promote screening uptake and awareness of
CRC symptoms is stated as a recommendation, with the aim of reducing the proportion of emergency
presentations and improving outcomes. However, increased uptake of screening and increased awareness
of, and presentation in, primary care of patients with low-risk symptoms could result in more invasive
investigations, such as colonoscopy, being conducted. Estimates from the charity Bowel Cancer UK10 have
suggested that there will be a 10–15% year-on-year increase in demand for colonoscopies, which impacts
on the 2-week suspected cancer referral time and NHS capacity.1 In addition, colonoscopy has associated
risks, which include bowel perforation, bleeding, infection and abdominal pain.11 A recent review reported
that most colonoscopies performed in symptomatic patients do not find either CRC or other serious bowel
disease, and do not yield changes to the therapeutic approach.12 The identification of tests that can help to
rule out CRC and select people who are more likely to benefit from further investigation is therefore an
important goal. It has been suggested that using quantitative immunochemical measurement of faecal Hb
concentration to select patients for referral has the potential to reduce unnecessary colonoscopies and
provide more accurate classification of patients than traditional, symptoms-based guidelines.13
This assessment provides a comprehensive summary of the evidence about the performance of faecal
immunochemical testing as a triage test for people, presenting in primary care settings, with lower
abdominal symptoms, who are at low risk for CRC according to the criteria defined in NG121 and for
whom a referral for secondary care investigation for possible CRC is being considered.
Intervention technologies
There are two major types of test for the presence of small amounts of blood in faeces: these are guaiac
based [guaiac faecal occult blood test (gFOBT)] or immunochemical based (FIT). Guaiac-based methods
detect the haem complex, whereas immunochemical methods specifically detect the globin moiety of
human Hb.
Guaiac faecal occult blood tests rely on the pseudo-peroxidase activity of haem. A faecal sample is placed
on to a paper that is impregnated with guaiac, to which hydrogen peroxide is applied as developer of the
test. In the presence of haem, a chemical reaction occurs, yielding a blue- or green-coloured product within
seconds. Usually, two faecal samples from each of three separate bowel motions are required.14 The test is
not specific for human blood and will also respond to animal blood, muscle protein and iron supplements.
In addition, certain vegetables contain constituents with peroxidase activity, which can lead to false-positive
(FP) results, although this can be minimised by waiting for 72 hours before development of the test.
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Bleeding gums or medicines that can cause gastrointestinal (GI) irritation or bleeding, for example aspirin
and non-steroidal anti-inflammatory drugs, can also result in a FP test result.15 In addition, a high intake of
vitamin C can cause a false-negative (FN) result. In consequence, dietary and medicine restrictions are often
imposed prior to testing.14 gFOBTs are not considered an intervention technology in this assessment.
Faecal immunochemical tests use antibodies that specifically recognise the globin of human Hb. Faecal
immunochemical testing has the potential to reduce FPs caused by upper GI bleeding because globin is
degraded in the upper GI tract and, therefore, is not present in faecal samples for faecal immunochemical
testing to detect. However, haem is resistant to degradation in the upper GI tract and, therefore, this
molecule remains in faecal samples and can be detected by guaiac faecal occult blood testing (FP). Usually,
only one faecal sample (but sometimes two) is collected and no dietary or medicine restriction is required.16
Faecal immunochemical testing can be either qualitative or quantitative, and both are available from many
different manufacturers with variable designs. Qualitative tests have an end point that is read as positive
or negative visually; usually they are of a lateral flow immunochromatographic design, similar to home
pregnancy tests. Faecal samples can be collected on to cards, similar to the traditional guaiac faecal occult
blood testing, or, more commonly, into specimen collection devices that use probes attached to the lid of
the device to transfer a few milligrams of faeces into a few millilitres of stabilising buffer in the device.
Each manufacturer sets their own cut-off faecal Hb concentration for a positive test and available qualitative
FITs are very different. The need for visual interpretation of the results can introduce interobserver variation.
Determination of the presence of a trace line in the test portion of the cassette is a subjective judgement,
which can sometimes be difficult. It is difficult to introduce quality control and, if qualitative FITs are
used outside laboratories, the stringent recommendations and guidelines for point-of-care tests must be
followed. Quantitative faecal immunochemical testing often uses immunoturbidimetric methods to measure
the actual concentration of faecal Hb. Analysis is usually automated, facilitating quality management
procedures. Most quantitative FITs require ‘wet’ collection, whereby samples are collected with a probe
attached to the lid of the specimen collection device and transferred into a small volume of buffer in the
device. The sample may degrade between collection and analysis if not handled properly14,16 because faecal
Hb is very unstable: indeed, faecal samples for faecal immunochemical testing must be collected into the
specimen collection devices and cannot be collected by patients into traditional collection pots that are then
returned to primary care for onward transport for FIT analysis.
A summary of the product properties of quantitative FIT assays that are available in the NHS in England
and Wales, and included in this assessment, is provided in Table 1.
Units for faecal immunochemical tests for haemoglobin
Different FITs use a variety of sampling methods, with variation in the mass of faeces collected and the
volume and characteristics of the buffer used in the sampling device. These differences make the comparisons
of test performance between FIT assay types difficult. FIT results can be expressed as Hb concentration in
the sampling device buffer (ng Hb/ml buffer) or as Hb concentration by mass of faeces (µg Hb/g faeces).
Initiatives aimed at standardising the units of measurement have resulted in recommendations, from the
World Endoscopy Organization Colorectal Cancer Screening Committee’s Expert Working Group on ‘FIT for
Screening’17 and the Guildford Medical Device Evaluation Centre,18 that manufacturers should adopt the use
of ‘µg Hb/g faeces’.
OC-Sensor
OC-Sensor (Eiken Chemical Co./MAST Diagnostics, Tokyo, Japan) is a quantitative faecal immunochemical
test. A sample is collected on a probe and inserted immediately into a unique specimen collection device
that contains buffer. Analysis is fully automated using the OC-PLEDIA analyser or the OC-Sensor IO
analyser – both quantitatively determine the concentrating of Hb present in faecal samples using polyclonal
antibodies for human Hb and latex agglutination turbidimetry.19,20 The OC-PLEDIA can process up to
320 samples per hour, with a capacity of 200 samples per run. The OC-Sensor IO analyser can process up
to 88 samples per hour, with a maximum capacity of 20 samples per run.
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HM-JACKarc system
The HM-JACKarc system (Kyowa Medex/Alpha Laboratories Ltd, Tokyo, Japan) is a fully automated
quantitative faecal immunochemical test. A sample is obtained using the insertion of a probe attached
to the cap of the specimen collection device, which is then inserted into a specialised collection tube
containing buffer. The system picks up a small volume from the specimen collection devices and adds
reagents, including latex reagent pre-coated with antibodies that are specific to the globin moiety of
human Hb. Binding of the latex reagent to globin that is present in the faecal sample creates a complex
that can be detected using turbidimetry. The system comprises an analyser, faecal sample collection
devices (the Extel Hemo-auto MC A device; Kyowa Medex/Alpha Laboratories Ltd, Tokyo, Japan), latex
agglutination reagents (Extel Hemo-Auto HS; Kyowa Medex/Alpha Laboratories Ltd) and buffer (Extel
Hemo-auto; Kyowa Medex/Alpha Laboratories Ltd). The test has a measuring range of 7–400 µg Hb/g
faeces. The HM-JACKarc analyser can process up to 200 samples per hour, with a maximum capacity of
80 samples per run.21
FOB Gold
The FOB Gold system (Sentinel/Sysmex, Sentinel Diagnostics, Milan, Italy) is an automated quantitative
faecal immunochemical test. Faecal samples are collected on probes, which are immersed immediately into
solution within the specimen collection device. This ensures sample stability (14 days at 2–8 °C or 7 days at
15–30 °C). The devices are then placed into an automated analyser. A latex agglutination assay is used
which is detected via turbidimetry.22 The FOB Gold kit has CE (Conformité Européene)-marked applications
for a range of clinical chemistry analysers, including those supplied by Roche, Siemens, Beckman Coulter
and Abbott. The test has a measuring range of 10 ng/ml to the highest calibrator concentration used, and
the instructions for use state that laboratories should establish their own population specific cut-off points.
Test throughput is dependent on the analyser that is used to process samples.
RIDASCREEN haemoglobin/haptoglobin complex
The RIDASCREEN Hb test (R-Biopharm, Darmstadt, Germany) is a quantitative human Hb/Hp complex
immunochemical test. Detection alone is automated. Samples are collected and kept in chilled storage
media. Before analysis, the samples are diluted with extraction buffer and mixed. This can be done
manually or using the DSX (DSX®, DYNEX Technologies, Chantilly, VA, USA) automated enzyme-linked
immunosorbent assay system. The test is run on a 96-well microtitre plate, which is pre-coated
with polyclonal antibodies for human haptoglobin (Hp). The sample solution is applied, followed by
a wash step and then application of monoclonal antibody for anti-Hb, which is conjugated to peroxidase.
In the presence of a Hb/Hp complex, a sandwich complex forms between the polyclonal and monoclonal
antibodies. After further washes, a substrate is added, which reacts with the peroxidase, creating a colour
change that can be detected by a plate reader. The values produced by the plate reader are interpreted
with the RIDA-SOFT Win.net software (R-Biopharm). The company recommends a cut-off value of > 2 µg/g
to determine a positive sample. The test has a limit of detection of 0.42 µg/g. The company suggests that
the determination of the Hb/Hp complexes has a diagnostic advantage: as the Hb/Hp complex is resistant
to decomposition by acids or proteolytic enzymes, it will maintain in the faeces after long periods in the
intestine. Thus, blood admixtures from larger intestinal polyps and colon carcinomas that are located
higher up in the intestine can also be recorded with high sensitivity.23 However, discussion with clinical
experts at the scoping stage of this assessment has suggested that this method may also result in an
increased number of FPs.
Potential advantages of faecal immunochemical testing
It has been suggested that faecal immunochemical testing may offer improved accuracy compared with
guaiac faecal occult blood testing, particularly in relation to the rule-out of CRC. Although most studies do
not provide evidence about the performance of the test in symptomatic populations, the idea that faecal
immunochemical testing may be associated with improved diagnostic performance relative to guaiac faecal
occult blood testing is supported by data from systematic reviews of studies that have been conducted
in screening populations.24,25 A meta-analysis25 of 18 studies demonstrated that faecal immunochemical
testing (OC-Sensor) had a higher sensitivity (87% vs. 47%) with similar specificity (93% vs. 92%) to guaiac
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faecal occult blood testing (Hemoccult® test, Beckman Coulter Inc., Brea, CA, USA) for screening for CRC.
More recent studies comparing faecal immunochemical testing to guaiac faecal occult blood testing in
screening populations have also reported increased sensitivity of faecal immunochemical testing for the
detection of CRC of between 31.7% and 61.5%, relative to guaiac faecal occult blood testing, with no
change in associated specificity.26–28 A recent study in symptomatic and asymptomatic patients scheduled
for diagnostic colonoscopy reported a smaller difference in sensitivity (14.7%).29 The results of these
studies indicate that faecal immunochemical testing may be associated with a decrease in the number of
FN results and potentially missed CRC, relative to guaiac faecal occult blood testing, but not a reduction in
FP results (inappropriate referrals).
This assessment systematically reviews the evidence about the performance of faecal immunochemical
testing as a triage test for people presenting in primary care settings, with lower abdominal symptoms,
who are at low risk for CRC according to the criteria defined in NG12,1 and for whom a referral
for secondary care investigation for possible CRC is being considered. We have preferentially sought
direct comparisons of faecal immunochemical testing and guaiac faecal occult blood testing, to inform
comparative cost-effectiveness modelling; however, our assessment also included studies of the diagnostic
accuracy of quantitative FIT assays alone (no comparison with gFOBT or other FIT). Where available, data
were collected on the use of different faecal Hb concentration cut-off points and/or multiple sampling
strategies in order to determine the best way to operationalise FIT use.
A meta-analysis of studies comparing faecal immunochemical testing and guaiac faecal occult blood
testing reported that faecal immunochemical testing was associated with a small increase in participation in
asymptomatic population-based screening (relative risk 1.16; 95% CI 1.03 to 1.30).30 Initial reports from the
NHS Bowel Cancer Screening Programme in England pilot of faecal immunochemical testing also indicate
that faecal immunochemical testing may be associated with increased uptake compared with guaiac faecal
occult blood testing (63.9% vs. 54.4% in 60-year-olds who were invited for screening for the first time).31
We are not aware of any similar studies on testing uptake (or compliance) in symptomatic populations, and
the extent to which the acceptability of FIT sample collection would be an issue for people with symptoms is
unclear. In order to inform this question, we have collected all of the available data on the return rates for
FIT sample collection devices that were issued to participants in the studies that were included in our
systematic review.
Comparator
The comparators for this technology are gFOBT1 and no faecal occult blood triage testing.
Care pathway
Testing for occult blood in faeces in patients presenting to primary
care settings
The NHS Bowel Cancer Screening Programme in England offers screening every 2 years to all men and
women aged between 60 and 74 years. People aged > 74 years can request a screening kit by contacting
the Programme. Screening is currently based on guaiac faecal occult blood testing, but FITs have been
recommended by the UK Screening Committee for this purpose and a pilot evaluation has already been
completed. FITs are currently recommended as the best non-invasive screening modality in all national and
international recommendations.32
According to NG12,1 patients should be referred for an appointment within 2 weeks if they have
suspected CRC, defined as:
l aged ≥ 40 years with unexplained weight loss and abdominal pain, or
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l aged ≥ 50 years with unexplained rectal bleeding, or
l aged ≥ 60 years with iron-deficiency anaemia or changes in their bowel habit
l tests showing occult blood in their faeces
l having a rectal or abdominal mass
l adults aged < 50 years with rectal bleeding and abdominal pain or change in bowel habit or weight
loss or iron-deficiency anaemia.
According to NG12,1 testing for occult blood in faeces should be offered to adult patients who present
with initial symptoms without rectal bleeding who are:
l aged ≥ 50 years with unexplained abdominal pain or weight loss
l aged < 60 years with changes in their bowel habit or iron-deficiency anaemia
l aged ≥ 60 years and having anaemia, even in the absence of iron deficiency.
Further testing following a positive test result for occult blood in faeces
Following a positive test result for occult blood in faeces, people in England are usually offered a
colonoscopy within 2 weeks of referral to establish a diagnosis.
The 2011 NICE clinical guideline (CG131)33 states that patients should be advised that one or more
investigations may be necessary to confirm or exclude a diagnosis of CRC. Colonoscopy is offered to
patients without significant comorbidity to confirm a diagnosis of CRC; if a suspicious lesion is detected
then a biopsy should be performed (unless contraindicated). For people with comorbidities, computed
tomography colonography (CTC) can be offered as an alternative to colonoscopy.
The Scottish Intercollegiate Guidelines Network (SIGN) 201134 guidance for CRC (updated in 2016) states
that patients aged > 40 years who present with new-onset, persistent or recurrent rectal bleeding should
be referred for investigation. Review of the patient by a regional clinical genetics service is recommended
for accurate risk assessment if family history of CRC is the principal indication for referral for investigation.
GPs should perform an abdominal and rectal examination on all patients with symptoms that are indicative
of CRC. A positive finding should expedite referral, but a negative rectal examination should not rule
out the need to refer. All symptomatic patients should have a full blood count; in cases of anaemia, the
presence of iron deficiency should be determined. When CRC is suspected clinically, the whole of the large
bowel should be examined:
l Colonoscopy is recommended as a very sensitive method of diagnosing CRC, enabling biopsy
and polypectomy.
l CTC can be used as a sensitive and safe alternative to colonoscopy.
Guidelines from clinical professional bodies follow a similar pattern: the Royal College of Radiologists
recommends that symptomatic patients with suspected CRC should receive evaluation/diagnosis by imaging
studies (colonoscopy, CTC or barium enema);35 the Association of Coloproctology of Great Britain and
Ireland recommends that patients with higher-risk symptoms should be fast-tracked in special clinics or
given urgent appointments in routine clinics. Patients so referred should be investigated with sigmoidoscopy
(flexible or rigid) plus a high-quality, double-contrast barium enema, or colonoscopy or CTC.36
Treatment of colorectal cancer
Following diagnosis and staging, CRC may be treated with surgery, chemotherapy and radiotherapy, or, in
some cases, with biological agents such as cetuximab. Treatment is dependent on the stage of the cancer
and is described in more detail in CG131.33
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Chapter 3 Assessment of clinical effectiveness
A systematic review was conducted to summarise the evidence on the clinical effectiveness of faecalimmunochemical testing as a triage step in the investigation of people, presenting in primary care, with
lower abdominal symptoms, who are at low risk for CRC according to the criteria defined in NG121 and for
whom a referral for secondary care investigation for possible CRC is being considered. Systematic review
methods followed the principles outlined in the Centre for Reviews and Dissemination (CRD) guidance for
undertaking reviews in health care37 and the NICE Diagnostic Assessment Programme manual.38
Systematic review methods
Search strategy
Search strategies were based on intervention (FIT assays) and target condition (CRC), as recommended in
the CRD guidance for undertaking reviews in health care37 and the Cochrane Handbook for Diagnostic
Test Accuracy Reviews.39
Candidate search terms were identified from target references, browsing database thesauri [e.g. MEDLINE
medical subject heading (MeSH) and EMBASE Emtree] and from existing reviews that were identified
during initial scoping searches. Strategy development involved an iterative approach, testing candidate text
and indexing terms across a sample of bibliographic databases, aiming to reach a satisfactory balance of
sensitivity and specificity. Search strategies were developed specifically for each database and the keywords
associated with faecal immunochemical tests for occult blood were adapted according to the configuration
of each database.
No restrictions on language, publication status or date of publication were applied. Searches took into
account generic and other product names for the intervention. The main EMBASE strategy for each search
was independently peer reviewed by a second Information Specialist, using the Canadian Agency for Drugs
and Technologies in Health (CADTH) Peer Review checklist.40 Identified references were downloaded in
EndNote X6 software (Thomson Reuters, CA, USA) for further assessment and handling. References in
retrieved articles were checked for additional studies. The final list of included papers was also checked on
PubMed for retractions, errata and related citations.41–44
The following databases were searched for relevant studies from database inception date to the most
recent date available:
l MEDLINE (via Ovid): 1946 to March Week 3 2016
l MEDLINE In-Process & Other Non-Indexed Citations, and Daily Update (via Ovid): to 29 March 2016
l MEDLINE Epub Ahead of Print (via Ovid): 20 June 2016
l EMBASE (via Ovid): 1974 to 29 March 2016
l The Cochrane Library:
¢ Cochrane Database of Systematic Reviews (CDSR) (via the internet): to Issue 3 of 12, March 2016
¢ Cochrane Central Register of Controlled Trials (CENTRAL) (via the internet): to Issue 2 of 12,
February 2016
¢ Database of Abstracts of Reviews of Effects (DARE) (via the internet): to Issue 2 of 4, April 2015
¢ Health Technology Assessment (HTA) database (via the internet): to Issue 1 of 4, January 2016
¢ NHS Economic Evaluation Database (NHS EED) (via the internet): to Issue 2 of 4, April 2015
l International Network of Agencies for Health Technology Assessment (INAHTA) Publications (via the
internet): to 30 March 2016: www.inahta.org/publications/
l National Institute for Health Research (NIHR) HTA programme (via the internet): to 30 March 2016
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l Aggressive Research Intelligence Facility (ARIF) database (via the internet): to 30 March 2016:
www.birmingham.ac.uk/research/activity/mds/projects/HaPS/PHEB/ARIF/index.aspx
l PROSPERO (International Prospective Register of Systematic Reviews) (via the internet): to 30 March
2016: www.crd.york.ac.uk/prospero/.
Completed and ongoing trials were identified by searches of the following resources:
l National Institutes of Health ClinicalTrials.gov: to 8 March 2016
www.clinicaltrials.gov/
l EU Clinical Trials Register: to 8 March 2016
www.clinicaltrialsregister.eu/ctr-search/search
l World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP): to 8 March 2016
www.who.int/ictrp/en/.
Electronic searches were undertaken for abstracts and poster presentations from the following conferences:
l American Gastroenterological Association – Digestive Disease Week (DDW): 2011–15
l Annual Meeting of the American Association for Clinical Chemistry and Laboratory Medicine
(AACC): 2011–15
l British Society of Gastroenterology (BSG) Annual Meeting: 2011–15
l EuroMedLab: IFCC-EFLM (International Federation of Clinical Chemistry and Laboratory Medicine/
European Federation of Clinical Chemistry and Laboratory Medicine) European Congress of Clinical
Chemistry and Laboratory Medicine: 2011–15
l United European Gastroenterology Week (UEGW): 2011–15.
Full search strategies are presented in Appendix 1.
Specialist members of the Assessment SubGroup and one additional clinical expert (CF) were contacted to
seek additional studies.
Inclusion and exclusion criteria
Inclusion criteria for each of the clinical effectiveness questions are summarised in Table 2. Studies that
fulfilled these criteria were eligible for inclusion in the review.
Inclusion screening and data extraction
Two reviewers (MW and SL) independently screened the titles and abstracts of all of the reports identified
by searches and any discrepancies were discussed and resolved by consensus. Full copies of all of the
studies that were deemed to be potentially relevant were obtained and the same two reviewers
independently assessed these for inclusion; any disagreements were resolved by consensus. Details of the
studies excluded at the full-paper screening stage are presented in Appendix 4.
When studies reported insufficient information (e.g. FIT assay not specified or incomplete accuracy data),
the authors were contacted to request additional information. The authors of studies that included a mixed
population (e.g. screening, surveillance and symptomatic patients) were contacted to request subgroup
data for symptomatic patients. Authors were initially contacted by e-mail, which was followed up with a
reminder e-mail after 2 weeks and, subsequently (where possible), by personal contact from a clinical
specialist member of the Assessment SubGroup (RL).
Studies cited in the materials provided by the manufacturers of FIT assays were first checked against the
project reference database, in Endnote; any studies that were not already identified by our searches were
screened for inclusion following the process described above.
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Data were extracted on the following: study details, inclusion and exclusion criteria, participant characteristics
(demographic characteristics, presenting symptoms, other CRC risk factors), target condition {CRC, advanced
neoplasia [high-risk adenoma (HRA) or CRC], other significant bowel disease outcomes (as reported)}, details
of the FIT (manufacturer, analyser used, definition of a cut-off point, sampling procedure, detection method,
etc.), details of any comparator test(s) (manufacturer, antibody, limit of quantitation, definition of cut-off
point, sampling procedure, detection method, etc.), details of the reference standard, definitions of the target
conditions, test performance outcome measures [numbers of true-positive (TP), FP, FN and true-negative (TN)
test results] and proportion of study participants who returned a FIT sample (extracted as an indicator of
acceptability). Data were extracted by one reviewer, using a piloted, standard data extraction form and
checked by a second reviewer (MW and SL); any disagreements were resolved by consensus. Full data
extraction tables are provided in Appendix 2.
Quality assessment
The methodological quality of included studies was assessed using QUADAS-2.45
TABLE 2 Inclusion criteria
Question
What is the accuracy of different
quantitative FIT assays, when the target
condition is CRC determined by
colonoscopy (the reference standard
method)?
What is the clinical effectiveness of faecal
immunochemical testing, compared with
guaiac faecal occult blood testing or no
triage, for achieving appropriate referral
for further investigation within the 2-week
suspected cancer referral target?
Participants People presenting with lower abdominal symptoms, who are being investigated for possible CRCa
Setting Primary care
Interventions
(index test)
Quantitative FIT assays listed in Table 1
Comparators Any other FIT method (including different
faecal Hb cut-off points or different numbers
of samples) or gFOBT or no comparator
gFOBT or no triage
Reference standard Colonoscopy NA
Outcomes Diagnostic accuracy (the numbers of TP, FN,
FP and TN test results), where the target
condition is CRC determined by colonoscopyb
Appropriate referral for secondary care
investigations with 2 weeks from presentation
(proportion of patients referred for secondary
care investigation in whom CRC was confirmed
and proportion of patients not referred for
secondary care investigation in whom CRC was
later diagnosedc), long-term CRC mortality,d
any patient acceptability/satisfaction or HRQoL
measures
Study design Diagnostic cohort studies RCTs (CCTs will be considered if no RCTs are
identified)
CCT, controlled clinical trial; HRQoL, health-related quality of life; IBD, inflammatory bowel disease; NA, not applicable;
RCT, randomised controlled trial; TN, true negative; TP, true positive.
a Studies will be included if the participant selection criteria are unclear but the population is described as symptomatic/
suspected CRC and not asymptomatic population-based screening; study authors will be contacted for additional details
as needed. Studies conducted in people with pre-existing GI comorbidities will be excluded.
b If studies report diagnostic accuracy data for other target conditions, in addition to CRC (e.g. adenoma, IBD, organic
bowel disease) then these data will also be extracted. Any reported data on test failure rates or measures of patient
acceptability/satisfaction will also be extracted.
c Patients who are not referred for secondary care investigation should be followed up for a minimum of 1 year.
d Studies reporting CRC mortality should have a minimum follow-up of 5 years.
DOI: 10.3310/hta21330 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 33
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Westwood et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
13
Note: Protocol change Studies that reported results for risk prediction scores that included faecal
immunochemical testing, as well as test accuracy data for faecal immunochemical testing, were assessed
using PROBAST (Prediction model study Risk Of Bias Assessment Tool)46 in addition to QUADAS-2.
Quality assessment was undertaken by one reviewer and checked by a second reviewer (MW and SL); any
disagreements were resolved by consensus or discussion with a third reviewer.
The results of the quality assessments are summarised and presented in tables and graphs in the results of
the systematic review, and are presented in full, by study, in Appendix 3.
Methods of analysis/synthesis
Sensitivity and specificity were calculated for each set of 2 × 2 data. The bivariate/hierarchical summary
receiver operating characteristic (HSROC) model was used to estimate summary sensitivity and specificity
with 95% CIs and prediction regions around the summary points, and to derive HSROC curves for
meta-analyses involving four or more studies.47–49 This approach allows for between-study heterogeneity
in sensitivity and specificity, and for the trade-off (negative correlation) between sensitivity and specificity
that is commonly seen in diagnostic meta-analyses. For meta-analyses with fewer than four studies we
estimated separate pooled estimates of sensitivity and specificity, using random-effects logistic regression.50
Heterogeneity was assessed visually using summary receiver operating characteristic (SROC) plots and
statistically using the variance of logit (sensitivity) and logit (specificity), for which ‘logit’ indicates the
logistic function: the smaller these values, the less heterogeneity between studies. Analyses were
performed in Stata 10 (StataCorp LP, College Station, TX, USA), using the metandi command. For analyses
that would not run in Stata we used Meta-DiSc (version 1.4, free source).51
Studies were grouped by FIT assay type, target condition and threshold. We compared the accuracy of
different FIT assays by tabulating summary estimates from analyses for commonly used thresholds.
Stratified results tables receiver operating characteristic (ROC) space plots were used to illustrate the
variation of test performance by threshold.
We used SROC plots to display summary estimates from analyses that included a minimum of four data points.
Results of the assessment of clinical effectiveness assessment
After initial screening of titles and abstracts, 113 papers were considered to be potentially relevant and
ordered for full-paper screening; of these, 21 papers13,52–71 were included in the review.
Additionally, four presentations72–75 were obtained through contact with a clinical expert (CF). One
unpublished manuscript was provided, through NICE, by the manufacturer of FOB Gold [e-mail from
Philippa Pinn, Sysmex UK Ltd, via Rebecca Albrow, NICE, to Marie Westwood, Kleijnen Systematic Reviews
(KSR) Ltd, 21 June 2016, personal communication]. Additional unpublished work was provided by the
clinical expert (CF) (e-mail from Callum Fraser, NHS Tayside, to Marie Westwood, KSR Ltd, 10 July 2016,
personal communication, ahead of publication). All potentially relevant studies cited in other documents
supplied by the test manufacturers had already been identified through other sources. Figure 1 shows the
flow of studies through the review process, and Appendix 4 provides details, with reasons for exclusions,
of all of the publications that were excluded at the full-paper screening stage. In total there were
10 included studies derived from 27 articles.
Seventy-four articles were excluded after full-text screening. Twelve articles76–86 could not be obtained and
one further article87 was published in Russian with no English abstract.
We contacted the authors of publications that reported data from studies with mixed populations
(symptomatic, screening and surveillance patients) to request separate data for the symptomatic subgroup;
when no additional data were obtained, these studies were excluded (see Appendix 4). The authors of two
studies56,58 provided additional test accuracy data, which were included in our review.
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Overview of included studies
Details of the 10 included studies and their associated references are provided in Table 3. Additional data
were supplied by the authors of two studies.56,58 In the case of Terhaar sive Droste et al.,58 the authors
provided overall data for symptomatic study from the master database, which holds data for all of their
publications (e-mail from Sietze van Turenhout, University Medical Center, Amsterdam, to Marie Westwood,
KSR Ltd, 12 June 2016, personal communication). The results section of this report cites studies using the
primary publication and, where this is different, the publication (shown in bold text in Table 3) in which the
referenced data were reported.
Additional records identified 
through other sources
• Information from 
   manufacturers, n = 1
• Contacting clinical experts, n = 5
• MEDLINE, n = 3198
• MEDLINE In-Process & Other Non-Indexed
   Citations, and Daily Update, n = 255
• EMBASE, n = 5255
• CENTRAL, n = 446
• DARE, n = 34
• CDSR, n = 25
• NHS EED, n = 103
• HTA, n = 27
• INAHTA Publications, n = 8
• NIHR HTA, n = 1
• ARIF Reviews Database, n = 17
• PROSPERO, n = 9
• MEDLINE Epub Ahead of Print, n = 80
• ClinicalTrials.gov, n = 51
• EU Clinical Trials Register, n = 1
• WHO ICRTP, n = 29
Records identified through database searching
 (total, n = 9539)
• AACC, n = 3
• AGA DDW, n = 92
• BSG, n = 6
• EuroMedLab, n = 5
• UEGW, n = 47
Conference searching
 (total, n = 153)
Records after duplicates removed
(n = 5847)
Records screened
(n = 5847)
Id
en
ti
fi
ca
ti
o
n
Sc
re
en
in
g
El
ig
ib
ili
ty
In
cl
u
d
ed
Records excluded
(n = 5734)
Total (n = 92)
Included studies 
(n = 10)
(25 publications and 
2 unpublished manuscripts) 
Additional unpublished 
data were obtained for 
2 published studies
• Full-text articles excluded, n = 77
• Full-text articles identified as 
   duplicates, n = 2
• Russian-language article, no 
   English abstract, n = 1
• Unobtainable articles, n = 12
Full-text articles assessed
for eligibility
(n = 113)
FIGURE 1 Flow of studies through the review process. AGA DDW, American Gastroenterological Association
Digestive Disease week; UEGW, United European Gastroenterology Federation Week.
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Five studies2,13,53,55,58 reported accuracy data for the OC-Sensor assay; one study52 used the IO analyser
(Eiken Chemical Co.), one study13 used the OC-Sensor Diana automated immunoturbidimetric analyser
(Eiken Chemical Co.), two studies53,58 used the MICRO desktop analyser (Eiken Chemical Co.) and one
study55 did not report the analyser used. Three studies56,57,75 reported accuracy data for the HM-JACKarc
automated system (Kyowa Medex, Tokyo, Japan). The remaining two studies reported accuracy data for
the FOB Gold assay; one used the Roche Modular P/917 analyser (Roche Diagnostics Ltd, West Sussex, UK),54
and the other used the SENTiFIT 270 analyser (Sentinel Diagnostics, Milan, Italy) (Philippa Pinn, personal
TABLE 3 Details of included studies
Details Country n Reference standard
HM-JACKarc
Thomas 201675 England 450 CT/colonoscopy
Godber 201656 Scotland 484 Colonoscopy
Macdonald 201571
Godber 201465
Auge 201657 Spain 208 Colonoscopy
Auge 201466
Auge 201572
FOB Gold system
Krivec 201154 Slovenia NR Colonoscopy
(Confidential information has been
removed)
(Confidential information
has been removed)
(Confidential information
has been removed)
(Confidential information
has been removed)
OC-Sensor
McDonald 201213 Scotland 280 Colonoscopy and flexible
sigmoidoscopy
Mowat 201552 Scotland 755 Colonoscopy
Steele 201474
Rodríguez-Alonso 201553 Spain 1003 Colonoscopy
Cubiella 2014 (COLONPREDICT)55 Spain 787 Colonoscopy
Diaz Ondina 201461
Cubiella 201573
Unpublished dataa
Terhaar sive Droste 201158 The Netherlands 2058 Colonoscopy
Oort 201163
van Turenhout 201069
van Turenhout 201459
van Turenhout 201262
van Turenhout 201168
Oort 201064
van Turenhout 201260
Larbi 201267
van Turenhout 201070
CT, computed tomography; NR, not reported.
a E-mail from Callum Fraser, personal communication.
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communication). There were no studies, using the RIDASCREEN Hb or the RIDASCREEN Hb/Hp complex
assays, which met the inclusion criteria for this assessment. None of the included studies reported data
comparing different FIT assays, or comparing one or more FIT assays with a gFOBT method. All of the studies
included in our systematic review were diagnostic cohort studies that reported data on the diagnostic
accuracy of faecal immunochemical testing for which the target condition was CRC or advanced neoplasia
(defined as CRC or HRA). Five studies13,52,56,58,75 reported additional accuracy data for various non-malignant
and composite target conditions.
Six of the diagnostic accuracy studies13,52,53,55,56,75 included in our systematic review also reported uptake
rates for participants who were invited to provide a sample for faecal immunochemical testing.
No randomised controlled trials (RCTs) or controlled clinical trials (CCTs) were identified; no studies
provided data on patient-relevant outcomes following faecal immunochemical testing compared with
guaiac faecal occult blood testing or no faecal occult blood testing.
All 10 of the included studies2,13,52–58,75 were conducted in Europe: one in England,75 three in Scotland,13,52,56
three published studies53,55,57 and one unpublished study (Philippa Pinn, personal communication) in
Spain, and one each in the Netherlands58 and Slovenia.54 Three studies52,53,55 were publicly funded, five
studies13,55–57,75 reported receiving some funding from manufacturers (including supply of test kits, reagents
and analysers), one study54 did not report details of funding and the unpublished study was conducted at
the request of the test manufacturer.
Full details of the characteristics of study participants, study inclusion and exclusion criteria, and FIT
assay used and reference standard are reported in the data extraction tables presented in Appendix 2
(see Tables 65 and 66).
Study quality
All studies included in this systematic review were diagnostic cohort studies. The methodological quality of
these studies was assessed using the QUADAS-2 tool45 (summarised in Table 4 and Figure 2). One of these
studies53 and an additional report73 and unpublished paper (Callum Fraser, personal communication) linked
to a second study55 reported the development and validation of risk prediction scores that included faecal
immunochemical testing, in addition to test accuracy results. These studies were assessed using PROBAST
(Table 5), as well as QUADAS-2. The full QUADAS-2 assessments for each study are provided in Appendix 3a
and PROBAST assessment results are provided in Appendix 3b.
Two studies54,75 were reported only as conference abstracts, with limited descriptions of methods.
Two studies55,57 were rated as ‘low’ risk of bias for all domains. (Confidential information has been
removed.) The main potential sources of bias, across the included studies, concerned flow and timing, and
application of the index test. Three studies13,52,75 were rated as ‘high’ risk of bias on the flow and timing
domain because some patients who returned a sample for faecal immunochemical testing or who agreed
to participate in the study were subsequently excluded from the analysis: Mowat et al. 201552 excluded
11% of participants who returned a FIT sample because they were not subsequently referred to secondary
care or because the referral was cancelled; Thomas et al. 201675 excluded 12.5% of participants who
returned a FIT sample (no reasons for exclusion were reported); McDonald et al. 201213 excluded 41%
of people who originally agreed to participate in the study (38% did not return a FIT sample before
endoscopy and 3% completed faecal immunochemical testing but not endoscopy). (Confidential
information has been removed.)
All of the included studies were rated as having ‘high’ concerns about applicability with respect to
participants. This was because no study reported data that were specific to the population that was defined
in the scope for this assessment (people presenting, in primary care settings, with lower abdominal
symptoms and who are at low risk for CRC according to the criteria defined in NG121). Only one study52
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was conducted in a primary care setting, reporting that faecal immunochemical testing was ordered by GPs
at the point of referral to secondary care. All of the studies included some participants who had symptoms
that may be considered to be associated with a higher probability of CRC, and which are components of
the criteria for 2-week referral as defined in NG121 (e.g. rectal bleeding). In addition, although all of the
included studies were conducted in Europe, only four studies13,52,56,75 were conducted in the UK (one in
England75 and three in Scotland13,52,56). Given that population studies have shown variation in faecal Hb
concentrations, and hence potential variation in optimal thresholds for faecal immunochemical testing
across different geographic location,88,89 this may limit the applicability of our findings to UK settings.
Diagnostic performance of the OC-Sensor faecal immunochemical test assay
Details of OC-Sensor studies
Five diagnostic cohort studies,13,52,53,55,58 reported in 17 publications,13,52,53,55,58–64,67–70,73,74 provided data
on the diagnostic performance of the OC-Sensor FIT assay. All five studies13,52,53,55,58 reported accuracy data,
for which CRC was the specified target condition,13,52,53,55,58 and one of these studies55 reported further
information about the sensitivity of faecal immunochemical testing for differentiating CRC stage and
location. The prevalence of CRC, diagnosed at colonoscopy, was 2.1% in the McDonald et al. study,13 3.0%
in the Rodríguez-Alonso et al. study,53 3.7% in the Mowat et al. study,52 5.4% in the symptomatic subgroup
from Terhaar sive Droste et al. study58 and 12.3% in the Cubiella et al. study.55 Four studies13,52,53,55 also
reported data for the composite target condition of advanced neoplasia (CRC or HRA); where a definition
was provided, HRA was defined as adenoma ≥ 10 mm in diameter, with villous architecture or high-grade
dysplasia.53,55 Three studies reported additional accuracy data various non-malignant and composite
target conditions.13,52,58
No study reported data that were specific to the population that was defined in the scope for this
assessment (people presenting, in primary care settings, with lower abdominal symptoms and who are at
low risk for CRC according to the criteria defined in NG121). Only one study52 was conducted in a primary
care setting, reporting that faecal immunochemical testing was ordered by GPs at the point of referral to
secondary care. In another study,53 faecal immunochemical testing was ordered either by GPs at the point
of referral or at the initial secondary care appointment. Two studies reported that faecal immunochemical
testing was requested after referral to secondary care and before colonoscopy13,55 but did not report
whether the test was requested by GPs or secondary care clinicians. The remaining study stated that
patients already scheduled for colonoscopy were asked to provide a sample for faecal immunochemical
testing before bowel preparation.58 Four52,53,55,58 of the five OC-Sensor studies13,52,53,55,58 explicitly reported
that they included only symptomatic participants and provided details of the presenting symptoms, and
the remaining study13 included patients referred for colonoscopy (no screening colonoscopies included).
However, all of the studies included some participants who had symptoms that may be considered to be
associated with a higher probability of CRC and that are components of the criteria for 2-week referral as
defined in NG121 (e.g. rectal bleeding). Presenting symptoms included altered bowel habit, rectal bleeding,
diarrhoea, constipation, abdominal pain, bloating, unspecified anaemia, iron-deficiency anaemia, weight
loss and palpable mass. Where reported, the median age of study participants was 64 years,52 67 years55
and 60 years,58 and the overall age range was 16–91 years. There were no data linking presenting
symptoms to age or sex. Full details of participant characteristics are provided in Appendix 2, Table 65.
All five studies13,52,53,55,58 reported data on the accuracy of OC-Sensor faecal immunochemical testing using
a single faecal sample. No data were available on the effects of multiple sampling on test performance in
symptomatic patients; one additional publication,63 associated with Terhaar sive Droste et al.,58 reported no
difference between various double sampling strategies and single sampling. However, this study was
conducted in a mixed population and additional subgroup data provided by the authors were only for
single sampling.
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Four studies13,52,53,55 reported information about uptake rates in participants invited to provide a sample for
faecal immunochemical testing.
Accuracy of OC-Sensor for the detection of colorectal cancer
Five studies13,52,53,55,58 reported data on the accuracy of OC-Sensor FIT using a single faecal sample, and
thresholds ranging from any detectable Hb (the limit of detection for the assay is 452,53 to 4058 µg Hb/g
faeces). Full test performance results for all thresholds evaluated in individual studies and summary
estimates, where these were calculated, are provided in Table 6. The variation in test performance
characteristics according to the threshold used is illustrated in a ROC space plot (Figure 3). Although test
performance did not vary greatly with threshold, as might be expected, sensitivity estimates generally
decreased and specificity estimates increased with increasing threshold. Specificity was low (< 50%) in
both of the studies that used any detectable Hb to define a positive test.52,53
The optimal test performance (maximising both sensitivity and specificity) appeared to occur with
thresholds of 10 or 15 µg Hb/g faeces, with most data being available for the 10 µg Hb/g faeces threshold.
The summary estimates of sensitivity and specificity, using the 10 µg Hb/g faeces threshold, were 92.1%
(95% CI 86.9% to 95.3%) and 85.8% (95% CI 78.3% to 91.0%), respectively, based on data from four
studies,13,52,53,58 (see Table 6 and Figure 4). Mowat et al.52 and Rodríguez-Alonso et al.53 reported data for
both the 10 µg Hb/g faeces threshold and the minimum threshold of any detectable Hb; the prevalence
of CRC in these two studies52,53 was 3.3%. Using test performance data from these two studies,52,53
and a CRC prevalence estimate of 3.3%, to consider the outcome of testing for a hypothetical cohort
of 1000 patients indicates that two CRCs would be missed using the 10 µg Hb/g faeces threshold and
198 unnecessary colonoscopies would be carried out (assuming that all patients with a positive FIT
result receive colonoscopy and all of the colonoscopies that are conducted in patients without CRC are
considered unnecessary); CRC would be correctly ruled out by faecal immunochemical testing, avoiding
colonoscopy, in 769 people (Figure 5a). Alternatively, using a very low threshold (any detectable Hb) would
result in no CRCs being missed, but would increase the number of ‘unnecessary’ colonoscopies to 548 and
reduce the number of people in whom CRC would be correctly ruled out to 419 (Figure 5b). Please see
subsequent sections for information on other significant bowel pathologies that may be detected by faecal
immunochemical testing and hence may form part of the FP or ‘unnecessary colonoscopy’ population.
Limited data from Cubiella et al.55 indicated that the sensitivity of OC-Sensor (using a threshold of
20 µg Hb/g faeces) is higher for more advanced stages of CRC [American Joint Committee on Cancer
(AJCC) stages II–IV] and is also higher for tumours of the distal colon than for tumours of the proximal
colon or rectum (Table 7).
Accuracy of OC-Sensor for the detection of advanced neoplasia (colorectal cancer
or high-risk adenoma)
Four of the studies described in the previous section also reported data on the accuracy of OC-Sensor FIT
using a single faecal sample, where the target condition was expanded to include CRC or HRA.13,52,53,55
The thresholds assessed ranged from any detectable Hb (the limit of detection for the assay is 4 µg Hb/g
faeces)52,53 to 20 µg Hb/g faeces.53 Full test performance results for all thresholds evaluated in individual
studies and summary estimates, where they were calculated, are provided in Table 8. The variation in test
performance characteristics according to the threshold used is illustrated in a ROC space plot (Figure 6).
For this expanded target condition, sensitivity estimates were low for all thresholds except any detectable
Hb; the summary sensitivity and specificity estimates for this threshold were 84.1% (95% CI 78.3% to
88.8%) and 45.2% (95% CI 42.7% to 47.7%), respectively, based on data from the same two studies52,53
that evaluated this threshold for the detection of CRC.
Expanding the target condition from CRC only, to include CRC or HRA, resulted in an increase in
prevalence from 3.3% to 11.5%.52,53 Using test performance data from these two studies,52,53 and an
estimate for the prevalence of advanced neoplasia of 11.5%, to consider the outcome of testing for a
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FIGURE 3 (Confidential information has been removed.)
FIGURE 4 (Confidential information has been removed.)
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FIGURE 5 Testing outcomes for a hypothetical cohort of 1000 patients using OC-Sensor at (a) the 10 µg Hb/g faeces
threshold; and (b) any detectable Hb, for the target condition CRC.
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hypothetical cohort of 1000 patients indicates that 18 advanced neoplasias would be missed, even when
using the minimum threshold of any detectable Hb. As data indicate that no CRCs would be missed at this
threshold (see previous section), it may be assumed that the missed cases would all be HRAs. Using the
any detectable Hb threshold, 485 unnecessary colonoscopies would be carried out (assuming that all
patients with a positive FIT result receive colonoscopy and all of the colonoscopies that are conducted in
patients without at least HRA are considered unnecessary); CRC and HRA would be correctly ruled out in
401 people (Figure 7a). If the 10 µg Hb/g faeces threshold were applied to the expanded target condition,
for hypothetical cohort of 1000 patients, the number of missed cases would increase from 2 to 42 (two
CRCs and 40 HRAs); using this threshold, 157 unnecessary colonoscopies would be carried out and CRC
and HRA would be correctly ruled out in 729 people (Figure 7b).
Accuracy of OC-Sensor for the detection of other/composite target conditions
Three studies13,52,58 reported accuracy data for target conditions other than CRC or advanced neoplasia
(CRC or HRA).
McDonald et al.13 evaluated the diagnostic performance of OC-Sensor (10 µg Hb/g faeces threshold) for two
composite target conditions: one including CRC and all adenomas and the other including CRC and all
adenomas plus inflammatory bowel disease (IBD). The sensitivity estimates were low for both composite
target conditions, 58.3% (95% CI 44.9% to 70.9%) and 57.0% (95% CI 45.8% to 67.6%), respectively,
and the corresponding specificity estimates were high, 98.6% (95% CI 96.1% to 99.7%) and 99.0%
(95% CI 96.3% to 99.9%). Mowat et al.52 reported similar test performance characteristics for the
10 µg Hb/g faeces threshold and a composite target condition that included CRC, HRA or IBD; the reported
sensitivity was 68.6% (95% CI 58.7% to 77.5%) and the specificity was 83.6% (95% CI 80.6% to 86.4%).
It should be noted that an important consequence of this increased specificity estimate, relative to that
reported for the target condition of CRC in the same cohort of patients, is that 45 of the 151 participants
TABLE 7 Sensitivity of OC-Sensor for determining the stage and location of CRC using a single faecal sample
Study
Target
condition Subgroup
Threshold
(µg Hb/g
faeces) TP FN Total n
Sensitivity %
(95% CI)
CRC location
Cubiella 2014
(COLONPREDICT)55
Rectum Participants
with CRC
≥ 20a 26 4 30 86.7 (69.3 to 96.2)
Distal colon Participants
with CRC
≥ 20a 40 4 44 90.9 (78.3 to 97.5)
Proximal colon Participants
with CRC
≥ 20a 19 4 23 82.6 (61.2 to 95.0)
CRC stage (AJCC classification)
Cubiella 2014
(COLONPREDICT)55
0 Participants
with CRC
≥ 20a 4 1 5 80 (28.4 to 99.5)
I Participants
with CRC
≥ 20a 12 3 15 80 (51.9 to 95.7)
II Participants
with CRC
≥ 20a 21 2 23 91.3 (72.0 to 98.9)
III Participants
with CRC
≥ 20a 35 5 40 87.5 (73.2 to 95.8)
IV Participants
with CRC
≥ 20a 12 1 13 92.3 (64.0 to 99.8)
a Converted from ‘ng Hb/ml buffer’ using a multiplication factor of 0.2.17,18
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(29.8%) who were classified as having FP FIT results for CRC actually had other significant bowel
pathologies (HRA or IBD) and may thus have benefited from secondary care investigation.52 Mowat et al.52
also reported test performance data for this composite target condition, using the minimum threshold of
any detectable Hb. This lowering of the threshold resulted in an increased estimate of sensitivity, 88.2%
(95% CI 80.4% to 93.8%), and lower specificity, 46.5% (95% CI 42.6% to 50.4%).52
Mowat et al.52 reported separate test performance estimates for the individual target conditions of HRA
and IBD. However, these estimates are likely to be of limited clinical relevance, as they appear to have
been calculated by classifying any patient who was not in the specified target condition category as
disease negative: for HRA estimates, patients with CRC (as well as those with low-risk adenoma IBD or
no significant findings) were classified as disease negative; for IBD, patients with CRC or HRA (as well as
those with no significant findings) were classified as disease negative. One further study58 calculated test
performance estimates for HRA using a range of thresholds from 10 to 40 µg Hb/g faeces; patients with
CRC were excluded from these analyses. Full test performance results for all of the thresholds and target
conditions that were evaluated in individual studies are provided in Table 9.
Acceptability of faecal immunochemical testing using OC-Sensor
The proportion of people who are invited to participate in faecal immunochemical testing and who return
a faecal sample can be regarded as a possible indicator of the acceptability of faecal immunochemical
testing. Four13,52,53,55 of the five OC-Sensor studies reported faecal immunochemical testing uptake rates
and these varied widely, ranging from 41% (in a study for which patients were sent an invitation to
participate along with their referral letter)13 to 98% (in a study for which patients were given the specimen
collection device at their initial consultation with a gastroenterologist).53 Full results are provided in Table 10.
Other outcome measures for faecal immunochemical testing using OC-Sensor
The primary care study by Mowat et al.52 reported a number of additional outcomes relating to referral
pathways for patients receiving faecal immunochemical testing. This study found that 11% (114/1031) of
patients for whom a FIT sample was analysed were subsequently not referred to secondary care.13 The
study13 also reported that 69% (715/1031) of patients for whom a FIT sample was analysed were referred
1.0
0.9
0.8
0.7
0.6
0.5
Se
n
si
ti
vi
ty
0.4
0.3
0.2
0.1
0.0
0.0 0.1 0.2 0.3 0.4 0.5
1 – specificity
0.6 0.7 0.8 0.9 1.0
Any detectable Hb
10 µg Hb/g faeces
15 µg Hb/g faeces
20 µg Hb/g faeces
FIGURE 6 Receiver operating characteristic space plot for the OC-Sensor assay using different thresholds for the
target condition of advanced neoplasia (CRC or HRA).
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straight to endoscopy and 20% (202/1031) were referred to an outpatient clinic; however, decisions about
the urgency of the referral appear to have been made prior to faecal immunochemical testing.
The Mowat et al. study52 was also the only OC-Sensor study to report information about the proportion of
returned samples that were considered to be unsuitable for FIT analysis; this was found to be < 1% (7/1043).13
1000
patients
(a)
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(> 10 µg Hb/g faeces)
CRC or HRA
(+ colonoscopy)
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No CRC or HRA
(– colonoscopy)
Correct referrals
for colonoscopy
Incorrect referrals
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2
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avoided correctly
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1000
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FIGURE 7 Testing outcomes for a hypothetical cohort of 1000 patients using OC-Sensor at (a) any detectable Hb,
for the target condition of advanced neoplasia (CRC or HRA); and (b) the 10 µg Hb/g faeces threshold.
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Prediction modelling results from OC-Sensor faecal immunochemical testing studies
Rodríguez-Alonso et al.53 also conducted multivariable analysis, using forward conditional logistic regression
modelling, with the aim of identifying independent predictors of CRC and advanced neoplasia. The CRC
analysis identified male gender (OR 2.39, 95% CI 1.039 to 5.519; p = 0.041), iron-deficiency anaemia
(OR 2.99, 95% CI 1.27 to 7.03; p = 0.012) and faecal Hb ≥ 10 µg Hb/g faeces (OR 86.60, 95% CI 11.70 to
641.16; p < 0.001) as independent predictors.53 The advanced neoplasia analysis identified male gender
(OR 2.36, 95% CI 1.50 to 3.40; p < 0.001), age (OR 1.36, 95% CI 1.13 to 1.63; p < 0.001) and faecal Hb
≥ 10 µg Hb/g faeces (OR 7.54, 95% CI 5.03 to 11.28; p < 0.001) as independent predictors; age was treated
a categorical variable in this model (≤ 40 years, 41–60 years, 51–60 years, 61–70 years, ≥ 70 years).53 None
of the NICE or SIGN 2-week referral criteria was identified as an independent predictor in either model,
provided that faecal Hb measured by faecal immunochemical testing was included in the model.53 The
results of modelling were used to derive a risk score for advanced neoplasia; the scoring system assigned
integer values to each independent predictor based on their coefficients from the logistic regression model.53
The score ranged from 0 to 11 points, with points assigned as follows: age < 40 years = 0 points, age
41–50 years = 1 point, age 51–60 years = 2 points, age 61–70 years = 3 points, age > 70 years = 4 points;
female gender = 0 points, male gender = 2 points; faecal Hb of < 10 µg Hb/g faeces = 0 points and faecal
Hb ≥ 10 µg Hb/g faeces = 5 points.53 The model was validated using a split sampling technique [data from
680 study participants (67.8%) were used to develop the model and data from 323 participants (32.2%)
were used for validation].53 In the validation sample, a risk score of ≥ 5 had a sensitivity for advanced
neoplasia of 88.1% (95% CI 74.3% to 96.0%) and a specificity of 63.3% (95% CI 57.4% to 69.0%).53
As part of the COLONPREDICT study,55 Cubiella et al. have also developed a prediction model for CRC in
symptomatic patients, based on FIT age and sex; this work has yet to be published in full, but was presented
at the 2015 meeting of the World Endoscopy Association Colorectal Cancer Screening Committee.73 A draft
of the full paper reporting the development and validation of a risk score, the Faecal haemoglobin, Age and
Sex Test (FAST) score, was provided ahead of publication (Callum Fraser, personal communication). The
logistic regression model used to develop the FAST score included sex, age as a continuous variable and
faecal Hb as a categorical variable (0, 0–20, 20–200, and ≥ 200 µg Hb/g faeces).73 The validation cohort for
this model used data from four studies13,52,53,56 that are included in this systematic review, and an additional
cohort recruited to the COLONPREDICT study55 between March 2014 and March 2015; in this latter cohort,
faecal immunochemical testing was measured using a variety of methods [OC-Sensor 202, OC-Auto 3 Latex
(Eiken Chemical Co.) and FOB Gold]. The thresholds used to assess the performance of the FAST score in the
TABLE 10 Acceptability of faecal immunochemical testing using OC-Sensor
Study
Point in the care pathway at which faecal
immunochemical testing was requested n
n
returned
Uptake
(%)
Mowat 201552 Faecal immunochemical testing was requested by
GPs at the point of referral to secondary care, and
sampling devices and patient instruction sheets
were distributed by practice nurses
2173 1043 48
Rodríguez-Alonso 201553 Patients were given the specimen collection device
at their initial consultation with a gastroenterologist
1054 1035 98
McDonald 201213 Patients were sent an invitation to participate along
with their referral letter. This was followed up by a
telephone call from a research nurse. Sample
collection devices and written and pictorial
instructions were provided by post
739 306 41
Cubiella 2014 (COLONPREDICT)55 Patients were invited to participate after they had
been referred for colonoscopy
825 799 97
n, number invited to participate in the study and supplied with a faecal sampling kit; n returned, number returning a faecal
sample for faecal immunochemical testing.
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validation cohort corresponded to the beta coefficients of the FAST score with 90% and 99% sensitivity in
the development cohort (4.5 and 2.12, respectively). In the validation cohort, a FAST score of ≥ 4.5 had a
sensitivity of 89.3% (95% CI 84.1% to 93.0%) and a specificity of 82.3% (95% CI 81.1% to 83.5%)
for CRC. In order to avoid missing any CRCs, a lower FAST score threshold of ≥ 2.12 was required; the
sensitivity and specificity estimates at this threshold were 100% (95% CI 97.7% to 100%) and 19.8%
(95% CI 18.6% to 21.1%), respectively. Post hoc analysis indicated that there were no significant
differences in FAST score performance, for the detection of CRC, when comparing patients referred for
colonoscopy from primary care with those referred from secondary care; CRC prevalence in the validation
cohort was similar in the two settings (5.6% in primary care and 4.9% in secondary care). The performance
of the FAST score was also assessed for the detection of the expanded target conditions of advanced
neoplasia (CRC or HRA) and significant colonic lesions; the definitions of these target conditions varied
between the studies included in the validation cohort. Studies that were conducted in Scotland defined HRA
as a lesion of ≥ 10 mm diameter or more than three lesions, and significant colonic lesions as CRC, HRA or
IBD.13,52,56 The published Spanish study53 and the additional, unpublished cohort from the COLONPREDICT
study55 defined HRA as a lesion of ≥ 10 mm diameter or with villous histology or high-grade dysplasia; in
these cohorts, the definition of significant colonic lesions included CRC, HRA, polyposis (> 10 polyps of any
histology including serrated lesions), colitis, polyps of ≥ 10 mm, complicated diverticular disease, colonic
ulcer or bleeding angiodysplasia). Sensitivity estimates for the lower FAST score threshold (2.12) remained
high (≥ 95%) for all of the target conditions. For the target condition ‘advanced neoplasia’, the sensitivity
estimates for the FAST score using the 4.5 and 2.12 thresholds were 60.7% (95% CI 56.6% to 64.7%) and
96.7% (95% CI 94.9% to 98.0%), respectively, and the corresponding specificity estimates were 85.4%
(95% CI 84.1% to 86.5%) and 21.5% (95% CI 20.1% to 22.9%). For the target condition ‘significant
colonic lesion’, the sensitivity estimates for the FAST score using the 4.5 and 2.12 thresholds were 57.8%
(95% CI 54.3% to 61.3%) and 94.5% (95% CI 92.6% to 96.0%), respectively, and the corresponding
specificity estimates were 87.4% (95% CI 86.2% to 88.5%) and 22.0% (95% CI 20.6% to 23.5%).
Diagnostic performance of the HM-JACKarc faecal immunochemical test assay
Details of HM-JACKarc studies
Three diagnostic cohort studies,56,57,75 reported in seven publications,56,57,65,66,71,72,75 provided data on the
diagnostic performance of the HM-JACKarc FIT assay. Two studies56,75 reported accuracy data, for which
CRC was the specified target condition. The prevalence of CRC, diagnosed at colonoscopy, was 2.2% in
the Godber et al. study56 and 4.9% in the Thomas et al. study.75 One of the CRC studies56 and one
additional study57 also reported data for the composite target condition of advanced neoplasia (CRC or
HRA). Each of the studies used a different definition of HRA; Auge et al.57 defined HRA based on size,
morphology or number of lesions (any lesion of ≥ 10 mm in diameter or with villous architecture or
high-grade dysplasia, or three or more non-advanced adenomas) and Godber et al.56 defined higher-risk
adenoma, based on size or number of lesions, using a combination of the BSG categories ‘high risk’
(five or more adenomas or three or more adenomas, at least one of which is of ≥ 10 mm in diameter)
and ‘intermediate risk’ (three or four small adenomas or at least one adenoma of ≥ 10 mm in diameter).90
Two studies56,75 reported additional accuracy data for various non-malignant and composite target
conditions.
No study reported data that were specific to the population that was defined in the scope for this
assessment (people presenting, in primary care settings, with lower abdominal symptoms, who are at low
risk for CRC according to the criteria defined in NG121). No studies were conducted in a primary care
setting; all three of the studies56,57,75 were conducted in outpatient clinics. One study56 stated that faecal
immunochemical testing was requested after referral for colonoscopy, and in the remaining two studies57,75
the timing of faecal immunochemical testing in relation to colonoscopy referral was unclear. One study,75
reported as a conference abstract, stated that only symptomatic patients were included, but did not report
details of presenting symptoms. The remaining two studies56,57 included patients who had been referred
for colonoscopy, and one study56 recorded presenting symptoms (reason for referral); both of the
studies56,57 that reported presenting symptoms included some participants who had symptoms that may be
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considered to be associated with a higher probability of CRC and that are components of the criteria for
2-week referral as defined in NG121 (e.g. rectal bleeding). Presenting symptoms included rectal bleeding/
haematochezia, abdominal pain, change in bowel habit, constipation or diarrhoea, anaemia and weight
loss. The median age of study participants was 67 years,75 63 years57 and 59 years,56 and the overall age
range was 16–93 years. There were no data linking presenting symptoms to age. One study57 reported
data on the effects of the sex of participants on the accuracy of HM-JACKarc for the detection of
advanced neoplasia. Full details of participant characteristics are provided in Appendix 2, Table 65.
All of the three studies56,57,75 reported data on the accuracy of HM-JACKarc FIT using a single faecal
sample. One study57 also compared the accuracy of single versus double sampling faecal immunochemical
testing for the detection of advanced neoplasia.
Two studies reported information about uptake rates in participants invited to provide a sample for faecal
immunochemical testing.56,75
Accuracy of HM-JACKarc for the detection of colorectal cancer
Two studies56,75 reported data on the accuracy of HM-JACKarc FIT using a single faecal sample and
thresholds of 10 µg Hb/g faeces56 and 7 µg Hb/g faeces.75 Full test performance results are provided in
Table 11. There was little variation in test performance between the 7- and 10 µg Hb/g faeces thresholds;
the sensitivity estimates were 91.3% and 100%, respectively, and the corresponding specificity estimates
were 76.6% and 79.2%.56,75 As with the OC-Sensor FIT assay, the optimal test performance (maximising
both sensitivity and specificity) appeared to occur with thresholds of 7 or 10 µg Hb/g faeces; none of
the HM-JACKarc studies reported test performance characteristics for any detectable Hb. Using test
performance data from the Godber et al. study56 – and a CRC prevalence estimate of 2.2% taken from
the same study – to consider the outcome of testing for a hypothetical cohort of 1000 patients indicates
that no CRCs would be missed using the 10 µg Hb/g faeces threshold, but 229 unnecessary colonoscopies
would be carried out (assuming that all of the patients with a positive FIT result receive colonoscopy and
that all colonoscopies conducted in patients without CRC are considered unnecessary). CRC would be
correctly ruled out in 750 people (Figure 8). Please see subsequent sections for information on other
significant bowel pathologies that may be detected by faecal immunochemical testing and hence may
form part of the FP or ‘unnecessary colonoscopy’ population.
Accuracy of HM-JACKarc for the detection of advanced neoplasia (colorectal cancer or
high-risk adenoma)
Two studies56,57 reported data on the accuracy of HM-JACKarc FIT using a single faecal sample, for which
the target condition was expanded to include CRC or HRA. Two studies56,57 assessed the diagnostic
performance of the 10 µg Hb/g faeces threshold for different definitions of this expanded target condition
(see Details of HM-JACKarc studies, above); these two studies56,57 reported very different estimates of
sensitivity (70% and 34.5%, respectively). In addition to the difference in the definition of HRA, the Auge
et al. study57 differed from Godber et al. study56 in that it included some patients who were undergoing
TABLE 11 Accuracy of HM-JACKarc for the detection of CRC using a single faecal sample
Study
Threshold
(µg Hb/g
faeces) TP FN FP TN
Total
n
2 × 2
data
Sensitivity %
(95% CI)
Specificity %
(95% CI)
aGodber
201656
≥ 10 11 0 116 380 507 Reported 100 (71.5 to 100)b 76.6 (72.6 to 80.3)b
aThomas
201675
≥ 7 21 2 89 338 450 Calculated 91.3 (72.0 to 98.9) 79.2 (75.3 to 83)
a Personal communication (e-mail from Ian Godber; Biochemistry Department, Monklands Hospital, NHS Lanarkshire,
to Marie Westwood, KSR Ltd, 8 June 2016).
b Calculated estimate.
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colonoscopy for polyp surveillance and excluded people with GI bleeding or active rectal bleeding; the
prevalence of CRC in the Auge et al. study57 was the lowest of any study included in this review (0.96%).57
Auge et al.57 reported test performance characteristics using a range of thresholds; sensitivity decreased
and specificity increased with increasing threshold, and the ‘any detectable Hb’ threshold was associated
with high sensitivity (96.6%) and very low specificity (10.6%). Full test performance results for all of
the thresholds that were evaluated in individual studies are provided in Table 12. The variation in test
performance characteristics according to the threshold used is illustrated in a ROC space plot (Figure 9).
1000
patients
251 + FIT
(> 10 µg Hb/g faeces)
CRC
(+ colonoscopy)
22
No CRC
(– colonoscopy)
Correct referrals
for colonoscopy
Incorrect referrals
for colonoscopy
229
749 – FIT
(< 10 µg Hb/g faeces)
CRC
(+ colonoscopy)
0
No CRC
(– colonoscopy)
CRC missed by FIT
Colonoscopy was
avoided correctly
749
FIGURE 8 Testing outcomes for a hypothetical cohort of 1000 patients using HM-JACKarc: the 10 µg Hb/g faeces
threshold, for the target condition of CRC.
TABLE 12 Accuracy of HM-JACKarc for the detection of advanced neoplasia (CRC or high-/higher-risk adenoma)
using a single faecal sample
Study
Threshold
(µg Hb/g
faeces) TP FN FP TN
Total
n
2 × 2
data
Sensitivity %
(95% CI)
Specificity %
(95% CI)
Any detectable Hb
Auge 201657 0a 28 1 160 19 208 Calculated 96.6 (82.8 to 93.4) 10.6 (6.9 to 15.9)
10 µg Hb/g faeces
Auge 201657 ≥ 10 10 19 23 156 208 Calculated 34.5 (19.9 to 52.7) 87.2 (81.6 to 91.3)
bGodber
201656
≥ 10 21 9 106 371 507 Reported 70.0 (50.6 to 85.3)c 77.8 (73.8 to 81.4)c
Other thresholds
Auge 201657 ≥ 20 9 20 13 166 208 Calculated 31 (17.3 to 49.2) 92.8 (88 to 95.7)
≥ 30 9 20 12 167 208 31 (17.3 to 49.2) 93.3 (88.7 to 96.1)
≥ 40 8 21 11 168 208 27.6 (14.7 to 45.7) 93.9 (89.4 to 96.6)
a The limit of detection for the assay is 0.6 µg Hb/g faeces or 0.6 ng/ml buffer.
b Ian Godber, personal communication.
c Calculated estimate.
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Based on the data from Godber et al.,56 expanding the target condition from CRC only to include CRC or
HRA resulted in an increase in prevalence from 2.2% to 5.9%. Using test performance data from this study –
and an estimate for the prevalence of advanced neoplasia of 5.9% – to consider the outcome of testing
for a hypothetical cohort of 1000 patients indicates that applying faecal immunochemical testing at the
10 µg Hb/g faeces threshold would result in 21 advanced neoplasias being missed. As data indicate that no
CRCs would be missed at this threshold (see previous section), it may be assumed that the missed cases
would all be higher-risk adenomas. Using the 10 µg Hb/g faeces threshold, 205 unnecessary colonoscopies
would be carried out (assuming that all patients with a positive FIT result receive colonoscopy and that all of
the colonoscopies that were conducted in patients without at least HRA are considered unnecessary); CRC
and higher-risk adenoma would be correctly ruled out in 727 people (Figure 10).
Data from Auge et al. study57 indicated that, in this population (CRC prevalence < 1%), high sensitivity
(good rule-out performance) could be achieved only by using the ‘any detectable Hb’ threshold; the
sensitivity at this threshold was 96.6%. This study57 also compared the performance of double sampling
with single sampling, and found that 100% sensitivity could be achieved by using the higher value from
two consecutive samples and the ‘any detectable Hb’ threshold. The use of two consecutive samples
increased sensitivity compared with single sampling, at all thresholds, but sensitivity remained low (< 50%)
throughout.57 Full results for single and double sampling at all of the thresholds that were evaluated are
provided in Table 13.
Auge et al.57 also reported lower sensitivity estimates, at all thresholds, when HM-JACKarc FIT was used, in
women than in men.57 Full results for test performance in men and women are provided in Table 14.
Accuracy of HM-JACKarc for the detection of other/composite target conditions
Two studies56,75 reported accuracy data for target conditions other than CRC or advanced neoplasia. Both
of the studies evaluated the performance of HM-JACKarc for the target condition ‘significant bowel
disease’; Thomas et al.75 defined significant bowel disease as CRC, HRA or IBD, and Godber et al.56 defined
significant bowel disease as CRC, higher-risk adenoma, IBD or colitis.
0.0
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0.6
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0.8
0.9
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10 µg Hb/g faeces
20 µg Hb/g faeces
30 µg Hb/g faeces
40 µg Hb/g faeces
FIGURE 9 Receiver operating characteristic space plot for the HM-JACKarc assay using different thresholds for the
target condition of advanced neoplasia (CRC or HRA).
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1000
patients
251 + FIT
(> 10 µg Hb/g faeces)
CRC or HRA
(+ colonoscopy)
46
No CRC
(– colonoscopy)
Correct referrals
for colonoscopy
Incorrect referrals
for colonoscopy
205
749 – FIT
(< 10 µg Hb/g faeces)
CRC
HRA
(+ colonoscopy)
0
22
No CRC
(– colonoscopy)
CRC or HRA missed by FIT
Colonoscopy was
avoided correctly
727
FIGURE 10 Testing outcomes for a hypothetical cohort of 1000 patients using HM-JACKarc: the 10 µg Hb/g faeces
threshold for the target condition of advanced neoplasia (CRC or HRA).
TABLE 13 Effects of multiple sampling on the accuracy of HM-JACKarc for the detection of advanced neoplasia
(CRC or HRA)
Study
Sampling
strategy
Threshold
(µg Hb/g
faeces) TP FN FP TN
Total
n
2 × 2
data
Sensitivity %
(95% CI)
Specificity %
(95% CI)
Auge
201657
First of two
consecutive
samples
0a 28 1 160 19 208 Calculated 96.6 (82.8 to 93.4) 10.6 (6.9 to 15.9)
Higher of two
consecutive
samples
0a 29 0 173 6 208 100 (88.3 to 100) 3.3 (1.5 to 7.1)
First of two
consecutive
samples
≥ 10 10 19 23 156 208 34.5 (19.9 to 52.7) 87.2 (81.6 to 91.3)
Higher of two
consecutive
samples
≥ 10 12 17 37 142 208 41.4 (25.5 to 59.3) 79.4 (73 to 84.7)
First of two
consecutive
samples
≥ 20 9 20 13 166 208 31 (17.3 to 49.2) 92.8 (88 to 95.7)
Higher of two
consecutive
samples
≥ 20 10 19 26 153 208 34.5 (19.9 to 52.7) 85.6 (83.5 to 92.9)
First of two
consecutive
samples
≥ 30 9 20 12 167 208 31 (17.3 to 49.2) 93.3 (88.7 to 96.1)
continued
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Thomas et al.75 reported sensitivity and specificity estimates of 72.1% and 80.6%, using a threshold of
7 µg Hb/g faeces, but did not provide sufficient information to extract 2 × 2 data,75 and Godber et al.56
reported similar sensitivity and specificity estimates of 68.9% and 80.2% for the 10 µg Hb/g faeces
threshold.56 Because the Godber et al. study56 assessed both this composite target condition and CRC
alone in the same patient cohort, we can see that the small increase in the specificity estimate, relative to
that reported for CRC, means that 26 of the 116 participants (22.4%) who were classified as having FP FIT
results for CRC actually had other significant bowel pathologies (HRA, IBD or colitis) and may thus have
benefited from secondary care investigation.
Godber et al.56 also reported test performance data using a range of thresholds from 10 to 40 µg Hb/g
faeces; there was little variation in the sensitivity and specificity of HM-JACKarc for ‘significant bowel
disease’ with increasing threshold.56 Full results for the accuracy of HM-JACKarc for detecting ‘significant
bowel disease’, at all thresholds investigated, are provided in Table 15.
TABLE 13 Effects of multiple sampling on the accuracy of HM-JACKarc for the detection of advanced neoplasia
(CRC or HRA) (continued )
Study
Sampling
strategy
Threshold
(µg Hb/g
faeces) TP FN FP TN
Total
n
2 × 2
data
Sensitivity %
(95% CI)
Specificity %
(95% CI)
Higher of two
consecutive
samples
≥ 30 10 19 25 154 208 34.5 (19.9 to 52.7) 86.1 (83.6 to 92.9)
First of two
consecutive
samples
≥ 40 8 21 11 168 208 27.6 (14.7 to 45.7) 93.9 (89.4 to 96.6)
Higher of two
consecutive
samples
≥ 40 10 19 21 158 208 34.5 (19.9 to 52.7) 88.3 (82.8 to 92.2)
a The limit of detection for the assay is 0.6 µg Hb/g faeces or 0.6 ng/ml buffer.
TABLE 14 Effects of participant sex on the accuracy of HM-JACKarc for the detection of advanced neoplasia
(CRC or HRA) using a single faecal sample
Study Subgroup
Threshold
(µg Hb/g
faeces) TP FN FP TN
Total
n
2 × 2
data
Sensitivity %
(95% CI)
Specificity %
(95% CI)
Auge
201657
Men 0a 17 0 69 6 92 Calculated 100 (81.6 to 100) 8 (3.7 to 16.4)
Women 0a 11 1 91 13 116 91.7 (64.6 to 98.5) 12.4 (7.4 to 20)
Men ≥ 10 8 9 10 65 92 47.1 (26.2 to 69) 86.7 (77.2 to 92.6)
Women ≥ 10 2 10 13 91 116 16.7 (4.7 to 44.8) 87.6 (79.8 to 92.6)
Men ≥ 20 7 10 6 69 92 41.2 (21.6 to 64) 92 (83.6 to 96.3)
Women ≥ 20 2 10 7 97 116 16.7 (4.7 to 44.8) 93.3 (86.8 to 96.7)
Men ≥ 30 7 10 6 69 92 41.2 (21.6 to 64) 92 (83.6 to 96.3)
Women ≥ 30 2 10 6 98 116 16.7 (4.7 to 44.8) 94.3 (88 to 97.3)
Men ≥ 40 7 10 6 69 92 41.2 (21.6 to 64) 92 (83.6 to 96.3)
Women ≥ 40 1 11 5 99 116 8.3 (1.5 to 35.4) 95.2 (89.3 to 97.9)
a The limit of detection for the assay is 0.6 µg Hb/g faeces or 0.6 ng/ml buffer.
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Acceptability of faecal immunochemical testing using HM-JACKarc
The proportion of people invited to participate in faecal immunochemical testing who return a faecal
sample can be regarded as a possible indicator of the acceptability of faecal immunochemical testing.
Two56,75 of the four HM-JACKarc studies reported FIT uptake rates. The proportion of samples returned
was higher (66%) in the study for which information and collection devices were provided at an outpatient
appointment75 than in the study that sent collection devices and information by post (56%).56 Full results
are provided in Table 16.
TABLE 15 Accuracy of HM-JACKarc for the detection of other/composite target conditions using a single
faecal sample
Study
Threshold
(µg Hb/g
faeces) TP FN FP TN
Total
n
2 × 2
data
Sensitivity %
(95% CI)
Specificity %
(95% CI)
Significant bowel disease (CRC or HRA or IBD)
Thomas
201675
≥ 7 µg Hb/g
faeces
NC NC NC NC 450 NA 72.1 (58.7 to 85.5) 80.6 (76.7 to 84.4)
Significant bowel disease (CRC or higher-risk adenoma or IBD or colitis)
Godber
201656
≥ 10 µg Hb/g
faeces
32 13 90 349 484 Calculated 68.9 (53.2 to 81.4) 80.2 (76.1 to 83.7)
≥ 20 µg Hb/g
faeces
29 16 63 376 484 64.4 (48.7 to 77.7) 85.7 (81.9 to 88.7)
≥ 15 µg Hb/g
faeces
31 14 77 362 484 66.7 (50.9 to 79.6) 83.1 (79.2 to 86.5)
≥ 25 µg Hb/g
faeces
29 16 55 384 484 64.4 (48.7 to 77.7) 87.5 (83.9 to 90.3)
≥ 30 µg Hb/g
faeces
29 16 50 389 484 64.4 (48.7 to 77.7) 88.6 (85.2 to 91.4)
≥ 35 µg Hb/g
faeces
29 16 47 392 484 64.4 (48.7 to 77.7) 89.2 (85.9 to 92)
≥ 40 µg Hb/g
faeces
29 16 44 395 484 64.4 (48.7 to 77.7) 90 (86.7 to 92.5)
NA, not applicable; NC, not calculable.
TABLE 16 Acceptability of faecal immunochemical testing using HM-JACKarc
Study
Point in the care pathway at which faecal immunochemical testing was
requested n
n
returned
Uptake
(%)
Thomas
201675
Faecal immunochemical testing was requested after the first secondary care
2-week wait clinic. Participants were given a pack that included a sample
collection device and pictorial instructions
773 514 66
Godber
201656
Patients were invited to participate after they had been referred for
colonoscopy. A letter of invitation to participate and a sample collection device
were sent with the materials sent for bowel cleansing prior to colonoscopy
909 507 56
n, number invited to participate in the study and supplied with a faecal sampling kit; n returned, number returning a faecal
sample for faecal immunochemical testing.
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Diagnostic performance of the FOB Gold faecal immunochemical test assay
Details of FOB Gold studies
Two diagnostic cohort studies provided data on the diagnostic performance of the FOB Gold FIT assay;
the Krivec et al. study54 was published as an conference abstract and provided only limited data,54 and the
other, Hospital Clinic de Barcelona 2015, was provided in confidence by the manufacturer (Philippa Pinn,
personal communication). Krivec et al.54 reported accuracy data for significant bowel disease (defined as
cancer polyps or bleeding) and Hospital Clinic de Barcelona 2015 (confidential information has been
removed). The prevalence of CRC was not reported in the Krivec et al. study54 (confidential information has
been removed).
No study clearly reported data that were specific to the population that was defined in the scope for this
assessment (people presenting, in primary care settings, with lower abdominal symptoms, who are at low risk
for CRC according to the criteria defined in NG121). Both study populations were reported as symptomatic
patients who had been referred for colonoscopy. Krivec et al.54 did not report any information about the age
of participants54 (confidential information has been removed). No details of presenting symptoms were
reported in either study. Full details of participant characteristics are provided in Appendix 2, Table 65.
Neither study reported information about uptake rates in participants who were invited to provide a
sample for faecal immunochemical testing, or any other outcome measure.
Accuracy of FOB Gold for the detection of colorectal cancer
(Confidential information has been removed.) Full test performance results for all thresholds evaluated are
provided in Table 17. (Confidential information has been removed), to consider the outcome of testing for
a hypothetical cohort of 1000 patients indicates that (confidential information has been removed). CRCs
would be missed and (confidential information has been removed) unnecessary colonoscopies would
be carried out (assuming that all patients with a positive FIT result receive colonoscopy and that all
colonoscopies conducted in patients without CRC are considered unnecessary); CRC would be correctly
ruled out by faecal immunochemical testing, avoiding colonoscopy, in (confidential information has been
removed) people (Figure 11).
Accuracy of FOB Gold for the detection of advanced neoplasia (colorectal cancer or
high-risk adenoma)
(Confidential information has been removed.) Full test performance results for all of the strategies
evaluated are provided in Table 18.
Accuracy of FOB Gold for the detection of other/composite target conditions
Both Krivec et al.54 and Hospital Clinic de Barcelona 2015 reported accuracy data for the composite target
condition ‘significant bowel disease’. Krivec et al.54 defined significant bowel disease as cancer, polyps or
bleeding, and reported a sensitivity of 45.2% and a specificity of 92.3%, using a threshold of 9 µg Hb/g
faeces.54 (Confidential information has been removed.) Full test performance results for both studies and
for all thresholds evaluated are provided in Table 19.
(Confidential information has been removed.) Full test performance results for all thresholds evaluated are
provided in Table 19.
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Diagnostic performance of the RIDASCREEN faecal immunochemical test assay
No studies were identified that assessed the diagnostic performance of RIDASCREEN Hb or RIDASCREEN
Hb/Hp complex in symptomatic patients.
Comparative diagnostic accuracy of different faecal immunochemical test assays
and guaiac faecal occult blood testing
No studies were identified that directly compared the performance of different FIT assays, or that
compared one or more FIT assays with a gFOBT method.
Selection of test strategies for inclusion in cost-effectiveness modelling
The selection of FIT accuracy data for use in cost-effectiveness modelling was based on the optimal
threshold (maximum sensitivity and specificity) for each assay method and the threshold required to proved
optimal rule-out performance (highest sensitivity and lowest number of cases missed). Because no studies
were identified which directly compared the performance of one or more FIT assays with a gFOBT method,
accuracy data for guaiac faecal occult blood testing used in the base case for cost-effectiveness modelling
were those used in the NG126 model. The primary study from which these data were taken, Gilbert et al.,91
was a retrospective study using a Swedish cancer registry, in which a diagnosis of CRC was classified as any
diagnosed CRC within 2 years of guaiac faecal occult blood testing; it was unclear whether or not all of the
patients who were included in the study had been symptomatic at the time of guaiac faecal occult blood
testing, and the prevalence of CRC, in the subgroup of study participants used to provide data for the
model was very low (0.36%). We therefore conducted scenario analyses using published estimates of
gFOBT accuracy obtained from studies that were identified during the process of inclusion screening for our
systematic review: Niv and Sperber92 and Bjerregaard et al.;93 although guaiac faecal occult blood testing
was not included in our systematic review, as an intervention, our searches included general terms for faecal
occult blood testing and guaiac faecal occult blood testing. Both of these studies92,93 were conducted in
symptomatic patients and the prevalence of CRC was 2.5% and 3.1%, respectively, making these studies
closer to the population defined for this assessment.
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Chapter 4 Assessment of cost-effectiveness
In this chapter we explore the cost-effectiveness of using quantitative faecal immunochemical tests for Hb(FIT) as a triage test for people presenting, in primary care settings, with lower abdominal symptoms who
are at low risk for CRC according to the criteria defined in NG12.1
Review of economic analyses of faecal immunochemical tests
Methods
Search strategy
Literature searches were performed to identify published economic evaluations and cost-effectiveness data.
Additional searches were conducted to identify adverse event/mortality data and utility studies for diagnostic
techniques and procedures for colorectal neoplasms that were not included within the scope of the clinical
effectiveness searches. All of the searches aimed to identify studies that could be used to support the
development of a health economic model to estimate the model input parameters and answer the research
questions of the assessment, but not to perform a systematic review. Searches were therefore pragmatic in
design and date limits were applied where appropriate.
Methodological study design filters were included in the search strategy where relevant. No restrictions on
language or publication status were applied. The main EMBASE strategy for each search was independently
peer reviewed by a second Information Specialist, using the CADTH Peer Review checklist.40 Identified
references were downloaded in EndNote X6 software for further assessment and handling. References in
retrieved articles were checked for additional studies.
Full search strategies are presented in Appendix 1.
Full cost-effectiveness studies were summarised and appraised using the Drummond checklist.94
Economic evaluations and cost studies
Economic evaluations and cost studies associated with colonoscopy, CTC, magnetic resonance imaging
and computed tomography (CT) scans were searched for on the following databases and resources, from
2005 to the most recent date available:
l MEDLINE (via Ovid): 2005 to March Week 4 2016
l MEDLINE In-Process & Other Non-Indexed Citations, and Daily Update (via Ovid): 2005 to 1 April 2016
l EMBASE (via Ovid): 2005 to 1 April 2016
l NHS EED (via the internet): 2005 to Issue 2 of 4, April 2015
l EconLit (via EBSCOhost): 2005 to 1 February 2016
l Cost-effectiveness Analysis Registry (via the internet): 2005 to April 2016: www.cearegistry.org/
l Research Papers in Economics (via the internet): 2005 to April 2016: http://repec.org/.
Adverse events and mortality data
Adverse events and mortality data that are associated with colonoscopy and CTC were searched for on the
following databases and resources, from database inception date to the most recent date available:
l MEDLINE (via Ovid): 1946 to March Week 4 2016
l MEDLINE In-Process & Other Non-Indexed Citations, and Daily Update (via Ovid): to 4 April 2016
l EMBASE (via Ovid): 1974 to 4 April 2016
l CENTRAL (via the internet): to Issue 3 of 12, March 2016.
DOI: 10.3310/hta21330 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 33
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Westwood et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
45
Utility data
Studies containing utility data that are associated with colonoscopy and CTC were searched for on the
following databases and resources, from database inception date to the most recent date available:
l MEDLINE (via Ovid): 1946 to March Week 4 2016
l MEDLINE In-Process & Other Non-Indexed Citations Daily Update (via Ovid): to 4 April 2016
l EMBASE (via Ovid): 1974 to 4 April 2016
l CENTRAL (via the internet): to Issue 3 of 12, March 2016
l NHS EED (via the internet): 2005 to Issue 2 of 4, April 2015
l School of Health and Related Research (ScHARR) Health Utilities Database (ScHARRHUD) (via the internet):
to 4 April 2016. www.scharrhud.org/.
Inclusion criteria and screening
Inclusion criteria as reported in Table 20 were applied. Relevant studies were identified in two stages.
Two researchers (ML and ICR) screened, independently, for possible inclusion, the titles and abstracts that
were returned by the search strategy. Disagreements were resolved by discussion. Full texts of the selected
studies were obtained. Two researchers (ML and ICR) examined these independently for inclusion or
exclusion, and disagreements were, again, resolved by discussion.
Results
The total number of potentially relevant economic papers that were initially retrieved by searches was 923.
In addition, 19 clinical guidelines relating to CRC were identified. Most of the economic studies that were
identified were excluded because they related to screening for CRC in asymptomatic populations. None of
the included studies directly assessed the decision problem of this diagnostic assessment.
The only included study was the one conducted to inform NG12.1,6 This study1,6 is reviewed in detail below.
Summary of the National Institute for Health and Care Excellence guideline 12
cost-effectiveness study
The aim of the NG12 study1,6 was to estimate the cost-effectiveness of five different investigations for
suspected CRC (FOBT, barium enema, flexible sigmoidoscopy, CTC or colonoscopy) ordered by primary
care practitioners for patients aged ≥ 40 years with a change in bowel habit as main symptom.6 The
characteristics of this study are summarised in Table 21. The base-case results indicated that both guaiac
faecal occult blood testing and barium enema were cost-effective compared with colonoscopy at a
threshold of £20,000 per quality-adjusted life-year (QALY) gained. However, an analysis that included all
of the comparators showed that barium enema would have been dominated by faecal immunochemical
testing [the incremental cost-effectiveness ratio (ICER) for faecal immunochemical testing vs. barium enema
being lower than barium enema vs. guaiac faecal occult blood testing] and that faecal immunochemical
testing would be cost-effective at a threshold of £20,000 per QALY gained.
TABLE 20 Inclusion criteria for cost-effectiveness studies
Type of studies Studies reporting cost-effectiveness/utility/benefit/minimisation analyses or economic evaluations
in general. No study design restrictions were applied. All of the studies were included, apart from
reviews, letters and comment articles
Type of participants Symptomatic people presenting in primary care settings in whom investigation for possible CRC
is being considered
Type of intervention FIT
Type of outcomes Costs or incremental costs and QALYs or other effectiveness units, such as LYs, reported together
with costs
LY, life-year; QALY, quality-adjusted life-year.
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Study quality
The results of the quality assessment of the NG12 study1,6 are presented in Table 22.
TABLE 22 Quality assessment of studies, using the Drummond checklist
Criteria NG12,1,6 2015
Study design
1. Was the research question stated? Yes
2. Was the economic importance of the research question stated? Yes
3. Was/were the viewpoint(s) of the analysis clearly stated and justified? Yes
4. Was a rationale reported for the choice of the alternative programmes or
interventions compared?
Yes
5. Were the alternatives being compared clearly described? No. It is not mentioned which individual
tests are considered to model faecal occult
blood testing and faecal immunochemical
testing. The other investigations
considered in the analysis (i.e. barium
enema, flexible sigmoidoscopy, CTC and
colonoscopy) are not described in detail in
the economic evaluation section, but
discussed throughout the clinical guideline
6. Was the form of economic evaluation stated? Yes
7. Was the choice of form of economic evaluation justified in relation to the
questions addressed?
Yes
Data collection
8. Was/were the source(s) of effectiveness estimates used stated? Yes
9. Were details of the design and results of the effectiveness study given
(if based on a single study)?
No. For some investigations considered
(e.g. accuracy of colonoscopy or CTC),
only the reference to a paper is given
10. Were details of the methods of synthesis or meta-analysis of estimates
given (if based on an overview of a number of effectiveness studies)?
NA
11. Was/were the primary outcome measure(s) for the economic evaluation
clearly stated?
Yes
12. Were the methods used to value health states and other benefits stated? Yes
13. Were the details of the subjects, from whom valuations were obtained,
given?
NA; utilities from literature
14. Were productivity changes (if included) reported separately? NA
15. Was the relevance of productivity changes to the study question
discussed?
NA
16. Were quantities of resources reported separately from their unit cost? No
17. Were the methods for the estimation of quantities and unit costs
described?
No
18. Were currency and price data recorded? Yes
19. Were details of price adjustments for inflation or currency conversion
given?
No. The only reference to price inflation is
the following sentence: ‘Data on lifetime
costs were taken from Tappenden et al.
2004 and inflated to 2014 prices’
20. Were details of any model used given? Yes
21. Was there a justification for the choice of model used and the key
parameters on which it was based?
Yes
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Study design
The economic evaluation presented in NG126 was a modelling study to assess the cost-effectiveness of
different investigations for CRC. The research question and the approach to economic evaluation were
stated clearly. Results were presented as costs per QALY gained. In the base-case analysis, the investigations
considered were faecal occult blood testing, barium enema and colonoscopy. In additional scenarios, flexible
sigmoidoscopy, CTC, faecal immunochemical testing and safety netting were incorporated to the analysis.
Results were presented in the form of full incremental analysis (i.e. all investigations compared at the same
time) and not in terms of pairwise comparisons of intervention against comparator. When faecal occult
blood testing and faecal immunochemical testing were considered, it was not mentioned which individual
assays are used to determine the input parameters of the model.
Data
When possible, the data that were used to inform the model input parameters were based on the
systematic literature review conducted in the clinical guideline. Otherwise, there was reliance on expert
opinion. A summary of the data sources for the different groups of input parameters is given below.
Prevalence of colorectal cancer
No evidence was found to inform the prevalence of CRC in the study population. Thus, the PPV of various
symptoms associated with CRC was used to inform this. The systematic review identified 22 studies as
relevant, but the evidence could not be pooled due to large heterogeneity. Therefore, the prevalence of
CRC was estimated based on the opinion of the guideline development group (GDG).
TABLE 22 Quality assessment of studies, using the Drummond checklist (continued )
Criteria NG12,1,6 2015
Analysis and interpretation of results
22. Was the time horizon of cost and benefits stated? Yes
23. Was the discount rate stated? Yes
24. Was the choice of rate justified? Yes
25. Was an explanation given if cost or benefits were not discounted? NA
26. Was/were the details of statistical test(s) and CIs given for stochastic
data?
Not explicitly but CIs and/or standard
errors reported (including reference)
27. Was the approach to sensitivity analysis described? Yes
28. Was the choice of variables for sensitivity analysis justified? Not explicitly but references reported
29. Were the ranges over which the parameters were varied stated? Yes
30. Were relevant alternatives compared? (That is, were appropriate
comparisons made when conducting the incremental analysis?)
Yes
31. Was an incremental analysis reported? Yes
32. Were major outcomes presented in a disaggregated form as well as
aggregated form?
No, only aggregated
33. Was the answer to the study question given? Yes
34. Did conclusions follow from the data reported? Yes
35. Were conclusions accompanied by the appropriate caveats? Yes
36. Were generalisability issues addressed? No
NA, not applicable.
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Natural history of disease
The initial distributions of cancer stages at diagnosis and disease-specific mortality were estimated using
data from the National Cancer Intelligence Network (NCIN).97 Age-related mortality probabilities were
calculated using data from published interim life tables for the UK ONS 2013.98 The study from Tappenden
et al.99 reports data on progression between cancer stages for people with undiagnosed CRC. As the GDG
considered that obtaining progression probabilities in patients with CRC would be unlikely, the probabilities
in Tappenden et al.99 were used in the model.
Diagnostic accuracy
Diagnostic accuracy was modelled using data on sensitivity and specificity from the systematic review. Six
papers were identified as relevant for faecal occult blood testing and three for barium enema. However, the
sensitivity and specificity reported in those papers could not be pooled because of the large heterogeneity
between the studies. Therefore, based on the GDG advice, the paper by Gillberg et al.91 was used for the
diagnostic accuracy of faecal occult blood testing, and the paper by Jensen et al.100 was chosen for barium
enema. For the remaining interventions that were considered in the decision problem, no relevant evidence
was identified. Data for these investigations were then collected by removing the ‘primary care’ filter from
the search. The following papers were considered to inform the accuracy of the remaining investigations:
Oono et al.101 for faecal immunochemical testing, Thompson et al.102 for flexible sigmoidoscopy, Pickhardt
et al.103 (only sensitivity) and Halligan et al.104 for CTC, and Pickhardt et al.103 for colonoscopy.
Adverse events
It was assumed that only colonoscopy and flexible sigmoidoscopy would require treatment for adverse
events. Data on adverse events that were associated with colonoscopy were obtained from the UK
colonoscopy audit from Gavin et al.105 As no data were found to inform the probability of adverse events for
flexible sigmoidoscopy, this was assumed to be the same as for colonoscopy, based on clinical expert opinion.
Costs
Price of tests and consultations were informed based on NHS Reference Costs 2012–13106 and the Personal
and Social Services Research Unit (PSSRU) 2013.107 Costs on adverse events were also taken from NHS
Reference Costs 2012–13.106 The prices used for faecal occult blood testing and faecal immunochemical
testing were estimated from the screening programme’s Southern Hub 2011.108 Lifetime costs for patients
with CRC were taken from the Tappenden et al. study99 and inflated to 2014 prices.
Utilities
The utilities that are associated with the different stages of cancer that were used in the model were
obtained from Ness et al.,95 although this paper assessed quality-of-life values in the USA using the
standard gamble technique and its results were not valued in the UK. For healthy patients, utilities were
taken from the Kind et al. study96 [a large UK-based study on population health using the EuroQol-5
Dimensions (EQ-5D) survey]. No adjustment was made for age.
Analysis and interpretation of results
The study was generally well conducted, although details of which specific assays were considered to
model faecal occult blood testing and faecal immunochemical testing were not reported, and the
generalisability of findings was not discussed. In addition, faecal immunochemical testing was considered
only in an additional analysis and not in the base case. The results showed that faecal immunochemical
testing was cost-effective compared with colonoscopy, and, when all of the investigations were included,
it remained cost-effective at a threshold of £20,000 per QALY. Given its recent date and UK setting, any
parameter estimates included in this study were considered to be relevant for this assessment (see Model
structure and methodology, below).
Other cost-effectiveness studies
The cost-effectiveness analysis in NG126 was largely based on the study by Allen et al.109 However, this
paper does not meet our inclusion criteria because faecal occult blood tests (FOBTs) were not considered in
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the analysis (the study109 investigated people with visible rectal bleeding and thus FOBTs were not
relevant to this population). The cost-effectiveness of four diagnostic strategies (watchful waiting, flexible
sigmoidoscopy, flexible sigmoidoscopy followed by air contrast barium enema, and colonoscopy) for
patients with rectal bleeding was evaluated in this modelling study. The study was performed from a
US-modified societal perspective. The authors concluded that colonoscopy was cost-effective compared
with flexible sigmoidoscopy, with an ICER of US$5480 per QALY. Watchful waiting, defined as bleeding
for 1 year followed by colonoscopy, was the most expensive strategy.
A second study, by Rae and Cleator,110 was identified, which assessed the cost-effectiveness of the
Hemoccult assay, the HO Sensa assay, the HemeSelect assay and a two-tier test combing HO Sensa and
HemeSelect. Only HemeSelect is a FIT assay; this is a qualitative method and, therefore, does not meet our
inclusion criteria. This study110 was observational and its results showed that the costs per cancer detected
were significantly lower for the two-tier test. Results were also presented for subgroups of asymptomatic
and symptomatic patients. Symptomatic patients were defined as those who have:
l a personal history of ulcerative colitis, Crohn’s disease or other IBDs, CRC, adenomas or polyps, or
l a family history of CRC or polyps, or
l one or more of the following symptoms: haemorrhoids, anal fissures, upper GI disease, diverticular
disease, miscellaneous lower GI disease, or non-specific symptoms such as diarrhoea, nausea, bloating,
fatigue, incontinence, visible blood in the faeces, melaena, weight loss, abdominal pain, anaemia,
rectal pain, change in faeces calibre or change in bowel habits. This definition does not match the
population specified for this assessment. The inclusion of people with a history or family history of
cancer and the use of a qualitative FIT method mean that the study by Rae and Cleator110 was
considered to be of limited value for the current decision problem.
Although the studies by Allen et al.109 and Rae and Cleator110 did not meet our inclusion criteria, their
characteristics are summarised in Appendix 5.
Model structure and methodology
A de novo health economic model was developed to explore the cost-effectiveness of using a quantitative FIT
for Hb (occult blood) as a triage step in the investigation of symptomatic people presenting in the primary
care who are at low risk of CRC, as defined in NG12.1 The cost-effectiveness of faecal immunochemical
testing was compared with both gFOBTs and no triage (referral straight to colonoscopy). The model consists
of three parts: (1) a decision model reflecting the diagnosis of CRC; (2) a Markov state-transition model to
estimate the long-term costs and effects [life-years (LYs) and QALYs] that are associated with the treatment
and progression of CRC; and (3) a Markov state-transition model to estimate the LYs and QALYs that are
associated with those who do not have CRC. Note that this second Markov model was not used to estimate
costs because any differences in costs between the tests in those without CRC are assumed to occur only in
the first year. The structure of the economic model used in this diagnostic assessment is similar to that
used in NG12.6 However, for some of the input parameters of our model, we could not find clear data from
the literature. Thus, expert opinion was of key importance to the success of the model implementation.
Therefore, we sent a questionnaire to 10 specialists; five of whom returned it, although not all questions
were completely answered. The full questionnaire is included in Appendix 6 (example questions included the
percentage of patients who would eventually remain symptomatic after a positive FIT/gFOBT result and the
plausible range for this percentage). The model used in the economic analyses of this diagnostic assessment
is described, in detail, below.
Diagnostic model structure
The model begins with a cohort of symptomatic patients, presenting in primary care in whom referral to
secondary care for investigation of possible CRC is being considered. A patient in the cohort is offered one
of the following choices: faecal immunochemical testing, guaiac faecal occult blood testing or no triage
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testing at all (referral straight to colonoscopy). A positive FIT or gFOBT results in referral to colonoscopy,
whereas a negative test results in a watchful waiting strategy, in which a repeated test or further
investigation can be performed when symptoms persist. Patients who had a FN gFOBT or FIT, and whose
symptoms persisted, were assumed to receive a colonoscopy and thus be diagnosed within 1 year should
they survive. Given the delay in diagnosis, it was also assumed that they would have an increased
probability of progressing to a worse cancer state (i.e. these patients enter the CRC Markov model in a
worse health state). This logically implies that no patients whose symptoms do not persist will have CRC,
that is, all FIT-/gFOBT-negative patients who become asymptomatic do not have the target condition.
These patients plus those found not to have CRC by colonoscopy were further modelled with a simple
alive or dead Markov model, as described below (see Healthy population Markov model). Colonoscopy is
considered to be the gold standard investigation for the diagnosis of CRC owing to its ability to visualise
the entire colon and allow biopsies to be performed.6 CTC is an alternative investigation of choice for
people who are unfit for colonoscopy, but does not include biopsy.6 For patients who test positive for CRC
after colonoscopy or CTC, it was assumed that contrast-enhanced CT of the chest, abdomen and pelvis
was performed, to determine the stage of disease. A time frame of 1 year was assumed for the diagnostic
model. A schematic representation of the decision-analytic model is provided in Figure 12.
Colorectal cancer Markov model structure
The disease natural history used in the model was consistent with the existing UK-based screening
economic models and divided the disease states by Dukes’ grading (i.e. stage A – tumour confined to the
mucosa; stage B – tumour infiltrating through muscle; stage C – lymph node metastases present; and
stage D – distant metastases).111 The structure of the Markov model was similar to the one used in NG12,6
where cancer stages were defined based on the Dukes’ grading system for CRC and then mapped into the
health states of the Markov model. The initial distribution of patients with CRC through the model’s health
states was determined by the probability of being in a certain Dukes’ stage. After the initial distribution of
patients in the CRC model was determined, it was assumed that patients may stay in their current health
state, progress to the health state representing the next worst stage of the condition or die (from CRC or
another cause). A schematic representation of the CRC model is provided in Figure 13. A lifetime horizon
with a 1-year cycle length captures the probability of progression for treated and untreated patients.
Healthy population Markov model
Colonoscopy is the reference standard used to determine the accuracy of quantitative FIT assays and
guaiac faecal occult blood testing, for which CRC is the target condition. Thus, it was assumed that
patients with a negative colonoscopy result do not have the target condition. It was also assumed that
patients with the target condition will remain symptomatic; it therefore follows that all patients with
a FN FIT or gFOBT result will remain symptomatic. All patients with a negative test result who become
asymptomatic were assumed not to have the target condition.
Patients who do not have the target condition were further modelled with a simple alive or dead Markov
model, as depicted in Figure 14. Survival estimates for this model were based on UK life tables.98 Hence,
patients entering this model can either die of any cause (including CRC, as a negative test result or a
negative colonoscopy does not imply that these patients will never develop CRC) or stay in the alive health
state. LYs and QALYs are accounted, but costs were not calculated in this model. This approach essentially
implies two main assumptions for the difference in outcomes between intervention and comparator for
those without CRC:
1. for life expectancy, this is caused only by a difference in mortality due to colonoscopy/CTC
2. for cost, this is due only to the difference in cost of guaiac faecal occult blood testing and colonoscopy/CTC.
This approach assumes that testing has no long-term (after 1 year) effect on costs or QALYs in disease-
negative people and is consistent with our approach taken in previous NICE diagnostic assessments.112 We
have assumed that, in patients without CRC, faecal occult blood testing would not significantly delay
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diagnosis of the underlying cause of presenting symptoms and hence would not incur any extra cost or
effect on mortality.
Model parameters
This section describes the input parameters used in the diagnostic model and in the Markov models and
how their values were estimated for the base case.
Diagnostic model
Probabilities for faecal immunochemical testing and guaiac faecal occult blood testing
diagnostic accuracy
Diagnostic accuracy was captured in the model using data on sensitivity and specificity that were obtained
from our systematic review. For the base-case scenario, we considered a threshold of 10 µg Hb/g faeces or
equivalent for the detection of CRC using a single faecal sample. This choice was based on the optimal
threshold (maximum sensitivity and specificity) for each assay method and the threshold required to prove
optimal rule-out performance (highest sensitivity and lowest number of cases missed), as explained in
Chapter 3 (see Selection of test strategies for inclusion in cost-effectiveness modelling). For this threshold and
target condition, our systematic review obtained data only for OC-Sensor and HM-JACKarc. Therefore, the
FOB Gold assay was not included in the base-case analysis. Pooled estimates for OC-Sensor (see Table 6)
were obtained from the studies by McDonald et al.,13 Mowat et al.,52 Rodríguez-Alonso et al.53 and Terhaar
sive Droste et al.58 Sensitivity and specificity for HM-JACKarc were obtained from Godber et al.56 and are
presented in Table 11. Finally, for guaiac faecal occult blood testing in the base-case scenario, we considered
the sensitivity and specificity estimates used in NG12.6 These estimates were reported by Gillberg et al.91
This study91 reports that the sensitivity of guaiac faecal occult blood testing is 75% and the specificity is
87%. However, in the NG12 economic model,6 reported gFOBT sensitivity is 50% and the specificity is 88%.
These figures were sourced from a subgroup of patients aged 41–50 years, because it was thought to better
reflect the population considered in the NG12 economic model6 (i.e. patients aged ≥ 40 years with a change
in bowel habit as main symptom). Nevertheless, our systematic review identified two papers92,93 reporting
data on gFOBT accuracy, which are thought to represent a better match for the population specified for this
diagnostic assessment. Therefore, additional scenarios, for which gFOBT accuracy data were based on these
two studies,92,93 were explored.
For the probabilistic sensitivity analysis (PSA), we assumed beta distributions for sensitivity and specificity.
The parameters of the beta distributions used in the base-case scenario are summarised in Table 23.
Technical details about the estimation of the parameters of the different probability distributions are given in
Appendix 10. Several scenarios based on different assumptions for the accuracy of faecal immunochemical
testing/guaiac faecal occult blood testing were explored. These are described below (see Scenario analyses).
Dukes’ A Dukes’ B Dukes’ C Dukes’ D Death
FIGURE 13 Colorectal cancer Markov model.
Alive Death
FIGURE 14 Healthy population Markov model.
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Our model also requires the calculation of the probability of having the condition or not, contingent on
the test performance. When the disease prevalence is known, sensitivity and specificity can be used to
calculate the PPVs and negative predictive values (NPVs) using the formulae below:
PPV =
sensitivity × prevalence
(sensitivity × prevalence) + ½(1− specificity) × (1− prevalence) (1)
and
NPV =
specificity × (1−prevalence)
½(1−sensitivity) × prevalence) + (specificity × (1− prevalence) . (2)
The prevalence of CRC in the base-case population was assumed to be 1.5%, the same as in NG12.6 For
the PSA, we assumed a triangular distribution of between 1% and 2%. The results of our systematic review
showed that, for a threshold 10 µg Hb/g faeces or equivalent, and CRC as target condition, prevalence
ranges between 2.1% and 5.4%. Therefore, the impact of this assumption on the cost-effectiveness results
was explored with additional scenario analyses, for which the most likely value for the prevalence was
assumed to be 3% and 5.4%, and with an additional scenario for which we used a triangular distribution
with, most likely, a value of 1.5% and limits of 1% and 5.4% in the PSA.
Assuming that the prevalence of CRC in the base-case population is 1.5%, PPV and NPV estimates were
calculated. Whereas the PPV was directly used as a node probability in the model (the probability labelled
‘C’ in Figure 12), the NPV was included in the model in the calculation of the probability that CRC is
present for symptomatic patients after a negative FIT/gFOBT (the probability labelled ‘G’ in Figure 12).
Details for probability (‘G’) are given below. PPV and NPV estimates for the base-case scenario are
summarised in Table 24.
TABLE 23 Sensitivity and specificity for OC-Sensor, HM-JACKarc and gFOBT, base case
Accuracy measure OC-Sensor HM-JACKarc gFOBT
Sensitivity (95% CI) 92.1% (86.9% to 95.3%) 100% (71.5% to 100%) 50% (15.0% to 85.0%)
Probability distribution
(parameters)
Beta (155.90, 13.45) Betaa (1.16, 0.23) Beta (2, 2)
Specificity (95% CI) 85.8% (78.3% to 91.0%) 76.6% (72.6% to 80.3%) 88% (85.0% to 89.0%)
Probability distribution
(parameters)
Beta (100.80, 16.65) Beta (380, 116) Beta (962, 137)
a As FN = 0 in this case, sampling from a beta distribution with FN as a parameter will not work. A numerical approach
was used to estimate the parameters shown here. The highest value of the mean for which the numerical approach
converged was 0.98. Therefore, this value was chosen as the mean value for the PSA. The 95% CI (71.5% to 100%)
was reproduced exactly. The median was 100%.
TABLE 24 The PPV and NPV for OC-Sensor, HM-JACKarc and gFOBT, base case
Accuracy measure OC-Sensor (%) HM-JACKarc (%) gFOBT (%)
PPV 8.9 6.1 5.7
NPV 99.8 100 99.1
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Probability of remaining symptomatic after a negative test result
The model assumes that only those patients with a negative test result, and whose symptoms do not
persist, do not receive a colonoscopy/CTC. Therefore, it is for this group of patients that most of the
savings in costs are expected, when the test strategies are compared with no triage (referral straight to
colonoscopy). We did not identify any data, from the literature, on the proportion of patients with a
negative faecal occult blood test result in whom symptoms will persist and who will eventually receive
a colonoscopy/CTC. This information was therefore derived from clinical expert opinion, using the
questionnaire described previously. In the questionnaire, we asked what percentage of patients who test
negative with faecal immunochemical testing/guaiac faecal occult blood testing would persist in their
symptoms and eventually undergo colonoscopy, and the plausible range for this percentage. In addition,
we asked for the percentage of patients who would receive a second FIT/gFOBT. The responses to these
two questions are presented in Table 25. It is essential to note that a second FIT/gFOBT is not considered
to be a replacement for a colonoscopy, given that only the latter is diagnostic. Ideally, we would have
liked to estimate the percentage of patients who get a colonoscopy that is contingent on the result of the
second FIT/gFOBT, but the data on accuracy of repeat test were unavailable and it was believed that
accuracy could not be adequately estimated by clinical experts. Therefore, in our model, having a second
FIT/gFOBT increases the costs of only 20% (see Table 25) of the patients who, after testing negative, will
remain symptomatic. The impact of this assumption on the cost-effectiveness results was explored in an
additional scenario.
We assumed that the percentages of test-negative patients who undergo colonoscopy and the percentages
who get a repeat FIT/gFOBT follow a triangular distribution, with the point estimate given by the experts
representing the mode of the distribution. After simulating from these triangular distributions, we were able
to estimate the pooled means and standard deviations (SDs) of the aforementioned probabilities, which are
further assumed to have beta distributions. For the probability of undergoing colonoscopy after a negative
result we found a mean of 32.5% and a SD of 7.3%, whereas for the mean probability and SD of getting a
second FOB test were 20% and 3.2%, respectively.
Probability that colorectal cancer is present for symptomatic patients after a negative
faecal immunochemical test/guaiac faecal occult blood test
This is the probability labelled ‘G’ in Figure 12. This probability can be calculated as ‘(1 – NPV)’, divided by
the probability of remaining symptomatic after a negative test result (the latter probability was estimated
by clinical experts as explained above); details of calculations are provided in Appendix 7. Defining ‘G’
as a quotient and having the probability of remaining symptomatic after a negative test result in the
denominator, which is assumed to follow a beta distribution, may cause numerical problems when
performing a PSA (numerical division by 0). Therefore, for the PSA, we assumed that the probability of
TABLE 25 Percentage of test negative patients who remain symptomatic (and undergo colonoscopy) or get a
second test, per expert
Expert
% of patients who
remain symptomatic
(undergo colonoscopy)
Lowest
(%)
Highest
(%)
% of patients who get
second FIT/gFOBT
Lowest
(%)
Highest
(%)
1 55 30 80 30 20 40
2 10 5 15 10 5 15
Mode (pooled
average)
32.5% – – 20 – –
SD 7.3 – – 3.2 – –
Parameters beta
distribution
α = 13.05; β = 27.11 – – α = 31.05; β = 124.20 – –
SD, standard deviation.
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remaining symptomatic after a negative test result was fixed to its mean value (0.325). The estimated
probability ‘G’ for the base-case scenario is summarised in Table 26.
Table 27 shows a summary of the probabilities used at the decision nodes in the diagnostic model.
These were labelled as ‘A’ to ‘J’ in Figure 12. Full derivations of the equations are provided in Appendix 7.
TABLE 26 Probability that CRC is present for symptomatic patients after negative FIT/gFOBT for OC-Sensor,
HM-JACKarc and gFOBT, base case
Accuracy measure OC-Sensor HM-JACKarc gFOBT
Probability (%) that CRC present for symptomatic patients after negative
FIT/gFOBT
0.4 0 2.65
TABLE 27 Probabilities at decision nodes in the diagnostic model
Label Definition Formula Base-case value (%)
A Probability that FIT/gFOBT is positive (sensitivity × prevalence) +
[(1 – specificity) × (1 – prevalence)]
OC-Sensor = 15.35
HM-JACKarc = 24.53
gFOBT = 13.02
B Probability that FIT/gFOBT is negative 1 – (A) OC-Sensor = 84.65
HM-JACKarc = 75.47
gFOBT = 86.98
C Probability that CRC is present after a positive
FIT/gFOBT
PPV OC-Sensor = 8.99
HM-JACKarc = 6.11
gFOBT = 5.75
D Probability that CRC is not present after a positive
FIT/gFOBT
1 – PPV OC-Sensor = 91.01
HM-JACKarc = 93.89
gFOBT = 94.25
E Probability that symptoms persist after a negative
FIT/gFOBT
NA – based on expert opinion 32.50
F Probability that symptoms do not persist after a
negative FIT/gFOBT
1 – (E) 67.50
G Probability that CRC is present for symptomatic
patients after a negative FIT/gFOBT
(1 – NPV)/(E) OC-Sensor = 0.43
HM-JACKarc = 0
gFOBT = 2.65
H Probability that CRC is not present for
symptomatic patients after a negative test
1 – (G) OC-Sensor = 99.57
HM-JACKarc = 100
gFOBT = 97.35
I Probability that CRC is present Prevalence 1.5
J Probability that CRC is not present 1 – (I) 98.5
NA, not applicable.
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Probability of being referred to colonoscopy or CTC after a positive test result:
If the gFOBT or FIT result is positive, patients are referred to either colonoscopy or CTC. To estimate the
percentage of patients who are referred to each of these options in the UK, we also relied on expert
opinion. The responses to this question are presented in Table 28.
We adopted the approach described above for estimating the probability of remaining symptomatic after
having a negative test result. In this case, for the probability of being referred to colonoscopy versus CTC
after a positive test result we calculated a mean of 88.3% and a SD of 1.49%. The impact of this
assumption was explored in an additional scenario.
Probability of adverse events associated with colonoscopy
Our diagnostic model considers the probability of experiencing adverse events that are associated with
colonoscopy. The economic model presented in the NG126 was used as a starting point for selecting the
adverse events to be included. The economic model in NG126 includes two adverse events that are related
to colonoscopy: bowel perforation and bleeding. Probability data for these adverse events were obtained
from Gavin et al.105 This study was a 2-week audit, performed in the UK, which provided data on
colonoscopy completion rates and associated adverse events.
A literature search was performed to assess whether or not the adverse events and associated probabilities
used in NG126 were complete and still appropriate for the current decision problem. Our search identified
five potentially relevant studies.113–117 These were four reviews113–116 and one population-based study.117 Two
of the reviews, by Manta et al.115 and Church,116 were overviews that did not include a systematic approach
to searching literature; neither did these reviews include further analysis. The two other reviews, by
Reumkens et al.113 and Day et al.,114 were systematic literature reviews and both included a meta-analysis.
The review by Day et al.114 studied adverse events in elderly patients who were undergoing colonoscopy.
Elderly patients were defined as those who were ≥ 65 years of age. Therefore, this study114 was of limited
relevance to the population that was specified for this assessment. The review by Reumkens et al.113 studied
post-colonoscopy complications in population-based studies. It is a very recent systematic review; it provides
estimates of adverse events rates, including CIs, and is not limited to a specific patient population. The
estimates provided for bowel perforation and bleeding are very similar to those in Gavin et al.,105 which
were the ones used in the cost-effectiveness analysis performed in NG12.6 The studies by Gavin et al.105 and
Saraste et al.18 were population-based studies. These were deemed to be of less relevance, as systematic
literature reviews are preferred over single studies. Therefore, the study by Reumkens et al.113 was deemed
to be the most appropriate study to populate the probability of adverse events due to colonoscopy in the
diagnostic model. The adverse events included in the model are bowel bleeding, perforation and death.
TABLE 28 Percentage of test positive patients who are referred to colonoscopy vs. CTC, per expert
Expert % of patients referred to colonoscopy Lowest Highest
1 75 NR NR
2 95 90 100
3 93 NR NR
4 90 85 95
Mean (pooled) 88.3 – –
SD 1.49 – –
Parameters beta distribution α= 417.40; β = 55.81 – –
NR, not reported.
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The corresponding probabilities and the parameters of a beta distribution used for the PSA are presented in
Table 29.
The probabilities of experiencing adverse events due to CTC are scarce in the literature. The study of
Burling et al.118 found that the proportion of patients with symptomatic perforation that was attributable
to CTC was 0.03% but none of these was classified as a serious adverse event. The same article states that
perforation rates for colonoscopy are four times higher than for CTC. No death events were reported and
the proportion of patients experiencing bleeding after examination was not described in this study. Owing
to the uncertainty around these parameters and in order to keep the model simpler, we assumed that, in
the base-case scenario, adverse event rates due to CTC were the same as those of colonoscopy. Give that
this assumption will result in an overestimation, it can be interpreted as a worst-case scenario regarding
the total number of adverse events. In addition, as, on average, only 11.7% of the patients receive CTC
(as opposed to colonoscopy) the impact of this assumption is expected to be very small. We explored the
impact of this assumption on the cost-effectiveness results by performing additional scenario analyses.
Costs
Direct costs included in the model are test costs, costs of colonoscopy/CTC, adverse event costs and CT
costs. Indirect costs parameters were not included in the model, given the perspective of the NHS.
Test costs
Faecal immunochemical testing and guaiac faecal occult blood testing cost estimates reported in the
literature vary quite significantly, and the assumptions made to derive those estimates are not clear in
the majority of cases. Therefore, in this section we present the cost estimates used in this diagnostic
assessment and the underlying assumptions leading to them. At the end of this section, several test costs
from different sources are compared (see Table 33).
Faecal immunochemical test To estimate the total costs of a FIT, we assumed that these include the
following subcategories: costs of the collection device, acquisition costs of the analyser, cost of materials
to analyse the collected sample (i.e. reagents, buffer, reaction cells, bottles) and costs of maintenance of
the analyser. The manufacturers were the only source of unit costs. Training costs and the costs of the
laboratory staff for analysing the test results were not included in the total costs because it was assumed
that these costs are the same for faecal immunochemical testing and guaiac faecal occult blood testing,
and, therefore, these costs have no impact on the incremental cost-effectiveness results when these two
alternatives are compared.
Costs of the collection device For both the FIT and gFOBT, a faecal sample from the patient is required.
The patient has to collect the sample at home. The collection device is an instrument, designed for patient
use, to collect the sample in a hygienic and easy way. Generally, the device consists of a vessel that
contains a buffer and a probe to collect the faecal sample.119
Acquisition costs of analyser Resource use data are needed to estimate the acquisition costs of the FIT
analysers. The report from the Association of Coloproctologists of Great Britain and Ireland 2015120
suggests that, for a population of 500,000, up to 6000 colonoscopies and 4000 flexible sigmoidoscopies
TABLE 29 Probability of experiencing adverse events due to colonoscopy
Adverse event Rate % (95% CI) Beta distribution parameters Source
Bleeding 0.26 (0.17 to 0.37) α = 25.82; β = 9887.90 Reumkens 2016113
Perforation 0.05 (0.04 to 0.07) α = 49.52; β = 91,719.86
Death 0.0029 (0.0011 to 0.0055) α = 6.40; β = 222,513
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will be needed annually if international comparisons and trends are followed. These figures were also
validated by expert opinion. Therefore, it was assumed that 10,000 colonoscopies would be required to
deal with referrals from primary care per 500,000 people. Assuming that there is one laboratory per
500,000 people and that 10,000 requests for faecal immunochemical testing are made each year (at 253
‘working days’ per annum) would imply that approximately 40 requests would be received each day. Thus,
only one analytical system would be needed, which would be run for only a short period of time. In order
to have the minimal turnaround time that is a prerequisite for such a service, the analyser would need to
be run each day. For the acquisition costs of the analyser, we considered the prices provided by the
manufacturers (list pricing based on the capital purchase of an instrument). As the time frame for the
diagnostic part of the health economic model is 1 year, the total cost of the analyser was used. A summary
of the estimated resource is presented in Table 30.
Costs of reagents Material costs include costs of the reagents, buffer, reaction cells and analyser cups.
For OC-Sensor, the manufacturer provided prices for only the reagents (£0.80). Therefore, it was assumed
that this price also includes the costs of buffers and other consumables. The manufacturer of HM-JACKarc
provided information on all of the materials. The costs of the buffers and reaction cells were given per
package. These were converted to costs per test.
Costs for maintenance of the analyser Maintenance costs include costs of calibration, costs of daily
controls, service costs and costs for cleaning the analyser. For OC-Sensor, only the costs of a calibration kit
and costs of daily controls were provided by the manufacturer. The costs of the calibration kit were given
per half-year for OC-Sensor. No information about calibration costs was provided for HM-JACKarc. The
manufacturer of OC-Sensor recommends that, before the analysis of samples, a single high and a single
low control should be analysed, that is, one low test and one high test per day. This information was not
provided for HM-JACKarc, and hence we assumed that it was the same. Finally, the cost of washing
material was provided only for HM-JACKarc.
Guaiac faecal occult blood test Costs of guaiac faecal occult blood testing were obtained from the
literature and from clinical experts. Estimates found in the literature range from (confidential information
has been removed) up to £9.57 per gFOBT. However, in most cases it is not clearly reported how the costs
were estimated. For those reasons, the cost estimate provided by clinical experts was chosen for the
base-case scenario. A summary of the different cost estimates for guaiac faecal occult blood testing
considered in this diagnostic assessment is given in Table 31.
Table 32 presents the estimated costs for the OC-Sensor and the HM-JACKarc FIT assays. The information
provided by the manufacturer did not allow the cost of the FOB Gold system to be estimated in detail,
hence FOB Gold is not included in Table 32; total cost is provided in Table 33.
A summary of the different cost estimates for faecal immunochemical testing that have been considered in
this diagnostic assessment and compared with the literature/other sources can found in Table 33.
TABLE 30 Estimated resource use
Resource usea
Average daily workload, UK 40
No. of samples analysed per year 10,000
No. of machines required to analyse daily workload (per year) 1
a Personal communication (e-mail from Callum Fraser, NHS Tayside, to Marie Westwood, KSR Ltd, 19 July 2016).
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TABLE 32 Costs of faecal immunochemical testing
Cost item OC-Sensor (£) HM-JACKarc (£)
Test costs
Reagents 0.80 0.49
Sample device 1.30 2.10
Total costs per test 2.10 2.59
Material costs
Measurement device (per year) 19,061.00 22,458.00
Measurement materials (per year)
Bottles NR 910.40a
Analyser control cups 40.00b NR
Maintenance (per year)
Service costs NR 0.00
Auto washer NR 10.18c
Calibration kit 1200.00d NR
Daily controlse 4048.00 11,134.53
Total costs of device and maintenance (per year) 24,349.00 34,513.11
Material cost per test 2.43 3.45
Total costs
Total cost per test (including material costs) 4.53 6.04
NR, not reported.
a £45.52 for 500 pieces, so £45.52 × (10,000/500).
b Cost for 1000 cups (one per year/laboratory).
c £30.55 for 200ml, so £30.55 × (10,000/30,000).
d One hundred kits per month.
e Assume four controls per day: one high and one low and two more for calibration. Then it is 253 × 4= 1012 per year.
£4 and £11 per control/calibration for OC-Sensor and HM-JACKarc, respectively.
TABLE 31 Comparison of gFOBT cost estimates
Total cost per test (£) Source
0.7758a Personal communication: e-mail from Callum Fraser, 19 July 2016
(Confidential information has been removed) Personal communication: e-mail from Jacqueline Murphy, 21 July 2016
9.57b Sharp 2012122
1.46c Whyte 2011123
4.86 NG126
a Includes only gFOBT kit (device, spatula, envelope and reagents).
b Inflated to 2015 prices and converted into UK pounds (reported in €): £1.71 kit, £7.86 processing and analysis.
c Includes gFOBT kit (device, spatula, envelope and reagents) £0.46, and processing costs (per test) £0.78, further inflated
to 2015 prices (£0.54 and £0.92, respectively).
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Other costs included in the diagnostic model
Estimates of the costs of colonoscopy, CTC and CT were obtained from the NHS Reference Costs 2014–15.124
We estimated the costs of colonoscopy as the average cost of diagnostic colonoscopy (for adults aged
≥ 19 years) with and without biopsy, because, as stated in NG12,6 a biopsy may be taken during the
colonoscopy investigation. For the CTC costs, we followed the approach by Halligan et al.104 and, in the
absence of a specific UK national cost for CTC, we used the cost of CT (more than three areas) as an
approximation. Finally, to estimate the CT costs, we calculated the average of all of the CT procedures that
were available for adults, that is, CT of one, two, three or more areas with or without (pre and/or post)
contrast and complex CT [Healthcare Resource Group (HRG) codes RD20A, RD21A, RD22Z, RD23Z, RD24Z,
RD25Z, RD26Z, RD27Z and RD28Z – Outpatient department].
Costs associated with GP and gastroenterology outpatient appointments were also considered in the
model. In particular, we assumed that the cost of colonoscopy/CTC includes the costs of a follow-up
appointment with a gastroenterologist. The definition of our patient population, as symptomatic people
presenting in the primary care who are at low risk of CRC, implies that patients have already visited the GP
(and therefore these costs have been incurred) before entering the model. Only for test-negative patients
whose symptoms persist were additional GP appointment costs considered.
Costs of bleeding and perforation were estimated based on the average length of hospital stay that
was associated with each of these adverse events. Average length of stay was obtained from the study
of Gavin et al.105 The average length of stay for bleeding due to colonoscopy was 1.7 days and for
perforation 9.1 days. To estimate the total costs, these were multiplied by the NHS cost of a regular
day or night admission.
All of these costs (with the input parameters used in the PSA) are summarised in Table 34.
Utilities
No evidence was found on the effects of bleeding and perforation on quality of life. Thus, in line with the
cost-effectiveness analysis performed in NG12,6 our diagnostic model did not include disutilities for adverse
events. In addition, as these events are often of short duration, the effects on quality of life can be assumed
to be negligible. Therefore, the only utilities that were considered in our diagnostic model were those
associated with the different stages of cancer (from Ness et al.95) and the general population sex- and
age-related utilities for healthy patients (from Kind et al.96). These utilities are described in detail below.
TABLE 33 Comparison of FIT cost estimates
FIT assay Total cost per test (£) Source
OC-Sensor 4.53 This diagnostic assessment
HM-JACKarc 6.04 This diagnostic assessment
FOB Gold 1.96 This diagnostic assessment
NR 2.15a Grazinni 2008121
NR 10.23b Sharp 2012122
NR 9.42c NG126
NR 3.63 Whyte 2011123
NR (Confidential information
has been removed)
Personal communication [e-mail from Jacqueline Murphy, Health
Economics Research Centre (HERC), Nuffield Department of Population
Health, University of Oxford, to Marie Westwood, KSR Ltd, 21 July 2016]
NR, not reported.
a Includes costs of FIT kit, reagents and consumables separately.
b Includes subtotal cost of kit plus consumables and processing costs (although it is unclear how the latter were estimated).
c Not mentioned how these were estimated.
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Colorectal cancer Markov model
Initial distribution of patients per Dukes’ stage
The initial distribution of patients with CRC over the model’s health states was determined by the probability
of being in a certain Dukes’ stage at diagnosis. In NG12,6 this was estimated using data from the NCIN,98
which showed the percentage of patients in England diagnosed at each stage of CRC between 1996 and
2002. The reported percentages per Dukes’ stage were 13%, 37%, 36% and 14% for stages A–D,
respectively, for 202,694 patients. The paper by Cubiella et al.,55 included in our systematic review (see
Chapter 3, Diagnostic performance of the OC-Sensor faecal immunochemical test assay), also reported the
sensitivity of OC-Sensor for determining the stage and location of CRC using a single faecal sample when a
threshold of ≥ 20 µg Hb/g faeces is considered. The total number of patients with CRC in this study was 91,
and the percentages per stages A–D were 16%, 25%, 44% and 14%, respectively. We also consulted
about this with our clinical experts and the percentages (average between four experts) per stages A–D were
19%, 35%, 32%, and 15%, respectively. All of these values are summarised in Table 35. For the base-case
scenario, we considered the estimates from NCIN as in NG12.6 The main reasons were that the sample size
used to obtain these estimates is large in NCIN and data were obtained from UK population; therefore, the
estimated percentages can be considered more reliable than those in Cubiella et al.55 In addition, estimates
derived from NCIN were similar to those provided by clinical experts who answered our questionnaire.
TABLE 34 Costs included in the diagnostic model
Type of cost
Mean
cost
(£)
Gamma
distribution
parameters HRG codes Source
Investigation
Diagnostic
colonoscopy
372 (4.12, 90.15) Average of FZ51Z (Diagnostic
Colonoscopy, 19 years and over)
and FZ52Z (with biopsy) –
Outpatient procedures
(Gastroenterology)
NHS Reference Costs
2014–15124
CTC 136 (9.18, 14.80) RD27Z (Computerised Tomography
Scan of more than three areas) –
Outpatient department
Halligan 2015104 and NHS
Reference Costs 2014–15124
CT 116 (7.56, 15.32) Average of RD20A, RD21A, RD22Z,
RD23Z, RD24Z, RD25Z, RD26Z,
RD27Z and RD28Z – Outpatient
department
NHS Reference Costs
2014–15124
Referral
GP visit 44 NA NA PSSRU 2015 – table 10.8b125
Gastroenterology
outpatient
appointment
135 (9.02, 14.97)a Total outpatient attendances –
Gastroenterology (Service code 301)
NHS Reference Costs
2014–15124
Adverse event
Bleeding 603 (9.02, 66.78)a RP (Regular Day or Night
Admissions) – £354.67; average
length of stay 1.7 days
Gavin 2012105 and NHS
Reference Costs 2014–15124
Perforation 3228 (9.02, 357.47)a RP (Regular Day or Night
Admissions) – £354.67; average
length of stay 9.1 days
Gavin 2012105 and NHS
Reference Costs 2014–15124
Death 0 NA Assumption
NA, not applicable.
a Parameters not reported. Calculated assuming 20% deviation from the mean.
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Probability of progression
The probability of progression was modelled as in NG12.6 In the clinical guideline, it was noted that
obtaining observed probabilities of progression for the patient population considered was unlikely.
Therefore, in the absence of such evidence, the probability of progression was estimated using progression
probabilities for undiagnosed patients with CRC, which were obtained from Tappenden et al.99 The
uncertainty within the model results resulting from this assumption was explored in the sensitivity analysis.
The progression probabilities used in the model are presented in Table 36.
Delayed diagnosis
Our model assumes that patients who had a FN gFOBT/FIT, and whose symptoms persisted, have an
increased probability of progressing to a worse cancer state, given the delay in diagnosis. This was
implemented in the model by shifting the initial distribution of patients per Dukes’ stages in Table 35
according to the progression probabilities shown in Table 36. Note that, for the base-case scenario, the
initial proportions of patients per Dukes’ stage were 13% (A), 37% (B), 36% (C) and 14% (D). Using the
annual progression probabilities for undiagnosed patients with CRC in Table 36, that is, assuming a delay
of 1 year, the proportions of patients per Dukes’ stage were estimated as 6% (A), 20% (B), 29% (C) and
45% (D). However, it was assumed that FN patients would persist in their symptoms and they would be
diagnosed within 1 year by colonoscopy or CTC. Therefore, it seems reasonable to assume that a delay of
1 year would overestimate the time to delayed diagnosis. For that reason, we assumed a delay of 6 months
for the base-case scenario. The probabilities of progression between Dukes’ stages at 6 months were
calculated by halving those in Table 36 (0.29 from A to B, 0.33 from B to C and 0.435 from C to D). This
method implicitly assumes a uniform distribution of yearly progression probabilities. Assuming a delay of
6 months, the proportions of patients per Dukes’ stage were estimated as 9% (A), 29% (B), 32% (C) and
30% (D). A summary of the number of cases per stage, with and without delay in diagnosis, are presented
in Table 37. In the PSA, this was modelled as a Dirichlet distribution, with the number of cases as the
parameters of the probability distribution.
TABLE 35 Number of cases (percentage) per stage at diagnosis of patients with CRC
Dukes’ stage
SourceA B C D
26,727
(13%)
74,784
(37%)
72,806
(36%)
28,377
(14%)
Patients diagnosed between 1996 and 2002, England (NICN)98
15 (16%) 23 (25%) 40 (44%) 13 (14%) Cubiella 2014 (COLONPREDICT)55
38,512
(19%)
70,943
(35%)
64,862
(32%)
30,404
(15%)
Expert opinion and assuming total figure in NCIN
TABLE 36 Probability of progression for undiagnosed CRC
CRC Dukes’ stage transition
Annual progression
probability – undiagnosed
CRC (95% CI) PSA distribution Source
A to B 0.58 (0.57 to 0.59) Uniform Tappenden 200799
B to C 0.66 (0.64 to 0.67)
C to D 0.87 (0.85 to 0.88)
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Survival probability per Dukes’ stage
Disease-specific mortality was also estimated using data from the NCIN, with the reported 5-year survival
rates used as a starting point for extrapolation.98 Tables 38 and 39 show the 5-year survival probabilities
with 95% CIs at each Dukes’ stage, and the observed survival probabilities at each year per Dukes’ stage,
from NCIN data, respectively.98
It was not possible to properly extrapolate survival curves beyond year 5 using these data. We therefore
used available 15-year predicted survival data from NG126 (e-mail from Matthew Prettyjohns, National
Collaborating Centre for Cancer, Cardiff, to Marie Westwood, KSR Ltd, 7 July 2016, personal
communication) to model CRC survival/mortality in the 15 first cycles of the CRC Markov model. These
probabilities are shown in Appendix 8. Furthermore, we assumed that, after year 15, CRC-related mortality
remains constant. However, overall mortality increases after year 15 owing to the inclusion of age-specific
mortality based on UK life tables.98 The annual mortality estimates and the parameters of beta distributions
used in the PSA are also shown in Appendix 8. Finally, we used two different data sources for the
transition probabilities: annual mortality per Dukes’ stage and annual progression (for undiagnosed
patients) between Dukes’ stages separately. To accommodate these two data sets in the CRC model,
TABLE 37 Number of cases (percentage) per stage at ‘initial’, ‘delayed 6 months’ and ‘delayed 1 year’ diagnosis of
patients with CRC
Number of cases
Dukes’ stage
A B C D
Initial 26,727 (13%) 74,784 (37%) 72,806 (36%) 28,377 (14%)
Delayed 6 months 18,976 (9%) 57,856 (29%) 65,814 (32%) 60,048 (30%)
Delayed 1 year 11,225 (6%) 40,928 (20%) 58,822 (29%) 91,718 (45%)
TABLE 38 Five-year relative survival of patients with CRC diagnosed between 1996 and 2002, England (NCIN)
Stage at diagnosis 5-year relative survival (%) 95% CI
Dukes’ A 93.20 92.5 to 93.9
Dukes’ B 77.00 76.4 to 77.5
Dukes’ C 47.70 47.1 to 48.3
Dukes’ D 6.60 6.1 to 7.0
TABLE 39 Yearly CRC survival per Dukes’ stage, England (NCIN)a
Year
Stage observed
Dukes’ A Dukes’ B Dukes’ C Dukes’ D
0 100 100 100 100
1 96.68 91.17 80.67 37.39
2 96.11 86.74 67.06 18.55
3 95.22 82.50 57.56 11.03
4 94.17 78.94 51.12 8.07
5 92.64 76.29 46.87 6.43
a Personal communication: e-mail from Matthew Prettyjohns, National Collaborating Centre for Cancer, Cardiff,
to Marie Westwood, KSR Ltd, 7 July 2016.
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we assumed that transitions between the states of the model occurred in two steps. First we calculated the
number of patients dying per cycle and then, conditional on survival, we calculated progression between
Dukes’ stages. The implications of these assumptions were explored in the sensitivity analysis, and further
discussed in Chapter 5 of this report.
Costs
Estimated total costs were collected over the modelled lifetime horizon. The costs considered in the model
reflect those that are relevant to the NHS and Personal Social Services. The total costs include initial and
follow-up investigations, staging, treatment, drug costs and any other resource use that may be required
(e.g. GP visit). All of the costs were taken from NG12.6 Data on lifetime costs associated with CRC (based
on the stage of cancer at diagnosis) were sourced from Tappenden et al.99 and inflated to 2015 prices using
the 2014/15 Hospital and Community Health Services index available from the PSSRU.125 All of the costs
applied in the model are shown in the Table 40. The costs associated with the health states of the CRC
Markov model were estimated as lifetime costs (i.e. one-off cost). To properly account for discounting, it is
necessary to calculate costs for each cycle of the Markov model (i.e. costs per year) in order to apply the
corresponding discount rate per year. We assume that these lifetime costs are uniformly distributed over
the model’s time horizon. It can be argued that this assumption may not reflect accurately the distribution
per year of lifetime costs. However, given the low CRC prevalence in the patient population, this
assumption is expected to have little impact on the model results.
Utilities
Health benefits were expressed in terms of LYs and QALYs (QALYs) gained. QALYs were estimated by
combining the LY estimates, with utility values associated, with being in a particular health state of the
CRC model. These utility values were sourced from the Ness et al. study95 and were also used in the
cost-effectiveness model developed for NG12.6 The study by Ness et al.95 concluded that factors such as
age and sex were not significant predictors for any utility value. Therefore, the utilities applied in the model
are dependent only on the CRC stage and remain constant for all model cycles. The utilities included in the
CRC Markov are presented in Table 41.
TABLE 40 Lifetime CRC costs included in the model
Cancer stage
Mean cost,
£ (SE) Gamma distribution parameters (α, β)a Source
Dukes’ A 10,681 (3959) (7.28, 1467.43) Tappenden 200799 (inflated to 2015)
Dukes’ B 18,011 (6676) (7.28, 2474.54)
Dukes’ C 29,139 (10,800) (7.28, 4002.88)
Dukes’ D 19,391 (7187) (7.28, 2663.76)
SE, standard error.
a Note: α = (mean/SE)2; β = SE2/mean.
TABLE 41 Utilities included in the CRC Markov model
Model state QoL Beta distribution (alpha, beta) Source
Dukes’ A 0.74 (145.00, 51.69) Ness 199995
Dukes’ B 0.70 (56.60, 24.53)
Dukes’ C 0.50 (33.78, 32.28)
Dukes’ D 0.25 (1.03, 2.35)
QoL, quality of life.
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Healthy population Markov model
This model accounted only for LYs and QALYs accrued on a healthy health state over a lifetime. Age- and
sex-specific all-cause mortality estimates were based on UK life tables.98 In particular, we assumed, for the
base-case scenario, patients aged ≥ 40 years, as in NG12.6 For the proportion of female patients, we used
the figures reported in the Gillberg et al. study,91 in which 715 females and 388 males were included.
Mortality estimates, and the corresponding parameters of a beta distribution for the PSA, can be found in
Appendix 9. Utilities were sourced from Kind et al.96 Unlike in NG12,6 for which only a mean utility value
equal to 0.79 was considered for all healthy patients, we included sex- and age-related utilities for every
cycle of the Markov model. These were calculated as a weighted average, using the proportion of females
reported in Gillberg et al.91 (35% male, 65% female). These utilities are presented in Table 42.
Overview of main model assumptions
Table 43 summarises the main assumptions made in our economic model.
TABLE 42 Age-specific utilities based on the general UK population that was included in the healthy population
Markov model
Age (years) Weighted average Males Females
35–44 Mean 0.91 0.91 0.91
SD 0.11 0.17 0.15
Beta (α, β) (5.24, 0.51) – –
45–54 Mean 0.85 0.84 0.85
SD 0.18 0.27 0.23
Beta (α, β) (2.49, 0.44) – –
55–64 Mean 0.80 0.78 0.81
SD 0.20 0.28 0.26
Beta (α, β) (2.40, 0.60) – –
65–74 Mean 0.78 0.78 0.78
SD 0.19 0.28 0.25
Beta (α, β) (2.92, 0.82) – –
≥ 75 Mean 0.72 0.75 0.71
SD 0.20 0.28 0.27
Beta (α, β) (2.90, 1.13) – –
TABLE 43 Main model assumptions
General Source
1. It was assumed that a lifetime horizon with a 1-year cycle length captures the probability of
progression for treated and untreated patients
Assumption/NG126
2. Any differences in costs between the tests in patients without CRC were assumed to occur only in
the first year
Assumption
3. Any differences in life expectancy between intervention and comparator for patients without CRC
are due only to the difference in mortality due to colonoscopy/CTC
4. Any differences in costs between intervention and comparator for patients without CRC are only
due to difference in cost of guaiac faecal occult blood testing and colonoscopy/CTC
5. Testing has no long-term (after 1 year) effect on costs or QALYs in disease-negative people. Thus,
in patients without CRC, faecal occult blood testing would not significantly delay diagnosis of the
underlying cause of presenting symptoms and hence would not incur any extra cost or effect on
mortality
continued
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TABLE 43 Main model assumptions (continued )
General Source
Diagnostic model
6. A time frame of 1 year was assumed for the diagnostic model NG126/expert
opinion
7. A positive FIT/gFOBT results in referral to colonoscopy
8. A negative FIT or gFOBT results in a watchful waiting strategy, in which a colonoscopy/CTC will be
performed when symptoms persist. A repeat FIT/gFOBT might also be performed, but referral to
colonoscopy/CTC is not modelled as being contingent on the results of the repeat test
9. The sensitivity and specificity of colonoscopy for detection of CRC is 100%. Thus, patients with a
positive colonoscopy/CTC all have CRC and those with a negative colonoscopy result do not have the
target condition
Assumption
10. The symptoms of all those patients with CRC who are FNs will persist such that they will all
receive a colonoscopy and thus be diagnosed (within 1 year) should they survive
NG126/expert
opinion
11. Patients who had FN gFOBT or FIT, and whose symptoms persisted, have an increased probability
of progressing to a worse cancer state due to the delay to diagnosis
12. Probability of delayed diagnosis of CRC was assumed to be the probability of progression within
Dukes’ states at 6 months
Assumption
13. TN, FP and FN patients who become asymptomatic do not have the target condition
14. The model assumes that only those patients with a negative test result, and whose symptoms do
not persist, do not receive a colonoscopy/CTC
15. A CT scan of the chest, abdomen and pelvis is performed for all of the patients testing positive
for CRC after colonoscopy or CTC, to estimate the stage (Dukes’ A–D) of the disease
NG126
16. For the base-case scenario, we considered a threshold of 10 µg Hb/g faeces or equivalent for the
detection of CRC using a single faecal sample. Other options were explored in sensitivity analyses
Assumption
17. The prevalence of CRC in the base-case population was assumed to be 1.5% NG126
CRC Markov model
18. After the initial distribution of patients in the CRC model is determined, patients may stay in their
current health state, progress to the health state representing the next worsening in the condition or
die (from CRC or another cause)
NG126
19. Costs associated with the health states of the CRC Markov model were estimated as lifetime
costs (i.e. one-off cost)
Healthy population Markov model
20. Patients entering this model can either die of all of the causes or stay in the ‘alive’ health state Assumption
21. We assumed for the base-case scenario patients aged ≥ 40 years NG126
Adverse events
22. The adverse events included in the diagnostic model are bowel bleeding, perforation and death Literature
23. Reduction of quality of life due to adverse events is assumed to be negligible within a lifetime Assumption
24. No costs of patients who die due to adverse events of colonoscopy
25. Adverse events due to CTC were assumed to be the same as those of colonoscopy
Test costs
26. Costs of laboratory staff to analyse the test were assumed to be the same for faecal
immunochemical testing and guaiac faecal occult blood testing
Assumption
27. Training costs and the costs of the laboratory staff for analysing the test results were not
included in the total costs because it was assumed that these are the same for faecal
immunochemical testing and guaiac faecal occult blood testing
28. Costs of the material needed to analyse a sample include costs of the reagents, buffer, reaction
cells and analyser cups
29. Maintenance costs for HM-JACKarc and OC-Sensor were assumed to be equal
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Model analyses
Expected costs and effects, the latter expressed in LYs and QALYs, were estimated for all of the diagnostic
tests considered in this assessment. Costs were estimated from the perspective of the NHS in England and
Wales. All costs and effects were discounted by 3.5%. The model’s time horizon was set to lifetime.
Incremental costs and incremental QALYs for each strategy compared with the next best alternative and
compared with the comparators (colonoscopy or guaiac faecal occult blood testing) were calculated. By
dividing the incremental costs by the incremental QALYs, the ICER was then calculated. The uncertainty
about the model input parameters and the potential impact on the model results were explored by scenario,
one-way deterministic analyses and PSAs. A series of one-way sensitivity analyses were conducted, whereby
the value of one input parameter was changed and its effect on the overall outcome was recorded and
assessed. The impact of statistical uncertainties regarding the model’s input parameters was explored
through PSA. The results of 5000 iterations were presented in the cost-effectiveness plane for all of the
interventions compared. Cost-effectiveness acceptability curves (CEACs) were used to describe the
probability of an intervention being considered cost-effective, given a threshold ICER. The different
probability distributions used in the PSA were described above (see Model structure and methodology).
Scenario analyses
Scenario analyses were performed to explore the impact on costs and QALYs of using different
assumptions on diagnostic accuracy of faecal immunochemical testing/guaiac faecal occult blood testing,
prevalence, test costs, initial and delayed CRC diagnosis, probability of CRC progression, probability
of remaining symptomatic after a negative test result, adverse events (including mortality) attributable to
colonoscopy, probability of being referred to colonoscopy (vs. CTC) and probability of receiving a second
FIT/gFOBT.
Diagnostic accuracy of faecal immunochemical testing/guaiac faecal occult blood testing
In the base-case scenario, we assumed for faecal immunochemical testing a threshold of 10 µg Hb/g faeces
or equivalent for the detection of CRC using a single faecal sample. For guaiac faecal occult blood testing
we assumed the accuracy estimates in NG12.6 In these additional scenarios, we considered other sources for
the accuracy estimates for guaiac faecal occult blood testing, other thresholds for faecal immunochemical
testing, and the inclusion of FOB Gold as an intervention in the analysis. A summary of the additional
scenarios on the accuracy of faecal immunochemical testing/guaiac faecal occult blood testing can be seen
in Table 44.
Prevalence of colorectal cancer
In the base-case scenario, it was assumed that the prevalence of CRC was 1.5%, as in NG12.6 We
explored the scenarios in which prevalence was assumed to be 3% (also explored in NG126) and 5.4%
(the highest value found in our systematic review). We considered an additional scenario with a wide
uncertainty range (mean 1.5%, lower limit 1% and upper limit 5.4%) to investigate how this would
impact on the PSA results.
TABLE 43 Main model assumptions (continued )
General Source
Other costs
30. Costs of colonoscopy/CTC, adverse event costs and CT costs were included in the diagnostic
model
NG126
31. We assumed that the cost of colonoscopy/CTC includes the costs of a follow-up appointment
with a gastroenterologist
Assumption/expert
opinion
32. For test-negative patients whose symptoms persist, an additional GP appointment cost was
considered
Assumption
33. Indirect costs parameters were not included in the model, given the perspective of the NHS
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Costs of faecal immunochemical testing/guaiac faecal occult blood testing
The cost estimates for faecal immunochemical testing and guaiac faecal occult blood testing that are
reported in the literature vary significantly and the assumptions made to derive those estimates are not
always presented in a transparent way. Whereas the cost estimates used in this diagnostic assessment are
properly reported, we acknowledge that there is uncertainty around the underlying assumptions leading to
them. For this reason, we considered additional scenarios on the test costs. In particular, we performed
threshold analyses on the cost differences between tests, and between tests and colonoscopy, to estimate
how large these cost differences should be so that the conclusions from the base-case scenario still hold.
Initial and delayed diagnosis
In the base-case scenario, the distribution of patients per Dukes’ stages was 13%, 37%, 36% and 14%,
for stages A–D, respectively.98 In these additional scenarios, we first considered the distribution of patients
reported by Cubiella et al.:55 this was 16%, 25%, 44% and 14%, for stages A–D, respectively. Then, the
distribution of patients estimated by the experts who filled in our questionnaire (19%, 35%, 32% and
15%, for stages A–D, respectively) was chosen. Finally, in the base-case scenario we assumed a delayed
diagnosis of 6 months for those patients testing negative with faecal immunochemical testing/guaiac
faecal occult blood testing who were persistent in their symptoms. This delay implied a distribution of
patients per Dukes’ stages equal to 9%, 29%, 32% and 30%, for stages A–D, respectively. For a 1-year
delay, this was 6%, 20%, 29% and 45%.
Colorectal cancer mortality and progression
In the base-case scenario, the probability of CRC progression was modelled as in NG12,6 using progression
probabilities for undiagnosed patients with CRC, which were obtained from the Tappenden et al. study.99
Mortality was modelled using observational data on mortality by CRC stage from the NCIN at the time
when the initial diagnosis took place.98 Thus, besides the limitation of using progression probabilities for
undiagnosed patients in a model in which patients are considered, it is also questionable whether or not
these mortality data included patients who might eventually progress, as the data looked at only the
initial diagnosis and subsequent mortality. Therefore, it might be reasonable to consider that the effect
of progression could be included in the mortality data. Hence, in this scenario, we considered the latter
assumption and the CRC progression probabilities were set to zero in the model.
TABLE 44 Scenario settings for accuracy of faecal immunochemical testing/guaiac faecal occult blood testing
Scenario Threshold FIT
FIT accuracy estimates (sensitivity,
specificity)a
gFOBT accuracy
estimates:
sensitivity,
specificity
Base case 10 µg Hb/g faeces OC-Sensor (92.1%, 85.8%); HM-JACKarc
(100%, 76.6%)
50.0%, 88.0%1
Accuracy–I 10 µg Hb/g faeces OC-Sensor (92.1%, 85.8%); HM-JACKarc
(100%, 76.6%)
69.2%, 73.2%92
Accuracy–II 10 µg Hb/g faeces OC-Sensor (92.1%, 85.8%); HM-JACKarc
(100%, 76.6%)
75%, 79.4%93
Accuracy–III 0 µg Hb/g faeces OC-Sensor (100%, 43.3%) 50.0%, 88.0%1
Accuracy–IV OC-Sensor ≥ 20 µg Hb/g faeces;
(confidential information has been
removed)
OC-Sensor (89.5%, 86.6%); (confidential
information has been removed)
50.0%, 88.0%1
Accuracy-V OC-Sensor and HM-JACKarc
10 µg Hb/g faeces; (confidential
information has been removed)
OC-Sensor (92.1%, 85.8%); HM-JACKarc
(100%, 76.6%); (confidential information has
been removed)
50.0%, 88.0%1
a Accuracy estimates for the OC-Sensor, HM-JACKarc and FOB Gold are reported in Tables 6, 11 and 17, respectively.
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Probability of persisting in symptoms after having a negative test result
In the base-case scenario, this probability was estimated by the experts who filled in our questionnaire.
This value was 32.5%. In this scenario we explored the consequences of doubling and halving this value.
Adverse events associated with colonoscopy
In the base-case scenario, we considered a mortality rate associated with colonoscopy of 0.0029%.
This was based on the study by Reumkens et al.113 To investigate the impact of this assumption on the
cost-effectiveness results, we considered in this scenario the highest value that was found in the literature
for the mortality due to colonoscopy; this was 0.0970% and it was reported by Day et al.114 for elderly
patients undergoing colonoscopy. Additionally, we explored a scenario for which no adverse events
(including mortality) were considered.
Probability of being referred to colonoscopy versus computed tomography colonography
The probability of undergoing colonoscopy as opposed to CTC was estimated to be 83% by four experts.
The study by Logan et al.126 found that, for approximately 98% of the screening patients with an abnormal
test result, the first investigation was colonoscopy. In this scenario, we assumed that all patients would
be referred to colonoscopy. Note that, as it was also assumed that adverse event rates were equal for
colonoscopy and CTC, differences between this and the base-case scenario are expected to be observed
only on the costs side.
Probability of receiving a second faecal immunochemical test/guaiac faecal occult
blood test
In our base-case scenario, we assumed that patients who after testing negative remain symptomatic were
referred for a colonoscopy or CTC. However, the clinical experts consulted indicated that approximately
20% of these patients would have a second FIT/gFOBT.
Results of cost-effectiveness analyses
Base-case analysis
The base-case lifetime results, reported as cost per QALY gained (ICER) per patient and strategy, are
summarised in Table 45. From these results, it is clear that the difference in QALYs between all of the
strategies is minimal and that the no triage strategy (referral straight to colonoscopy) is the most
expensive one.
Note that, where the question is whether or not to recommend faecal immunochemical testing instead of
guaiac faecal occult blood testing, then the pairwise comparisons of the different FIT assays against gFOBT
assays may be more informative than the full incremental analysis shown above. The base-case ICERs for
TABLE 45 Lifetime results for all of the strategies in the base-case scenario (deterministic)
QALYs Cost (£) Incremental QALYs Incremental cost (£) ICER (£)
gFOBT 18.6219 232.28
OC-Sensor 18.6239 244.42 0.00198 12.14 6133
No triage
(referral straight
to colonoscopy)
18.6239 503.67 Dominated by HM-JACKarca
HM-JACKarc 18.6242 274.75 0.0003 30.33 88,798
a ‘No triage’ is not dominated by the OC-Sensor. There is, in fact, a minor difference in QALYs in favour of no triage,
which cannot be observed when the figures are rounded to the fourth decimal place.
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the two interventions against guaiac faecal occult blood testing are presented in Table 46. In both cases,
the ICER was < £30,000. Therefore, both interventions are deemed cost-effective compared with guaiac
faecal occult blood testing. Table 46 also shows the results obtained when the comparator is no triage
(referral straight to colonoscopy). The HM-JACKarc strategy dominates no triage (referral straight to
colonoscopy); it results in more QALYs and it is cost saving. It should be noted that, the ICER obtained
when the OC-Sensor was compared with no triage (referral straight to colonoscopy) is extremely high
(£4,133,559) but that this results from both negative incremental costs and incremental QALYs (i.e. the
ICER is in the south-west quadrant of the cost-effectiveness plane); in this case, the cost savings outweigh
the loss in QALYs and, therefore, the OC-Sensor strategy is more cost-effective than no triage (referral
straight to colonoscopy).
Finally, Table 47 shows the breakdown of the total costs and total QALYs for all of the strategies that were
included in the analysis. As some values were very small (e.g. number of adverse events or deaths), the
number of patients per outcome of the diagnostic model is multiplied by 1000. Costs and QALYs are
shown per patient, for consistency with Table 45 above. Note that number of patients with the disease
might be lower than the prevalent CRC population. This is simply because in the model we assumed three
possible outcomes of colonoscopy: positive, negative and death. Therefore, those dead, who eventually
had CRC, were not counted as having the disease. The number of positive tests was the largest for
HM-JACKarc (245.36), followed by OC-Sensor (153.50) and gFOBT (130.28). In the model, all of these
patients were assumed to be referred for further investigation with colonoscopy or CTC. Following further
investigation, the number of patients with CRC who had a positive FIT was 14.99 for HM-JACKarc,
13.80 for OC-Sensor and 7.49 for gFOBT. Thus, all patients with CRC tested positive with HM-JACKarc,
compared with approximately 92% with OC-Sensor and 50% with gFOBT. The immediate consequence
of this was that diagnosis of CRC was delayed in no patients tested with HM-JACKarc, in 8% of patients
tested with OC-Sensor and in 50% of patients with with gFOBT. The apparent advantage of FIT with respect
to gFOBT in detecting patients with CRC earlier comes at the cost of performing more colonoscopies, as the
total number of colonoscopies performed was 490.62 for HM-JACKarc, 428.61 for OC-Sensor and 412.95
for gFOBT. This also implies that total costs and risks associated with colonoscopy are higher for FIT than for
gFOBT. Because of this, and because performing a FIT was estimated to have a higher cost than gFOBT, the
HM-JACKarc diagnostic strategy was more expensive (£255.27) than the OC-Sensor (£225.16) and gFOBT
(£214.17) strategies. All testing strategies were clearly cheaper than no triage (£484.19).
Differences in QALYs between the four strategies were minimal. For HM-JACKarc, OC-Sensor and no
triage (referral straight to colonoscopy), the total QALYs gained were 0.9048 per patient for the first year
(diagnostic phase). For gFOBT this was 0.9044. In fact, there was a difference in QALYS between HM-JACKarc,
OC-Sensor and no triage (referral straight to colonoscopy) observed at the fifth decimal place. QALYs were
the highest for HM-JACKarc, followed by no triage (referral straight to colonoscopy) and OC-Sensor. This
was because for HM-JACKarc no delayed diagnosis was observed. Thus, the difference in QALYs between
HM-JACKarc and no triage (referral straight to colonoscopy) was due only to the number of colonoscopies.
This was smaller for HM-JACKarc and, therefore, fewer deaths occurred with this strategy. When compared
with OC-Sensor, both no triage (referral straight to colonoscopy) and HM-JACKarc strategies, resulted in more
TABLE 46 Lifetime results for intervention vs. comparator in the base-case scenario (deterministic)
Incremental
QALYs
Incremental
cost (£) ICER (£)
HM-JACKarc vs. gFOBT 0.0023 42.47 18,296
HM-JACKarc vs. no triage (referral straight to colonoscopy) 0.0003 –228.92 HM-JACKarc dominates
OC-Sensor vs. gFOBT 0.0020 12.14 6133
OC-Sensor vs. no triage (referral straight to colonoscopy) –0.0001 –259.25 4,133,559
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colonoscopies being performed, implying more deaths with the last two strategies. However, for OC-Sensor,
delayed diagnosis was observed, and this seemed to ‘outweigh’ the gain in QALYs due to fewer deaths.
Note, finally, that the differences in costs and QALYs observed in the two Markov models between the
four strategies were also minimal. The healthy population Markov model was used to account for lifetime
QALYs of patients who did not have the target condition. The number of QALYs accrued in this model was
simply determined by the initial number of patients entering in the model. This was the highest for guaiac
faecal occult blood testing, as this was the strategy leading to the fewest colonoscopies and, therefore,
the fewest deaths. Hence, the total number of QALYs estimated by the healthy population Markov model
was 17.6971 for gFOBT and OC-Sensor (higher than gFOBT in the fifth decimal place), 17.6970 for
HM-JACKarc and 17.6968 for no triage (referral straight to colonoscopy). Likewise, the total costs and
QALYs estimated by the CRC Markov model were determined only by the initial distribution of patients per
Dukes’ stage entering in the model. Note that all of the four strategies correctly diagnosed all CRC alive
patients. Thus, although the total number of patients entering the model was approximately the same
(prevalence minus those who died) for all of the strategies, differences in staging were observed, due to
delayed diagnosis, with the gFOBT and OC-Sensor strategies. Because of this, estimated costs (£19.48) and
QALYs (0.0222) were higher for no triage (referral straight to colonoscopy) and HM-JACKarc, as for these
two strategies no delayed diagnosis was observed. Compared with gFOBT and OC-Sensor, these patients
with CRC were healthier and, therefore, lived longer, but also incurred more costs. For gFOBT, diagnosis of
CRC was delayed in 50% of patients, the highest among the four strategies compared. Thus, costs and
QALYs estimated by the CRC Markov model for gFOBT were the lowest (£18.10 and 0.0203, respectively).
Finally, for OC-Sensor, 8% delayed diagnosis was observed. Therefore, costs (£19.26) and QALYs (0.0219)
estimated by the CRC Markov model for this strategy were similar to (but slightly lower than) those
estimated for HM-JACKarc and no triage (referral straight to colonoscopy).
Sensitivity analysis
The cost-effectiveness results from the PSA are very similar to the deterministic results except that, in this
simulation, the ICERs calculated in the PSA were lower than those shown in Table 45. These results are
presented in Table 48.
The probabilistic ICERs for the two interventions compared with every comparator are shown in Table 49.
These results are also similar to those presented in Table 46 for the deterministic case, and so are the
conclusions drawn.
The scatterplot of the PSA outcomes in the cost-effectiveness plane in Figure 15 shows that the uncertainty
around QALYs is similar for all of the strategies, but the uncertainty around costs is clearly larger (and with
higher cost values) for the no triage (referral straight to colonoscopy) strategy. The CEACs for each strategy
are shown in Figure 16. It can be observed that at low values of the ICER threshold, the probability of
being cost-effective is higher for those strategies with lower costs (i.e. gFOBT and OC-Sensor). As the ICER
threshold increases, the CEAC for HM-JACKarc increases, whereas those for gFOBT and OC-Sensor decrease.
TABLE 48 Lifetime results for all of the strategies in the base-case scenario (probabilistic)
QALYs Cost (£) Incremental QALYs Incremental cost (£) ICER (£)
gFOBT 18.6415 230.49 NA NA NA
OC-Sensor 18.6439 242.51 0.0024 12.02 5039
No triage (referral straight to
colonoscopy)
18.6440 500.60 Dominated by HM-JACKarc
HM-JACKarc 18.6444 272.50 0.0005 29.99 61,619
NA, not applicable.
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TABLE 49 Lifetime results for intervention vs. comparator in the base-case scenario (probabilistic)
Incremental
QALYs
Incremental
cost (£) ICER (£)
HM-JACKarc vs. gFOBT 0.0029 42.01 14,626
HM-JACKarc vs. no triage (referral straight to colonoscopy) 0.0004 –228.10 HM-JACKarc dominates
OC-Sensor vs. gFOBT 0.0024 12.02 5039
OC-Sensor vs. no triage (referral straight to colonoscopy) –0.0001 –258.09 2,578,543
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FIGURE 15 Cost-effectiveness plane with PSA outcomes for all of the strategies in the base-case scenario.
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FIGURE 16 Cost-effectiveness acceptability curves for all of the strategies in the base-case scenario.
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Both CEACs for HM-JACKarc and gFOBT seem to converge to 0.5, but for all values of the ICER threshold
considered in this analysis the cost-effectiveness probability for gFOBT was the highest. In particular, at the
ICER threshold equal £30,000, the cost-effectiveness probabilities for gFOBT, HM-JACKarc, OC-Sensor and no
triage (referral straight to colonoscopy) were 0.47, 0.41, 0.11 and 0.01, respectively.
Pairwise comparisons of the two different FIT assays against the two comparators included in this
diagnostic assessment (gFOBT and no triage) were also explored in the PSA. The results are presented
in Figure 17 (cost-effectiveness planes) and Figure 18 (CEACs). When the comparator was no triage
(referral straight to colonoscopy), all PSA outcomes were located in the southern quadrants of the
cost-effectiveness plane, indicating cost savings. They seem to be evenly scattered over the two quadrants.
Thus, for approximately half of the PSA outcomes the cost savings due to faecal immunochemical testing
do not outweigh the loss in QALYs and, therefore, the FIT strategies are no more cost-effective than no
triage (referral straight to colonoscopy). However, as most of the PSA outcomes are located very close
to the y-axis (where incremental QALYs are zero), no triage (referral straight to colonoscopy) will be
cost-effective compared with HM-JACKarc, or OC-Sensor, only for very large values of the ICER threshold.
In fact, this was not observed for any of the values of the ICER threshold that were considered in the
CEACs shown in Figure 18. When the comparator was gFOBT, the PSA outcomes were mostly located in
the northern quadrants of the cost-effectiveness plane (given that faecal immunochemical testing is more
expensive). When the intervention was the OC-Sensor, we observed PSA outcomes scattered over the four
quadrants of the cost-effectiveness plane, indicating that there is large uncertainty about which strategy is
the most cost-effective. Note, finally, that the probabilistic ICERs for both HM-JACKarc compared with
gFOBT (£14,626) and OC-Sensor compared with gFOBT (£5039) were estimated to be in the north-east
quadrant of the cost-effectiveness plane, with an ICER of < £30,000, meaning that on average the FIT
strategies are cost-effective compared with gFOBT. However, this is not readily apparent when we
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FIGURE 17 Cost-effectiveness plane with PSA outcomes for intervention vs. comparator in the base-case scenario.
(a) Cost-effectiveness plane – HM-JACKarc vs. no test; (b) cost-effectiveness plane – HM-JACKarc vs. gFOBT;
(c) cost-effectiveness plane – OC-Sensor vs. no test; and (d) cost-effectiveness plane – OC-Sensor vs. gFOBT.
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FIGURE 18 Cost-effectiveness acceptability curves for intervention vs. comparator in the base-case scenario.
(a) Acceptability curves (HM-JACKarc vs. no test); (b) acceptability curves (HM-JACKarc vs. gFOBT); (c) acceptability
curves (OC-Sensor vs. no test); and (d) acceptability curves (OC-Sensor vs. gFOBT).
ASSESSMENT OF COST-EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
78
observed the CEACs in Figure 18, as these cross each other at values of the ICER threshold that are much
larger than the probabilistic ICERs. This can be explained by the asymmetry of the distribution of the PSA
outcomes on the cost-effectiveness plane. Nevertheless, given the small difference in QALYs between all of
the strategies observed in the results, the conclusions from the PSA regarding which strategy is the most
cost-effective are expected to be sensitive to changes in the accuracy estimates. This is explored in several
scenarios within the next section.
Scenario analysis
In the scenarios presented below, only the most significant differences with respect to the base-case
scenario are discussed. Complete results are provided in Appendix 11.
Diagnostic accuracy of faecal immunochemical test/guaiac faecal occult blood test
Accuracy scenario I: guaiac faecal occult blood test accuracy estimates based on the
Niv and Sperber study
In this scenario analysis, we considered the accuracy estimates for guaiac faecal occult blood testing
reported by Niv and Sperber,92 as these are considered more representative of the population of this
diagnostic assessment than those reported in NG12.6 The only difference with respect to the base-case
results can be observed in the gFOBT estimates. In this case, the total QALYs and total costs estimated per
patient were 18.6227 and £277.54, respectively. Thus, in this scenario, guaiac faecal occult blood testing
was dominated by both FIT strategies. Probabilistic results show that the main difference with respect to
the base-case scenario was that guaiac faecal occult blood testing was now clearly less cost-effective.
This can be seen in the CEACs plot for all of the strategies in Figure 19, where guaiac faecal occult blood
testing is the most cost-effective strategy only when the ICER threshold ranges between (approximately)
£12,750 and £24,500 (whereas in the base-case gFOBT was the most cost-effective strategy for the whole
range of ceiling ratios that were considered in the analysis). The CEACs for each intervention compared
with guaiac faecal occult blood testing separately are presented in Figure 20. These show that both
interventions are more cost-effective than guaiac faecal occult blood testing for all of the ceiling ratio
values that were considered in this analysis.
Accuracy scenario II: guaiac faecal occult blood test accuracy estimates based on the
Bjerregaard et al. study
The accuracy estimates for guaiac faecal occult blood testing reported in Bjerregaard et al.93 were
considered for this scenario, as these are also regarded as more representative of the population of this
diagnostic assessment than those in NG12.6 In this scenario, the total QALYs and total costs estimated
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FIGURE 19 Cost-effectiveness acceptability curves for all of the strategies: alternative gFOBT accuracy estimates.
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per gFOBT patient were 18.6230 and £258.97, respectively. Thus, guaiac faecal occult blood testing was
dominated by the OC-Sensor. The ICER reported when the intervention was HM-JACKarc was £13,482.
Therefore, at the common value of the ceiling ratio of £30,000, HM-JACKarc was deemed cost-effective
compared with guaiac faecal occult blood testing. All of the CEACs were similar to those in the scenario
for which the gFOBT accuracy estimates were obtained from Niv and Sperber92 and, therefore, they are not
shown here. The main difference with respect to the previous scenario is that guaiac faecal occult blood
testing is now the most cost-effective strategy when the ICER threshold ranges between (approximately)
£12,250 and £23,500. The CEACs for each intervention compared with guaiac faecal occult blood testing
are also similar, but the cost-effectiveness probability for guaiac faecal occult blood testing is now higher.
Accuracy scenario III: faecal immunochemical test threshold any detectable haemoglobin
(OC-Sensor only)
In this scenario, a threshold of any detectable Hb was assumed for faecal immunochemical testing.
The idea of this scenario is to look at the effects of using a threshold at the lowest level that faecal
immunochemical testing is able to detect. For this threshold, our systematic review obtained data only for
the OC-Sensor. The total QALYs and total costs estimated per patient for the OC-Sensor strategy were
18.6240 and £375.40, respectively. For gFOBT and no triage (referral straight to colonoscopy) these were
as in the base-case scenario. In this case, no triage (referral straight to colonoscopy) was dominated by the
OC-Sensor, and the ICER obtained when the OC-Sensor was compared with gFOBT was £65,192. Thus, at
the common value of the ceiling ratio of £30,000, the OC-Sensor was not cost-effective compared with
gFOBT. This is illustrated in the CEAC presented in Figure 21.
(a)
Pr
o
b
ab
ili
ty
 t
h
at
 a
 
tr
ea
tm
en
t 
is
 o
p
ti
m
al
0.0
0.2
0.4
0.6
0.8
1.0
0 10 20 30 40 50
Cost/QALY (£000)
gFOBT
HM-JACKarc
(b)
Pr
o
b
ab
ili
ty
 t
h
at
 a
 
tr
ea
tm
en
t 
is
 o
p
ti
m
al
0.0
0.2
0.4
0.6
0.8
1.0
0 10 20 30 40 50
Cost/QALY (£000)
gFOBT
OC-Sensor
FIGURE 20 Cost-effectiveness acceptability curves for intervention vs. gFOBT, alternative gFOBT accuracy estimates.
(a) acceptability curves – HM-JACKarc vs. gFOBT; and (b) acceptability curves – OC-Sensor vs. gFOBT.
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Accuracy scenario IV: faecal immunochemical test threshold of ≥ 20 µg Hb/g faeces
(OC-Sensor and FOB Gold)
In this scenario, we assumed a threshold of ≥ 20 µg Hb/g faeces. For this threshold, our systematic review
obtained data for the OC-Sensor assay and also for the FOB Gold assay. Although the reliability of
the accuracy data for the latter was questionable, as explained in detail in Chapter 3 (see Diagnostic
performance of the FOB Gold faecal immunochemical test assay), we decided to include this FIT assay in
this scenario. Deterministic results are shown in Table 50. The no triage (referral straight to colonoscopy)
strategy was the most expensive, but also the strategy with the most QALYs. However, as in previous
scenarios, little difference in QALYs was observed between any of the strategies.
The ICERs for the two interventions in comparison with guaiac faecal occult blood testing are shown in
Table 51. In both cases, the ICER was very low (around £5000). Therefore, the two interventions are
cost-effective compared with gFOBT. Table 51 also shows the results obtained when the comparator is no
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FIGURE 21 Cost-effectiveness acceptability curves for OC-Sensor vs. gFOBT: scenario – any detectable Hb.
TABLE 50 Lifetime results for all of the strategies in the scenario of FIT threshold of ≥ 20 µgHb/g faeces (deterministic)
QALYs Cost (£)
Incremental
QALYs
Incremental
cost (£) ICER (£)
gFOBT 18.6219 232.28
FOB Gold 18.6237 240.62 0.0018 8343 4725
OC-Sensor 18.6238 241.83 0.0001 1210 12,576
No triage (referral straight to colonoscopy) 18.6239 503.67 0.0002 261,839 1,449,585
TABLE 51 Lifetime results for intervention vs. comparator: FIT threshold of ≥ 20 µg Hb/g faeces (deterministic)
Incremental QALYs Incremental cost (£) ICER (£)
FOB Gold vs. gFOBT 0.0018 8.34 4725
FOB Gold vs. no triage (referral straight to colonoscopy) –0.0003 –263.05 950,102
OC-Sensor vs. gFOBT 0.0019 9.55 5131
OC-Sensor vs. no triage (referral straight to colonoscopy) –0.0002 –261.84 1,449,585
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triage (referral straight to colonoscopy). In both cases, the ICERs obtained were very high, but these result
from both negative incremental costs and incremental QALYs. In this case, the cost savings outweigh
the loss in QALYs and thus the FIT strategies are more cost-effective than no triage (referral straight
to colonoscopy).
The CEACs of all of the strategies presented in Figure 22 show that guaiac faecal occult blood testing is the
strategy with the highest probability of being cost-effective for all of the values of the ceiling ratio considered
in this analysis. In particular, at an ICER threshold equal to 30,000, this probability was approximately 0.5.
The probability of being cost-effective was similar for both interventions, but slightly higher for the FOB Gold.
Compared with no triage (referral straight to colonoscopy), both interventions have a higher probability of
being cost-effective for all of the values of the ICER threshold considered in the analysis (CEACs not shown).
CEACs for each intervention compared with gFOBT are shown in Figure 23. We can observe that, at lower
values of the ICER threshold, the gFOBT has a higher probability of being cost-effective because the
interventions are more expensive. However, as the ICER threshold increases, the probability of the two
interventions being cost-effective also increases and becomes slightly higher than that for gFOBT, although
in both cases the probability is close to 0.5.
Accuracy scenario V: threshold of ≥ 10 µg Hb/g faeces (base case) including FOB Gold
In this scenario, we included the FOB Gold assay as well as the interventions and comparators that were
considered in the base case. We assumed a threshold of 6.8 µg Hb/g faeces for the FOB Gold test, as this
was the closest available value to the base-case threshold of ≥ 10 µg Hb/g faeces, and because for this
threshold the FOB Gold test showed performance characteristics (sensitivity and specificity) similar to those
for the other FITs at the base-case threshold. In the full incremental deterministic analysis, the FOB Gold
assay was dominated by the OC-Sensor, and, as no triage (referral straight to colonoscopy) was dominated
by HM-JACKarc, the results of this scenario reduce to those in the base case presented in Table 45. The
ICER of FOB Gold compared with gFOBT was £15,720, and compared with no triage (referral straight to
colonoscopy) was £2,273,829 (in the south-west quadrant of the cost-effectiveness plane). Thus, in both
cases, FOB Gold is cost-effective given the common threshold ICER of £30,000. The CEACs for each
strategy are shown in Figure 24. It can be observed that the FOB Gold strategy has a low probability of
being cost-effective. This is not surprising, as the full incremental analysis results showed that FOB Gold
was dominated by the OC-Sensor. The rest of the CEACs are similar to those obtained in the base-case
scenario (see Figure 16).
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FIGURE 22 Cost-effectiveness acceptability curves for all of the strategies: FIT threshold of ≥ 20 µg Hb/g faeces.
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The CEACs in Figure 25 show that the probability of FOB Gold being cost-effective compared with no triage
(referral straight to colonoscopy) is high even at large values of the ceiling ratio of the ICER threshold.
However, gFOBT clearly more cost-effective than FOB Gold at lower values of the ICER threshold. As the
ceiling ratio increases, the probability of being cost-effective for both strategies seems to converge to 0.5.
Prevalence of colorectal cancer
The results of the scenarios with prevalence 3% and 5.4% were similar to those in the base case (Tables 52
and 53). In particular, the ICERs obtained in the scenarios in which the two interventions are compared with
(a)
Pr
o
b
ab
ili
ty
 t
h
at
 a
 
tr
ea
tm
en
t 
is
 o
p
ti
m
al
0.0
0.2
0.4
0.6
0.8
1.0
0 10 20 30 40
Cost/QALY (£000)
gFOBT
FOB Gold
(b)
Pr
o
b
ab
ili
ty
 t
h
at
 a
 
tr
ea
tm
en
t 
is
 o
p
ti
m
al
0.0
0.2
0.4
0.6
0.8
1.0
0 10 20 30 40
Cost/QALY (£000)
gFOBT
OC-Sensor
FIGURE 23 Cost-effectiveness acceptability curves for intervention vs. gFOBT: FIT threshold of ≥ 20 µg Hb/g faeces.
(a) Acceptability curves – FOB Gold vs. gFOBT; and (b) acceptability curves – OC-Sensor vs. gFOBT.
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FIGURE 24 Cost-effectiveness acceptability curves for all of the strategies in the scenario including FOB Gold.
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FIGURE 25 Cost-effectiveness acceptability curves for FOB Gold vs. comparator in the scenario including FOB Gold.
(a) Acceptability curves – FOB Gold vs. no test; and (b) acceptability curves – FOB Gold vs. gFOBT.
TABLE 52 Lifetime results for intervention vs. comparator, prevalence 3% (deterministic)
Incremental QALYs Incremental cost (£) ICER (£)
HM-JACKarc vs. gFOBT 0.0047 45.68 9754
HM-JACKarc vs. no triage (referral straight to colonoscopy) 0.0003 –225.34 –820,612
OC-Sensor vs. gFOBT 0.0040 15.19 3829
OC-Sensor vs. no triage (referral straight to colonoscopy) –0.0004 –255.83 578,092
TABLE 53 Lifetime results for intervention vs. comparator, prevalence 5.4% (deterministic)
Incremental QALYs Incremental cost (£) ICER (£)
HM-JACKarc vs. gFOBT 0.0085 50.80 6004
HM-JACKarc vs. no triage (referral straight to colonoscopy) 0.0003 –219.62 –820,054
OC-Sensor vs. gFOBT 0.0071 20.06 2808
OC-Sensor vs. no triage (referral straight to colonoscopy) –0.0011 –250.36 238,380
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gFOBT are lower than those ICERs obtained in the base-case scenario (< £10,000). Thus, in both cases,
the two interventions are deemed cost-effective.
The scenario with an asymmetrical CI changed only the probabilistic results. For this scenario, we assumed
a triangular distribution with the most likely value of 1.5% and limits of 1% and 5.4%. Note that, for this
choice of parameters, the mean of the triangular distribution is 2.6%. The main consequence of this choice
was that the PSA outcomes were more scattered over the cost-effectiveness plane (especially on the QALYs
axis), but all CEACs were very similar to those obtained in the base-case scenario (results not shown).
Costs of faecal immunochemical test/guaiac faecal occult blood test (threshold analysis)
For this analysis, we first considered a hypothetical situation in which all test costs were £0. Then we
calculated what the cost difference between HM-JACKarc and gFOBT, and between the OC-Sensor and
gFOBT, should be in order to obtain an ICER of (approximately) £30,000. From this analysis, we concluded
that HM-JACKarc could be up to £32 more expensive than gFOBT while still keeping the ICER < £30,000.
OC-Sensor could be up to £51 more expensive than gFOBT. Compared with the no triage (referral straight
to colonoscopy) strategy, both FIT strategies were already so much cheaper in the base case that the cost
of the tests themselves could be increased by well over £200 and still be cost-effective. Thus, no threshold
analysis was needed for this comparator.
Initial and delayed diagnosis
Changing the probability of being in a certain Dukes’ stage influenced only the outcomes calculated from
the Markov models, as these probabilities are not input parameters for the diagnostic (decision tree)
model. Note that, in the base-case scenario, the percentages of patients in each Dukes’ stage were 13%,
37%, 36% and 14% for stages A–D, respectively.98 In these additional scenarios, we first considered the
distribution of patients reported in a study included in our systematic review (Cubiella et al.55); this was
16%, 25%, 44% and 14% for stages A–D, respectively, that is, more patients in stages A and C, but
fewer in stage B. The results in Table 54 are similar to those in the base case, with a slight loss in QALYs
for all of the strategies and also lower costs. Both interventions dominated no triage (referral straight to
colonoscopy) and, when compared with gFOBT, both ICERs were < £30,000. The PSA results (not shown
here) did not show any significant difference with respect to those in the base case.
The distribution of patients (estimated by the experts) who filled in our questionnaire was 19%, 35%,
32% and 15%, for stages A–D, respectively. Thus, there would be more patients in stages A and D, but
fewer in stages B and C. The results were also similar to those in the base case, but now with a slight
gain in QALYs and an increase in costs for all of the strategies (Table 55). In this case, only HM-JACKarc
dominated no triage (referral straight to colonoscopy). The ICER for OC-Sensor compared with no triage
(referral straight to colonoscopy) was high, but in the south-west quadrant of the cost-effectiveness plane.
Therefore, OC-Sensor was cost-effective. When compared with gFOBT both ICERs were < £30,000.
The PSA results did not show any significant difference with respect to those in the base case either.
TABLE 54 Lifetime results for intervention vs. comparator, initial distribution from a study in our systematic
review (deterministic)
Incremental QALYs Incremental cost (£) ICER (£)
HM-JACKarc vs. gFOBT 0.0019 42.22 22,319
HM-JACKarc vs. no triage (referral straight to colonoscopy) 0.0003 –228.92 –820,947
OC-Sensor vs. gFOBT 0.0016 11.93 7370
OC-Sensor vs. no triage (referral straight to colonoscopy) 0.0000 –259.21 –46,570,596
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Finally, note that in the base-case scenario we assumed a delayed diagnosis of 6 months for those patients
who were testing negative with faecal immunochemical testing/gFOBT and were persistent in their
symptoms. The 6-month delay implied a distribution of patients, per Dukes stage, equal to 9%, 29%, 32%
and 30%, for stages A–D, respectively; for a 1-year delay, this was 6%, 20%, 29% and 45%, respectively,
that is, most patients were in stage D. The results shown in Table 56 are similar to those in the base case,
with a slight loss in QALYs for gFOBT and OC-Sensor, and also lower costs. Note that, in the base-case
scenario, HM-JACKarc detected all patients with CRC. Therefore, the assumption on the delay of diagnosis
had no impact on these results.
Colorectal cancer mortality and progression
The impact of not considering CRC progression explicitly in the model was explored in this scenario.
The full incremental results in Table 57 were similar to those in the base case, with a slight gain in QALYs
for all of the strategies and an increase in costs.
When the interventions were compared with gFOBT and no triage (referral straight to colonoscopy)
separately (Table 58), we observed, as in previous scenarios, that HM-JACKarc dominated no triage
(referral straight to colonoscopy); the ICER for OC-Sensor compared with no triage (referral straight to
colonoscopy) was large but in the south-west quadrant of the cost-effectiveness plane (hence, OC-Sensor
was cost-effective); and the ICERs obtained when the comparator was gFOBT were both < £30,000 (and,
therefore, both were cost-effective).
TABLE 55 Lifetime results for intervention vs. comparator, initial distribution by clinical experts (deterministic)
Incremental QALYs Incremental cost (£) ICER (£)
HM-JACKarc vs. gFOBT 0.0032 42.90 13,574
HM-JACKarc vs. no triage (referral straight to colonoscopy) 0.0003 –228.92 –820,947
OC-Sensor vs. gFOBT 0.0027 12.50 4655
OC-Sensor vs. no triage (referral straight to colonoscopy) –0.0002 –259.32 1,322,872
TABLE 56 Lifetime results for intervention vs. comparator, 1-year delayed diagnosis (deterministic)
Incremental QALYs Incremental cost (£) ICER (£)
HM-JACKarc vs. gFOBT 0.0047 43.85 9360
HM-JACKarc vs. no triage (referral straight to colonoscopy) 0.0003 –228.92 –820,947
OC-Sensor vs. gFOBT 0.0040 13.30 3352
OC-Sensor vs. no triage (referral straight to colonoscopy) –0.0004 –259.47 592,092
TABLE 57 Lifetime results for all of the strategies: scenario – without CRC progression (deterministic)
QALYs Cost (£) Incremental QALYs Incremental cost (£) ICER (£)
gFOBT 18.701 263.92 NA NA NA
OC-Sensor 18.711 279.10 0.0101 15.18 1508
No triage (referral straight
to colonoscopy)
18.713 538.93 Dominated by HM-JACKarc
HM-JACKarc 18.713 310.01 0.0019 30.90 16,528
NA, not applicable.
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The main difference with respect to the base-case PSA is that results are now more favourable to the
interventions, as can be observed in the CEACs for all of the strategies in Figure 26 and the CEACs for the
interventions against gFOBT in Figure 27.
Probability of persisting in symptoms after having a negative test result
In the base-case scenario, this probability was estimated by the experts who filled in our questionnaire.
This value was 32.5%. In this scenario we explored the consequences of doubling and halving this value.
Doubling the probability of persisting in symptoms after having a negative result had a minor impact on the
estimated QALYs, as can be seen in Table 59. This resulted in a slight loss in QALYs for all of the testing
strategies owing to an increase in the number of patients with a delayed diagnosis. The impact on costs
was large, as this implies a larger number of colonoscopies for all of the testing strategies. The ICERs for
the interventions compared with gFOBT were low (both < £10,000). In addition, as in previous scenarios,
no triage (referral straight to colonoscopy) was dominated by HM-JACKarc and the ICER of OC-Sensor
compared with no triage was high, and it lay in the south-west quadrant of the cost-effectiveness plane.
The PSA results (not shown) were similar to those in the base case, but in this scenario the interventions
were more likely to be deemed cost-effective.
When the probability of persistent symptoms after having a negative result was halved (Table 60), the
opposite was observed. Nevertheless, in this case, no triage (referral straight to colonoscopy) was
dominated by both interventions and the ICERs for both HM-JACKarc and OC-Sensor compared with
gFOBT were < £30,000.
TABLE 58 Lifetime results for intervention vs. comparator: scenario – without CRC progression (deterministic)
Incremental QALYs Incremental cost (£) ICER (£)
HM-JACKarc vs. gFOBT 0.0119 46.09 3859
HM-JACKarc vs. no triage (referral straight to colonoscopy) 0.0003 –228.92 –820,947
OC-Sensor vs. gFOBT 0.0101 15.18 1508
OC-Sensor vs. no triage (referral straight to colonoscopy) –0.0016 –259.83 163,305
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FIGURE 26 Cost-effectiveness acceptability curves for all of the strategies: scenario – without CRC progression.
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FIGURE 27 Cost-effectiveness acceptability curves for intervention against gFOBT in the scenario without CRC
progression. (a) Acceptability curves – HM-JACKarc vs. gFOBT; and (b) acceptability curves – OC-Sensor vs. gFOBT.
TABLE 59 Lifetime results for all of the strategies: scenario – double probability of persisting in symptoms after
negative test result (deterministic)
QALYs Cost (£)
Incremental
QALYs
Incremental
cost (£) ICER (£)
gFOBT 18.6217 381.09
OC-Sensor 18.6237 389.26 0.0020 8.17 4118
No triage (referral straight to colonoscopy) 18.6239 503.67 Dominated by HM-JACKarc
HM-JACKarc 18.6241 403.87 0.0004 14.61 36,534
TABLE 60 Lifetime results for all of the strategies: scenario – half probability of persisting in symptoms after
negative test result (deterministic)
QALYs Cost (£)
Incremental
QALYs
Incremental
cost (£) ICER (£)
gFOBT 18.6220 157.88
No triage (referral straight to colonoscopy) 18.6239 503.67 Dominated by OC-Sensor
OC-Sensor 18.6239 172.01 0.0020 14.13 7143
HM-JACKarc 18.6243 210.19 0.0003 38.19 114,546
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Adverse events associated with colonoscopy
We first considered the highest value found in the literature for the mortality due to colonoscopy. This was
0.0970%, and it was reported by Day et al.114 for elderly patients. This can be seen as a worst-case scenario
regarding mortality due to colonoscopy. As expected, the main differences with respect to the base-case
scenario were observed for those strategies for which the number of colonoscopies was larger: no triage
(referral straight to colonoscopy) and HM-JACKarc. The results are shown in Table 61; in particular, no
triage (referral straight to colonoscopy) was dominated by all of the strategies. Whereas the ICER for
OC-Sensor compared with gFOBT was < £10,000, the ICER for HM-JACKarc compared with gFOBT was
£45,271. Thus, at the common value for the ICER threshold of £30,000, HM-JACKarc was not cost-effective
compared with gFOBT.
When no adverse events were considered (Table 62), no triage (referral straight to colonoscopy) was
dominated by HM-JACKarc. This was expected because the difference in QALYs between these two
strategies observed in the base-case scenario was due to only the adverse events. In this case, as no
adverse events were considered, the QALYs estimated were exactly the same. Likewise, differences in
QALYs between faecal immunochemical testing and gFOBT are not present in this scenario. Therefore, the
results of this scenario are slightly more favourable to faecal immunochemical testing than those in the
base-case scenario.
Probability of being referred to colonoscopy versus computed tomography colonography
In this scenario, we assumed that all patients would be referred to colonoscopy. The results are presented
in Table 63.
As expected, differences between this and the base-case scenario were minor and due to the increase in
the costs of colonoscopy. For this reason, the results were slightly better for gFOBT, as this was the
strategy that required fewer colonoscopies.
Probability of receiving a second faecal immunochemical test/guaiac faecal occult
blood test
In this scenario, we assumed that (on average) 20% of the patients who remain symptomatic after testing
negative on FIT/gFOBT had a second FIT/gFOBT. The results are shown in Table 64.
TABLE 61 Lifetime results for all of the strategies: scenario – high mortality associated to colonoscopy (deterministic)
QALYs Cost (£)
Incremental
QALYs
Incremental
cost (£) ICER (£)
No triage (referral straight to colonoscopy) 18.6064 503.65 Dominated by gFOBT
gFOBT 18.6148 232.26
HM-JACKarc 18.6157 274.73 Dominated by OC-Sensor
OC-Sensor 18.6165 244.40 0.0017 12.14 7144
TABLE 62 Lifetime results for all of the strategies: scenario – no adverse events associated to colonoscopy (deterministic)
QALYs Cost (£)
Incremental
QALYs
Incremental
cost (£) ICER (£)
gFOBT 18.6221 230.97
OC-Sensor 18.6241 243.06 0.0020 12.09 6081
No triage (referral straight to colonoscopy) 18.6245 500.49 Dominated by HM-JACKarc
HM-JACKarc 18.6245 273.19 0.0004 30.13 80,244
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As expected, having a second FIT/gFOBT increased the costs of the patients who tested negative on FIT/
gFOBT and remained symptomatic. This increase in costs had little impact on the cost-effectiveness results,
as, on average, 32.5% of the patients testing negative would persist in their symptoms and 20% of these
patients would get the second test. Thus, this increase would have an effect on only 6.5% of the patients
who tested negative on FIT/gFOBT.
TABLE 63 Lifetime results for all of the strategies: scenario – all patients referred to colonoscopy, as opposed to
CTC (deterministic)
QALYs Cost (£)
Incremental
QALYs
Incremental
cost (£) ICER (£)
gFOBT 18.6219 243.73
OC-Sensor 18.6239 256.31 0.0020 12.58 6352
No triage (referral straight to colonoscopy) 18.6239 531.40 Dominated by HM-JACKarc
HM-JACKarc 18.6242 288.36 0.0003 32.05 93,832
TABLE 64 Lifetime results for all of the strategies: scenario – FIT-/gFOBT-negative patients who persist in symptoms
get a second test (deterministic)
QALYs Cost (£)
Incremental
QALYs
Incremental
cost (£) ICER (£)
gFOBT 18.6219 232.32
OC-Sensor 18.6239 244.67 0.0020 12.35 6237
No triage (referral straight to colonoscopy) 18.6239 503.67 Dominated by HM-JACKarc
HM-JACKarc 18.6242 275.05 0.0003 30.38 88,936
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Chapter 5 Discussion
Statement of principal findings
Clinical effectiveness
All of the studies included in the systematic review were diagnostic cohort studies reporting accuracy data.
Eight published studies13,52,53,55–58,75 and one unpublished study (Hospital Clinic de Barcelona 2015; Philippa
Pinn, personal communication) assessed accuracy of a quantitative FIT method for the target condition of
CRC or for the composite target condition of advanced neoplasia (CRC or HRA); the remaining study,54 which
was published as a conference abstract, reported accuracy data for only the composite target condition
‘significant bowel disease’ (defined as CRC polyps or bleeding). Five studies13,52,53,55,58 reported accuracy data
for the OC-Sensor assay. Three studies56,57,75 reported accuracy data for the HM-JACKarc automated system.
One study,54 published as an abstract, and one unpublished study (Hospital Clinic de Barcelona 2015)
reported accuracy data for the FOB Gold assay. No studies using the RIDASCREEN Hb or the RIDASCREEN
Hb/Hp complex assays met the inclusion criteria for this assessment. Two studies of OC-Sensor53,55 also
developed risk scores for CRC or advanced neoplasia that included faecal immunochemical testing; in the
case of the COLONPREDICT study,55 risk score development was reported in a separate publication,73 namely
a manuscript, which was provided ahead of publication (Callum Fraser, personal communication). None
of the included studies reported data comparing different FIT assays, or comparing one or more FIT assays
with a gFOBT method. No RCTs or CCTs were identified, and no studies provided data on patient-relevant
outcomes following faecal immunochemical testing compared with gFOBT or no faecal occult blood testing.
No study reported data that were specific to the population defined in the scope for this assessment
(people presenting, in primary care settings, with lower abdominal symptoms who are at low risk for CRC
according to the criteria defined in NG121). Only one study52 was conducted in a primary care setting, and
this study reported that faecal immunochemical testing was ordered by GPs at the point of referral to
secondary care. In addition, all of the studies included some participants who had symptoms that may be
considered to be associated with a higher probability of CRC and that are components of the criteria for
2-week referral as defined in NG121 (e.g. rectal bleeding).
When faecal immunochemical testing was based on a single faecal sample and a threshold of 10 µg Hb/g
faeces was applied, sensitivity estimates indicated that a negative test using either OC-Sensor and HM-JACKarc
may be considered adequate to rule out CRC; the summary estimate of sensitivity for C-Sensor was 92.1%
(95% CI 86.9% to 95.3%), based on four studies, and the only study of HM-JACKarc to assess the 10 µg Hb/g
faeces cut-off point reported a sensitivity of 100% (95% CI 71.5% to 100%).56 The corresponding specificity
estimates were 85.8% (95% CI 78.3% to 91.0%) and 76.6% (95% CI 72.6% to 80.3%), respectively.
(Confidential information has been removed.) When a hypothetical cohort of 1000 patients is considered,
assuming prevalence estimates derived from the included studies, the estimated number of CRC cases that
would be missed using each of the three FIT assays (OC-Sensor and HM-JACKarc 10 µg Hb/g faeces threshold
and (confidential information has been removed) is 2, 0 and (confidential information has been removed),
respectively; under the same assumptions, the number of ‘unnecessary’ colonoscopies carried out on people
without CRC would be 198, 229 and (confidential information has been removed), respectively (see Chapter 3,
Results of the assessment of clinical effectiveness assessment, see Figures 5a, 9 and 11). Reducing the threshold
to ‘any detectable Hb’ produced summary estimates of sensitivity and specificity, for OC-Sensor, of 100%
(95% CI 87.7% to 100%) and 43.4% (95% CI 39.7% to 47.1%), based on two studies. For the hypothetical
cohort of 1000 patients, this lowering of the threshold would result in no cases of CRC being missed, but
would increase the number of ‘unnecessary’ colonoscopies from 198 to 548 (see Figure 5b). No study of
HM-JACKarc assessed the any detectable Hb threshold for CRC. (Confidential information has been removed.)
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No study reported data on the effects of patient age, sex or presenting symptoms, or on the effects of
multiple sampling, on the accuracy of faecal immunochemical testing for the target condition of CRC.
However, the results of multivariable regression analyses indicate that participant age73 and sex,53,73 but not
presenting symptoms (NICE and SIGN 2-week referral criteria),53 as well as faecal Hb concentration,53,73
are independent predictors of CRC. Validation of the FAST score (Cubiella et al. 2016;127 Callum Fraser,
personal communication), which incorporates age, sex and faecal Hb concentration, has suggested that a
score threshold of 2.12 (range of score not reported) can be used to reliably rule out CRC (sensitivity
100%, 95% CI 97.7% to 100%); however, the specificity of the score is very low (19.8%, 95% CI 18.6 to
21.1%) at this threshold.
If a lower diagnostic threshold is applied, that is, the target condition includes HRA as well as CRC (advanced
neoplasia), then the rule-out performance of all FIT methods is reduced. For faecal immunochemical testing
based on a single faecal sample and a threshold of 10 µg Hb/g faeces, the sensitivity estimates indicated that
neither a negative OC-Sensor nor a negative HM-JACKarc FIT would be likely to be considered adequate to
rule out CRC; the summary estimate of sensitivity for OC-Sensor was 62.9% (95% CI 55.9% to 69.4%),
based on three studies, and the estimate of sensitivity for HM-JACKarc was 70.0% (95% CI 50.6% to
85.3%), based on one study.56 The corresponding specificity estimates were 84.6% (95% CI 82.8% to
86.2%) and 77.8% (95% CI 73.8% to 81.4%), respectively. One additional study57 reported sensitivity and
specificity estimates for HM-JACKarc at the 10 µg Hb/g faeces threshold and any detectable Hb thresholds;
however, this study57 differed from others in the systematic review in that it included some patients who
were undergoing colonoscopy for polyp surveillance and excluded people with GI bleeding or active rectal
bleeding; the prevalence of CRC in this study was the lowest of any included study (0.96%).57 When a
hypothetical cohort of 1000 patients is considered, assuming that prevalence estimates have been derived
from the included studies, the estimated number of HRA cases that would be missed using either of the two
FIT assays (OC-Sensor and HM-JACKarc at the 10 µg Hb/g faeces threshold) is 40 and 22, respectively; under
the same assumptions the number of ‘unnecessary’ colonoscopies carried out on people without CRC would
be 157 and 205, respectively (see Chapter 3, Results of the assessment of clinical effectiveness assessment,
Figures 7a and 10). (Confidential information has been removed.) Using the OC-Sensor assay and a
threshold of any detectable Hb increased the summary estimate of sensitivity to 84.1% (95% CI 78.3% to
88.8%), with a corresponding specificity estimate of 45.2% (95% CI 42.7% to 47.7%). For the hypothetical
cohort of 1000 patients, this lower threshold would still result in 18 cases of HRA being missed and 485
‘unnecessary’ colonoscopies being conducted in people without HRA or CRC (see Figure 7a).
Only the Auge et al. study57 reported any data on the effects of patient characteristics (sex) and number
of faecal samples tested on the accuracy of faecal immunochemical testing for the target condition of
advanced neoplasia. However, the results of multivariable regression analyses indicate that participant
age53,73 and sex,53,73 but not presenting symptoms (NICE and SIGN 2-week referral criteria),53 as well as
faecal Hb concentration,53,73 are independent predictors of advanced neoplasia. Validation of two risk
scores based on the analyses (both incorporating age, sex Hb concentration) gave increased estimates of
sensitivity and specificity. One study reported sensitivity and specificity estimates of 88.1% (95% CI 74.3%
to 96.0%) and 63.3% (95% CI 57.4% to 69.0%), for a threshold of ‘5’ on a score with a scale of 0–11.53
The FAST score (Cubiella et al. 2016;127 Callum Fraser, personal communication) threshold of 2.12 (range
of score not reported) gave sensitivity and specificity estimates of 96.7% (95% CI 94.9% to 98.0%) and
21.5% (95% CI 20.1% to 22.9%). These data suggest that risk scores may have the potential to provide a
more reliable rule-out method than faecal immunochemical testing alone at lower thresholds of disease.
No studies were identified which assessed the diagnostic performance of RIDASCREEN Hb or RIDASCREEN
Hb/Hp complex in symptomatic patients, and no studies were identified which directly compared the
performance of different FIT assays, or which compared one or more FIT assays with a gFOBT method.
The selection of FIT accuracy data for use in cost-effectiveness modelling was based on the optimal
threshold (maximum sensitivity and specificity) for each assay method and the threshold required to provide
optimal rule-out performance (highest sensitivity and lowest number of cases missed). Because no studies
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were identified which directly compared the performance of one or more FIT assays with a gFOBT method,
accuracy data for gFOBT that were used in the base case for cost-effectiveness modelling were those
used in the NG12 model.6 The primary study from which these data were taken, Gillberg et al.,91 was a
retrospective study using a Swedish cancer registry, in which a diagnosis of CRC was classified as any
diagnosed CRC within 2 years of guaiac faecal occult blood testing. It was unclear whether or not all of the
patients included in the study had been symptomatic at the time of guaiac faecal occult blood testing, and
the prevalence of CRC, in the subgroup of study participants used to provide accuracy data for the model,
was very low (0.36%); the prevalence of CRC for the whole population of the Gillberg et al. study91 (1.8%)
was closer to the prevalence estimate that was used in the NG12 model6 (1.5%). Because of these
problems with the Gillberg et al. study91 data, we chose to conduct scenario analyses using published
estimates of gFOBT accuracy in symptomatic patients obtained from studies that were identified during the
process of inclusion screening for our systematic review: the Niv and Sperber92 and Bjerregaard et al.93
studies. Both of these studies were conducted in symptomatic patients and the prevalence of CRC was
2.5% and 3.1%, respectively, making these studies closer to the population defined for this assessment.
Cost-effectiveness
We assessed the cost-effectiveness of using quantitative faecal immunochemical tests for Hb (faecal
immunochemical testing) as a triage test for people presenting, in primary care settings, with lower
abdominal symptoms who are at low risk for CRC according to the criteria defined in NG12.1 Our review
of economic analysis found no papers or reports assessing specifically this decision problem. The most
relevant study was the one conducted in NG12,6 which estimated the cost-effectiveness of five different
investigations (i.e. faecal occult blood testing, barium enema, flexible sigmoidoscopy, CTC or colonoscopy)
for suspected CRC ordered in primary care for patients aged 40 years and over with a change in bowel
habit as the main symptom. This study was used to guide a part of the development of our diagnostic
assessment model.
Diagnostic accuracy of faecal immunochemical testing was captured in the model using data on sensitivity
and specificity for the detection of CRC using a single faecal sample obtained from our systematic review.
For the base-case scenario, we considered a threshold of 10 µg Hb/g faeces or equivalent. For this
threshold, our systematic review obtained data only for OC-Sensor and HM-JACKarc. The comparators
chosen for this diagnostic assessment were gFOBTs and no triage (referral straight to colonoscopy). For
gFOBT, we considered the sensitivity and specificity estimates used in NG121 (base-case scenario) and in
two papers identified in our systematic review (scenario analyses) that were thought to represent a better
match for the population that was specified for this diagnostic assessment. Additionally, the FOB Gold FIT
system was included as an intervention in scenario analyses, despite the limitations of the accuracy data
found in our systematic review, as described in Chapter 3.
The base-case cost-effectiveness results suggested that the difference in QALYs between all of the
strategies included in this assessment is minimal and that the ‘no triage’ strategy (referral to colonoscopy)
is the most expensive. Overall, faecal immunochemical testing was cost-effective when compared with no
triage. This was either because the latter was dominated (less effective and more costly) or because the
ICERs obtained were high, but in the south-west quadrant of the cost-effectiveness plane, that is, faecal
immunochemical testing was slightly less effective, but cheaper, than no triage. In this case the cost
savings could be said to ‘outweigh’ the slight loss in QALYs. When the comparator was gFOBT, the
cost-effectiveness results showed that faecal immunochemical testing was more effective and more costly
than gFOBT, but the ICERs obtained were below the common threshold ICER of £30,000, and thus the
interventions can also be considered cost-effective. However, it should be noted that the PSA results
showed that this finding should be interpreted with caution. Because the PSA outcomes were scattered
over the four quadrants of the cost-effectiveness plane in an asymmetrical fashion, gFOBT had in general
a high probability of being cost-effective (especially at low values of the ICER threshold) and sometimes
gFOBT was the strategy with the highest probability of being cost-effective.
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The results of the different scenario analyses did not differ substantively from the base-case results. The
scenarios for which the accuracy estimates for gFOBT were based on the studies by Niv and Sperber92 and
Bjerregaard et al.93 (those that are considered more representative of the population of this diagnostic
assessment) were more favourable than the base-case scenario with regard to the interventions. In only
two scenarios would FIT strategies be considered to be not cost-effective because the ICER exceeded the
£30,000 threshold. The highest ICER was obtained when OC-Sensor was compared with gFOBT when a
threshold of any detectable Hb was assumed for this FIT assay (£65,192). This was expected, as reducing
the threshold for FIT results in the test being less effective in avoiding colonoscopies, that is, this threshold
is associated with the highest number of FPs. When HM-JACKarc was compared with gFOBT in the
scenario with high mortality due to colonoscopy, the ICER was £45,271.
Strengths and limitations of assessment
Clinical effectiveness
Extensive literature searches were conducted in an attempt to maximise retrieval of relevant studies. These
included electronic searches of a variety of bibliographic databases, as well as screening of clinical trials
registers and conference abstracts to identify unpublished studies. Because of the known difficulties in
identifying test accuracy studies using study design-related search terms,128 search strategies were
developed to maximise sensitivity at the expense of reduced specificity. Thus, large numbers of citations
were identified and screened, relatively few of which met the inclusion criteria of the review.
The possibility of publication bias remains a potential problem for all systematic reviews. Considerations
may differ for systematic reviews of test accuracy studies. It is relatively simple to define a positive result
for studies of treatment, for example a significant difference between the treatment and control groups,
which favours treatment. This is not the case for test accuracy studies, which measure agreement between
index test and reference standard. It would seem likely that studies finding greater agreement (high
estimates of sensitivity and specificity) will be published more often; however, the relative priorities given to
sensitivity and specificity estimates may vary depending on the intended application of the test. In addition,
test accuracy data are often collected as part of routine clinical practice, or by retrospective review of
records; test accuracy studies are not subject to the formal registration procedures applied to RCTs and are
therefore more easily discarded when results appear unfavourable. The extent to which publication bias
occurs in studies of test accuracy remains unclear; however, simulation studies have indicated that the
effect of publication bias on meta-analytic estimates of test accuracy is minimal.129 Formal assessment
of publication bias in systematic reviews of test accuracy studies remains problematic and reliability is
limited.39 We did not undertake a statistical assessment of publication bias in this review. However, our
search strategy included a variety of routes to identify unpublished studies and resulted in the inclusion
of a number of conference abstracts.
Despite our extensive searches, no studies were identified that assessed the diagnostic performance of
RIDASCREEN Hb or RIDASCREEN Hb/Hp complex in symptomatic patients. We identified one article that
assessed the performance of Hb/Hp complex in faeces for detecting CRC; the reported sensitivity and
specificity estimates were 77% and 95%, using a threshold of 2 µg/g faeces.130 The test manufacturer
stated, of this study, that: ‘My understanding is that all of the patients were symptomatic’ (e-mail from
Andrea Lennerz, R-Biopharm AG, Germany, via Rebecca Albrow, NICE, to Marie Westwood, KSR Ltd,
27 May 2016, personal communication). However, this study did not meet the inclusion criteria for our
systematic review, as it used an early developmental immunoluminometric assay for Hb/Hp complex and
not an assay that is currently commercially available or in use in a NHS laboratory.
No studies were identified which directly compared the performance of different FIT assays, or which
compared one or more FIT assays to a gFOBT method; therefore, all of the data included in this assessment
refer to the clinical effectiveness of individual FIT methods and not to their comparative effectiveness.
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Although gFOBT was not one of the interventions included in our systematic review, it was considered to
be a comparator for cost-effectiveness modelling. In order to inform cost-effectiveness modelling, our
searches therefore included general terms for faecal occult blood testing and guaiac faecal occult blood
testing. Diagnostic accuracy studies of gFOBT conducted in symptomatic patients, retrieved by these
searches, were identified during the systematic review process. However, we do not consider that we have
conducted a full systematic review of guaiac faecal occult blood testing in symptomatic patients, as our
searches did not include terms for gFOBT product names and our inclusion criteria specified only those
studies of gFOBT that included a comparison to one or more FIT methods.
Clear inclusion criteria were specified in the protocol for this review, a copy of which is available online
(www.nice.org.uk/guidance/GID-DG10005/documents/final-protocol). The eligibility of studies for inclusion
is therefore transparent. In addition, we have provided specific reasons for exclusion for all of the studies
which were considered potentially relevant at initial citation screening and were subsequently excluded on
assessment of the full publication (see Appendix 4). The review process followed recommended methods
to minimise the potential for error and/or bias;37 studies were independently screened for inclusion by two
reviewers, and data extraction and quality assessment were undertaken by one reviewer and checked by a
second (MW and SL). Any disagreements were resolved by consensus.
All of the studies included in this review were assessed for risk of bias and applicability using the QUADAS-2
tool,45 which is recommended by the Cochrane Collaboration.39 QUADAS-2 is structured into four key
domains: participant selection, index test, reference standard and the flow of patients through the study
(including timing of tests). Each domain is rated for risk of bias (low, high or unclear); the participant selection,
index test and reference standard domain are also separately rated for concerns regarding the applicability
of the study to the review question (low, high or unclear). The results of the QUADAS-2 assessment are
reported, in full, for all of the included studies in Appendix 3 and are summarised in Chapter 3 (see Study
quality). Those studies that reported development of risk scores, in addition to test accuracy data, were also
assessed using the PROBAST tool.46 PROBAST has been designed to assess both the risk of bias and concerns
regarding applicability of a study that evaluates (develops and/or validates) a multivariable diagnostic or
prognostic prediction model. It has a domain-based structure, similar to that of QUADAS-2, and is intended to
be used for the assessment of primary studies that are included in a systematic review. PROBAST is not yet
published, but has been used with the consent of the steering group, of which the lead author of this
assessment report is a member.
This assessment includes information on the development and validation of risk scores that incorporate
faecal Hb levels measured by faecal immunochemical testing, as well as test accuracy data for faecal
immunochemical testing alone. Available data on the performance characteristics of such scores have
been included in order to inform the question of whether or not the performance characteristics of faecal
immunochemical testing can be improved by using it as part of a simple scoring system that includes other
information that is readily available to medical practitioners.
All of the studies included in our systematic review were conducted in Europe; however, only four
studies13,52,56,75 were conducted in the UK (one in England75 and three in Scotland13,52,56). Given that
population studies have shown variation in faecal Hb concentrations, and hence potential variation in
optimal thresholds for faecal immunochemical testing, across different geographic location,88,89 this may
limit the applicability of our findings to UK settings. In addition, the definitions of HRA used in UK studies
are generally based on number and size of lesions, as per BSG guidelines,90 whereas those conducted in
mainland Europe have used definitions that also include morphology. However, it should also be noted that
validation data for the FAST score (Callum Fraser, personal communication) indicated that there was no
significant difference in the sensitivity of the tool (for either CRC or advanced neoplasia) between Scotland
and Spain, the two countries where the majority of studies in our systematic review were conducted.
Although the sample sizes of studies included in our systematic review were generally large for diagnostic
accuracy studies (median n = 474, range 83–2058), it should be noted that study samples may not be
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representative of all of those people presenting in primary care with symptoms as specified in NG12.1
Only three of the studies13,52,56 included in our systematic review explicitly reported the number of people
who were invited to participate, and proportions agreeing were relatively low (64%,13 56%56 and 48%52),
implying that study samples may be self-selecting for more motivated patients.
A further limitation of the study populations is that no study reported data that were specific to the
population that was defined in the scope for this assessment (people presenting, in primary care settings,
with lower abdominal symptoms who are at low risk for CRC according to the criteria defined in
NG121). Only one study52 was conducted in a primary care setting, and this study reported that faecal
immunochemical testing was ordered by GPs at the point of referral to secondary care. Although the
primary care study might be considered the most applicable to this setting, because it is the only study to
allow a change in referral decision based on FIT result, this design also gives rise to a risk of bias, as 11% of
participants who returned a FIT sample were excluded from the analysis because they were not subsequently
referred to secondary care or the referral was cancelled.52 All of the studies included some participants who
had symptoms that may be considered to be associated with a higher probability of CRC and which are
components of the criteria for 2-week referral as defined in NG121 (e.g. rectal bleeding). The prevalence of
CRC and advanced neoplasia is likely to differ with different presenting symptoms and with the health-care
setting in which testing is undertaken (primary care vs. secondary care); the median prevalence of CRC
reported in the studies included in our systematic review was 3.0% (range 1.0–12.3%) compared with the
estimate of 1.5% for the relevant symptomatic group used in NG12.6 Although it is known that the prevalence
of the target condition can affect test performance characteristics,7 there are insufficient data to adequately
assess these effects for the use of faecal immunochemical testing in symptomatic patients. The results of our
systematic review do not suggest significant differences in test performance between the primary care study52
and other included studies that used the same FIT assay, threshold(s) and target condition (see Chapter 3,
Diagnostic performance of the OC-Sensor faecal immunochemical test assay). Similarly, validation data for the
FAST score (Callum Fraser, personal communication) indicated that there was no significant difference in the
sensitivity or specificity estimates for the score between primary and secondary care settings.
Systematic reviews conducted previously have assessed the test characteristics of various FIT assays in
screening settings8,131 and compared the performance of faecal immunochemical testing for CRC screening
with that of gFOBT.24,25 However, given the potential for target condition prevalence to affect test
performance characteristics,7 it is important to determine the diagnostic accuracy of faecal immunochemical
testing in the population of interest; we are not aware of any previous systematic review on this topic. We
identified one large systematic review132 that assessed the value of symptoms and additional diagnostic tests
for CRC, used in symptomatic patients in primary care. However, the searches for this review were completed
in 2008 and identified only three studies of quantitative FIT assays. Our searches identified all of the three
studies:133–135 one study133 was excluded from this assessment because it included a mixed population of
symptomatic, screening and high-risk patients and no separate data for the symptomatic subgroup, and the
remaining two studies134,135 were excluded because they used development stage Hb/Hp complex tests, which
are not currently available in the NHS. Additionally, Williams et al.136 have recently published a systematic
review of risk prediction models for CRC or HRA in people with symptoms. This review136 included 15 risk
models, none of which included faecal Hb measured by faecal immunochemical testing (or any other
method) as a variable. Our systematic review is the first to assess the performance of faecal immunochemical
testing, as a triage test for CRC, in people with symptoms and to consider the potential utility of applying
faecal immunochemical testing as part of a simple risk score.
Cost-effectiveness
A major strength of our analysis is that it is the first study to assess the cost-effectiveness of faecal
immunochemical testing as a triage test for symptomatic low-risk people presenting in primary care
settings, based on a systematic review of the accuracy of faecal immunochemical testing. The input
parameters used to model the accuracy of faecal immunochemical testing in the diagnostic part of the
cost-effectiveness model (decision tree) were informed by a comprehensive high-quality systematic
literature review on the clinical effectiveness of several FIT assays. For consistency, we sourced costs
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(other than those for faecal immunochemical testing and gFOBT) and CRC natural progression parameters
from the current clinical guideline NG12.6 These parameters were updated to their most recent values
when deemed necessary. Although many of the input parameters of our cost-effectiveness model are the
same as those described in NG12,6 the ones pertaining to faecal immunochemical testing differed because
we performed cost-effectiveness analyses for specific FIT assays. In NG12,6 faecal immunochemical testing
was included only as a single intervention and only in a scenario analysis.
A further strength of our study is that it includes detailed data on resource use and equipment costs for
faecal immunochemical testing. Data on resource use were obtained from expert opinion (e-mail from
Callum Fraser, NHS Tayside, to Marie Westwood, KSR Ltd, 19 July 2016, personal communication). This
was important because figures on resource use for the population considered in this diagnostic assessment
are scarce in the literature; we could not find any published study. Data on equipment costs were obtained
from the relevant companies and are presented in a detailed and transparent way in this diagnostic
assessment. This was also important because, in the papers found, which assessed the costs of faecal
immunochemical testing, it was not always clear how the total costs were estimated from resource use
and equipment costs.
Finally, we have considered a large variety of scenarios to explore the uncertainties around the assumptions
that were made in the cost-effectiveness model and, in order to quantify these uncertainties in a statistical
way, we performed PSAs for all of them.
The secondary care aspects of our model are a simplification of what actually occurs in practice. The ‘no
triage’ comparator arm would be more accurately described as ‘no FIT/gFOBT’, as the secondary care
consultation with a gastroenterologist clearly forms part of the triage before colonoscopy. The model
structure follows a similar approach to that used in NG12,6 in that it assumes that all of the patients with a
positive FIT/gFOBT and all of the patients in the ‘no FIT/gFOBT’ arm receive colonoscopy. However, the
alternative would involve trying to estimate the proportion of patients whom the gastroenterologist would
refer for colonoscopy without faecal immunochemical testing/gFOBT (this proportion would apply to the
‘no FIT/gFOBT’ arm). We would also need to estimate the effect that the positive FIT/gFOBT result has on
the gastroenterologist’s probability of requesting colonoscopy (numbers referred from the FIT/gFOBT-
positive pathway). We are not aware of any published data to inform these parameters, and asking
clinicians for estimates of their own performance (the accuracy of their referral decisions) has a high risk
of bias.
There is a potential problem with the population, which is based on NG12,6 in that it is likely to be
heterogeneous, such that many patients might better be treated with a watchful waiting strategy rather
than being referred immediately to secondary care. The model assumes that all of the patients who
present with the symptoms specified in NG126 would be treated in the same way by the GP. Hence, we
cannot capture the role of the GP’s clinical judgement in ruling out other possible explanations for the
presenting symptoms for which faecal immunochemical testing/gFOBT would not be helpful. In practice,
this is may be less of a problem than it appears, as the evidence from our systematic review is in a clinically
appropriate population (those for whom the GP is considering referral to secondary care or for whom a
referral decision has already been made). The prevalence of CRC in this population is also uncertain;
NG126 relied on expert opinion to provide an estimate, which was 1.5%. In the absence of any data that
were specific to this population, we also chose this value for the base case, although we tested the effect
of using prevalence as observed in the accuracy studies from our systematic review.
There is a potential for patients with a FIT FP test for CRC to benefit from referral to secondary care/
colonoscopy for diagnosis and treatment of conditions other than CRC (see Chapter 5, Clinical effectiveness).
This is not captured in our model, which is, therefore, likely to underestimate the cost-effectiveness of faecal
immunochemical testing.
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The limitations described for clinical effectiveness regarding the lack, or the poor quality, of accuracy data
for the different FIT assays are also applicable to the assessment of cost-effectiveness. Accuracy data were
not available for all of the relevant FIT methods and there were no studies that compared more than one
FIT method or that compared faecal immunochemical testing with gFOBT.
We lacked data to inform the parts of the diagnostic model that followed a FIT or gFOBT negative result.
Therefore, we assumed that those who have CRC would remain symptomatic and would be diagnosed
using colonoscopy or CTC. However, we did not know how many non-patients with CRC would also
remain symptomatic; hence, we sought expert opinion. We also had to seek expert opinion on the number
of patients who would get a second FIT/gFOBT, as well as the time to diagnosis of CRC. We did not seek
expert opinion on the accuracy of a second FIT/gFOBT, even though we had no data, because we believe
that this is something that cannot be reliably estimated by a clinician. We therefore sent out a questionnaire
to 10 specialists, five of whom returned it, although not all of the questions were completely answered. We
also conducted scenario analyses on the proportion who were symptomatic and time to diagnosis.
In the absence of data for this population, the probability of undergoing colonoscopy, as opposed to CTC,
was estimated to be 83% by the experts (four answers). However, this value seems to be low compared
with the screening population. Logan et al.126 found that, for approximately 98% of the screening patients
with an abnormal test result, the first investigation was colonoscopy. However, the ratio of colonoscopy to
CTC seems to vary by centre and ranges from 0.3% to 9.1%;137 therefore, this parameter was varied in
the scenario analysis.
In the base-case scenario, we assumed that adverse event rates for CTC were the same as those for
colonoscopy. However, Burling et al.19 reported that perforation rates for colonoscopy are four times higher
than for CTC. No death events were reported and the proportion of patients experiencing bleeding after
examination was not described. Thus, it is likely that our assumption would result in an overestimation of
the total number of adverse events. Nevertheless, as there is uncertainty around the appropriate estimates
for these adverse events, we decided to keep this assumption and interpret it as a worst-case scenario
regarding the total number of adverse events. We explored the impact of this assumption on the
cost-effectiveness results by performing additional scenario analyses.
Cost estimates for faecal immunochemical testing and gFOBT reported in the literature vary significantly.
In particular, the costs of faecal immunochemical testing found in the literature ranged from £1.96 to
£10.23 per test, and from (confidential information has been removed) to £9.57 per gFOBT. The estimated
costs for the OC-Sensor and the HM-JACKarc FIT assays used in this diagnostic assessment were £4.53 and
£6.04, respectively. Although the cost estimates used in this diagnostic assessment are properly reported,
we acknowledge that there is uncertainty around the underlying assumptions leading to them. For
example, it can be seen that, in Table 32, information for certain costs categories is missing. This may lead
to an underestimation of the cost estimates for faecal immunochemical testing. On the other hand, the
manufacturers indicated that the prices provided were also subject to discount, which could imply a lower
cost in practice. Ideally, training and staff costs should have been included for faecal immunochemical
testing and gFOBT. However, information about training and staff costs is scarce and, when available,
relates to dedicated service provision for the national screening programme. For this reason, we decided
not to include these costs in our health economic model. Nevertheless, as FIT assays use automated
immunoassay platforms, which are standard in clinical laboratories, we believe that training costs would
be minimal. To overcome these limitations, we performed threshold analyses on the cost differences
between tests.
Our diagnostic model did not include reduction in quality of life (disutilities) for the adverse events that are
associated with colonoscopy. Although no evidence was found on the effects of bleeding and perforation
on quality of life, some effects on quality of life might be expected. Nevertheless, as these events are often
of short duration, the effects on quality of life can be assumed negligible. Kapidzic et al.138 also reported
a slight reduction in quality of life for participants in a screening programme who had a positive result.
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This was due to the anxiety of knowing that they tested positive. However, these anxiety episodes can also
be assumed to be of short duration, with minimal effects on overall quality of life.
As mentioned in Chapter 3 (see Methods of analysis/synthesis), the sensitivity and specificity point estimates
for the OC-Sensor assay were derived using the bivariate model, which accounts for the correlation between
sensitivity and specificity. However, in the PSA, sensitivity and specificity were sampled independently from
the beta distributions presented in Table 23. Thus, the PSA does not account for the correlation between
sensitivity and specificity. This was a pragmatic choice, as insufficient data were available to allow an analysis
accounting for correlation for the HM-JACKarc or the FOB Gold assays.
The effect of a delayed CRC diagnosis was assumed to be mediated through the probability of progression
within Dukes’ states, for undiagnosed patients, given a delay in the base case of 6 months. This was because
the proportion of patients per Dukes’ stage for 6 months seemed to match reasonably well with the idea
that FN patients would remain symptomatic and thus be picked up well within 1 year. Estimates for delayed
diagnosis were also obtained from clinical experts, although only three of the experts who received our
questionnaire answered this question; expert estimates were even lower, with two of them estimating a
delay of approximately 2–3 months, whereas the third expert estimated this at between 1 and 2 months.
A delay of 1 year also seems to be too long because it would result in 45% at Dukes’ stage D. This was
deemed too high, given that the initial proportion of patients at stage D was 14%. The only published source
that we found reporting delayed diagnosis was the Meester et al. study.139 This study used a microsimulation
model to calculate the effect of delay to colonoscopy on an average-risk population cohort in the USA who
underwent annual FIT screening (from the age of 50 to 75 years), with follow-up colonoscopy examinations
for individuals with positive results in the following 12 months. For the scenario of diagnostic follow-up at
12 months from a positive FIT, diagnosed cancers shifted towards more advanced stages, but still with only
8% in stage D. Regardless of the precise delay and its effect on progression, the cost-effectiveness results did
not change significantly assuming 6 months’ or 1 year’s delay and so we decided not to run an additional
scenario for a smaller delay. Note, however, that, as the delay in diagnosis diminishes, the differences in
QALYs between the strategies decrease as well. In a hypothetical scenario with no delay, the difference in
QALYs will be caused only by mortality. In this situation, the strategy with the least number of colonoscopies
(gFOBT) is likely to dominate all of the others.
Colorectal cancer mortality was modelled using observational data by CRC stage at the time of diagnosis
from the NCIN,98 as used in NG12.6 Patients who survive might eventually progress, thus increasing
mortality. It was not clear the extent to which the effect of progression was included. We chose to include
a separate estimate of the rate of progression as in NG12.6 However, the progression probabilities, which
were obtained from Tappenden et al.,99 were for undiagnosed patients with CRC. This is an obvious
limitation, as diagnosed patients are considered in the model following colonoscopy. We also did not
model separately the effect of treatment on patients with CRC mortality or cost, assuming that the
estimates of mortality and cost were from all diagnosed patients with CRC, including those who had been
treated and indeed ‘cured’. This does mean that the effect of newer treatments and thus the effect of
delay to diagnosis cannot be taken into account.
Despite the limitations of the model for CRC progression described above, it should be emphasised that the
lifetime cost-effectiveness results of this diagnostic assessment are completely determined by the results of
the diagnostic part of the economic model. Thus, any difference between the strategies observed in the
lifetime results was already captured in the diagnostic phase. Beyond the diagnostic model, the differences
between the strategies were very small because these were caused only by the number of CRC-diagnosed
patients and the distribution of these between Dukes’ stages. Given that death (due to colonoscopy) in the
diagnostic phase is almost negligible, we could roughly estimate these as 15 patients with CRC from a
hypothetical cohort of 1000 (as the estimated prevalence of the disease is 1.5%). Therefore, any difference
in the lifetime results between the strategies will be caused by only these 15 patients. Hence, all of the
limitations and uncertainties of the model for CRC progression will have a minimal impact on the model
results of this diagnostic assessment. If the disease prevalence, the life expectancy or the costs and benefits
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of the treatments and surveillance of the population with the disease are likely to make a difference in the
lifetime cost-effectiveness results then all of the limitations of the CRC model should be explored with
extra caution.
Finally, we would like to emphasise the importance of specificity on the cost-effectiveness results. This can
be partly explained, for example, with simple algebra. As described in Chapter 4 (see Model parameters),
the probability that FIT/gFOBT is positive can be calculated as (sensitivity × prevalence) + [(1 – specificity) ×
(1 – prevalence)]. The first part of this equation (sensitivity × prevalence) is the probability of a TP, that is, of
sending patients who will be diagnosed with CRC. The second part [(1 – specificity) × (1 – prevalence)] is
the probability of a FP, that is, of wrongly sending healthy patients for colonoscopy. It is clear that in a
situation for which the prevalence is low, the weight of specificity on this equation is larger than that of
sensitivity, that is, any change in specificity will have a greater effect on the probability of FPs than any
change in sensitivity will have on the probability of TPs. In this diagnostic assessment, the prevalence of
CRC in the base-case population was assumed to be 1.5%. This means that the probability of a FP can
vary from 0 to 0.985, whereas the probability of a TP can vary only from 0 to 0.015. The question then is
what are the consequences, in terms of cost and QALYs, of either not missing TPs or avoiding FPs. People
without CRC might be subjected to unnecessary colonoscopies, incur unnecessary cost and experience
unnecessary adverse events (including death). On the other hand, patients with CRC might receive an
earlier diagnosis, resulting in an increased number of QALYs. In fact, there was very little difference in
QALYs between the FIT/gFOBT and the ‘no triage test’, which indicates little difference between avoiding
FPs or not missing TPs in terms of health effects. Nevertheless, it appears that, in our model, improved
specificity does outweigh improved sensitivity. This was clearly shown by the fact that OC-Sensor was
almost identical to ‘no triage test’ in terms of QALYs, but cheaper, whereas HM-JACKarc, with its higher
sensitivity and lower specificity, produced fewer QALYs and was more costly than OC-Sensor. This effect
was also observed in the scenario analyses using the estimates of gFOBT accuracy from Niv and Sperber92
and Bjerregaard et al.,93 where, with respect to the base-case scenario, sensitivity increased more than
specificity decreased (approximately 20–25% vs. 9–15%). The net effect of these changes was that the
cost-effectiveness results for gFOBT were worse than those obtained in the base-case scenario.
Uncertainties
Clinical effectiveness
There remain a number of areas of uncertainty in relation to the performance characteristics of faecal
immunochemical testing in specific patient subgroups and test combinations.
Population data indicate that concentrations of faecal Hb vary with age and sex, being higher in men and
the elderly.88,140 Further, a recent study conducted in Scotland found that faecal Hb concentrations also
increased with increasing levels of deprivation (measured using the Scottish Index of Multiple Deprivation)
and that this trend remained after controlling for age and sex.141 Thus, at any cut-off concentration, more
men, more older people and more people in high deprivation groups are likely to have a positive result on
faecal immunochemical testing. The performance of faecal immunochemical testing in these subgroups,
within the symptomatic population, is therefore an important consideration for this assessment; optimal
thresholds may differ between subgroups and may also differ depending on the geographic location in
which the test is being applied. The baseline characteristics of our included studies (where reported)
indicated that the average age of participants ranged from 59 to 67 years (total range was 16–94 years)
and the percentage of males ranged from 40.4% to 56%. However, only one of the studies included in
our systematic review compared the accuracy of a FIT assay (HM-JACKarc) in men and women,57 and no
study compared different age groups. The study reporting separate data for men and women found that,
at all thresholds, the observed sensitivity of HM-JACKarc for advanced neoplasia was higher in men than in
women and the observed specificity was similar for men and women.57 This indicates that, at any given
threshold, more women than men with CRC or HRA may be missed by using a FIT as a triage test to
determine referral to secondary care. However, it should be noted that this study differed from others in
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the systematic review in that it included some patients who were undergoing colonoscopy for polyp
surveillance and excluded people with GI bleeding or active rectal bleeding; the prevalence of CRC in this
study was the lowest of any included study (0.96%).57 More data are needed to adequately assess whether
or not there are clinically relevant differences in test performance between men and women, and these
data are needed for all FIT assays. We did not identify any studies that compared the accuracy of faecal
immunochemical testing in different age groups, or with varying levels of deprivation. Validation data
for the FAST score (Callum Fraser, personal communication) indicated that there were no significant
differences in the sensitivity of this tool between men and women and between patients aged < 50 years
and those who were ≥ 50 years old.
The effects on FIT performance of using multiple faecal samples per patient remain unclear. One published
study57 and one unpublished study, Hospital Clinic de Barcelona 2015 (Philippa Pinn, personal communication),
included in our systematic review, compared single sampling with double sampling, and both asked
participants to collect two consecutive faecal samples. The Auge et al. study57 used HM-JACKarc and reported
that sensitivity for advanced neoplasia was increased (at all thresholds) when the highest value from two
consecutive FIT samples was used, compared with using only the first sample; in this study, FIT results were
discordant in 39.2% of participants. The Hospital Clinic de Barcelona 2015 study (confidential information
has been removed). There is currently insufficient information about intra-individual variation in faecal Hb
concentration over time to determine the clinical utility of multiple sampling.
The scope of this assessment did not include evaluation of the performance characteristics of faecal
immunochemical testing when used in combination with other biomarkers. However, we identified one
study142 that did not meet the inclusion criteria for our systematic review because it used an obsolete FIT
assay, but that reported data on the performance characteristics of faecal immunochemical testing in
combination with faecal calprotectin, M2-PK or both (for which a positive result was defined as at least
one test being positive) for the target conditions of CRC and HRA, as well as data on the performance
characteristics of faecal immunochemical testing alone. Faecal calprotectin is an inflammatory marker,
whereas M2-PK is a key enzyme in tumour metabolism.142 This study142 found that, in all cases, the addition
of at least one further test to faecal immunochemical testing resulted in markedly increased sensitivity and
decreased specificity. The sensitivity and specificity estimates for faecal immunochemical testing alone and
CRC were 61.7% (95% CI 47.4% to 74.2%) and 88.8% (95% CI 84.1% to 92.3%), respectively; for
the combination of faecal immunochemical testing and faecal calprotectin these estimates were 90.9%
(95% CI 78.8% to 96.4%) and 35.9% (95% CI 29.7% to 42.6%), respectively; for faecal immunochemical
testing and M2-PK, sensitivity and specificity were 91.5% (95% CI 80.1% to 96.6%) and 57.1% (95% CI
50.6% to 63.2%), respectively, and, for all of the three markers, they were 95.7% (85.7% to 98.8%) and
24.1% (18.8% to 30.2%), respectively.142 Although all of the sensitivity estimates were generally lower, this
pattern was repeated when the target condition was advanced neoplasia.142 However, the FIT threshold in
this study (20 µg Hb/g faeces) was higher than that which the results of our systematic review indicate is likely
to be the optimal threshold (10 µg Hb/g faeces or a lower threshold). A second study143 of accuracy for the
target condition of advanced neoplasia, which did not meet the inclusion criteria for this assessment because
it used a qualitative FIT method, also found that combining faecal calprotectin with faecal immunochemical
testing (where a positive result was defined as either or both tests positive) resulted in increased sensitivity
and decreased specificity [92% (95% CI 82% to 97%) and 49% (95% CI 43% to 54%)] compared with
faecal immunochemical testing alone [74% (95% CI 62% to 83%) and 82% (95% CI 78% to 86%)].143
The effectiveness of combining other biomarkers with quantitative faecal immunochemical testing (at the
threshold at which faecal immunochemical testing is likely to be used in practice) remains unclear. We did not
identify any data about the effects of adding faecal calprotectin (or any other biomarker) to risk scores that
include faecal immunochemical testing. A study provided ahead of publication (e-mail from Karel Moons,
University Medical Center, Utrecht, the Netherlands, to Marie Westwood, KSR Ltd, 20 June 2016, personal
communication) reported the development of a multivariable diagnostic model for significant colorectal
disease (defined as CRC, adenoma of > 10mm, IBD or diverticulitis). This model included age, symptoms,
digital rectal examination, and point-of-care FITs and faecal calprotectin tests. The authors concluded that this
model may avoid approximately 30% of colonoscopy referrals from primary care at the cost of delaying
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around 6% of diagnoses (mostly HRA or diverticulitis); whether faecal calprotectin adds value, over and
above point-of-care FIT was uncertain. Given the trade-off between ease of use/simplicity and diagnostic
performance, the clinical value of including additional variables (e.g. symptoms and further diagnostic tests)
in risk scores for CRC and/or other significant bowel disease is likely to require further investigation.
There is uncertainty about downstream consequences of using faecal immunochemical testing to triage
symptomatic patients in primary care. It can be seen from the findings of our systematic review (see, in
Chapter 3, the sections relating to the diagnostic performance of the OC-Sensor, HM-JACKarc, FOB Gold
and RIDASCREEN FIT assays) that triage using faecal immunochemical testing at thresholds around
10 µg Hb/g faeces has the potential to correctly rule out CRC and avoid colonoscopy in approximately
75% of symptomatic patients and that this estimate does not appear to vary greatly between FIT assays.
Further, the relatively high proportion of FIT FPs observed when the target condition is CRC may be
mitigated by the detection of other bowel pathologies in these patients; we estimate that between 22.5%
and 93% of patients with a positive FIT and no CRC will have other significant bowel pathologies,
depending largely on how many, and which, diagnoses are included in the target condition.
The full potential benefits of faecal immunochemical testing in symptomatic patients, including those
relating to diagnoses other than CRC, remain unclear. This issue may be particularly important in younger
patients, in whom the prevalence of CRC is lowest and other diagnoses are more likely. Our systematic
review identified a recently published protocol for a cluster randomised trial (NCT02308384) of a clinical
education intervention (provision of a starting package of faecal immunochemical testing with clinical
instructions, including guidance on interpretation of results) in general practices in Denmark, which may
partially address these issues.144 The stated aim of this trial is to assess the diagnostic value and clinical
implications of using faecal immunochemical testing, in general practice, for patients presenting with
non-alarm symptoms of CRC (‘low risk, but not no risk’). This population is defined as patients aged
≥ 30 years with symptoms and signs of CRC, but who do not meet the Danish Cancer Patient Pathway
referral criteria; typical indications are given as change in bowel habit, abdominal pain, anaemia or
decrease in Hb of > 10%, non-specific symptoms (weight loss, fatigue, loss of appetite). The specified
outcome measures for clinical impact are age- and sex-standardised number and rate of urgent referrals
for CRC; age- and sex-standardised number and rate of colonoscopies; all colonoscopy findings by ICD-10
code; age- and sex-standardised number of CRCs diagnosed; stage distribution of CRC diagnosed (I–IV).
This trial has the potential to inform the clinical effectiveness component of this assessment, but will not
address all potentially relevant applications of faecal immunochemical testing, as it is designed to assess
faecal immunochemical testing as a rule-in test, with all patients who have a positive result (≥ 50 µg/l Hb,
equivalent to 10 µg Hb/g faeces using OC-Sensor) receiving urgent colonoscopy referral; interpretation
guidance in the protocol states that a negative FIT should not exclude CRC.
Finally, the acceptability of faecal immunochemical testing, as indicated by reported sample return rates,
varied widely between the studies included in our systematic review. There is evidence that faecal
immunochemical testing is more acceptable, when used as a screening test/method, than gFOBT; the use
of faecal immunochemical testing in screening programmes results in increased uptake compared with
gFOBT.145 However, these data are unlikely to be transferable to symptomatic patients, for whom factors
such as the setting in which the test is requested, and advice and information received directly from
clinicians, will affect uptake rates. It therefore remains unclear whether or not the method of assessing
faecal occult blood has any effect on uptake in patients who are symptomatic.
Cost-effectiveness
The main uncertainties described for the review of clinical effectiveness also apply to the assessment of
cost-effectiveness. These are caused by a lack of clinical effectiveness data for the performance characteristics
of faecal immunochemical testing in specific patient subgroups and for the effects of using multiple faecal
samples. Once these uncertainties are resolved, the cost-effectiveness of faecal immunochemical testing
could be assessed for different subgroups of patients (e.g. elderly) and faecal immunochemical testing using
multiple faecal samples per patient could be included as an intervention in our cost-effectiveness model.
DISCUSSION
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Chapter 6 Conclusions
Implications for service provision
There is evidence to suggest that triage using faecal immunochemical testing, when used at a threshold
of 10 µg Hb/g faeces for OC-Sensor or HM-JACKarc, may be sufficient to rule out CRC in symptomatic
patients. In addition, the relatively high proportion of FIT FPs observed when the target condition is CRC
may be mitigated by the potential to diagnose other bowel pathologies in these patients. There was
insufficient evidence to adequately assess the diagnostic performance of FOB Gold in symptomatic patients.
No evidence about the diagnostic performance of RIDASCREEN Hb or RIDASCREEN Hb/Hp complex in
symptomatic patients was identified. No studies were identified that directly compared the performance of
different FIT assays, or that compared one or more FIT assays with a gFOBT method; therefore, the relative
effectiveness of different methods of measuring faecal occult blood remains uncertain.
The base-case cost-effectiveness results suggested that the difference in QALYs between all of the strategies
included in this assessment is minimal and that the ‘no triage’ strategy (referral to colonoscopy) is the most
expensive. Overall, faecal immunochemical testing appeared to be cost-effective when compared with no
triage or gFOBT. The results of the different scenario analyses did not differ substantively from the base-case
results. However, the scenarios for which the accuracy estimates for gFOBT were based on studies that were
considered to be more representative of the population of this diagnostic assessment were more favourable
than the base-case scenario with regard to faecal immunochemical testing. The results of our analysis
suggest that faecal immunochemical testing could provide a cost-effective (cost-saving) triage option for
patients whose symptoms are not considered high risk for CRC.
Suggested research priorities
Further, large diagnostic cohort studies are needed to fully evaluate the performance of quantitative faecal
immunochemical testing in the setting (primary care) and population (symptomatic patients who are at
low risk of CRC, as defined in NG121) specified in the scope for this assessment. Studies comparing the
performance of different FIT assays are also needed; such studies should be direct comparisons, involving
patients providing multiple samples from a single bowel movement.
If adoption of the FOB Gold, RIDASCREEN Hb or RIDASCREEN Hb/Hp complex is to be considered, studies
are needed to evaluate the diagnostic accuracy of these tests in symptomatic patients and to determine
optimal thresholds.
If FIT is introduced into routine practice in primary care, a post-implementation audit would be valuable. For
example, this could be used to investigate the proportion of FIT-negative patients who go on to have a
colonoscopy as well as the delay to getting the colonoscopy. This would improve cost-effectiveness modelling,
given that these two parameters had to be estimated using expert opinion. In addition, patients could be
followed up to measure mortality and progression, particularly as, as in NG12,6 the cost-effectiveness analysis
relied on data on progression from those who were undiagnosed.
Studies comparing the effectiveness of different approaches to safety netting in patients who have
negative FIT results may be useful in optimising care pathways.
Multivariable prediction modelling studies may be useful to assess the independent predictive value of a
positive FIT result, in the context of other clinical risk factors and tests. This approach may be considered to
be the most efficient method of capturing the effects of clinical judgement. Prediction modelling studies
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should consider the trade-off between the potential for improved model performance and ease of use
(the extent to which the components of any risk score developed are readily available to GPs).
Studies that are designed to capture the full potential benefits of faecal immunochemical testing in
symptomatic patients, including those relating to diagnoses other than CRC, are likely to be informative.
This issue may be particularly important in younger patients, among whom the prevalence of CRC is
lowest and other diagnoses are more likely. An example of such a study might be a cluster RCT, in which
primary care practices are randomised to use FIT triage in the relevant patient group or refer all patients
in the relevant symptomatic group to secondary care; outcomes could include urgent referral rates,
colonoscopy rates and all diagnoses at colonoscopy.
Further diagnostic cohort studies, or subgroup analyses of existing data sets, are needed to fully explore
the possible variation in the accuracy of FIT assays and optimal thresholds in relevant subgroups, for
example sex and age.
Studies exploring the diagnostic accuracy of faecal immunochemical testing using multiple samples and
faecal immunochemical testing in combination with other biomarkers (e.g. faecal calprotectin or M2-PK),
sequential testing using faecal immunochemical testing and other biomarkers, as well as comparisons
between faecal immunochemical testing and other biomarkers, may also be of value.
CONCLUSIONS
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of York; 2009. URL: www.york.ac.uk/inst/crd/SysRev/!SSL!/WebHelp/SysRev3.htm (accessed
23 March 2011).
148. Papaioannou D, Brazier JE, Paisley S. Figure 4: Common Free-text Terms for Electronic Database
Searching for HSUVs. In NICE DSU Technical Support Document 9: The Identification, Review and
Synthesis of Health State Utility Values from the Literature. 2011. URL: www.nicedsu.org.uk
(accessed 18 August 2011).
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Appendix 1 Literature search strategies
Clinical effectiveness searches
MEDLINE (via Ovid): 1946 to March Week 3 2016
Date searched: 30 March 2016.
Records found: 3198.
1. ((immunochem$ or immuno-chem$ or immunohistochem$ or immuno-histochem$ or immunol$ or
immunochromatographic or immuno-chromatographic or immunoassay or immuno assay) adj4 (f?ecal
or f?eces or stool or stools)).ti,ab,ot,hw. (910)
2. iFOBT.ti,ab,ot,hw. (83)
3. 1 or 2 (932)
4. F?ecal h?emoglobin.ti,ab,ot,hw. (94)
5. H?emoccult.ti,ab,ot,hw. (669)
6. FOBT.ti,ab,ot,hw. (1013)
7. (guaiac$ or gFOBT).ti,ab,ot,hw. (3444)
8. Guaiac/ (319)
9. or/4-8 (4898)
10. (f?ecal or f?eces or stool or stools).ti,ab,ot,hw. (246,345)
11. occult blood/ or occult blood.ti,ab,ot,hw. (6307)
12. (test$ or measur$ or screen$ or exam$).ti,ab,ot,hw. (6,577,832)
13. 10 and 11 and 12 (3172)
14. 3 or 9 or 13 (7254)
15. exp colorectal neoplasms/ (162,552)
16. exp cecal neoplasms/ (4892)
17. ((colorect$ or rectal$ or rectum$ or colon$ or sigma$ or sigmo$ or rectosigm$ or bowel$ or anal
or anus) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or
adenocarcinoma$ or sarcoma$ or adenom$ or lesion$)).ti,ab,ot,hw. (199,488)
18. CRC.ti,ab,ot. (13,848)
19. ((cecum or cecal or caecum or caecal or il?eoc?ecal or il?eoc?ecum) adj3 (cancer$ or neoplas$ or
oncolog$ or malignan$ or tumo?r$ or carcinoma$ or adenocarcinoma$ or sarcoma$ or adenom$ or
lesion$)).ti,ab,ot. (1846)
20. (large intestin$ adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or
adenocarcinoma$ or sarcoma$ or adenom$ or lesion$)).ti,ab,ot. (1675)
21. (lower intestin$ adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or
adenocarcinoma$ or sarcoma$ or adenom$ or lesion$)).ti,ab,ot. (26)
22. 15 or 16 or 17 or 18 or 19 or 20 or 21 (208,172)
23. 14 and 22 (3206)
24. (FOB gold$ or FOBgold$).ti,ab. (11)
25. (jack-arc$ or jackarc$ or HM-JACKarc$).ti,ab. (0)
26. (RIDASCREEN$ H?emo$ or RIDASCREEN$ Hapto$).ti,ab. (1)
27. (OC Sensor$ or OC-Sensor$ or OC Pledia$ or OC-Pledia$).ti,ab. (38)
28. or/24-27 (43)
29. 23 or 28 (3208)
30. exp animals/ not (exp animals/ and humans/) (4,205,567)
31. 29 not 30 (3198)
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MEDLINE In-Process & Other Non-Indexed Citations, MEDLINE Daily Update (via Ovid):
March 29, 2016
Date searched: 30 March 2016.
Records found: 255.
1. ((immunochem$ or immuno-chem$ or immunohistochem$ or immuno-histochem$ or immunol$ or
immunochromatographic or immuno-chromatographic or immunoassay or immuno assay) adj4
(f?ecal or f?eces or stool or stools)).ti,ab,ot,hw. (134)
2. iFOBT.ti,ab,ot,hw. (9)
3. 1 or 2 (138)
4. F?ecal h?emoglobin.ti,ab,ot,hw. (16)
5. H?emoccult.ti,ab,ot,hw. (23)
6. FOBT.ti,ab,ot,hw. (72)
7. (guaiac$ or gFOBT).ti,ab,ot,hw. (321)
8. Guaiac/ (0)
9. or/4-8 (418)
10. (f?ecal or f?eces or stool or stools).ti,ab,ot,hw. (18,710)
11. occult blood/ or occult blood.ti,ab,ot,hw. (302)
12. (test$ or measur$ or screen$ or exam$).ti,ab,ot,hw. (671,105)
13. 10 and 11 and 12 (202)
14. 3 or 9 or 13 (632)
15. exp colorectal neoplasms/ (220)
16. exp cecal neoplasms/ (1)
17. ((colorect$ or rectal$ or rectum$ or colon$ or sigma$ or sigmo$ or rectosigm$ or bowel$ or anal
or anus) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or
adenocarcinoma$ or sarcoma$ or adenom$ or lesion$)).ti,ab,ot,hw. (14,744)
18. CRC.ti,ab,ot. (2522)
19. ((cecum or cecal or caecum or caecal or il?eoc?ecal or il?eoc?ecum) adj3 (cancer$ or neoplas$ or
oncolog$ or malignan$ or tumo?r$ or carcinoma$ or adenocarcinoma$ or sarcoma$ or adenom$ or
lesion$)).ti,ab,ot. (197)
20. (large intestin$ adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or
adenocarcinoma$ or sarcoma$ or adenom$ or lesion$)).ti,ab,ot. (40)
21. (lower intestin$ adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or
adenocarcinoma$ or sarcoma$ or adenom$ or lesion$)).ti,ab,ot. (0)
22. 15 or 16 or 17 or 18 or 19 or 20 or 21 (15,079)
23. 14 and 22 (254)
24. (FOB gold$ or FOBgold$).ti,ab. (2)
25. (jack-arc$ or jackarc$ or HM-JACKarc$).ti,ab. (3)
26. (RIDASCREEN$ H?emo$ or RIDASCREEN$ Hapto$).ti,ab. (0)
27. (OC Sensor$ or OC-Sensor$ or OC Pledia$ or OC-Pledia$).ti,ab. (3)
28. or/24-27 (6)
29. 23 or 28 (255)
30. exp animals/ not (exp animals/ and humans/) (3648)
31. 29 not 30 (255)
MEDLINE Epub Ahead of Print (via Ovid): June 20, 2016
Date searched: 21 June 2016.
Records found: 80.
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1. ((immunochem$ or immuno-chem$ or immunohistochem$ or immuno-histochem$ or immunol$ or
immunochromatographic or immuno-chromatographic or immunoassay or immuno assay) adj4 (f?ecal
or f?eces or stool or stools)).ti,ab,ot,hw. (36)
2. iFOBT.ti,ab,ot,hw. (3)
3. 1 or 2 (37)
4. F?ecal h?emoglobin.ti,ab,ot,hw. (4)
5. H?emoccult.ti,ab,ot,hw. (1)
6. FOBT.ti,ab,ot,hw. (24)
7. (guaiac$ or gFOBT).ti,ab,ot,hw. (77)
8. Guaiac/ (0)
9. or/4-8 (102)
10. (f?ecal or f?eces or stool or stools).ti,ab,ot,hw. (1652)
11. occult blood/ or occult blood.ti,ab,ot,hw. (73)
12. (test$ or measur$ or screen$ or exam$).ti,ab,ot,hw. (131,690)
13. 10 and 11 and 12 (65)
14. 3 or 9 or 13 (156)
15. 15 exp colorectal neoplasms/ (0)
16. exp cecal neoplasms/ (0)
17. ((colorect$ or rectal$ or rectum$ or colon$ or sigma$ or sigmo$ or rectosigm$ or bowel$ or anal
or anus) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or
adenocarcinoma$ or sarcoma$ or adenom$ or lesion$)).ti,ab,ot,hw. (3630)
18. CRC.ti,ab,ot. (799)
19. ((cecum or cecal or caecum or caecal or il?eoc?ecal or il?eoc?ecum) adj3 (cancer$ or neoplas$ or
oncolog$ or malignan$ or tumo?r$ or carcinoma$ or adenocarcinoma$ or sarcoma$ or adenom$ or
lesion$)).ti,ab,ot. (16)
20. (large intestin$ adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or
adenocarcinoma$ or sarcoma$ or adenom$ or lesion$)).ti,ab,ot. (12)
21. (lower intestin$ adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or
adenocarcinoma$ or sarcoma$ or adenom$ or lesion$)).ti,ab,ot. (0)
22. 15 or 16 or 17 or 18 or 19 or 20 or 21 (3677)
23. 14 and 22 (80)
24. (FOB gold$ or FOBgold$).ti,ab. (1)
25. (jack-arc$ or jackarc$ or HM-JACKarc$).ti,ab. (0)
26. (RIDASCREEN$ H?emo$ or RIDASCREEN$ Hapto$).ti,ab. (0)
27. (OC Sensor$ or OC-Sensor$ or OC Pledia$ or OC-Pledia$).ti,ab. (5)
28. or/24-27 (5)
29. 23 or 28 (80)
30. exp animals/ not (exp animals/ and humans/) (0)
31. 29 not 30 (80)
EMBASE (via Ovid): 1974 to 2016 March 29
Date searched: 30 March 2016.
Records found: 5255.
1. Fecal Immunochemical Test/ [EMTREE candidate term 13.1.16] (135)
2. ((immunochem$ or immuno-chem$ or immunohistochem$ or immuno-histochem$ or immunol$ or
immunochromatographic or immuno-chromatographic or immunoassay or immuno assay) adj4 (f?ecal
or f?eces or stool or stools)).ti,ab,ot,hw. (1630)
3. iFOBT.ti,ab,ot,hw. (164)
4. 1 or 2 or 3 (1672)
5. F?ecal h?emoglobin.ti,ab,ot,hw. (155)
6. H?emoccult.ti,ab,ot,hw. (866)
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7. FOBT.ti,ab,ot,hw. (1857)
8. (guaiac$ or gFOBT).ti,ab,ot,hw. (5159)
9. Guaiac/ (696)
10. or/5-9 (7538)
11. (f?ecal or f?eces or stool or stools).ti,ab,ot,hw. (347,542)
12. occult blood/ or occult blood.ti,ab,ot,hw. (11,184)
13. (test$ or measur$ or screen$ or exam$).ti,ab,ot,hw. (9,112,793)
14. 11 and 12 and 13 (5121)
15. 4 or 10 or 14 (11,582)
16. exp colon tumor/ (239,813)
17. exp rectum tumor/ (182,401)
18. exp colon cancer/ (191,557)
19. exp rectum cancer/ (148,462)
20. ((colorect$ or rectal$ or rectum$ or colon$ or sigma$ or sigmo$ or rectosigm$ or bowel$ or anal
or anus) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or
adenocarcinoma$ or sarcoma$ or adenom$ or lesion$)).ti,ab,ot,hw. (318,031)
21. CRC.ti,ab,ot. (27,205)
22. ((cecum or cecal or caecum or caecal or il?eoc?ecal or il?eoc?ecum) adj3 (cancer$ or neoplas$ or
oncolog$ or malignan$ or tumo?r$ or carcinoma$ or adenocarcinoma$ or sarcoma$ or adenom$ or
lesion$)).ti,ab,ot. (2649)
23. (large intestin$ adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or
adenocarcinoma$ or sarcoma$ or adenom$ or lesion$)).ti,ab,ot. (1929)
24. (lower intestin$ adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or
adenocarcinoma$ or sarcoma$ or adenom$ or lesion$)).ti,ab,ot. (29)
25. or/16-24 (329,839)
26. 15 and 25 (5264)
27. (FOB gold$ or FOBgold$).ti,ab. (27)
28. (jack-arc$ or jackarc$ or HM-JACKarc$).ti,ab. (7)
29. (RIDASCREEN$ H?emo$ or RIDASCREEN$ Hapto$).ti,ab. (2)
30. (OC Sensor$ or OC-Sensor$ or OC Pledia$ or OC-Pledia$).ti,ab. (151)
31. or/27-30 (169)
32. 26 or 31 (5274)
33. animal/ (1,733,374)
34. animal experiment/ (1,919,080)
35. (rat or rats or mouse or mice or murine or rodent or rodents or hamster or hamsters or pig or pigs or
porcine or rabbit or rabbits or animal or animals or dogs or dog or cats or cow or bovine or sheep or
ovine or monkey or monkeys).ti,ab,ot,hw. (6,178,883)
36. or/33-35 (6,178,883)
37. exp human/ (16,972,709)
38. human experiment/ (350,478)
39. or/37-38 (16,974,155)
40. 36 not (36 and 39) (4,862,933)
41. 32 not 40 (5255)
The Cochrane Library (Wiley) (via the internet)
www.cochranelibrary.com/
Date searched: 30 March 2016.
Records found:
l CDSR: Issue 3 of 12, March 2016: 25 records
l DARE: Issue 2 of 4, April 2015: 34 records
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l HTA Database: Issue 1 of 4, January 2016: 27 records
l NHS EED: Issue 2 of 4, April 2015: 103 records
l CENTRAL: Issue 2 of 12, February 2016: 446 records.
#1 (immunochem* or “immuno-chem*” or immunohistochem* or “immuno-histochem*” or immunol*)
near/4 (f*ecal or f*eces) (237)
#2 iFOBT (14)
#3 “F*ecal h*emoglobin” (15)
#4 H*emoccult (143)
#5 FOBT (247)
#6 gFOBT or guaiac (132)
#7 [mh ^guaiac] (30)
#8 f*ecal or f*eces or stool or stools (9516)
#9 MeSH descriptor: [Occult Blood] this term only (480)
#10 “occult blood” (907)
#11 #9 or #10 (907)
#12 test* or measur* or screen* or exam* (430,115)
#13 #8 and #11 and #12 (683)
#14 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #13 (931)
#15 MeSH descriptor: [Colorectal Neoplasms] explode all trees (6053)
#16 MeSH descriptor: [Cecal Neoplasms] explode all trees (9)
#17 (colorec* or rectal* or rectum* or colon* or sigma* or sigmo* or rectosigm* or bowel* or anal
or anus) near/3 (cancer* or neoplas* or oncolog* or malignan* or tumo*r* or carcinoma* or
adenocarcinoma* or sarcoma* or adenom* or lesion*) (12,274)
#18 CRC (1334)
#19 (cecum or cecal or caecum or caecal or il*eoc*ecal or il*eoc*ecum) near/3 (cancer* or neoplas* or
oncolog* or malignan* or tumo*r* or carcinoma* or adenocarcinoma* or sarcoma* or adenom* or
lesion*) (99)
#20 “large intestin*” near/3 (cancer* or neoplas* or oncolog* or malignan* or tumo*r* or carcinoma* or
adenocarcinoma* or sarcoma* or adenom* or lesion*) (54)
#21 “lower intestin*” near/3 (cancer* or neoplas* or oncolog* or malignan* or tumo*r* or carcinoma* or
adenocarcinoma* or sarcoma* or adenom* or lesion*) (0)
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#22 #15 or #16 or #17 or #18 or #19 or #20 or #21 (12627)
#23 #14 and #22 (638)
#24 “FOB gold*” or “FOBgold*” (2)
#25 “jack-arc*” or “jackarc*” or “HM-JACKarc*” (0)
#26 “RIDASCREEN* Haemo*” or “RIDASCREEN* Hemo*” or “RIDASCREEN* Hapto*” (0)
#27 “OC Sensor*” or “OC-Sensor*” or “OC Pledia*” or “OC-Pledia*” (16)
#28 #24 or #25 or #26 or #27 (16)
#29 #23 or #28 (638) (CDSR: 25; DARE: 34; HTA: 27; NHS EED: 103; CENTRAL: 446)
International Network of Agencies for Health Technology Assessment Publications
www.inahta.org/publications/
Date searched: 30 March 2016.
Records found: 8.
Search terms Records found
Faeces 0
Feces 0/2
Faecal 1/2
Fecal 7/20
Guaiac 4/4
Total (before deduplication) 12
Total (after deduplication) 8
National Institute for Health Research Health Technology Assessment programme
www.nets.nihr.ac.uk/projects?collection=netscc&meta_P_sand=Project
Date searched: 30 March 2016.
Records found: 1.
Search terms Records found
Faeces 0/3
Feces 0
Faecal 1/13
Fecal 0/3
Guaiac 0
Total (before deduplication) 1
Total (after deduplication) 1
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Aggressive Research Intelligence Facility Reviews Database
www.birmingham.ac.uk/research/activity/mds/projects/HaPS/PHEB/ARIF/databases/index.aspx
Date searched: 30 March 2016.
Records found: 17.
Search terms Records found
Faeces 0/2
Feces 0/1
Faecal 8/23
Fecal 12/20
Guaiac 3/3
Total (before deduplication) 23
Total (after deduplication) 17
PROSPERO (via internet)
www.crd.york.ac.uk/prospero/
Date searched: 30 March 2016.
Records found: 9.
Search terms Records found
Faeces 1/9
Feces 2/14
Faecal 1/38
Fecal 8/50
Guaiac 4/4
Total (before deduplication) 16
Total (after deduplication) 9
ClinicalTrials.gov (via internet)
https://clinicaltrials.gov/
Date searched: 8 March 2016.
Records found: 51.
Search terms
Records
found
“faecal immunochemical” OR “fecal immunochemical” OR “faecal immuno-chemical” OR “fecal immuno-
chemical” OR iFOBT OR “FOB Gold” OR FOBGold OR JACKarc OR RIDASCREEN OR “OC Sensor” OR “OC
Pledia”
51
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European Union Clinical Trials Register (via internet)
www.clinicaltrialsregister.eu/ctr-search/search
Date searched: 8 March 2016.
Records found: 1.
Search terms
Records
found
“faecal immunochemical” OR “fecal immunochemical” OR “faecal immuno-chemical” OR “fecal
immuno-chemical” OR iFOBT OR FOBT OR “FOB Gold” OR FOBGold OR JACKarc OR RIDASCREEN OR
“OC Sensor” OR “OC Pledia”
1
International Clinical Trials Registry Platform (via internet)
http://apps.who.int/trialsearch/
Date searched: 8 March 2016.
Records found: 29.
Search terms
Records
found
faecal immunochemical OR fecal immunochemical OR faecal immuno-chemical OR fecal immuno-chemical OR
iFOBT OR FOB Gold OR FOBGold OR JACKarc OR RIDASCREEN OR OC Sensor OR OC Pledia
29
American Gastroenterological Association – Digestive Disease Week 2011–15
Date searched: 13 April 2016.
Records found: 92.
www.gastrojournal.org/content/ddw_abstracts
2011 DDW Abstract Supplement
www.gastrojournal.org/issue/S0016-5085%2811%29X6001-8
2012 DDW Abstract Supplement
www.gastrojournal.org/issue/S0016-5085%2812%29X6001-3
2013 DDW Abstract Supplement
www.gastrojournal.org/issue/S0016-5085%2813%29X6001-9
2014 DDW Abstract Supplement
www.gastrojournal.org/issue/S0016-5085%2814%29X6001-4
2015 DDW Abstract Supplement
www.gastrojournal.org/issue/S0016-5085%2815%29X6001-X
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Search terms 2011 2012 2013 2014 2015 TOTAL
“faecal immunochemical” 1 5 0 2 3
“fecal immunochemical” 9 7 14 16 15
“faecal immuno-chemical” 0 0 0 0 0
“fecal immuno-chemical” 0 0 0 0 0
iFOBT 4 0 3 1 10
“FOB Gold” 0 0 0 0 0
FOBGold 0 0 0 0 0
JACKarc 0 0 0 0 0
RIDASCREEN 0 0 0 0 0
“OC Sensor” 0 1 0 0 0
“OC Pledia” 0 0 0 0 0
TOTAL (after deduplication) 14 14 17 19 28 92
Annual Meeting of the American Association for Clinical Biochemistry and
Laboratory Medicine 2011–15
Date searched: 13 April 2016.
Records found: 3.
www.aacc.org/science-and-research/annual-meeting-abstracts-archive
2011 AACC Annual Meeting
www.aacc.org/∼/media/files/annual-meeting/2011/aacc_11_fullabstract.pdf?la=en
2012 AACC Annual Meeting
www.aacc.org/∼/media/files/annual-meeting/2012/aacc_12_abstractbookfinalcomplete.pdf?la=en
2013 AACC Annual Meeting
www.aacc.org/∼/media/files/annual-meeting/2013/aacc_13_abstractbook_complete.pdf?la=en
2014 AACC Annual Meeting
www.aacc.org/∼/media/files/annual-meeting/2014/abstracts/aacc_14_abstractbook_1_combined.pdf?la=en
2015 AACC Annual Meeting
www.aacc.org/∼/media/files/annual-meeting/2015/abstracts-2/aacc2015_abstractbook_final_completer1.
pdf?la=en
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Search terms 2011 2012 2013 2014 2015 TOTAL
faecal immunochemical 0 0 0 0 0
fecal immunochemical 1 0 0 1 0
faecal immuno-chemical 0 0 0 0 0
fecal immuno-chemical 0 0 0 0 0
FIT 1 0 0 1 0
iFOBT 0 0 0 0 0
FOB Gold 0 0 1 1 0
FOBGold 0 0 0 1 0
JACKarc 0 0 0 0 0
RIDASCREEN 0 0 0 0 0
OC Sensor 0 0 0 0 0
OC Pledia 0 0 0 0 0
TOTAL (after deduplication) 1 0 1 1 0 3
British Society of Gastroenterology Annual Meeting 2011–15
Date searched: 13 April 2016.
Records found: 6.
www.bsg.org.uk/education/meeting/index.html
British Society of Gastroenterology Annual Meeting 2011
www.bsg.org.uk/images/stories/docs/education/2011_bsg_prog_text.pdf
British Society of Gastroenterology Annual Meeting 2012
www.bsg.org.uk/images/stories/docs/education/2012_ddf_prog_text.pdf
British Society of Gastroenterology Annual Meeting 2013
www.bsg.org.uk/images/stories/docs/education/2013_bsg_prog_text.pdf
British Society of Gastroenterology Annual Meeting 2014
www.bsg.org.uk/images/stories/docs/education/2014_bsg_prog_text.pdf
2015 – 2nd Digestive Disorders Federation Conference 22–25 June 2015 – Joint conference with The
Association of Coloproctology of Great Britain & Ireland (ACPGBI), Association of Upper Gastrointestinal
Surgeons (AUGIS), British Association for Parenteral and Enteral Nutrition (BAPEN), British Association for
the Study of the Liver (BASL), British Society of Gastroenterology (BSG)
http://gut.bmj.com/content/64/Suppl_1.toc
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Search terms 2011 2012 2013 2014 2015 TOTAL
faecal immunochemical 0 0 1 1 3
fecal immunochemical 0 0 0 0 0
faecal immuno-chemical 0 0 0 0 0
fecal immuno-chemical 0 0 0 0 0
FIT 0 1 1 0 3
iFOBT 0 0 0 0 0
FOB Gold 0 0 0 0 0
FOBGold 0 0 0 0 0
JACKarc 0 0 0 0 0
RIDASCREEN 0 0 0 0 0
OC Sensor 0 0 0 0 1
OC Pledia 0 0 0 0 0
TOTAL (after deduplication) 0 1 1 1 3 6
EuroMedLab: International Federation of Clinical Chemistry and Laboratory Medicine/
European Federation of Clinical Chemistry and Laboratory Medicine, European Congress
of Clinical Chemistry and Laboratory Medicine 2011–15 (every 2 years)
Date searched: 13 April 2016.
Records found: 5.
www.ifcc.org/ifcc-congresses-and-conferences/ifcc-eflm-euromedlab-congresses/
EuroMedLab 2011 – 19th IFCC-EFCC European Congress of Clinical Chemistry and Laboratory Medicine
http://ukb.lf1.cuni.cz/abstrakta/ifcc2011_abstr.pdf
EuroMedLab 2013 - 20th IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicine
www.sibioc.it/bc/numero/bcnum/132
EuroMedLab 2015 – 21st IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicine
www.degruyter.com/view/j/cclm.2015.53.issue-s1/issue-files/cclm.2015.53.issue-s1.xml
Search terms 2011 2013 2015 TOTAL
faecal immunochemical 0 1 1
fecal immunochemical 0 2 0
faecal immuno-chemical 0 0 0
fecal immuno-chemical 0 0 0
FIT 0 1 1
iFOBT 0 0 0
FOB Gold 1 1 0
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Search terms 2011 2013 2015 TOTAL
FOBGold 0 0 0
JACKarc 0 0 0
RIDASCREEN 0 0 0
OC Sensor 0 0 1
OC Pledia 0 0 0
TOTAL (after deduplication) 1 2 2 5
United European Gastroenterology Week 2011–15
Date searched: 4 May 2016.
Records found: 47.
www.ueg.eu/week/
23rd United European Gastroenterology Week
Barcelona, Spain. October 24–28, 2015
www.ueg.eu/epaper/UEGWeek.2015.FinalProgramme/files/assets/common/downloads/publication.pdf
22nd United European Gastroenterology Week
Vienna, Austria. October 18–22, 2014
www.ueg.eu/fileadmin/user_upload/documents/week14/ueg%20week%202014_final_programme.pdf
21st United European Gastroenterology Week
Berlin, Germany. October 12–16, 2013
www.ueg.eu/fileadmin/user_upload/documents/Week13/ueg_week_2013_final_programme.pdf
20th United European Gastroenterology Week
Amsterdam, the Netherlands. October 20–24, 2012
www.ueg.eu/fileadmin/user_upload/documents/Week13/ueg_week_2012.final_programme.pdf
19th United European Gastroenterology Week 2011
Stockholm, Sweden. October 21–26, 2011
www.hungaronotes.hu/minden/UEGW2011.pdf
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Search terms 2011 2012 2013 2014 2015 TOTAL
faecal immunochemical 2 3 1 1 2
fecal immunochemical 0 6 2 4 6
faecal immuno-chemical 0 0 0 0 0
fecal immuno-chemical 0 0 0 0 0
FIT 6 4 3 2 4
iFOBT 0 0 1 0 0
FOB Gold 0 0 0 0 0
FOBGold 0 0 0 0 0
JACKarc 0 0 0 0 0
RIDASCREEN 0 0 0 0 0
OC Sensor 0 0 0 0 0
OC Pledia 0 0 0 0 0
TOTAL (after deduplication) 8 13 7 7 12 47
Cost-effectiveness searches
Economic evaluations and cost studies
MEDLINE (via Ovid): 1946 to March Week 4 2016
Date searched: 4 April 2016.
Records found: 818.
1. exp Colonoscopy/ (23,858)
2. Colonoscop$.ti,ab,ot,hw. (28,519)
3. Coloscop$.ti,ab,ot,hw. (579)
4. Sigmoidoscop$.ti,ab,ot,hw. (6409)
5. or/1-4 (32,887)
6. Colonography, Computed Tomographic/ (1746)
7. virtual colonoscop$.ti,ab,ot,hw. (501)
8. CT colonograph$.ti,ab,ot,hw. (1107)
9. CT pneumocolon.ti,ab,ot,hw. (12)
10. computed tomographic colonograph$.ti,ab,ot,hw. (263)
11. computed tomographic pneumocolon.ti,ab,ot,hw. (0)
12. or/6-11 (2091)
13. Magnetic Resonance Imaging/ (309,510)
14. magnetic resonance imaging.ti,ab,ot,hw. (360,372)
15. (MRI or MRIs or NMRI).ti,ab,ot,hw. (148,957)
16. (magneti?ation transfer adj1 imaging).ti,ab,ot,hw. (413)
17. MR imaging.ti,ab,ot,hw. (32,911)
18. NMR imaging.ti,ab,ot,hw. (1135)
19. magnetic resonance tomography.ti,ab,ot,hw. (1668)
20. MR tomography.ti,ab,ot,hw. (342)
21. chemical shift imaging.ti,ab,ot,hw. (794)
22. proton spin tomography.ti,ab,ot,hw. (34)
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23. zeugmatography.ti,ab,ot,hw. (22)
24. or/13-23 (393,772)
25. exp Tomography, X-Ray Computed/ (334,373)
26. (CAT scan$ or CT scan$ or CT x-ray$ or CT xray$).ti,ab,ot,hw. (66,895)
27. (comput$ tomograph$ or computed xray tomograph$ or computed x-ray tomograph$ or computeri?ed
axial tomograph$).ti,ab,ot,hw. (196,347)
28. electron beam tomograph$.ti,ab,ot,hw. (375)
29. tomodensitometry.ti,ab,ot,hw. (584)
30. or/25-29 (424,513)
31. 5 or 12 or 24 or 30 (763,480)
32. exp colorectal neoplasms/ (162,710)
33. exp cecal neoplasms/ (4892)
34. ((colorect$ or rectal$ or rectum$ or colon$ or sigma$ or sigmo$ or rectosigm$ or bowel$ or anal
or anus) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or
adenocarcinoma$ or sarcoma$ or adenom$ or lesion$)).ti,ab,ot,hw. (199,696)
35. CRC.ti,ab,ot. (13,878)
36. ((cecum or cecal or caecum or caecal or il?eoc?ecal or il?eoc?ecum) adj3 (cancer$ or neoplas$ or
oncolog$ or malignan$ or tumo?r$ or carcinoma$ or adenocarcinoma$ or sarcoma$ or adenom$ or
lesion$)).ti,ab,ot. (1846)
37. (large intestin$ adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or
adenocarcinoma$ or sarcoma$ or adenom$ or lesion$)).ti,ab,ot. (1676)
38. (lower intestin$ adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or
adenocarcinoma$ or sarcoma$ or adenom$ or lesion$)).ti,ab,ot. (26)
39. or/32-38 (208,381)
40. 31 and 39 (26,596)
41. economics/ (26,664)
42. exp “costs and cost analysis”/ (195,358)
43. economics, dental/ (1876)
44. exp “economics, hospital”/ (21,229)
45. economics, medical/ (8858)
46. economics, nursing/ (3933)
47. economics, pharmaceutical/ (2608)
48. (economic$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).ti,ab.
(471,438)
49. (expenditure$ not energy).ti,ab. (18,999)
50. (value adj1 money).ti,ab. (24)
51. budget$.ti,ab. (18,713)
52. or/41-51 (601,712)
53. ((energy or oxygen) adj cost).ti,ab. (2826)
54. (metabolic adj cost).ti,ab. (868)
55. ((energy or oxygen) adj expenditure).ti,ab. (17,419)
56. or/53-55 (20,370)
57. 52 not 56 (597,185)
58. letter.pt. (876,097)
59. editorial.pt. (373,604)
60. historical article.pt. (328,206)
61. or/58-60 (1,561,761)
62. 57 not 61 (567,144)
63. 40 and 62 (1448)
64. limit 63 to yr = “2005-Current” (818)
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Economics terms based on Costs filter:
l Centre for Reviews and Dissemination (CRD). Search strategies: NHS EED MEDLINE using OvidSP
(Economics Filter). York: CRD; 2014. URL: www.crd.york.ac.uk/crdweb/searchstrategies.asp (accessed
2 June 2014).146
MEDLINE In-Process & Other Non-Indexed Citations, MEDLINE Daily Update
(via Ovid): 1 April 2016
Date searched: 4 April 2016.
Records found: 103.
1. exp Colonoscopy/ (28)
2. Colonoscop$.ti,ab,ot,hw. (2422)
3. Coloscop$.ti,ab,ot,hw. (7)
4. Sigmoidoscop$.ti,ab,ot,hw. (207)
5. or/1-4 (2536)
6. Colonography, Computed Tomographic/ (0)
7. virtual colonoscop$.ti,ab,ot,hw. (43)
8. CT colonograph$.ti,ab,ot,hw. (94)
9. CT pneumocolon.ti,ab,ot,hw. (0)
10. computed tomographic colonograph$.ti,ab,ot,hw. (26)
11. computed tomographic pneumocolon.ti,ab,ot,hw. (0)
12. or/6-11 (146)
13. Magnetic Resonance Imaging/ (448)
14. magnetic resonance imaging.ti,ab,ot,hw. (18,196)
15. (MRI or MRIs or NMRI).ti,ab,ot,hw. (18,665)
16. (magneti?ation transfer adj1 imaging).ti,ab,ot,hw. (41)
17. MR imaging.ti,ab,ot,hw. (1820)
18. NMR imaging.ti,ab,ot,hw. (73)
19. magnetic resonance tomography.ti,ab,ot,hw. (29)
20. MR tomography.ti,ab,ot,hw. (6)
21. chemical shift imaging.ti,ab,ot,hw. (49)
22. proton spin tomography.ti,ab,ot,hw. (0)
23. zeugmatography.ti,ab,ot,hw. (0)
24. or/13-23 (30,159)
25. exp Tomography, X-Ray Computed/ (392)
26. (CAT scan$ or CT scan$ or CT x-ray$ or CT xray$).ti,ab,ot,hw. (7114)
27. (comput$ tomograph$ or computed xray tomograph$ or computed x-ray tomograph$ or computeri?ed
axial tomograph$).ti,ab,ot,hw. (23,966)
28. electron beam tomograph$.ti,ab,ot,hw. (8)
29. tomodensitometry.ti,ab,ot,hw. (14)
30. or/25-29 (28,315)
31. 5 or 12 or 24 or 30 (56,276)
32. exp colorectal neoplasms/ (154)
33. exp cecal neoplasms/ (1)
34. ((colorect$ or rectal$ or rectum$ or colon$ or sigma$ or sigmo$ or rectosigm$ or bowel$ or anal
or anus) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or
adenocarcinoma$ or sarcoma$ or adenom$ or lesion$)).ti,ab,ot,hw. (14,543)
35. CRC.ti,ab,ot. (2480)
36. ((cecum or cecal or caecum or caecal or il?eoc?ecal or il?eoc?ecum) adj3 (cancer$ or neoplas$ or
oncolog$ or malignan$ or tumo?r$ or carcinoma$ or adenocarcinoma$ or sarcoma$ or adenom$ or
lesion$)).ti,ab,ot. (195)
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37. (large intestin$ adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or
adenocarcinoma$ or sarcoma$ or adenom$ or lesion$)).ti,ab,ot. (38)
38. (lower intestin$ adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or
adenocarcinoma$ or sarcoma$ or adenom$ or lesion$)).ti,ab,ot. (0)
39. or/32-38 (14,877)
40. 31 and 39 (1940)
41. economics/ (3)
42. exp “costs and cost analysis”/ (205)
43. economics, dental/ (0)
44. exp “economics, hospital”/ (19)
45. economics, medical/ (0)
46. economics, nursing/ (0)
47. economics, pharmaceutical/ (0)
48. (economic$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).ti,
ab. (71,397)
49. (expenditure$ not energy).ti,ab. (2126)
50. (value adj1 money).ti,ab. (4)
51. budget$.ti,ab. (2907)
52. or/41-51 (74,321)
53. ((energy or oxygen) adj cost).ti,ab. (377)
54. (metabolic adj cost).ti,ab. (116)
55. ((energy or oxygen) adj expenditure).ti,ab. (1622)
56. or/53-55 (2060)
57. 52 not 56 (73,745)
58. letter.pt. (32,301)
59. editorial.pt. (24,232)
60. historical article.pt. (183)
61. or/58-60 (56,696)
62. 57 not 61 (73,074)
63. 40 and 62 (114)
64. limit 63 to yr=“2005 -Current” (103)
Economics terms based on Costs filter:
l Centre for Reviews and Dissemination (CRD). Search Strategies: NHS EED MEDLINE using OvidSP
(Economics Filter). York: CRD; 2014. URL: www.crd.york.ac.uk/crdweb/searchstrategies.asp (accessed
2 June 2014).146
EMBASE (via Ovid): 1974 to 1 April 2016
Date searched: 4 April 2016.
Records found: 2333.
1. Colonoscopy/ (54,012)
2. Sigmoidoscopy/ (10,176)
3. Colonoscop$.ti,ab,ot,hw. (61,058)
4. Coloscop$.ti,ab,ot,hw. (987)
5. Sigmoidoscop$.ti,ab,ot,hw. (11,721)
6. or/1-5 (67,824)
7. computed tomographic colonography/ (3341)
8. virtual colonoscop$.ti,ab,ot,hw. (723)
9. CT colonograph$.ti,ab,ot,hw. (1574)
10. CT pneumocolon.ti,ab,ot,hw. (21)
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11. computed tomographic colonograph$.ti,ab,ot,hw. (3369)
12. computed tomographic pneumocolon.ti,ab,ot,hw. (0)
13. or/7-12 (3740)
14. nuclear magnetic resonance imaging/ (556,588)
15. Magnetic resonance imaging.ti,ab,ot,hw. (629,542)
16. (MRI or MRIs or NMRI).ti,ab,ot,hw. (272,277)
17. (magneti?ation transfer adj1 imaging).ti,ab,ot,hw. (571)
18. MR imaging.ti,ab,ot,hw. (42,912)
19. NMR imaging.ti,ab,ot,hw. (1406)
20. magnetic resonance tomography.ti,ab,ot,hw. (1496)
21. MR tomography.ti,ab,ot,hw. (344)
22. chemical shift imaging.ti,ab,ot,hw. (982)
23. proton spin tomography.ti,ab,ot,hw. (11)
24. zeugmatography.ti,ab,ot,hw. (26)
25. or/14-24 (662,853)
26. exp computer assisted tomography/ (713,414)
27. (CAT scan$ or CT scan$ or CT x-ray$ or CT xray$).ti,ab,ot,hw. (117,999)
28. (comput$ tomograph$ or computed xray tomograph$ or computed x-ray tomograph$ or computeri?ed
axial tomograph$).ti,ab,ot,hw. (351,851)
29. electron beam tomograph$.ti,ab,ot,hw. (2201)
30. tomodensitometry.ti,ab,ot,hw. (716)
31. or/26-30 (771,131)
32. 6 or 13 or 25 or 31 (1,312,128)
33. exp colon tumor/ (240,252)
34. exp rectum tumor/ (182,819)
35. exp colon cancer/ (191,943)
36. exp rectum cancer/ (148,848)
37. ((colorect$ or rectal$ or rectum$ or colon$ or sigma$ or sigmo$ or rectosigm$ or bowel$ or anal
or anus) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or
adenocarcinoma$ or sarcoma$ or adenom$ or lesion$)).ti,ab,ot,hw. (318,696)
38. CRC.ti,ab,ot. (27,373)
39. ((cecum or cecal or caecum or caecal or il?eoc?ecal or il?eoc?ecum) adj3 (cancer$ or neoplas$ or
oncolog$ or malignan$ or tumo?r$ or carcinoma$ or adenocarcinoma$ or sarcoma$ or adenom$ or
lesion$)).ti,ab,ot. (2651)
40. (large intestin$ adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or
adenocarcinoma$ or sarcoma$ or adenom$ or lesion$)).ti,ab,ot. (1929)
41. (lower intestin$ adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or
adenocarcinoma$ or sarcoma$ or adenom$ or lesion$)).ti,ab,ot. (29)
42. or/33-41 (330,526)
43. 32 and 42 (52,394)
44. health-economics/ (35,302)
45. exp economic-evaluation/ (240,103)
46. exp health-care-cost/ (231,067)
47. exp pharmacoeconomics/ (177,750)
48. or/44-47 (530,895)
49. (econom$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).ti,ab.
(725,833)
50. (expenditure$ not energy).ti,ab. (28,158)
51. (value adj2 money).ti,ab. (1676)
52. budget$.ti,ab. (28,112)
53. or/49-52 (753,216)
54. 48 or 53 (1,043,923)
55. letter.pt. (930,553)
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56. editorial.pt. (504,001)
57. note.pt. (634,165)
58. or/55-57 (2,068,719)
59. 54 not 58 (947,501)
60. (metabolic adj cost).ti,ab. (1063)
61. ((energy or oxygen) adj cost).ti,ab. (3494)
62. ((energy or oxygen) adj expenditure).ti,ab. (23,677)
63. or/60-62 (27,341)
64. 59 not 63 (941,755)
65. exp animal/ (21,427,388)
66. exp animal-experiment/ (1,922,177)
67. nonhuman/ (4,721,186)
68. (rat or rats or mouse or mice or hamster or hamsters or animal or animals or dog or dogs or cat or
cats or bovine or sheep).ti,ab,sh. (5,295,240)
69. or/65-68 (23,039,014)
70. exp human/ (16,996,370)
71. exp human-experiment/ (350,705)
72. 70 or 71 (16,997,816)
73. 69 not (69 and 72) (6,042,168)
74. 64 not 73 (867,075)
75. 43 and 74 (3250)
76. limit 75 to yr= “2005-Current” (2333)
Economics terms based on Costs filter:
l Centre for Reviews and Dissemination (CRD). Search Strategies: NHS EED EMBASE using OvidSP
(Economics Filter). York: CRD; 2014. URL: www.crd.york.ac.uk/crdweb/searchstrategies.asp (accessed
4 April 2016).146
NHS Economic Evaluation Database (Wiley) (via the internet): Issue 2 of 4, April 2015
Date searched: 4 April 2016.
Records found: 126.
#1 MeSH descriptor: [Colonoscopy] explode all trees (1772)
#2 Colonoscop* or Coloscop* or Sigmoidoscop* (3631)
#3 #1 or #2 (3631)
#4 MeSH descriptor: [Colonography, Computed Tomographic] explode all trees (128)
#5 “virtual colonoscop*” or “CT colonograph*” or “CT pneumocolon” or “computed tomographic
colonograph*” or “computed tomographic pneumocolon” (200)
#6 #4 or #5 (218)
#7 MeSH descriptor: [Magnetic Resonance Imaging] this term only (5990)
#8 “magnetic resonance imaging” or MRI or MRIs or NMRI (13,927)
#9 “magneti?ation transfer” near/1 imaging (18)
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#10 “MR imaging” or “NMR imaging” or “magnetic resonance tomography” or “MR tomography” (854)
#11 “chemical shift imaging” or “proton spin tomography” or zeugmatography (20)
#12 #7 or #8 or #9 or #10 or #11 (14,073)
#13 [mh “Tomography, X-Ray Computed”] (4799)
#14 “CAT scan*” or “CT scan*” or “CT x-ray*” or “CT xray*” (2684)
#15 “comput* tomograph*” or “computed xray tomograph*” or “computed x-ray tomograph*” or
“computeri?ed axial tomograph*” (8685)
#16 “electron beam tomograph*” or tomodensitometry (45)
#17 #13 or #14 or #15 or #16 (11,656)
#18 #3 or #6 or #12 or #17 (27,348)
#19 MeSH descriptor: [Colorectal Neoplasms] explode all trees (6056)
#20 MeSH descriptor: [Cecal Neoplasms] explode all trees (9)
#21 (colorect* or rectal* or rectum* or colon* or sigma* or sigmo* or rectosigm* or bowel* or anal or
anus) near/3 (cancer* or neoplas* or oncolog* or malignan* or tumor* or tumour* or carcinoma* or
adenocarcinoma* or sarcoma* or adenom* or lesion*) (12,310)
#22 CRC (1341)
#23 (cecum or cecal or caecum or caecal or ileocecal or ilaeocaecal or ileocecum or ilaeocaecum) near/3
(cancer* or neoplas* or oncolog* or malignan* or tumor* or tumour* or carcinoma* or adenocarcinoma*
or sarcoma* or adenom* or lesion*) (98)
#24 “large intestin*” near/3 (cancer* or neoplas* or oncolog* or malignan* or tumor* or tumour* or
carcinoma* or adenocarcinoma* or sarcoma* or adenom* or lesion*) (54)
#25 “lower intestin*” near/3 (cancer* or neoplas* or oncolog* or malignan* or tumor* or tumour* or
carcinoma* or adenocarcinoma* or sarcoma* or adenom* or lesion*) (0)
#26 #19 or #20 or #21 or #22 or #23 or #24 or #25 (12,665)
#27 #18 and #26 Publication Year from 2005 to 2016, in Economic Evaluations (126)
EconLit (via EBSCOhost): 2005 to 1 February 2016
Date searched: 5 April 2016.
Records found: 13.
S1 Colonoscop* or Coloscop* or Sigmoidoscop* (24)
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S2 “virtual colonoscop*” or “CT colonograph*” or “CT pneumocolon” or “computed tomographic
colonograph*” or “computed tomographic pneumocolon” (4)
S3 “magnetic resonance imaging” or MRI or MRIs or NMRI (115)
S4 “magneti?ation transfer” N1 imaging (0)
S5 “MR imaging” or “NMR imaging” or “magnetic resonance tomography” or “MR tomography” (1)
S6 “chemical shift imaging” or “proton spin tomography” or zeugmatography (0)
S7 “CAT scan*” or “CT scan*” or “CT x-ray*” or “CT xray*” (15)
S8 “comput* tomograph*” or “computed xray tomograph*” or “computed x-ray tomograph*” or
“computeri?ed axial tomograph*” (28)
S9 “electron beam tomograph*” or tomodensitometry (0)
S10 S1 OR S2 OR S3 or S4 or S5 or S6 or S7 or S8 or S9 (173)
S11 (colorect* or rectal* or rectum* or colon* or sigma* or sigmo* or rectosigm* or bowel* or anal or
anus) N3 (cancer* or neoplas* or oncolog* or malignan* or tumor* or tumour* or carcinoma* or
adenocarcinoma* or sarcoma* or adenom* or lesion*) (104)
S12 CRC (332)
S13 (cecum or cecal or caecum or caecal or ileocecal or ilaeocaecal or ileocecum or ilaeocaecum) N3
(cancer* or neoplas* or oncolog* or malignan* or tumor* or tumour* or carcinoma* or adenocarcinoma*
or sarcoma* or adenom* or lesion*) (0)
S14 “large intestin*” N3 (cancer* or neoplas* or oncolog* or malignan* or tumor* or tumour* or
carcinoma* or adenocarcinoma* or sarcoma* or adenom* or lesion*) (0)
S15 “lower intestin*” N3 (cancer* or neoplas* or oncolog* or malignan* or tumor* or tumour* or
carcinoma* or adenocarcinoma* or sarcoma* or adenom* or lesion*) (0)
S16 S11 OR S12 OR S13 OR S14 OR S15 (410)
S17 S10 AND S16 (14)
S18 (ZR “2005”) or (ZR “2006”) or (ZR “2007”) or (ZR “2008”) or (ZR “2009”) or (ZR “2010”) or
(ZR “2011”) or (ZR “2012”) or (ZR “2013”) or (ZR “2014”) or (ZR “2015”) or (ZR “2016”) (638,824)
S19 S17 AND S18 (13)
Cost-Effectiveness Analysis Registry (via the internet)
https://research.tufts-nemc.org/cear4/Home.aspx
Date searched: 5 April 2016.
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Records found: 96.
Search term (basic search) Records found
colonoscopy 24
Computed tomographic colonography 0
CTC 1
coloscopy 0
sigmoidoscopy 11
magnetic resonance imaging 21
MRI 28
CT scan 11
CAT scan 0
TOTAL 96
Research Papers in Economics IDEAS database (via internet)
https://ideas.repec.org/
Date searched: 5 April 2016.
Records found: 21.
(colonoscopy | “computed tomographic colonography” | “CT colonography” | coloscopy | sigmoidoscopy |
“magnetic resonance imaging” | MRI | “CT scan” | “CAT scan”) + (colorectal | rectal | rectum | colon |
bowel | intestine)
Adverse events and mortality data
MEDLINE (via Ovid): 1946 to March Week 4 2016
Date searched: 5 April 2016.
Records found: 759.
1. exp colorectal neoplasms/ (162,710)
2. exp cecal neoplasms/ (4892)
3. ((colorect$ or rectal$ or rectum$ or colon$ or sigma$ or sigmo$ or rectosigm$ or bowel$ or anal
or anus) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or
adenocarcinoma$ or sarcoma$ or adenom$ or lesion$)).ti,ab,ot,hw. (199,696)
4. CRC.ti,ab,ot. (13,878)
5. ((cecum or cecal or caecum or caecal or il?eoc?ecal or il?eoc?ecum) adj3 (cancer$ or neoplas$ or
oncolog$ or malignan$ or tumo?r$ or carcinoma$ or adenocarcinoma$ or sarcoma$ or adenom$ or
lesion$)).ti,ab,ot. (1846)
6. (large intestin$ adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or
adenocarcinoma$ or sarcoma$ or adenom$ or lesion$)).ti,ab,ot. (1676)
7. (lower intestin$ adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or
adenocarcinoma$ or sarcoma$ or adenom$ or lesion$)).ti,ab,ot. (26)
8. 1 or 2 or 3 or 4 or 5 or 6 or 7 (208,381)
9. exp Colonoscopy/ae, mo [Adverse Effects, Mortality] (1888)
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10. Colonography, Computed Tomographic/ae, mo [Adverse Effects, Mortality] (82)
11. ((colonoscop$ or coloscop$ or sigmoidoscop$) adj3 (safe or safety or side effect$ or undesirable effect$
or treatment emergent or tolerability)).ti,ab. (185)
12. ((colonoscop$ or coloscop$ or sigmoidoscop$) adj3 (adverse adj2 (effect or effects or reaction or
reactions or event or events or outcome or outcomes))).ti,ab. (39)
13. ((colonoscop$ or coloscop$ or sigmoidoscop$) adj3 (mortalit$ or dead or death or deaths or died or
fatal$)).ti,ab. (118)
14. ((CT colonograph$ or CT pneumocolon or computed tomographic colonograph$ or computed
tomographic pneumocolon) adj3 (safe or safety or side effect$ or undesirable effect$ or treatment
emergent or tolerability)).ti,ab. (11)
15. ((CT colonograph$ or CT pneumocolon or computed tomographic colonograph$ or computed
tomographic pneumocolon) adj3 (adverse adj2 (effect or effects or reaction or reactions or event or
events or outcome or outcomes))).ti,ab. (4)
16. ((CT colonograph$ or CT pneumocolon or computed tomographic colonograph$ or computed
tomographic pneumocolon) adj3 (mortalit$ or dead or death or deaths or died or fatal$)).ti,ab. (3)
17. or/9-16 (2209)
18. 8 and 17 (762)
19. exp animals/ not (exp animals/ and humans/) (4,208,134)
20. 18 not 19 (759)
Adverse events filter based on:
l Appendix 4: Searching for adverse events. In Centre for Reviews and Dissemination (CRD). Systematic
Reviews: CRD’s Guidance for Undertaking Reviews in Health Care: An Update of CRD’s Guidance.
York: University of York; 2009. pp. 253–4.147
MEDLINE In-Process & Other Non-Indexed Citations, MEDLINE
Daily Update (via Ovid): 4 April 2016
Date searched: 5 April 2016.
Records found: 20.
1. exp colorectal neoplasms/ (302)
2. exp cecal neoplasms/ (9)
3. ((colorect$ or rectal$ or rectum$ or colon$ or sigma$ or sigmo$ or rectosigm$ or bowel$ or anal
or anus) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or
adenocarcinoma$ or sarcoma$ or adenom$ or lesion$)).ti,ab,ot,hw. (14,770)
4. CRC.ti,ab,ot. (2502)
5. ((cecum or cecal or caecum or caecal or il?eoc?ecal or il?eoc?ecum) adj3 (cancer$ or neoplas$ or
oncolog$ or malignan$ or tumo?r$ or carcinoma$ or adenocarcinoma$ or sarcoma$ or adenom$ or
lesion$)).ti,ab,ot. (205)
6. (large intestin$ adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or
adenocarcinoma$ or sarcoma$ or adenom$ or lesion$)).ti,ab,ot. (38)
7. (lower intestin$ adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or
adenocarcinoma$ or sarcoma$ or adenom$ or lesion$)).ti,ab,ot. (0)
8. 1 or 2 or 3 or 4 or 5 or 6 or 7 (15,116)
9. exp Colonoscopy/ae, mo [Adverse Effects, Mortality] (2)
10. Colonography, Computed Tomographic/ae, mo [Adverse Effects, Mortality] (0)
11. ((colonoscop$ or coloscop$ or sigmoidoscop$) adj3 (safe or safety or side effect$ or undesirable effect$
or treatment emergent or tolerability)).ti,ab. (25)
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12. ((colonoscop$ or coloscop$ or sigmoidoscop$) adj3 (adverse adj2 (effect or effects or reaction or
reactions or event or events or outcome or outcomes))).ti,ab. (10)
13. ((colonoscop$ or coloscop$ or sigmoidoscop$) adj3 (mortalit$ or dead or death or deaths or died or
fatal$)).ti,ab. (12)
14. ((CT colonograph$ or CT pneumocolon or computed tomographic colonograph$ or computed
tomographic pneumocolon) adj3 (safe or safety or side effect$ or undesirable effect$ or treatment
emergent or tolerability)).ti,ab. (1)
15. ((CT colonograph$ or CT pneumocolon or computed tomographic colonograph$ or computed
tomographic pneumocolon) adj3 (adverse adj2 (effect or effects or reaction or reactions or event or
events or outcome or outcomes))).ti,ab. (0)
16. ((CT colonograph$ or CT pneumocolon or computed tomographic colonograph$ or computed
tomographic pneumocolon) adj3 (mortalit$ or dead or death or deaths or died or fatal$)).ti,ab. (0)
17. or/9-16 (47)
18. 8 and 17 (20)
19. exp animals/ not (exp animals/ and humans/) (2786)
20. 20 18 not 19 (20)
Adverse events filter based on:
l Appendix 4: Searching for adverse events. In Centre for Reviews and Dissemination. Systematic
Reviews: CRD’s Guidance for Undertaking Reviews in Health Care: An Update of CRD’s Guidance.
York: University of York; 2009. pp. 253–4.147
EMBASE (via Ovid): 1974 to 4 April 2016
Date searched: 5 April 2016.
Records found: 539.
1. exp colon tumor/ (240,283)
2. exp rectum tumor/ (182,837)
3. exp colon cancer/ (191,971)
4. exp rectum cancer/ (148,865)
5. ((colorect$ or rectal$ or rectum$ or colon$ or sigma$ or sigmo$ or rectosigm$ or bowel$ or anal
or anus) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or
adenocarcinoma$ or sarcoma$ or adenom$ or lesion$)).ti,ab,ot,hw. (31,732)
6. CRC.ti,ab,ot. (27,377)
7. ((cecum or cecal or caecum or caecal or il?eoc?ecal or il?eoc?ecum) adj3 (cancer$ or neoplas$ or
oncolog$ or malignan$ or tumo?r$ or carcinoma$ or adenocarcinoma$ or sarcoma$ or adenom$ or
lesion$)).ti,ab,ot. (2651)
8. (large intestin$ adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or
adenocarcinoma$ or sarcoma$ or adenom$ or lesion$)).ti,ab,ot. (1929)
9. (lower intestin$ adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or
adenocarcinoma$ or sarcoma$ or adenom$ or lesion$)).ti,ab,ot. (29)
10. or/1-9 (330,564)
11. colonoscopy/ae, co [Adverse Drug Reaction] (346)
12. sigmoidoscopy/ae, co [Adverse Drug Reaction, Complication] (70)
13. computed tomographic colonography/ae, co [Adverse Drug Reaction] (10)
14. ((colonoscop$ or coloscop$ or sigmoidoscop$) adj3 (safe or safety or side effect$ or undesirable effect$
or treatment emergent or tolerability)).ti,ab. (398)
15. ((colonoscop$ or coloscop$ or sigmoidoscop$) adj3 (adverse adj2 (effect or effects or reaction or
reactions or event or events or outcome or outcomes))).ti,ab. (101)
16. ((colonoscop$ or coloscop$ or sigmoidoscop$) adj3 (mortalit$ or dead or death or deaths or died or
fatal$)).ti,ab. (224)
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17. ((CT colonograph$ or CT pneumocolon or computed tomographic colonograph$ or computed
tomographic pneumocolon) adj3 (safe or safety or side effect$ or undesirable effect$ or treatment
emergent or tolerability)).ti,ab. (14)
18. ((CT colonograph$ or CT pneumocolon or computed tomographic colonograph$ or computed
tomographic pneumocolon) adj3 (adverse adj2 (effect or effects or reaction or reactions or event or
events or outcome or outcomes))).ti,ab. (5)
19. ((CT colonograph$ or CT pneumocolon or computed tomographic colonograph$ or computed
tomographic pneumocolon) adj3 (mortalit$ or dead or death or deaths or died or fatal$)).ti,ab. (3)
20. or/11-19 (1117)
21. 10 and 20 (543)
22. animal/ (1,738,058)
23. animal experiment/ (1,920,454)
24. (rat or rats or mouse or mice or murine or rodent or rodents or hamster or hamsters or pig or pigs or
porcine or rabbit or rabbits or animal or animals or dogs or dog or cats or cow or bovine or sheep or
ovine or monkey or monkeys).ti,ab,ot,hw. (6,186,843)
25. or/22-24 (6,186,843)
26. exp human/ (16,998,345)
27. human experiment/ (350,771)
28. or/26-27 (16,999,791)
29. 25 not (25 and 28) (4,867,829)
30. 21 not 29 (539)
Adverse events filter based on:
l Appendix 4: searching for adverse events. In Centre for Reviews and Dissemination (CRD). Systematic
Reviews: CRD’s Guidance for Undertaking Reviews in Health Care: An update of CRD’s Guidance.
York: University of York; 2009. pp. 253–4.147
Cochrane Central Register of Controlled Trials (Wiley) (via internet): issue 3 of 12,
March 2016
Date searched: 5 April 2016.
Records found: 114.
#1 MeSH descriptor: [Colorectal Neoplasms] explode all trees (6056)
#2 MeSH descriptor: [Cecal Neoplasms] explode all trees (9)
#3 (colorect* or rectal* or rectum* or colon* or sigma* or sigmo* or rectosigm* or bowel* or anal or
anus) near/3 (cancer* or neoplas* or oncolog* or malignan* or tumor* or tumour* or carcinoma* or
adenocarcinoma* or sarcoma* or adenom* or lesion*) (12,310)
#4 CRC (1341)
#5 (cecum or cecal or caecum or caecal or ileocecal or ilaeocaecal or ileocecum or ilaeocaecum) near/3
(cancer* or neoplas* or oncolog* or malignan* or tumor* or tumour* or carcinoma* or adenocarcinoma*
or sarcoma* or adenom* or lesion*) (98)
#6 “large intestin*” near/3 (cancer* or neoplas* or oncolog* or malignan* or tumor* or tumour* or
carcinoma* or adenocarcinoma* or sarcoma* or adenom* or lesion*) (54)
#7 “lower intestin*” near/3 (cancer* or neoplas* or oncolog* or malignan* or tumor* or tumour* or
carcinoma* or adenocarcinoma* or sarcoma* or adenom* or lesion*) (0)
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#8 #1 or #2 or #3 or #4 or #5 or #6 or #7 (12,665)
#9 MeSH descriptor: [Colonoscopy] explode all trees and with qualifier(s): [Adverse effects - AE, Mortality -
MO] (159)
#10 MeSH descriptor: [Colonography, Computed Tomographic] explode all trees and with qualifier(s):
[Adverse effects - AE, Mortality - MO] (6)
#11 (colonoscop* or coloscop* or sigmoidoscop*) near/3 (safe or safety or “side effect*” or “undesirable
effect*” or “treatment emergent” or tolerability) (143)
#12 (colonoscop* or coloscop* or sigmoidoscop*) near/3 (adverse near/2 (effect or effects or reaction or
reactions or event or events or outcome or outcomes)) (271)
#13 (colonoscop* or coloscop* or sigmoidoscop*) near/3 (mortalit* or dead or death or deaths or died or
fatal*) (55)
#14 (“CT colonograph*” or “CT pneumocolon” or “computed tomographic colonograph*” or
“computed tomographic pneumocolon”) near/3 (safe or safety or “side effect*” or “undesirable effect*”
or “treatment emergent” or tolerability) (3)
#15 (“CT colonograph*” or “CT pneumocolon” or “computed tomographic colonograph*” or
“computed tomographic pneumocolon”) near/3 (adverse near/2 (effect or effects or reaction or reactions
or event or events or outcome or outcomes)) (1)
#16 (“CT colonograph*” or “CT pneumocolon” or “computed tomographic colonograph*” or
“computed tomographic pneumocolon”) near/3 (mortalit* or dead or death or deaths or died or fatal*) (3)
#17 #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 (445)
#18 #8 and #17 in Trials (114)
Adverse events filter based on:
l Appendix 4: searching for adverse events. In Centre for Reviews and Dissemination (CRD). Systematic
Reviews: CRD’s Guidance for Undertaking Reviews in Health Care: An upDate of CRD’s Guidance.
York: University of York; 2009. pp. 253–4.147
Utility data
MEDLINE (via Ovid): 1946 to March Week 4 2016
Date searched: 5 April 2016.
Records found: 142.
1. exp Colonoscopy/ (23,858)
2. Colonoscop$.ti,ab,ot,hw. (28,519)
3. Coloscop$.ti,ab,ot,hw. (579)
4. Sigmoidoscop$.ti,ab,ot,hw. (6409)
5. or/1-4 (32,887)
6. Colonography, Computed Tomographic/ (1746)
7. virtual colonoscop$.ti,ab,ot,hw. (501)
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8. CT colonograph$.ti,ab,ot,hw. (1107)
9. CT pneumocolon.ti,ab,ot,hw. (12)
10. computed tomographic colonograph$.ti,ab,ot,hw. (263)
11. computed tomographic pneumocolon.ti,ab,ot,hw. (0)
12. or/6-11 (2091)
13. 5 or 12 (33,666)
14. exp colorectal neoplasms/ (162,710)
15. exp cecal neoplasms/ (4892)
16. ((colorect$ or rectal$ or rectum$ or colon$ or sigma$ or sigmo$ or rectosigm$ or bowel$ or anal
or anus) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or
adenocarcinoma$ or sarcoma$ or adenom$ or lesion$)).ti,ab,ot,hw. (199,696)
17. CRC.ti,ab,ot. (13,878)
18. ((cecum or cecal or caecum or caecal or il?eoc?ecal or il?eoc?ecum) adj3 (cancer$ or neoplas$ or
oncolog$ or malignan$ or tumo?r$ or carcinoma$ or adenocarcinoma$ or sarcoma$ or adenom$ or
lesion$)).ti,ab,ot. (1846)
19. (large intestin$ adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or
adenocarcinoma$ or sarcoma$ or adenom$ or lesion$)).ti,ab,ot. (1676)
20. (lower intestin$ adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or
adenocarcinoma$ or sarcoma$ or adenom$ or lesion$)).ti,ab,ot. (26)
21. or/14-20 (208,381)
22. 13 and 21 (17,376)
23. quality-adjusted life years/ or quality of life/ (141,086)
24. (sf36 or sf 36 or sf-36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or shortform thirtysix
or shortform thirty six or short form thirty six or short form thirtysix or short form thirty six).ti,ab,ot.
(16,837)
25. (sf6 or sf 6 or sf-6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six).ti,
ab,ot. (1063)
26. (sf12 or sf 12 or sf-12 or short form 12 or shortform 12 or sf twelve or sftwelve or shortform twelve or
short form twelve).ti,ab,ot. (3105)
27. (sf6D or sf 6D or sf-6D or short form 6D or shortform 6D or sf six D or sfsixD or shortform six D or
short form six D).ti,ab,ot. (486)
28. (sf20 or sf 20 or sf-20 or short form 20 or shortform 20 or sf twenty or sftwenty or shortform twenty
or short form twenty).ti,ab,ot. (343)
29. (sf8 or sf 8 or sf-8 or short form 8 or shortform 8 or sf eight or sfeight or shortform eight or short
form eight).ti,ab,ot. (283)
30. “health related quality of life”.ti,ab,ot. (23,887)
31. (Quality adjusted life or Quality-adjusted-life).ti,ab,ot. (6861)
32. “assessment of quality of life”.ti,ab,ot. (1231)
33. (euroqol or euro qol or eq5d or eq 5d).ti,ab,ot. (4671)
34. (hql or hrql or hqol or h qol or hrqol or hr qol).ti,ab,ot. (11,290)
35. (hye or hyes).ti,ab,ot. (54)
36. health$ year$ equivalent$.ti,ab,ot. (38)
37. (hui or hui1 or hui2 or hui3 or hui4 or hui-4 or hui-1 or hui-2 or hui-3).ti,ab,ot. (947)
38. (quality time or qwb or quality of well being or “quality of wellbeing” or “index of wellbeing” or
“index of well being”).ti,ab,ot,hw. (630)
39. (Disability adjusted life or Disability-adjusted life or health adjusted life or health-adjusted life or “years
of healthy life” or healthy years equivalent or “years of potential life lost” or “years of health life
lost”).ti,ab,ot. (1999)
40. (QALY$ or DALY$ or HALY$ or YHL or HYES or YPLL or YHLL or qald$ or qale$ or qtime$ or
AQoL$).ti,ab,ot. (7724)
41. (timetradeoff or time tradeoff or time trade-off or time trade off or TTO or Standard gamble$ or
“willingness to pay”).ti,ab,ot. (4122)
42. 15d.ti,ab,ot. (1230)
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43. (HSUV$ or health state$ value$ or health state$ preference$ or HSPV$).ti,ab,ot. (247)
44. (utilit$ adj3 (“quality of life” or valu$ or scor$ or measur$ or health or life or estimat$ or elicit$ or
disease$)).ti,ab,ot. (7273)
45. (utilities or disutili$).ti,ab,ot. (4335)
46. (Functional Assessment of Cancer Therapy$ or FACT-G).ti,ab,ot. (1334)
47. (QLQ-C30 or QLQ-C-30 or EORTC QLQ$ or “European Organization for Research and Treatment of
Cancer Quality of Life Questionnaire” or “EORTC Quality of Life Questionnaire”).ti,ab,ot. (2735)
48. or/23-47 (167,380)
49. 22 and 48 (142)
50. animals/ not (animals/ and humans/) (4,175,932)
51. 49 not 50 (142)
Health-related quality of life (HRQoL) free-text terms based on:
l Figure 4: Common free-text terms for electronic database searching for HSUVs. In Papaioannou D,
Brazier JE, Paisley S. NICE DSU Technical Support Document 9: The Identification, Review and Synthesis
of Health State Utility Values from the Literature. 2011. URL: www.nicedsu.org.uk (accessed
18 August 2011).147
MEDLINE In-Process & Other Non-Indexed Citations, MEDLINE Daily Update
(via Ovid): 4 April 2016
Date searched: 5 April 2016.
Records found: 15.
1. exp Colonoscopy/ (37)
2. Colonoscop$.ti,ab,ot,hw. (2467)
3. Coloscop$.ti,ab,ot,hw. (7)
4. Sigmoidoscop$.ti,ab,ot,hw. (208)
5. or/1-4 (2581)
6. Colonography, Computed Tomographic/ (1)
7. virtual colonoscop$.ti,ab,ot,hw. (43)
8. CT colonograph$.ti,ab,ot,hw. (95)
9. CT pneumocolon.ti,ab,ot,hw. (0)
10. computed tomographic colonograph$.ti,ab,ot,hw. (26)
11. computed tomographic pneumocolon.ti,ab,ot,hw. (0)
12. or/6-11 (147)
13. 5 or 12 (2635)
14. exp colorectal neoplasms/ (302)
15. exp cecal neoplasms/ (9)
16. ((colorect$ or rectal$ or rectum$ or colon$ or sigma$ or sigmo$ or rectosigm$ or bowel$ or anal
or anus) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or
adenocarcinoma$ or sarcoma$ or adenom$ or lesion$)).ti,ab,ot,hw. (14,770)
17. CRC.ti,ab,ot. (2502)
18. ((cecum or cecal or caecum or caecal or il?eoc?ecal or il?eoc?ecum) adj3 (cancer$ or neoplas$ or
oncolog$ or malignan$ or tumo?r$ or carcinoma$ or adenocarcinoma$ or sarcoma$ or adenom$ or
lesion$)).ti,ab,ot. (205)
19. (large intestin$ adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or
adenocarcinoma$ or sarcoma$ or adenom$ or lesion$)).ti,ab,ot. (38)
20. (lower intestin$ adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or
adenocarcinoma$ or sarcoma$ or adenom$ or lesion$)).ti,ab,ot. (0)
21. or/14-20 (15,116)
22. 13 and 21 (1285)
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23. quality-adjusted life years/ or quality of life/ (344)
24. (sf36 or sf 36 or sf-36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or shortform thirtysix
or shortform thirty six or short form thirty six or short form thirtysix or short form thirty six).ti,ab,ot.
(1882)
25. (sf6 or sf 6 or sf-6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six).ti,ab,ot.
(480)
26. (sf12 or sf 12 or sf-12 or short form 12 or shortform 12 or sf twelve or sftwelve or shortform twelve or
short form twelve).ti,ab,ot. (462)
27. (sf6D or sf 6D or sf-6D or short form 6D or shortform 6D or sf six D or sfsixD or shortform six D or
short form six D).ti,ab,ot. (68)
28. (sf20 or sf 20 or sf-20 or short form 20 or shortform 20 or sf twenty or sftwenty or shortform twenty
or short form twenty).ti,ab,ot. (14)
29. (sf8 or sf 8 or sf-8 or short form 8 or shortform 8 or sf eight or sfeight or shortform eight or short
form eight).ti,ab,ot. (48)
30. “health related quality of life”.ti,ab,ot. (3528)
31. (Quality adjusted life or Quality-adjusted-life).ti,ab,ot. (999)
32. “assessment of quality of life”.ti,ab,ot. (123)
33. (euroqol or euro qol or eq5d or eq 5d).ti,ab,ot. (882)
34. (hql or hrql or hqol or h qol or hrqol or hr qol).ti,ab,ot. (1608)
35. (hye or hyes).ti,ab,ot. (3)
36. health$ year$ equivalent$.ti,ab,ot. (2)
37. (hui or hui1 or hui2 or hui3 or hui4 or hui-4 or hui-1 or hui-2 or hui-3).ti,ab,ot. (136)
38. (quality time or qwb or quality of well being or “quality of wellbeing” or “index of wellbeing” or
“index of well being”).ti,ab,ot,hw. (58)
39. (Disability adjusted life or Disability-adjusted life or health adjusted life or health-adjusted life or “years
of healthy life” or healthy years equivalent or “years of potential life lost” or “years of health life
lost”).ti,ab,ot. (336)
40. (QALY$ or DALY$ or HALY$ or YHL or HYES or YPLL or YHLL or qald$ or qale$ or qtime$ or
AQoL$).ti,ab,ot. (1165)
41. (timetradeoff or time tradeoff or time trade-off or time trade off or TTO or Standard gamble$ or
“willingness to pay”).ti,ab,ot. (628)
42. 15d.ti,ab,ot. (118)
43. (HSUV$ or health state$ value$ or health state$ preference$ or HSPV$).ti,ab,ot. (32)
44. (utilit$ adj3 (“quality of life” or valu$ or scor$ or measur$ or health or life or estimat$ or elicit$ or
disease$)).ti,ab,ot. (951)
45. (utilities or disutili$).ti,ab,ot. (652)
46. (Functional Assessment of Cancer Therapy$ or FACT-G).ti,ab,ot. (168)
47. (QLQ-C30 or QLQ-C-30 or EORTC QLQ$ or “European Organization for Research and Treatment of
Cancer Quality of Life Questionnaire” or “EORTC Quality of Life Questionnaire”).ti,ab,ot. (372)
48. or/23-47 (9820)
49. 22 and 48 (12)
50. animals/ not (animals/ and humans/) (2780)
51. 49 not 50 (12)
HRQoL free-text terms based on:
l Figure 4: Common free-text terms for electronic database searching for HSUVs. In Papaioannou D,
Brazier JE, Paisley S. NICE DSU Technical Support Document 9: The Identification, Review and Synthesis
of Health State Utility Values from the Literature. 2011. URL: www.nicedsu.org.uk (accessed
18 August 2011).148
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EMBASE (via Ovid): 1974 to 4 April 2016
Date searched: 5 April 2016.
Records found: 208.
1. Colonoscopy/ (54,017)
2. Sigmoidoscopy/ (10,176)
3. Colonoscop$.ti,ab,ot,hw. (61,064)
4. Coloscop$.ti,ab,ot,hw. (987)
5. Sigmoidoscop$.ti,ab,ot,hw. (11,721)
6. or/1-5 (67,830)
7. computed tomographic colonography/ (3342)
8. virtual colonoscop$.ti,ab,ot,hw. (723)
9. CT colonograph$.ti,ab,ot,hw. (1574)
10. CT pneumocolon.ti,ab,ot,hw. (21)
11. computed tomographic colonograph$.ti,ab,ot,hw. (3370)
12. computed tomographic pneumocolon.ti,ab,ot,hw. (0)
13. or/7-12 (3741)
14. 6 or 13 (69,101)
15. exp colon tumor/ (240,283)
16. exp rectum tumor/ (182,837)
17. exp colon cancer/ (191,971)
18. exp rectum cancer/ (148,865)
19. ((colorect$ or rectal$ or rectum$ or colon$ or sigma$ or sigmo$ or rectosigm$ or bowel$ or anal
or anus) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or
adenocarcinoma$ or sarcoma$ or adenom$ or lesion$)).ti,ab,ot,hw. (318,732)
20. CRC.ti,ab,ot. (27,377)
21. ((cecum or cecal or caecum or caecal or il?eoc?ecal or il?eoc?ecum) adj3 (cancer$ or neoplas$ or
oncolog$ or malignan$ or tumo?r$ or carcinoma$ or adenocarcinoma$ or sarcoma$ or adenom$ or
lesion$)).ti,ab,ot. (2651)
22. (large intestin$ adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or
adenocarcinoma$ or sarcoma$ or adenom$ or lesion$)).ti,ab,ot. (1929)
23. (lower intestin$ adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or
adenocarcinoma$ or sarcoma$ or adenom$ or lesion$)).ti,ab,ot. (29)
24. or/15-23 (330,564)
25. 14 and 24 (33,692)
26. quality adjusted life year/ or quality of life index/ (17,805)
27. Short Form 12/ or Short Form 20/ or Short Form 36/ or Short Form 8/ (18,197)
28. “International Classification of Functioning, Disability and Health”/ or “ferrans and powers quality of
life index”/ or “gastrointestinal quality of life index”/ (2090)
29. (sf36 or sf 36 or sf-36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or shortform thirtysix
or shortform thirty six or short form thirty six or short form thirtysix or short form thirty six).ti,ab,ot.
(28,658)
30. (sf6 or sf 6 or sf-6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six).ti,ab,ot.
(1719)
31. (sf12 or sf 12 or sf-12 or short form 12 or shortform 12 or sf twelve or sftwelve or shortform twelve or
short form twelve).ti,ab,ot. (5712)
32. (sf6D or sf 6D or sf-6D or short form 6D or shortform 6D or sf six D or sfsixD or shortform six D or
short form six D).ti,ab,ot. (945)
33. (sf20 or sf 20 or sf-20 or short form 20 or shortform 20 or sf twenty or sftwenty or shortform twenty
or short form twenty).ti,ab,ot. (373)
34. (sf8 or sf 8 or sf-8 or short form 8 or shortform 8 or sf eight or sfeight or shortform eight or short
form eight).ti,ab,ot. (539)
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35. “health related quality of life”.ti,ab,ot. (37,958)
36. (Quality adjusted life or Quality-adjusted-life).ti,ab,ot. (11,553)
37. “assessment of quality of life”.ti,ab,ot. (2056)
38. (euroqol or euro qol or eq5d or eq 5d).ti,ab,ot. (10,075)
39. (hql or hrql or hqol or h qol or hrqol or hr qol).ti,ab,ot. (19,883)
40. (hye or hyes).ti,ab,ot. (100)
41. health$ year$ equivalent$.ti,ab,ot. (40)
42. (hui or hui1 or hui2 or hui3 or hui4 or hui-4 or hui-1 or hui-2 or hui-3).ti,ab,ot. (2395)
43. (quality time or qwb or “quality of well being” or “quality of wellbeing” or “index of wellbeing” or
index of well being).ti,ab,ot,hw. (886)
44. (Disability adjusted life or Disability-adjusted life or health adjusted life or health-adjusted life or “years
of healthy life” or healthy years equivalent or “years of potential life lost” or “years of health life
lost”).ti,ab,ot. (2768)
45. (QALY$ or DALY$ or HALY$ or YHL or HYES or YPLL or YHLL or qald$ or qale$ or qtime$ or
AQoL$).ti,ab,ot. (14,817)
46. (timetradeoff or time tradeoff or time trade-off or time trade off or TTO or Standard gamble$ or
“willingness to pay”).ti,ab,ot. (6976)
47. 15d.ti,ab,ot. (1920)
48. (HSUV$ or health state$ value$ or health state$ preference$ or HSPV$).ti,ab,ot. (377)
49. (utilit$ adj3 (“quality of life” or valu$ or scor$ or measur$ or health or life or estimat$ or elicit$ or
disease$)).ti,ab,ot. (12,545)
50. (utilities or disutili$).ti,ab,ot. (7816)
51. (Functional Assessment of Cancer Therapy$ or FACT-G).ti,ab,ot. (2475)
52. (QLQ-C30 or QLQ-C-30 or EORTC QLQ$ or “European Organization for Research and Treatment of
Cancer Quality of Life Questionnaire” or “EORTC Quality of Life Questionnaire”).ti,ab,ot. (5757)
53. or/26-52 (124,961)
54. 25 and 53 (208)
55. animal/ (1,738,058)
56. animal experiment/ (1,920,454)
57. (rat or rats or mouse or mice or murine or rodent or rodents or hamster or hamsters or pig or pigs or
porcine or rabbit or rabbits or animal or animals or dogs or dog or cats or cow or bovine or sheep or
ovine or monkey or monkeys).ti,ab,ot,hw. (6,186,843)
58. or/55-57 (6,186,843)
59. exp human/ (16,998,345)
60. human experiment/ (350,771)
61. or/59-60 (16,999,791)
62. 58 not (58 and 61) (4,867,829)
63. 54 not 62 (208)
HRQoL free-text terms based on:
l Figure 4: Common free-text terms for electronic database searching for HSUVs. In Papaioannou D,
Brazier JE, Paisley S. NICE DSU Technical Support Document 9: The Identification, Review and Synthesis
of Health State Utility Values from the Literature. 2011. URL: www.nicedsu.org.uk (accessed
18 August 2011).148
NHS Economic Evaluation Database (Wiley) (via the internet): Issue 2 of 4, April 2015;
Cochrane Central Register of Controlled Trials (Wiley) (via the internet): Issue 3 of 12,
March 2016
Date searched: 6 April 2016.
Records found: NHS EED 84, CENTRAL 22.
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#1 MeSH descriptor: [Colonoscopy] explode all trees (1772)
#2 Colonoscop* or Coloscop* or Sigmoidoscop* (3631)
#3 #1 or #2 (3631)
#4 MeSH descriptor: [Colonography, Computed Tomographic] explode all trees (128)
#5 “virtual colonoscop*” or “CT colonograph*” or “CT pneumocolon” or “computed tomographic
colonograph*” or “computed tomographic pneumocolon” (200)
#6 #4 or #5 (218)
#7 #3 or #6 (3684)
#8 MeSH descriptor: [Colorectal Neoplasms] explode all trees (6056)
#9 MeSH descriptor: [Cecal Neoplasms] explode all trees (9)
#10 (colorect* or rectal* or rectum* or colon* or sigma* or sigmo* or rectosigm* or bowel* or anal or
anus) near/3 (cancer* or neoplas* or oncolog* or malignan* or tumor* or tumour* or carcinoma* or
adenocarcinoma* or sarcoma* or adenom* or lesion*) (12,310)
#11 CRC (1341)
#12 (cecum or cecal or caecum or caecal or ileocecal or ilaeocaecal or ileocecum or ilaeocaecum) near/3
(cancer* or neoplas* or oncolog* or malignan* or tumor* or tumour* or carcinoma* or adenocarcinoma*
or sarcoma* or adenom* or lesion*) (98)
#13 “large intestin*” near/3 (cancer* or neoplas* or oncolog* or malignan* or tumor* or tumour* or
carcinoma* or adenocarcinoma* or sarcoma* or adenom* or lesion*) (54)
#14 “lower intestin*” near/3 (cancer* or neoplas* or oncolog* or malignan* or tumor* or tumour* or
carcinoma* or adenocarcinoma* or sarcoma* or adenom* or lesion*) (0)
#15 #8 or #9 or #10 or #11 or #12 or #13 or #14 (12,665)
#16 #7 and #15 (1672)
#17 MeSH descriptor: [Quality-Adjusted Life Years] this term only (4067)
#18 MeSH descriptor: [Quality of Life] this term only (17,726)
#19 sf36 or “sf 36” or “sf-36” or “short form 36” or “shortform 36” or “sf thirtysix” or “sf thirty six” or
“shortform thirtysix” or “shortform thirty six” or “short form thirty six” or “short form thirtysix” or “short
form thirty six” (6863)
#20 sf6 or “sf 6” or “sf-6” or “short form 6” or “shortform 6” or “sf six” or sfsix or “shortform six” or
“short form six” (154)
#21 sf12 or “sf 12” or “sf-12” or “short form 12” or “shortform 12” or “sf twelve” or sftwelve or
“shortform twelve” or “short form twelve” (1132)
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#22 sf6D or “sf 6D” or “sf-6D” or “short form 6D” or “shortform 6D” or “sf six D” or sfsixD or
“shortform six D” or “short form six D” (206)
#23 sf20 or “sf 20” or “sf-20” or “short form 20” or “shortform 20” or “sf twenty” or sftwenty or
“shortform twenty” or “short form twenty” (78)
#24 sf8 or “sf 8” or “sf-8” or “short form 8” or “shortform 8” or “sf eight” or sfeight or “shortform
eight” or “short form eight” (66)
#25 “health related quality of life” (7949)
#26 “Quality adjusted life” or “Quality-adjusted-life” (6898)
#27 “assessment of quality of life” (348)
#28 euroqol or “euro qol” or eq5d or “eq 5d” (3194)
#29 hql or hrql or hqol or “h qol” or hrqol or “hr qol” (3007)
#30 hye or hyes (58)
#31 “health* year* equivalent*” (5)
#32 hui or hui1 or hui2 or hui3 or hui4 or “hui-4” or “hui-1” or “hui-2” or “hui-3” (2929)
#33 “quality time” or qwb or “quality of well being” or “quality of wellbeing” or “index of wellbeing” or
“index of well being” (238)
#34 “Disability adjusted life” or “Disability-adjusted life” or “health adjusted life” or “health-adjusted life”
or “years of healthy life” or “healthy years equivalent” or “years of potential life lost” or “years of health
life lost” (370)
#35 QALY* or DALY* or HALY* or YHL or HYES or YPLL or YHLL or qald* or qale* or qtime* or
AQoL* (5551)
#36 timetradeoff or “time tradeoff” or “time trade-off” or “time trade off” or TTO or “Standard
gamble*” or “willingness to pay” (2030)
#37 15d (116)
#38 HSUV* or “health state* value*” or “health state* preference*” or HSPV* (89)
#39 utilit* near/3 (“quality of life” or valu* or scor* or measur* or health or life or estimat* or elicit* or
disease*) (4790)
#40 utilities or disutili* (1711)
#41 “Functional Assessment of Cancer Therapy*” or “FACT-G” (588)
#42 “QLQ-C30” or “QLQ-C-30” or “EORTC QLQ*” or “European Organization for Research and
Treatment of Cancer Quality of Life Questionnaire” or “EORTC Quality of Life Questionnaire” (1174)
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#43 #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or
#31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 (39,531)
#44 #16 and #43 in Trials and Economic Evaluations (106)
HRQoL free-text terms based on:
l Figure 4: Common free-text terms for electronic database searching for HSUVs. In Papaioannou D,
Brazier JE, Paisley S. NICE DSU Technical Support Document 9: The Identification, Review and Synthesis
of Health State Utility Values from the literaTure. 2011. URL: www.nicedsu.org.uk (accessed
18 August 2011).147
School of Health and Related Research Health Utilities Database (via the internet)
www.scharrhud.org/
Date searched: 6 April 2016.
Records found: 10.
colorectal or rectal or rectum or colon or bowel or intestine [Any field]
and
cancer or neoplasm or neoplasms or tumor or tumour [Any field].
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Appendix 2 Data extraction tables
TABLE 65 Baseline study details
Study Details Selection criteria Participant details
Test
manufacturer
Auge 201657 l Inclusion criteria: Adult patients,
attending a hospital outpatient
clinic for the investigation of
lower abdominal symptoms or
polyp surveillance
l Exclusion criteria: Patients
undergoing CRC screening;
history of GI bleeding; active
rectal bleeding; menstruation;
haematuria; known
ulcerative colitis
l Study setting: Outpatient clinic
l Point in care pathway at which
the test is given: Testing was
requested in a secondary care
outpatient clinic
l Total no. tested: 208
l Median age (range): 63
(22–86) years
l Male (%): 44.2
l Altered bowel habit (%): NR
l Rectal bleeding (%): NR
l Diarrhoea (%): NR
l Abdominal pain (%): NR
l Anaemia (unspecified)
(%): NR
l Weight loss (%): NR
l Palpable mass (%): NR
l Constipation (%): NR
l Anaemia (iron deficiency)
(%): NR
l NICE criteria for urgent
referral (%): NR
l SIGN criteria for urgent
referral (%): NR
l Clinical suspicion of CRC
(%): NR
Kyowa Medex,
Japan
Related publications:
Auge 2014;66 Auge 201572
Country: Spain
Funding: Menarini
Diagnósticos, S.A.,
provided instruments,
reagents and technical
support
Recruitment: December
2013 to March 2014
Study design: Diagnostic
cohort
Cubiella 2014
(COLONPREDICT)55
l Inclusion criteria: Adult
outpatients, with GI symptoms,
referred from primary and
secondary health care
l Exclusion criteria: Pregnancy;
undergoing colonoscopy for
surveillance following previous
history of colonic disease;
requiring hospital admission;
symptoms had ceased within
3 months before the evaluation
l Study setting: Mixed
l Point in care pathway at which
the test is given: Testing was
requested after referral to the
gastroenterology outpatient clinic
and before colonoscopy
l Comments: Data were also
presented for the diagnostic
performance of individual signs
and symptoms and for NICE and
SIGN referral criteria. Patients
were recruited from primary care
and outpatient settings
l Total no. tested: 787
(completed protocol)
l Median age (range): 67
(22–91) years
l Male (%): 51.1
l Altered bowel habit
(%): 56.2
l Rectal bleeding (%): 64
l Diarrhoea (%): NR
l Abdominal pain (%): 44.5
l Anaemia (unspecified)
(%): NR
l Weight loss (%): 21.2
l Palpable mass (%): 2.3
l Constipation (%): 29.2
l Anaemia (iron deficiency)
(%): NR
l NICE criteria for urgent
referral (%): 38.1
l SIGN criteria for urgent
referral (%): 60.4
l Clinical suspicion of CRC
(%): NR
Eiken
Chemical Co.,
Tokyo, Japan
Related publications:
Diaz Ondina 2014;61
Cubiella 201573
Country: Spain
Funding: Instituto de
Salud Carlos III, Madrid,
Spain (PI11/00094)
Recruitment: April 2012
to November 2012
Study design: Diagnostic
cohort
Godber 201656 l Inclusion criteria: Patients
(age > 16 years) who had been
referred from primary care for
endoscopic examination of the
lower GI tract. Most common
reasons for referral included
altered bowel habit, constipation
or diarrhoea, abdominal pain,
l Total no. tested: 507 [tested
for faecal immunochemical
testing and colonoscopy
attempted (484 analysed)]
l Median age (range): 59
(16–89) years
l Male (%): 42.6
Kyowa Medex,
Japan
Related publications:
Macdonald 2015;71
Godber 201465
Country: Scotland
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TABLE 65 Baseline study details (continued )
Study Details Selection criteria Participant details
Test
manufacturer
fresh rectal bleeding, follow-up of
previous disease, anaemia, weight
loss and abnormal CT findings
l Exclusion criteria: Referred for
investigation of a positive test
result from the Scottish Bowel
Screening Programme
l Study setting: Outpatient clinic
l Point in care pathway at which
the test is given: Testing was
requested after referral
for endoscopy
l Altered bowel habit
(%): 37.9
l Rectal bleeding (%): 15.2
l Diarrhoea (%): NR
l Abdominal pain (%): 17.9
l Anaemia (unspecified)
(%): 4.5
l Weight loss (%): 1.6
l Palpable mass (%): NR
l Constipation (%): NR
l Anaemia (iron deficiency)
(%): NR
l NICE criteria for urgent
referral (%): NR
l SIGN criteria for urgent
referral (%): NR
l Clinical suspicion of CRC
(%): NR
Funding: NHS
Lanarkshire; analyser,
training and consumables
were supplied by Kyowa
Medex Co., Ltd, Tokyo,
Japan
Recruitment: June 2013
to December 2013
Study design: Diagnostic
cohort
(Confidential information
has been removed)
(Confidential information has been
removed)
l (Confidential information has
been removed)
(Confidential
information
has been
removed)
Krivec 201154 l Inclusion criteria: Adult
symptomatic patients, undergoing
endoscopic and/or histological
examinations
l Exclusion criteria: NR
l Study setting: Unclear
l Point in care pathway at which
the test is given: Unclear (patients
scheduled for endoscopy)
l Comments: Abstract only
l Median age (range): NR
l Male (%): NR
l Altered bowel habit (%): NR
l Rectal bleeding (%): NR
l Diarrhoea (%): NR
l Abdominal pain (%): NR
l Anaemia (unspecified)
(%): NR
l Weight loss (%): NR
l Palpable mass (%): NR
l Constipation (%): NR
l Anaemia (iron deficiency)
(%): NR
l NICE criteria for urgent
referral (%): NR
l SIGN criteria for urgent
referral (%): NR
l Clinical suspicion of CRC
(%): NR
Sentinel
Diagnostics
Related publications:
None
Country: Slovenia
Funding: NR
Recruitment: NR to NR
Study design: Diagnostic
cohort
McDonald 201213 l Inclusion criteria: Patients
(age > 16 years) who had been
referred from primary care for
endoscopic examination of the
lower GI tract. Reasons for
referral included rectal bleeding,
change in bowel habit,
iron-deficiency anaemia,
abdominal pain, bloating,
polyp/CRC surveillance, family
history and assessment of IBD
l Exclusion criteria: Referred for
investigation of a positive test
result from the Scottish Bowel
Screening Programme
l Study setting: Outpatient clinic
l Point in care pathway at which
the test is given: Testing was
requested after referral
for endoscopy
l Total no. tested: 280
(completed FIT and
endoscopy)
l Age range: 16–89 years, for
all included participants
l Male (%): 40.4
l Altered bowel habit (%): NR
l Rectal bleeding (%): NR
l Diarrhoea (%): NR
l Abdominal pain (%): NR
l Anaemia (unspecified)
(%): NR
l Weight loss (%): NR
l Palpable mass (%): NR
l Constipation (%): NR
l Anaemia (iron deficiency)
(%): NR
l NICE criteria for urgent
referral (%): NR
Eiken
Chemical Co.,
Tokyo, JapanRelated publications:
None
Country: Scotland
Funding: Chief Scientist
Office; analyser, training
and consumables supplied
by Mast Diagnostics
Division
Recruitment: February
2010 to March 2012
Study design: Diagnostic
cohort
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TABLE 65 Baseline study details (continued )
Study Details Selection criteria Participant details
Test
manufacturer
l SIGN criteria for urgent
referral (%): NR
l Clinical suspicion of CRC
(%): NR
Mowat 201552 l Inclusion criteria: All adult
patients referred for investigation
of bowel symptoms for any of the
following reasons: rectal bleeding,
anaemia, diarrhoea, altered bowel
habit, abdominal pain and
weight loss
l Exclusion criteria: NR
l Study setting: Primary care
l Point in care pathway at which
the test is given: Testing was
ordered by GPs at the point of
referring patients to secondary
care
l Comments: Data were also
presented for the diagnostic
performance of individual signs
and symptoms, and for the most
common findings at colonoscopy
l Total no. tested: 755
(completed FIT and
endoscopy)
l Median age (range): 64
(16–90) years
l Male (%): NR
l Altered bowel habit
(%): 42.8
l Rectal bleeding (%): 34.2
l Diarrhoea (%): 16.8
l Abdominal pain (%): 11
l Anaemia (unspecified) (%): 6
l Weight loss (%): 0.9
l Palpable mass (%): 0.3
l Constipation (%): NR
l Anaemia (iron deficiency)
(%): NR
l NICE criteria for urgent
referral (%): NR
l SIGN criteria for urgent
referral (%): NR
l Clinical suspicion of CRC
(%): NR
Eiken
Chemical Co.,
Tokyo, JapanRelated publications:
Steele 201474
Country: Scotland
Funding: Detect cancer
early, Scottish Government
Recruitment: October
2013 to March 2014
Study design: Diagnostic
cohort
Rodríguez-Alonso 201553 l Inclusion criteria: Adult patients
(age > 18 years) referred for
diagnostic colonoscopy; referrals
were from GPs, community
gastroenterologists and
hospital environments
l Exclusion criteria: Adenoma
surveillance; CRC surveillance;
hospitalised patients; previous
colectomy; IBD; polyp syndromes
l Study setting: Mixed
l Point in care pathway at which
the test is given: Testing was
requested by the GP or at the
time of the initial secondary
care consultation
l Comments: Data were also
presented for the diagnostic
performance of individual signs
and symptoms and for NICE and
SIGN referral criteria, and for
findings at colonoscopy
l Total no. tested: 1003
(completed FIT and
endoscopy)
l Median age (range): NR
l Male (%): 46.8
l Altered bowel habit (%): NR
l Rectal bleeding (%): 34.2
l Diarrhoea (%): 23.5
l Abdominal pain (%): 35.4
l Anaemia (unspecified)
(%): NR
l Weight loss (%): 19
l Palpable mass (%): NR
l Constipation (%): 12.1
l Anaemia (iron deficiency)
(%): 18.8
l NICE criteria for urgent
referral (%): 29.5
l SIGN criteria for urgent
referral (%): 31.2
l Clinical suspicion of CRC
(%): NR
Eiken
Chemical Co.,
Tokyo, JapanRelated publications:
None
Country: Spain
Funding: Societat
Catalana de Digestologia,
Catalonia, Spain; Instituto
de Salud Carlos III; FIS
grants
Recruitment: September
2011 to October 2012
Study design: Diagnostic
cohort
Terhaar sive Droste
201158
l Inclusion criteria: Adult patients
referred for colonoscopy
l Exclusion criteria: No informed
consent; hemicolectomy; IBD; age
< 18 years
l Study setting: Outpatient clinic
l Point in care pathway at which
the test is given: Patients
scheduled for colonoscopy were
requested to perform a FIT before
l Total no. tested: (confidential
information has been
removed)
l Clinical suspicion of CRC
(%): 2.8
l Comments: Some patients
had multiple symptoms;
patients were assigned to a
symptom group based on
the most severe symptom
experienced, that is, in order
Related publications:
Oort 2011;63,69 van
Turenhout 2014;59 van
Turenhout 2012;62 van
Turenhout 2011;68 Oort
2010;64 van Turenhout
2012;60 Larbi 2012;67
van Turenhout 201070
continued
DOI: 10.3310/hta21330 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 33
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Westwood et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
155
TABLE 65 Baseline study details (continued )
Study Details Selection criteria Participant details
Test
manufacturer
bowel preparation
for colonoscopy
l Comments: Data for the
symptomatic subgroup were
provided, in confidence, by the
authors (Sietze van Turenhout,
personal communication)
of rectal bleeding, anaemia,
clinical suspicion of CRC,
change in bowel habit
Country: The Netherlands
Funding: Nycomed BV;
Hoofddorp to ‘the
Amsterdam Gutclub’; the
OC-Sensor MICRO desktop
analyser was provided by
Eiken Chemical Co.,
Tokyo, Japan
Recruitment: May 2006
to May 2010
Study design: Diagnostic
cohort
Thomas 201675 l Inclusion criteria: Adult
symptomatic patients, recruited
after their first 2-week wait clinic
at University Hospitals Coventry
and Warwickshire NHS Trust, UK
l Exclusion criteria: NR
l Study setting: Outpatient clinic
l Point in care pathway at which
the test is given: Testing was
requested in secondary care.
Patients were recruited after their
first 2-week wait clinic
l Comments: Abstract only
l Total no. tested: 450
l Median age (range): 67
(29–93) years
l Male (%): NR
l Altered bowel habit (%): NR
l Rectal bleeding (%): NR
l Diarrhoea (%): NR
l Abdominal pain (%): NR
l Anaemia (unspecified)
(%): NR
l Weight loss (%): NR
l Palpable mass (%): NR
l Constipation (%): NR
l Anaemia (iron deficiency)
(%): NR
l NICE criteria for urgent
referral (%): NR
l SIGN criteria for urgent
referral (%): NR
l Clinical suspicion of CRC
(%): NR
Kyowa Medex,
Tokyo, Japan
Related publications:
None
Country: England
Funding: Reagents and
FIT devices provided by
industry
Recruitment: March 2015
to March 2016
Study design: Diagnostic
cohort
NR, not reported.
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Appendix 3 Assessments of study quality
A. QUADAS-2 assessments
Auge 201657
DOMAIN 1: PATIENT SELECTION
A. RISK OF BIAS
Consecutive patients, requiring colonoscopy for lower abdominal symptoms or polyp surveillance
Was a consecutive or random sample of patients enrolled? Yes
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? RISK: Low
B. APPLICABILITY
Patients referred for colonoscopy, some polyp surveillance patients included, symptoms not specified
Do the included patients match the question? Concerns: High
DOMAIN 2: INDEX TEST(S)
A. RISK OF BIAS
Patients collected two consecutive faecal samples, which were stored at 4 °C until analysis. Faecal immunochemical testing
was conducted before colonoscopy
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the index test have introduced bias? RISK: Low
B. APPLICABILITY
Are there concerns that the index test, its conduct or interpretation differ from the review
question?
Concerns: Low
DOMAIN 3: REFERENCE STANDARD
A. RISK OF BIAS
Colonoscopy was performed blind to the results of the symptoms questionnaire and faecal immunochemical testing
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index test? Yes
Could the reference standard, its conduct or its interpretation have introduced bias? RISK: Low
B. APPLICABILITY
Is there concern that the target condition, as defined by the reference standard, does not
match the review question?
Concerns: Low
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DOMAIN 4: FLOW AND TIMING
A. RISK OF BIAS
All participants appeared to have been included in the analysis. Colonoscopy was conducted 5 days after the index test
Was there an appropriate time interval between the index test and reference standard? Yes
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? RISK: Low
Cubiella 2014 (COLONPREDICT)55
DOMAIN 1: PATIENT SELECTION
A. RISK OF BIAS
Consecutive patients, with GI symptoms, referred from primary and secondary health care
Was a consecutive or random sample of patients enrolled? Yes
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? RISK: Low
B. APPLICABILITY
Patients referred from a mixture of primary and secondary care. Symptoms included some not specified in NG121
(e.g. rectal bleeding)
Do the included patients match the question? Concerns: High
DOMAIN 2: INDEX TEST(S)
A. RISK OF BIAS
No details of sample collection and storage. Faecal immunochemical testing was performed the week before colonoscopy
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it prespecified? Unclear
Could the conduct or interpretation of the index test have introduced bias? RISK: Low
B. APPLICABILITY
Are there concerns that the index test, its conduct or interpretation differ from the review
question?
Concerns: Low
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DOMAIN 3: REFERENCE STANDARD
A. RISK OF BIAS
Colonoscopy was performed blind to the results of the symptoms questionnaire and faecal immunochemical testing
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index test? Yes
Could the reference standard, its conduct or its interpretation have introduced bias? RISK: Low
B. APPLICABILITY
Is there concern that the target condition, as defined by the reference standard, does not
match the review question?
Concerns: Low
DOMAIN 4: FLOW AND TIMING
A. RISK OF BIAS
Faecal immunochemical testing was performed 1 week before colonoscopy; 26 patients who did not return a faecal sample
and 12 who did not attend for colonoscopy were excluded from the study
Was there an appropriate time interval between the index test and reference standard? Yes
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? RISK: Low
Godber 201656
DOMAIN 1: PATIENT SELECTION
A. RISK OF BIAS
Patients who had been referred from primary care for endoscopic examination of the lower GI tract
Was a consecutive or random sample of patients enrolled? Yes
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? RISK: Low
B. APPLICABILITY
Patients who were referred for colonoscopy for reasons, which include the following: altered bowel habit, constipation or
diarrhoea, abdominal pain, fresh rectal bleeding, follow-up of previous disease, anaemia, weight loss and abnormal CT
findings
Do the included patients match the question? Concerns: High
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DOMAIN 2: INDEX TEST(S)
A. RISK OF BIAS
Patients collected single faecal samples and returned by post. Sample stored at 4 °C. Samples were analysed using a
HM-JACKarc automated immunoturbidimetric analyser. The index test was conducted before colonoscopy. ROC analysis
was reported, but data were extracted for a range of specified thresholds
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it prespecified? Unclear
Could the conduct or interpretation of the index test have introduced bias? RISK: Low
B. APPLICABILITY
Are there concerns that the index test, its conduct or interpretation differ from the review
question?
Concerns: Low
DOMAIN 3: REFERENCE STANDARD
A. RISK OF BIAS
Colonoscopy was performed by the endoscopy service
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index test? Unclear
Could the reference standard, its conduct or its interpretation have introduced bias? RISK: Unclear
B. APPLICABILITY
Is there concern that the target condition, as defined by the reference standard, does not
match the review question?
Concerns: Low
DOMAIN 4: FLOW AND TIMING
A. RISK OF BIAS
The time interval between index test and reference standard was not reported; 402 people declined to participate, 23
(4.5%) failed colonoscopy
Was there an appropriate time interval between the index test and reference standard? Unclear
Did all patients receive a reference standard? No
Did patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? RISK: Low
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Hospital Clinic de Barcelona 2015
DOMAIN 1: PATIENT SELECTION
A. RISK OF BIAS
(Confidential information has been removed)
(Confidential information has been removed) (Confidential information has been removed)
(Confidential information has been removed) (Confidential information has been removed)
(Confidential information has been removed) (Confidential information has been removed)
Could the selection of patients have introduced bias? (Confidential information has been removed)
B. APPLICABILITY
(Confidential information has been removed)
Do the included patients match the question? (Confidential information has been removed)
DOMAIN 2: INDEX TEST(S)
A. RISK OF BIAS
(Confidential information has been removed)
(Confidential information has been removed) (Confidential information has been removed)
(Confidential information has been removed) (Confidential information has been removed)
Could the conduct or interpretation of the index test have
introduced bias?
(Confidential information has been removed)
B. APPLICABILITY
Are there concerns that the index test, its conduct or interpretation
differ from the review question?
(Confidential information has been removed)
DOMAIN 3: REFERENCE STANDARD
A. RISK OF BIAS
(Confidential information has been removed)
(Confidential information has been removed) (Confidential information has been removed)
(Confidential information has been removed) (Confidential information has been removed)
Could the reference standard, its conduct or its interpretation have
introduced bias?
(Confidential information has been removed)
B. APPLICABILITY
Is there concern that the target condition, as defined by the
reference standard, does not match the review question?
(Confidential information has been removed)
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DOMAIN 4: FLOW AND TIMING
A. RISK OF BIAS
(Confidential information has been removed)
(Confidential information has been removed) (Confidential information has been removed)
(Confidential information has been removed) (Confidential information has been removed)
(Confidential information has been removed) (Confidential information has been removed)
(Confidential information has been removed) (Confidential information has been removed)
Could the patient flow have introduced bias? (Confidential information has been removed)
Krivec 201154
DOMAIN 1: PATIENT SELECTION
A. RISK OF BIAS
Symptomatic patients undergoing endoscopic and/or histological examinations
Was a consecutive or random sample of patients enrolled? Unclear
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? RISK: Unclear
B. APPLICABILITY
Symptomatic adults undergoing endoscopy and/or histology, patients already referred and symptoms not specified
Do the included patients match the question? Concerns: High
DOMAIN 2: INDEX TEST(S)
A. RISK OF BIAS
No details of sample collection or storage/processing were reported. The FIT cut-off point was derived from ROC analysis
Were the index test results interpreted without knowledge of the results of the reference standard? Unclear
If a threshold was used, was it prespecified? No
Could the conduct or interpretation of the index test have introduced bias? RISK: High
B. APPLICABILITY
Are there concerns that the index test, its conduct or interpretation differ from the review
question?
Concerns: Low
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DOMAIN 3: REFERENCE STANDARD
A. RISK OF BIAS
Endoscopy and/or histological examination
Is the reference standard likely to correctly classify the target condition? Unclear
Were the reference standard results interpreted without knowledge of the results of the index test? Unclear
Could the reference standard, its conduct or its interpretation have introduced bias? RISK: Unclear
B. APPLICABILITY
Is there concern that the target condition, as defined by the reference standard, does not
match the review question?
Concerns: High
DOMAIN 4: FLOW AND TIMING
A. RISK OF BIAS
The time interval between index test and reference standard was not reported. No exclusions were reported
Was there an appropriate time interval between the index test and reference standard? Unclear
Did all patients receive a reference standard? Unclear
Did patients receive the same reference standard? unclear
Were all patients included in the analysis? Unclear
Could the patient flow have introduced bias? RISK: Unclear
McDonald 201213
DOMAIN 1: PATIENT SELECTION
A. RISK OF BIAS
Patients who had been referred from primary care for endoscopic examination of the lower GI tract
Was a consecutive or random sample of patients enrolled? Yes
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? RISK: Low
B. APPLICABILITY
Patients who were referred for colonoscopy for the following reasons: rectal bleeding, change in bowel habit,
iron-deficiency anaemia, abdominal pain, bloating, polyp/CRC surveillance, family history and assessment of IBD
Do the included patients match the question? Concerns: High
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DOMAIN 2: INDEX TEST(S)
A. RISK OF BIAS
Patients collected single faecal samples and returned by post. No details of sample storage. Samples were analysed using a
OC-Sensor. The index test was conducted before colonoscopy. ROC analysis was reported, but data were extracted for the
prespecified 50-ng/ml threshold
Were the index test results interpreted without knowledge of the results of the reference
standard?
Yes
If a threshold was used, was it prespecified? Unclear
Could the conduct or interpretation of the index test have introduced bias? RISK: Low
B. APPLICABILITY
Are there concerns that the index test, its conduct or interpretation differ from the review
question?
Concerns: Low
DOMAIN 3: REFERENCE STANDARD
A. RISK OF BIAS
Colonoscopy and flexible sigmoidoscopy were performed in the Endoscopy Unit
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index
test?
Unclear
Could the reference standard, its conduct or its interpretation have introduced bias? RISK: Unclear
B. APPLICABILITY
Is there concern that the target condition, as defined by the reference standard, does not
match the review question?
Concerns: Unclear
DOMAIN 4: FLOW AND TIMING
A. RISK OF BIAS
The median time between faecal immunochemical testing and colonoscopy was 9 days (range 1–112 days); 265 declined to
participate, 15 completed faecal immunochemical testing only, 138 completed endoscopy only, 30 did not complete faecal
immunochemical testing/endoscopy, 11 excluded (faecal immunochemical testing completed after endoscopy/sample not
dated/sample arrived after endoscopy)
Was there an appropriate time interval between the index test and reference standard? Yes
Did all patients receive a reference standard? No
Did patients receive the same reference standard? No
Were all patients included in the analysis? No
Could the patient flow have introduced bias? RISK: High
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Mowat 201552
DOMAIN 1: PATIENT SELECTION
A. RISK OF BIAS
All adult patients referred for investigation of bowel symptoms over a 6-month period
Was a consecutive or random sample of patients enrolled? Yes
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? RISK: Low
B. APPLICABILITY
Adult patients referred (straight to endoscopy or outpatient clinic followed by referral to endoscopy) by GP for investigation
of bowel symptoms, who returned faecal tests (1043/2173) and underwent lower endoscopy. Symptoms included some not
specified in NG121 (e.g. rectal bleeding). The low rate of return may mean that included participants are not representative
of those who would undergo the test in practice
Do the included patients match the question? Concerns: High
DOMAIN 2: INDEX TEST(S)
A. RISK OF BIAS
Patients collected samples from a single faeces, which were returned to the GP surgery at room temperature and stored at
4 °C (FHb) or –20 °C (FC) prior to analysis to ensure stability. FHb measurement was performed using a single OC-Sensor IO
analyser. Any FHb sample that was reported by the analytical system as a positive numerical result of > 0 mg/g was
considered as a ‘detectable FHb’. Samples with results above the upper analytical limits were not diluted and reassayed but
reported as greater than that upper concentration limit. FHb results were converted from the instrument-generated ‘ng/ml’
to the internationally recommended unit of ‘mg/g’ by multiplying by 0.2. The laboratory has a total quality management
system in place and is accredited to ISO 15189-based standards
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it prespecified? Unclear
Could the conduct or interpretation of the index test have introduced bias? RISK: Low
B. APPLICABILITY
Are there concerns that the index test, its conduct or interpretation differ from the review
question?
Concerns: Low
FC, faecal calprotectin; FHb, faecal haemoglobin.
DOMAIN 3: REFERENCE STANDARD
A. RISK OF BIAS
Patients referred to endoscopy were investigated within 6 weeks of referral. The endoscopy units participate in the
accreditation scheme of the Joint Accreditation Group on GI Endoscopy. Participating clinicians and endoscopists were blind
to the faecal test results. All findings were recorded on the endoscopy reporting system by the endoscopist. The diagnoses
of CRC, HRA and IBD were confirmed following assessment by a GI pathologist
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index test? Yes
Could the reference standard, its conduct or its interpretation have introduced bias? RISK: Low
B. APPLICABILITY
Is there concern that the target condition, as defined by the reference standard, does not
match the review question?
Concerns: Low
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DOMAIN 4: FLOW AND TIMING
A. RISK OF BIAS
Patients referred for endoscopy were investigated within 6 weeks of referral; 1003 patients not returning the faecal test,
114 patients not referred by GP, 18 patients with a cancelled referral, 60 patients cancelling or not attending endoscopy,
78 patients referred to outpatients but not referred for endoscopy
Was there an appropriate time interval between the index test and reference standard? Yes
Did all patients receive a reference standard? No
Did patients receive the same reference standard? yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? RISK: High
Rodríguez-Alonso 201553
DOMAIN 1: PATIENT SELECTION
A. RISK OF BIAS
Symptomatic, adult patients referred for diagnostic colonoscopy
Was a consecutive or random sample of patients enrolled? Unclear
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? RISK: Unclear
B. APPLICABILITY
Symptomatic adult patients referred for colonoscopy. Symptoms included some not specified in NG121 (e.g. rectal bleeding);
66.3% of participants were referred from primary care
Do the included patients match the question? Concerns: High
DOMAIN 2: INDEX TEST(S)
A. RISK OF BIAS
Patients collected single faecal samples and were asked to store the sample at < 4 °C and to return it within 7 days.
Samples were analysed using OC-Sensor and a MICRO desktop analyser (Eiken). The index test was conducted before
colonoscopy
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the index test have introduced bias? RISK: Low
B. APPLICABILITY
Are there concerns that the index test, its conduct or interpretation differ from the review
question?
Concerns: Low
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DOMAIN 3: REFERENCE STANDARD
A. RISK OF BIAS
Colonoscopies were performed by experienced endoscopists who were blind to FIT results
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index test? Yes
Could the reference standard, its conduct or its interpretation have introduced bias? RISK: Low
B. APPLICABILITY
Is there concern that the target condition, as defined by the reference standard, does not
match the review question?
Concerns: Low
DOMAIN 4: FLOW AND TIMING
A. RISK OF BIAS
Time to colonoscopy was determined by the level of Hb detected and NICE/SIGN guidelines. All colonoscopies were
completed within 16 weeks; 19 patients not returning the faecal test were excluded from the study; 22 patients with
incomplete colonoscopy, and 10 patients who did not attend for colonoscopy, were excluded from the analyses
Was there an appropriate time interval between the index test and reference standard? Yes
Did all patients receive a reference standard? No
Did patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? RISK: Low
Terhaar sive Droste 201158
DOMAIN 1: PATIENT SELECTION
A. RISK OF BIAS
All adult patients referred for colonoscopy to one of five hospitals in the Netherlands; subgroup data for symptomatic
patients were provided by the lead author
Was a consecutive or random sample of patients enrolled? Yes
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? RISK: Low
B. APPLICABILITY
Symptomatic adult patients referred for colonoscopy. Symptoms included some not specified in NG121 (e.g. rectal bleeding).
Testing was conducted after referral for colonoscopy
Do the included patients match the question? Concerns: High
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DOMAIN 2: INDEX TEST(S)
A. RISK OF BIAS
Patients collected a sample on the day before colonoscopy and before the start of bowel preparation. Samples were
stored at –5 °C and analysed within 1 week. Technicians performing FIT analyses were blind to clinical data
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the index test have introduced bias? RISK: Low
B. APPLICABILITY
Are there concerns that the index test, its conduct or interpretation differ from the review
question?
Concerns: Low
DOMAIN 3: REFERENCE STANDARD
A. RISK OF BIAS
Endoscopists were blinded to the results of faecal immunochemical testing
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index test? Yes
Could the reference standard, its conduct or its interpretation have introduced bias? RISK: Low
B. APPLICABILITY
Is there concern that the target condition, as defined by the reference standard, does not
match the review question?
Concerns: Low
DOMAIN 4: FLOW AND TIMING
A. RISK OF BIAS
Colonoscopy was conducted 1 day after faecal immunochemical testing. Patients with incomplete colonoscopy or
inadequate bowel cleansing, as judged by the endoscopist (number not reported), were excluded from the analyses
Was there an appropriate time interval between the index test and reference standard? Yes
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? RISK: Unclear
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Thomas 201675
DOMAIN 1: PATIENT SELECTION
A. RISK OF BIAS
Symptomatic patients were recruited after their first 2-week wait clinic; 64 patients were excluded after faecal
immunochemical testing (no reason reported)
Was a consecutive or random sample of patients enrolled? Unclear
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? RISK: Unclear
B. APPLICABILITY
Symptomatic adults, tested after referral to secondary care
Do the included patients match the question? Concerns: High
DOMAIN 2: INDEX TEST(S)
A. RISK OF BIAS
No details of sample collection or storage/processing were reported. The cut-off point was predefined as the lower limit of
the assay. CT/colonoscopy was conducted after faecal immunochemical testing
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the index test have introduced bias? RISK: Low
B. APPLICABILITY
Are there concerns that the index test, its conduct or interpretation differ from the review
question?
Concerns: Low
DOMAIN 3: REFERENCE STANDARD
A. RISK OF BIAS
CT/colonoscopy, no further details reported
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index test? Unclear
Could the reference standard, its conduct or its interpretation have introduced bias? RISK: Unclear
B. APPLICABILITY
Is there concern that the target condition, as defined by the reference standard, does not
match the review question?
Concerns: Low
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DOMAIN 4: FLOW AND TIMING
A. RISK OF BIAS
The time between faecal immunochemical testing and colonoscopy was not reported; 259 patients not returning the faecal
test were excluded from the study, 64 patients were excluded after faecal testing (no reason for exclusion was reported
and it was unclear whether these patients underwent colonoscopy)
Was there an appropriate time interval between the index test and reference standard? Unclear
Did all patients receive a reference standard? Unclear
Did patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? RISK: High
B. PROBAST assessments
Cubiella 2015 (COLONPREDICT)73 and personal communication,* ahead
of publication
(*Callum Fraser, personal communication.)
DOMAIN 1: Participant selection
A. Risk of bias
Describe the sources of data and criteria for participant selection: The development cohort consisted of consecutive,
symptomatic patients included in a previous diagnostic accuracy study.55 The validation cohort consisted of patients
included in four further published studies,13,52,53,56 plus an additional unpublished cohort. FIT assay methods differed
between studies and within the unpublished cohort
Dev Val
1. Were participants defined and assessed in a similar way to participants in the model development
study?
No
2. Were appropriate data sources used, e.g. cohort, RCT or nested case–control study data? Yes Yes
3. Were all inclusions and exclusions of participants appropriate? Yes Yes
Risk of bias introduced by selection of participants RISK: (low/high/unclear) Low Low
Rationale of bias rating: FIT assay methods differed between studies and within the unpublished cohort used in validation.
However, the effect of different assay methods on risk score performance was assessed
B. Applicability
Describe included participants, setting and dates: Symptomatic adult patients referred for colonoscopy. Symptoms included
some not specified in NG121 (e.g. rectal bleeding). Not all participants were referred from primary care
Concern that the included participants and setting do not match the
review question
CONCERN: (low/high/
unclear)
High High
Rationale of applicability rating: The study population is not a complete match for that specified in the scope for this
assessment
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DOMAIN 2: Predictors
A. Risk of bias
List and describe predictors included in the final model, e.g. definition and timing of assessment: Sex, age (continuous
variable) and ‘µg Hb/g faeces’ (categorical: undetectable, 0–19, 20–199 and ≥ 200). No further details were reported.
Colonoscopy was conducted after faecal immunochemical testing
Dev Val
1. Were predictors defined and assessed in a similar way for all participants? Yes No
2. Were predictors defined and assessed in a similar way to predictors in the development model? No
3. Were predictor assessments made without knowledge of outcome data? Yes Yes
4. Are all predictors available at the time the model is intended to be used? Yes Yes
Risk of bias introduced by predictors or their assessment RISK: (low/high/
unclear)
High High
Rationale of bias rating: FIT methods used in validation differed from those used in development
B. Applicability
Concern that the definition, assessment or timing of predictors in the
model do not match the review question
CONCERN: (low/
high/unclear)
High High
Rationale of applicability rating: Faecal immunochemical testing used OC-Sensor, but was undertaken after patients had
already been referred for colonoscopy
DOMAIN 3: Outcome
A. Risk of bias
Describe the outcome and how it was defined and determined: Models were reported for the outcomes CRC and
advanced neoplasia, both determined by colonoscopy. The definition of advanced neoplasia varied between the studies
used in the validation cohort
Dev Val
1. Was the outcome determined appropriately? Yes Yes
2. Was a prespecified or standard outcome definition used? Yes No
3. Were predictors excluded from the outcome definition? Yes Yes
4. Was the outcome defined and determined in a similar way for all participants? Yes No
5. Was the outcome defined and determined in a similar way to the outcome in the model
development study?
No
6. Was the outcome determined without knowledge of predictor information? Unclear Unclear
Risk of bias introduced by the outcome or its determination RISK: (low/high/
unclear)
Low High
Rationale of bias rating: The definition of HRA varied between the studies used in the validation cohort.
B. Applicability
At what time point was the outcome determined: The time point at which the outcome was determined varied between
studies, but all colonoscopies were completed within 16 weeks
If a composite outcome was used, describe the relative frequency/distribution of each contributing outcome: NA
Concern that the outcome, its definition, timing or determination do
not match the review question
CONCERN: (low/
high/unclear)
Low Low
Rationale of applicability rating:
NA, not applicable.
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DOMAIN 4: Sample size and participant flow
Risk of bias
Describe numbers of participants, number of candidate predictors, outcome events and events per candidate predictor:
1572 participants were included in the development sample and 3976 in the validation sample. The number of candidate
variables and total number of participants with the outcome were not reported
Describe the time interval between predictor assessment and outcome determination: The time between predictor and
outcome assessment varied between studies included in the validation cohort, but the maximum time between predictor
assessment and outcome determination was 16 weeks
Describe any participants who were excluded from the analysis: Participants who did not complete faecal immunochemical
testing or colonoscopy were excluded
Describe missing data on predictors and outcomes, as well as methods used for missing data: No details were reported
Dev Val
1. Were there a reasonable number of participants with the outcome? Unclear Unclear
2. Was the time interval between predictor assessment and outcome
determination appropriate?
Yes Yes
3. Were all enrolled participants included in the analysis? No No
4. Were participants with missing data handled appropriately? Unclear Unclear
Risk of bias introduced by sample size or participant flow RISK: (low/high/unclear) Unclear Unclear
Rationale of bias rating: Modelling methods were not reported in sufficient detail to adequately assess risk of bias
DOMAIN 5: Analysis
Risk of bias
Describe how the model was developed (predictor selection, optimism, risk groups, model performance): No details
reported
Describe whether and how the model was validated, either internally (e.g. bootstrapping, cross validation, random split
sample) or externally (e.g. temporal validation, geographical validation, different setting, different type of participants): The
external validation cohort comprised five different studies, which were separate from the study used as the development
cohort
Describe the performance measures of the model, e.g. (re)calibration, discrimination, (re)classification, net benefit: R2
(measure of variation), Akaike information criterion and Bayesian information criterion. The study describes the diagnostic
accuracy of a risk score based on the model results
Dev Val
1. Were continuous and categorical predictors handled appropriately? Yes
2. Was selection of predictors based on univariable analysis avoided? Unclear
3. Were any complexities in the data (e.g. competing risks, multiple events per individual) accounted
for appropriately?
Unclear Unclear
4. Were relevant model performance measures evaluated, e.g. (re)calibration and discrimination? Unclear Unclear
5. Was model overfitting and optimism in model performance accounted for? Unclear
6. Do predictors and their assigned weights in the final model correspond with the results from
multivariable analysis?
Unclear
Risk of bias introduced by the analysis RISK: (low/high/unclear) Unclear Unclear
Rationale of bias rating: Modelling methods were not reported in sufficient detail to adequately assess the risk of bias
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Overall judgement about risk of bias and applicability of the prediction model evaluation
Overall judgement of risk of bias RISK: (low/high/unclear) High
Summary of sources of potential bias: Modelling methods were not reported in sufficient detail to adequately assess the
risk of bias; however, faecal immunochemical testing methods and advanced neoplasia definitions varied between the
studies included in the validation cohort
Overall judgement of applicability CONCERN: (low/high/unclear) High
Summary of applicability concerns: The study population is not a complete match for that specified in the scope for this
assessment
Rodríguez-Alonso 201553
DOMAIN 1: Participant selection
A. Risk of bias
Describe the sources of data and criteria for participant selection: Participants were patients included in prospective
diagnostic accuracy study. The study included patients aged > 18 years, referred for diagnostic colonoscopy between
September 2011 and October 2102. Patients referred for adenoma surveillance or post-surgical surveillance of CRC, and
those with a history of previous colectomy, IBD or polyp syndromes were excluded. Diagnosis was established by
colonoscopy. Validation of the model used a split sample procedure
Dev Val
1. Were participants defined and assessed in a similar way to participants in the model development
study?
Yes
2. Were appropriate data sources used, e.g. cohort, RCT or nested case–control study data? Yes Yes
3. Were all inclusions and exclusions of participants appropriate? Yes Yes
Risk of bias introduced by selection of participants RISK: (low/high/unclear) Low Low
Rationale of bias rating:
B. Applicability
Describe included participants, setting and dates: Symptomatic adult patients referred for colonoscopy. Symptoms included
some not specified in NG121 (e.g. rectal bleeding); 66.3% of participants were referred from primary care
Concern that the included participants and setting do not match the
review question
CONCERN: (low/high/
unclear)
High High
Rationale of applicability rating: The study population is not a complete match for that specified in the scope for this
assessment
DOI: 10.3310/hta21330 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 33
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Westwood et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
177
DOMAIN 2: Predictors
A. Risk of bias
List and describe predictors included in the final model, e.g. definition and timing of assessment: Male gender, iron-
deficiency anaemia (not defined) and Hb level ≥ 10 µg/g faeces were included in the final model for CRC. No further details
were reported. Colonoscopy was conducted after faecal immunochemical testing and other initial assessments, and
endoscopists were blinded to test results
Dev Val
1. Were predictors defined and assessed in a similar way for all participants? Unclear Unclear
2. Were predictors defined and assessed in a similar way to predictors in the development model? Unclear
3. Were predictor assessments made without knowledge of outcome data? Yes Yes
4. Are all predictors available at the time the model is intended to be used? Yes Yes
Risk of bias introduced by predictors or their assessment RISK: (low/high/
unclear)
Unclear Unclear
Rationale of bias rating: Reporting of the model development and validation methods was limited
B. Applicability
Concern that the definition, assessment or timing of predictors in the
model do not match the review question
CONCERN: (low/
high/unclear)
High High
Rationale of applicability rating: Faecal immunochemical testing used OC-Sensor, but was undertaken after patients had
already been referred for colonoscopy and attended an assessment appointment
DOMAIN 3: Outcome
A. Risk of bias
Describe the outcome and how it was defined and determined: Models were reported for the outcomes CRC and
advanced neoplasia, both determined by colonoscopy. Advanced neoplasia was defined as CRC or HRA (lesion ≥ 10-mm
diameter, villous component or high-grade dysplasia). Endoscopists were blinded to test results
Dev Val
1. Was the outcome determined appropriately? Yes Yes
2. Was a prespecified or standard outcome definition used? Yes Yes
3. Were predictors excluded from the outcome definition? Yes Yes
4. Was the outcome defined and determined in a similar way for all participants? Yes Yes
5. Was the outcome defined and determined in a similar way to the outcome in the model development
study?
Yes
6. Was the outcome determined without knowledge of predictor information? Yes Yes
Risk of bias introduced by the outcome or its determination RISK: (low/high/
unclear)
Low Low
Rationale of bias rating:
B. Applicability
At what time point was the outcome determined: All colonoscopies were completed within 16 weeks
If a composite outcome was used, describe the relative frequency/distribution of each contributing outcome: NA
Concern that the outcome, its definition, timing or determination do not
match the review question
CONCERN: (low/high/
unclear)
Low Low
Rationale of applicability rating:
NA, not applicable.
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DOMAIN 4: Sample size and participant flow
Risk of bias
Describe numbers of participants, number of candidate predictors, outcome events and events per candidate predictor: 680
participants were included in the development sample and 323 in the validation sample. There were 14 candidate variables
in the initial analysis. A total of 30 study participants had CRC and 133 had advanced neoplasia
Describe the time interval between predictor assessment and outcome determination: The maximum time between
predictor assessment and outcome determination was 16 weeks
Describe any participants who were excluded from the analysis: Participants who did not complete faecal immunochemical
testing or colonoscopy were excluded
Describe missing data on predictors and outcomes, as well as methods used for missing data: No details were reported
Dev Val
1. Were there a reasonable number of participants with the outcome? Unclear Unclear
2. Was the time interval between predictor assessment and outcome determination
appropriate?
Yes Yes
3. Were all enrolled participants included in the analysis? No No
4. Were participants with missing data handled appropriately? Unclear Unclear
Risk of bias introduced by sample size or participant flow RISK: (low/high/unclear) Unclear Unclear
Rationale of bias rating: Modelling methods were not reported in sufficient detail to adequately assess risk of bias
DOMAIN 5: Analysis
Risk of bias
Describe how the model was developed (predictor selection, optimism, risk groups, model performance): A multivariate
analysis based on forward conditional logistic regression was performed. Factors were included in the multivariate models,
based on based on their univariate association with CRC or advanced neoplasia (p < 0.05). Factors not reaching statistical
significance were also included if they were judged to be ‘clinically relevant or biologically plausible’
Describe whether and how the model was validated, either internally (e.g. bootstrapping, cross validation, random split
sample) or externally (e.g. temporal validation, geographical validation, different setting, different type of participants): The
internal validity of the model was assessed using a random split sampling technique. No further details were reported
Describe the performance measures of the model, e.g. (re)calibration, discrimination, (re)classification, net benefit: Not
reported; the study describes the diagnostic accuracy of a risk score based on the model results
Dev Val
1. Were continuous and categorical predictors handled appropriately? Unclear
2. Was selection of predictors based on univariable analysis avoided? No
3. Were any complexities in the data (e.g. competing risks, multiple events per individual) accounted
for appropriately?
Unclear Unclear
4. Were relevant model performance measures evaluated, e.g. (re)calibration and discrimination? Unclear Unclear
5. Was model overfitting and optimism in model performance accounted for? Unclear
6. Do predictors and their assigned weights in the final model correspond to the results from
multivariable analysis?
Unclear
Risk of bias introduced by the analysis RISK: (low/high/unclear) High High
Rationale of bias rating: Modelling methods were not reported in sufficient detail to adequately assess the risk of bias;
however, selection of predictors based on univariate analysis was reported
DOI: 10.3310/hta21330 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 33
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Westwood et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
179
Overall judgement about risk of bias and applicability of the prediction model evaluation
Overall judgement of risk of bias RISK: (low/high/unclear) High
Summary of sources of potential bias: Modelling methods were not reported in sufficient detail to adequately assess the
risk of bias; however, selection of predictors based on univariate analysis was reported
Overall judgement of applicability CONCERN: (low/high/unclear) High
Summary of applicability concerns: The study population is not a complete match for that specified in the scope for this
assessment
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Appendix 4 Excluded studies
To be included in the review, studies had to fulfil the following criteria:
l Population Adults (≥ 18 years of age) presenting with symptoms suggestive of possible CRC.
l Setting Primary care.
l Index test Quantitative faecal immunochemical testing [OC-Sensor, HM-JACKarc, FOB Gold,
RIDASCREEN Hb (R-Biopharm, Darmstadt, Germany), RIDASCREEN Hb/Hp complex].
l Reference standard Colonoscopy.
l Outcome Sufficient data to construct 2 × 2 table of test performance.
The table below summarises studies that were screened for inclusion, based on full-text publication, but
which did not fulfil one or more of the above criteria. Studies were assessed sequentially against criteria;
the first criterion failed is classified as the reason for exclusion. The table shows which of the criteria each
study fulfilled (‘Yes’) and on which items it failed (‘No’), as well as any which were ‘Unclear’. Articles that
did not report primary research were not assessed further. Any criteria that are not applicable to a study
are marked ‘NA’. When population was the only reason for exclusion and studies reported a mixed
population, authors were contacted to request subgroup data for symptomatic patients; this is noted in
the comments column.
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Appendix 6 Questionnaire and information sent
to clinical experts
One of the goals of our assessment is to explore the cost-effectiveness of using a quantitative faecalimmunochemical test (FIT) for haemoglobin (occult blood) as a triage test in the investigation of
symptomatic people presenting in the primary care setting who are at low risk of colorectal cancer (CRC).
The cost-effectiveness of FIT will be compared with guaiac faecal occult blood tests (gFOBT) and with no
triage (referral straight to colonoscopy).
A health economic model is currently being developed to address the question above. The model consists
of two parts:
1. the diagnostic model – a decision tree reflecting the diagnosis of CRC, and
2. the CRC model – a Markov state-transition model to estimate the long-term costs and effects
associated with the treatment and progression of CRC.
Information about the diagnostic performance of FIT will be derived from the systematic review component
of our assessment; however, additional information about the patient pathway after FIT testing is needed
in order to fully populate the model. Specific questions regarding modelling assumptions are listed below.
Any information that you are able to provide (from publications, unpublished data or personal experience)
would be very much appreciated.
The model begins with a cohort of symptomatic patients, presenting in primary care, who require
investigation for possible CRC. A patient in the cohort can have one of the following tests: FIT, gFOBT or no
triage testing at all (referral straight to colonoscopy). A positive test will result in referral to colonoscopy while
a negative test will result in a watchful waiting strategy in which a repeated test or further investigation
can be performed when symptoms persist. A schematic representation of the decision-analytic model is
given below:
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Patient compliance
1) What percentage of symptomatic patients (not yet referred for colonoscopy) would you expect to return
a faecal sample for FIT or gFOBT?
Please provide your answer here:
Lowest estimate Most likely estimate Highest estimate
FIT
gFOBT
2) What percentage of patients not returning a sample would then need to be referred to colonoscopy?
Please provide your answer here:
Lowest estimate Most likely estimate Highest estimate
3) What percentage of patients do not consent to colonoscopy?
Please provide your answer here:
Lowest estimate Most likely estimate Highest estimate
Of those testing positive with FIT/gFOBT?
In those referred without triage?
Colonoscopy versus CT colonography
4) If the gFOBT or FIT result is positive, patients are referred to either colonoscopy or CT colonography
(CTC). What would be the (estimated) percentage of patients that receive colonoscopy versus CTC in
the UK?
Please provide your answer here:
Lowest estimate Most likely estimate Highest estimate
Colonoscopy
CTC
Other (please specify)
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Negative test result FIT/gFOBT
5) What percentage of those patients who test negative with FIT/gFOBT will eventually
undergo colonoscopy?
Please provide your answer here:
Lowest estimate Most likely estimate Highest estimate
6) Could you also estimate the time interval to getting this colonoscopy?
Please provide your answer here:
Lowest estimate Most likely estimate Highest estimate
7) What percentage of those patients that test negative with FIT/gFOBT would get a second FIT/gFOBT?
Please provide your answer here:
Lowest estimate Most likely estimate Highest estimate
Positive test result FIT/gFOBT
8) What is the average time interval between presentation and colonoscopy?
No triage
9) What is the average time-interval between presentation and colonoscopy?
Positive test result colonoscopy
10) The study population is symptomatic patients at low risk, presenting in primary care, with lower
abdominal symptoms, who require investigation for possible CRC. In those who eventually have a
colonoscopy and are staged by CT what percentage would be found to be in each of the Dukes’ stages
(I, II, III, IV)?
DOI: 10.3310/hta21330 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 33
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Westwood et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
199
Please provide your answer here:
Lowest estimate Most likely estimate Highest estimate
Dukes’ stage I
Dukes’ stage II
Dukes’ stage III
Dukes’ stage IV
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Appendix 7 Equations used to estimates
probabilities in the diagnostic (decision tree) model
The probabilities used at the decision nodes in the diagnostic model, labelled as (A)–(J) in Figure 12,were summarised in Table 27. Most of them are functions of the sensitivity and specificity of the tests
and the prevalence of the disease in the patient population. In this appendix we provide full derivations of
those equations.
(A) Probability that faecal immunochemical test/guaiac faecal occult
blood test is positive
By the Law of Total Probability and the definitions of sensitivity, specificity and prevalence, the following
holds: P[T+] = P[T+|CRC+] × P[CRC+] + P[T+|CRC–] × P[CRC–] = (sensitivity × prevalence) + [(1 – specificity) ×
(1 – prevalence)].
(B) Probability that faecal immunochemical test/guaiac faecal
occult blood test is negative
This was calculated as 1 – (A).
(C) Probability that colorectal cancer is present after a positive
faecal immunochemical test/guaiac faecal occult blood test
This is the definition of the PPV. For the PSA, we assumed a beta distribution on the PPV.
(D) Probability that colorectal cancer is not present after a positive faecal
immunochemical test/guaiac faecal occult blood test
This was calculated as 1 – PPV.
(E) Probability that symptoms persist after a negative faecal
immunochemical test/guaiac faecal occult blood test
This was estimated based on expert opinion (mean value 0.325). A beta distribution was assumed for
the PSA.
(F) Probability that symptoms do not persist after a negative faecal
immunochemical test/guaiac faecal occult blood test
This was calculated as 1 – (E).
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(G) Probability that colorectal cancer is present for symptomatic patients
after a negative faecal immunochemical test/guaiac faecal occult
blood test
This was calculated as (1 – NPV)/(E). The full derivation is as follows.
Note that this probability cannot be directly estimated, as we do not have data on the ‘specificity’ of
persisting in symptoms, that is, we have assumed that persisting in symptoms is perfectly sensitive (all
patients with CRC with test negative will persist in their symptoms), but there will also be some ‘FPs’
(patients whose symptoms persist after testing negative that will not have CRC). With the data we have,
we can estimate the joint probability of (E) and (G) as follows.
The probability of persisting in symptoms after testing negative was estimated based on expert opinion.
This is (E) in the diagnostic model. We denote this probability as P[symp|T–] here. Note that this will include
patients with and without CRC (denoted by CRC+ and CRC–, respectively). Therefore, we need to
calculate the following probabilities:
l P[symp and CRC+|T–]: probability of remaining symptomatic and CRC+ after testing negative.
l P[symp and CRC–|T–]: probability of remaining symptomatic and CRC– after testing negative.
l P[no symp and CRC+|T–]: probability of becoming asymptomatic and CRC+ after testing negative.
l P[no symp and CRC–|T–]: probability of becoming asymptomatic and CRC– after testing negative.
By the Law of Total Probability, we have that:
P½sympjT− = P½symp and CRC−jT− + P½symp and CRC+ jT− (3)
P½no sympjT− = P½no symp and CRC−jT− + P½no symp and CRC+ jT−. (4)
As we are assuming that P[no symp and CRC+|T–] = 0 (i.e. all patients with CRC remain symptomatic),
equation 4 reduces to:
P½no sympjT− = P½no symp and CRC−jT−. (5)
Applying the Law of Total Probability again, we have that P[CRC + |T–] = P[symp and CRC+|T–] + P[no
symp and CRC+|T–], which also reduces to:
P½CRC+ jT− = P½symp and CRC+ jT−. (6)
Thus, the probability of having CRC given test negative is equal to the probability of being symptomatic
and having CRC given test negative (as we had assumed). Rearranging equation 6 and substituting into
equation 3, we have that:
P½symp and CRC−jT− = P½sympjT−−P½CRC + jT−. (7)
As P[CRC+|T–] is defined as 1 – NPV, we can conclude that:
P½symp and CRC+ jT− = 1−NPV (8)
P½symp and CRC−jT− = P½sympjT−− (1−NPV) (9)
P½no symp and CRC+ jT− = 0 (10)
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P½no symp and CRC−jT− = 1−P½sympjT−. (11)
It should be emphasised that equation 8 is the joint probability of (E) and (G); equation 9 is the joint
probability of (E) and (H); and equation 10 is the probability (F). Thus, (G) can be estimated as (1 – NPV)/(E).
There are two potential problems here:
As P[symp|T–] was estimated by experts independently of the accuracy estimates of faecal immunochemical
testing/gFOBT and the prevalence, it might not be guaranteed that P[symp and CRC–|T–], equation 9, is always
positive. Note that the experts estimated the mean P[symp|T–] as 0.325. For example, when the accuracy
data from Mowat et al.52 (threshold of 0 µg Hb/g faeces for the detection of CRC using a single faecal sample)
was used, the NPV was high enough (0.9948 if based on prevalence in study or 0.9979 if based on 1.5%
prevalence) to keep the equation positive, but this would be a problem if the NPV fell below 0.675 (i.e.
1 – 0.325). With the data we have, this is probably not a problem, but particular attention must be taken
when the PSA is run.
The second potential problem is that, we have shown that, conditional on testing negative, the probability of
remaining symptomatic and having CRC was 1 – NPV. However, as we previously mentioned, that is not the
probability needed for the model, we need (G). We have shown above that (G) = (1 – NPV)/P[symp|T–]. This
is not a problem when the mode is run deterministically, but having P[symp|T–] in the denominator, which is
assumed to follow a beta distribution, causes numerical problems when performing the PSA (numerical
division by 0). For that reason, for the PSA, we decided to consider (G) = (1 – NPV)/mean(P[symp|T–]),
where mean(P[symp|T–]) = 0.325, given by the experts.
Note, finally, that there should be no uncertainty from being symptomatic in estimating the probability
of having the disease given test negative. This is because in equation 8 we concluded that
P[symp and CRC+|T–] = 1–NPV. This is the joint probability of (E) and (G), but, in the model, this joint
probability is calculated as P[symp|T–] × (1 – NPV)/mean(P[symp|T–]), where P[symp|T–] and mean(P[symp|T–])
do not cancel each other out. Therefore, our model is likely to overestimate the uncertainty around this
probability.
(H) Probability that colorectal cancer is not present for
symptomatic patients after a negative test
This was calculated as 1 – (G).
(I) Probability that colorectal cancer is present
This was estimated as the prevalence of CRC in our population.
Note that this is equivalent to the probability of having a positive colonoscopy in the no triage (referral
straight to colonoscopy) arm of the diagnostic model (thus colonoscopy only). As prevalence is defined as
the proportion of the population with the condition and given that we are assuming that colonoscopy
is a perfect diagnostic for CRC, the prevalence is indeed the probability that we need. In NG121 it was
assumed that the prevalence of CRC in the base-case population was 1.5%. This value was obtained from
experts. Further, a range of variation was assumed and then a uniform or triangular probability distribution
can be used to include this parameter in the PSA.
(J) Probability that colorectal cancer is not present
This was calculated as 1 – (I).
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Appendix 8 Annual survival/mortality rates
included in the colorectal cancer Markov model
TABLE 69 Predicted 15-year CRC survival probability by Dukes’ stage used in NG121
Year Dukes’ A predicted Dukes’ B predicted Dukes’ C predicted Dukes’ D predicted
0 100 100 100 100
1 97.211 92.233 82.357 38.112
2 95.541 85.403 65.111 17.669
3 94.577 81.644 56.749 11.270
4 93.900 79.078 51.476 8.192
5 93.377 77.144 47.725 6.396
6 92.953 75.598 44.865 5.225
7 92.595 74.316 42.581 4.404
8 92.286 73.222 40.696 3.798
9 92.015 72.271 39.103 3.333
10 91.773 71.431 37.731 2.965
11 91.555 70.679 36.532 2.668
12 91.356 70.000 35.470 2.422
13 91.173 69.381 34.520 2.217
14 91.004 68.812 33.664 2.042
15 90.848 68.287 32.886 1.891
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Appendix 9 Annual mortality rates included in
the healthy population Markov model
TABLE 71 Annual mortality rate, by age, used in the healthy population Markov model
Age Weighted average annual mortality Beta distribution (α) Beta distribution (β)
40 0.0010 98,337 101
41 0.0011 98,227 111
42 0.0012 98,109 118
43 0.0013 97,981 127
44 0.0014 97,846 135
45 0.0015 97,704 143
46 0.0016 97,552 152
47 0.0016 97,392 160
48 0.0018 97,220 172
48 0.0018 97,220 172
49 0.0019 97,036 184
50 0.0021 96,836 199
51 0.0023 96,618 218
52 0.0025 96,379 240
53 0.0027 96,115 264
54 0.0030 95,823 291
55 0.0034 95,502 322
56 0.0037 95,148 353
57 0.0041 94,760 388
58 0.0045 94,336 425
59 0.0049 93,873 463
60 0.0054 93,369 503
61 0.0059 92,824 545
62 0.0064 92,235 590
63 0.0069 91,599 635
64 0.0075 90,915 684
65 0.0081 90,180 735
66 0.0088 89,387 793
67 0.0096 88,532 855
68 0.0105 87,608 924
69 0.0115 86,604 1004
continued
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TABLE 71 Annual mortality rate, by age, used in the healthy population Markov model (continued )
Age Weighted average annual mortality Beta distribution (α) Beta distribution (β)
70 0.0127 85,512 1092
71 0.0140 84,321 1191
72 0.0155 83,021 1299
73 0.0172 81,604 1417
74 0.0191 80,060 1544
75 0.0212 78,382 1678
76 0.0234 76,562 1819
77 0.0260 74,593 1969
78 0.0289 72,465 2129
79 0.0321 70,167 2298
80 0.0358 67,688 2479
81 0.0400 65,016 2672
82 0.0448 62,140 2877
83 0.0505 59,047 3092
84 0.0569 55,734 3313
85 0.0643 52,204 3531
86 0.0727 48,468 3736
87 0.0821 44,553 3914
88 0.0925 40,501 4052
89 0.1040 36,366 4135
90 0.1164 32,212 4154
91 0.1298 28,111 4101
92 0.1442 24,134 3977
93 0.1597 20,352 3782
94 0.1762 16,831 3521
95 0.1938 13,628 3203
96 0.2123 10,786 2842
97 0.2315 8334 2452
98 0.2512 6280 2054
99 0.2718 4607 1673
100 0.2935 3283 1324
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Appendix 10 Technical details about
parameter estimation
For all input parameters of the model included in the PSA, a certain measure of variation around the meanvalue is needed. This measure of variation is usually reported as a standard error (SE), 95% CI or 25% and
75% quartiles. With this information, the input parameters of the model can be fit to appropriate probability
distributions (e.g. beta for sensitivity and specificity, gamma for costs, etc.) by estimating the parameters of
the corresponding probability distributions. For some input parameters of the model (e.g. utilities for Dukes’
stages), the parameters of the probability distributions were reported in the literature and included directly in
our model.
When the SE is reported, the parameters of a beta distribution can be obtained from the mean and SE as
α =mean × [(mean × (1 –mean)/(SE)2) – 1] and β = (1 –mean) × [(mean × (1 –mean)/SE2) – 1]. This is the
case for example of the sensitivity for the OC-Sensor. Similarly, the parameters of a gamma distribution
can be obtained from the mean and SE as α = (mean/SE)2 and β = SE2/mean. This is done, for example,
with the costs associated to Dukes’ stages.
When a CI or any other uncertainty range is reported, parameter estimation is not as straightforward as in
the examples mentioned above, and more complex numerical procedures have to be applied. In those
situations, the parameters of the probability distribution functions were estimated in R, version 3.3.1 (The R
Foundation for Statistical Computing, Vienna, Austria), using different methods. As probability distribution
functions are usually multivariate functions (more than one parameter needs to be estimated), R methods to
solve non-linear multivariate equations are preferred. In particular, the R function nleqslv (package nleqslv –
https://cran.r-project.org/web/packages/nleqslv/nleqslv.pdf) was used. However, in some cases, this method
did not converge and, therefore, it did not provide a solution. In those situations, after trying some other
multivariate methods available in R, which also failed to find a solution, a univariate approach, the function
uniroot (https://stat.ethz.ch/R-manual/R-devel/library/stats/html/uniroot.html) from the package stats, or a
simulation approach were used. In this appendix, we describe, with the help of a few examples, the
problems encountered and the solutions proposed. Complete results can be found in the file ‘Parameter
calculator.R’.
Example 1: probability of bleeding
The mean reported was 2.6% and the 95% CI was (1.7% to 3.7%). In this case, the multivariate method
nleqslv worked well. The idea behind this approach is to find the two parameters α and β such that the
2.5% percentile of a beta distribution is 1.7% and the 97.5% percentile of a beta distribution is 3.7%.
This can be expressed in R as the two equations below:
F1 = pbeta(0:0017, x1, x2)−0:025 (12)
F2 = pbeta(0:0017, x1, x2)−0:975 (13)
These equations were solved with the nleqslv function and the solutions obtained were α = 25.82748 and
β = 9887.901. The complete R code can be found in the file ‘Parameter calculator.R’.
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Example 2: sensitivity for the HM-JACKarc system
The sensitivity for HM-JACKarc was obtained from a single study that reported a mean = 1 and
95% CI = (0.715 to 1.00). Because the mean is exactly 1, a beta distribution could not be properly fit. In
this case, we used the uniroot function because it provided a better fit. However, the mean had to be set
to 0.98, otherwise the method would not converge.
The idea behind this approach is to find the parameter α such that the mean of a beta distribution is 0.98
and (for example) the 2.5% percentile of a beta distribution is 0.715 (the 97.5% can also be used). The
latter can be expressed in R as the following equation:
F1 = pbeta(0:715, alpha, beta)−0:025. (14)
Note also that for the beta distribution the following equation always holds:
β = (α/mean)−α: (15)
Thus, substitution in F1 above yields:
F1 = pbeta½0:175, alpha, (alpha/mean)−alpha−0:025: (16)
This equation was solved with the uniroot function and the solution obtained was α = 1.169235. With this
value of α and the assumed mean, β = 0.02386193. The complete R code can be found in the file
‘Parameter calculator.R’.
Example 3: cost of colonoscopy
The mean reported was £372, the lower quartile £141 and the upper quartile £474. The multivariate
methods we tried did not work for the gamma distribution. Therefore, the uniroot function was also
used here.
In this case, the idea behind this method is to find the shape parameter such that the mean of a gamma
distribution is £372 and (for example) the upper quartile of a gamma distribution is £474 (the lower
quartile can also be used). The latter can be expressed in R as the following equation:
F1 = pgamma(474, shape, scale = scale)−0:75: (17)
Note also that for the gamma distribution the following equation always holds:
scale =mean/shape. (18)
Thus, substitution in F1 above yields:
F1 = pgamma(474, shape, scale =mean/shape)−0:75: (19)
This equation was solved with the uniroot function and the solution obtained was shape= 4.126228. With this
value and the mean, scale= 90.15498. The complete R code can be found in the file ‘Parameter calculator.R’.
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Appendix 11 Results (full incremental and
intervention versus comparator) of base case and
scenario analyses
TABLE 72 Lifetime results for all of the strategies in the base-case scenario (deterministic)
QALYs Cost (£) Incremental QALYs Incremental cost (£) ICER (£)
gFOBT 18.6219 232.28 NA NA NA
OC-Sensor 18.6239 244.42 0.0020 12.14 6133
No triage (referral straight
to colonoscopy)
18.6239 503.67 Dominated by HM-JACKarc
HM-JACKarc 18.6242 274.75 –0.0003 –30.33 88,798
NA, not applicable.
TABLE 73 Lifetime results for intervention vs. comparator in the base-case scenario (deterministic)
Incremental QALYs Incremental cost (£) ICER (£)
HM-JACKarc vs. gFOBT 0.0023 42.47 18,296
HM-JACKarc vs. no triage
(referral straight to colonoscopy)
0.0003 –228.92 HM-JACKarc dominates
OC-Sensor vs. gFOBT 0.0020 12.14 6133
OC-Sensor vs. no triage (referral
straight to colonoscopy)
–0.0001 –259.25 4,133,559
TABLE 74 Lifetime results for all of the strategies in the base-case scenario (probabilistic)
QALYs Cost (£) Incremental QALYs Incremental cost (£) ICER (£)
gFOBT 18.6415 230.49 NA NA NA
OC-Sensor 18.6439 242.51 0.0024 12.02 5039
No triage (referral straight
to colonoscopy)
18.6440 500.60 Dominated by HM-JACKarc
HM-JACKarc 18.6444 272.50 0.0005 29.99 61,619
NA, not applicable.
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TABLE 75 Lifetime results for intervention vs. comparator in the base-case scenario (probabilistic)
Incremental QALYs Incremental cost (£) ICER (£)
HM-JACKarc vs. gFOBT 0.0029 42.01 14,626
HM-JACKarc vs. no triage
(referral straight to colonoscopy)
0.0004 –228.10 HM-JACKarc dominates
OC-Sensor vs. gFOBT 0.0024 12.02 5039
OC-Sensor vs. no triage (referral
straight to colonoscopy)
–0.0001 –258.09 2,578,543
TABLE 76 Lifetime results for all of the strategies in the scenario that a proportion of patients receives a second
FIT/gFOBT: results for all of the strategies (deterministic)
QALYs Cost (£) Incremental QALYs Incremental cost (£) ICER (£)
gFOBT 18.6219 232.32 NA NA NA
OC-Sensor 18.6239 244.67 0.002 12.35 6237
No triage (referral straight
to colonoscopy)
18.6239 503.67 Dominated by HM-JACKarc
HM-JACKarc 18.6242 275.05 0.0003 30.38 88,936
NA, not applicable.
TABLE 77 Lifetime results for intervention vs. comparator in the scenario that a proportion of patients receives a
second FIT/gFOBT: results for all of the strategies (deterministic)
Incremental QALYs Incremental cost (£) ICER (£)
HM-JACKarc vs. gFOBT 0.0023 43 18,405
HM-JACKarc vs. no triage
(referral straight to colonoscopy)
0.0003 –229 HM-JACKarc dominates
OC-Sensor vs. gFOBT 0.0020 12 6237
OC-Sensor vs. no triage (referral
straight to colonoscopy)
–0.0001 –259 4,129,585
TABLE 78 Lifetime results for all of the strategies in the scenario that a proportion of patients receives a second
FIT/gFOBT: results for all of the strategies (probabilistic)
QALYs Cost (£) Incremental QALYs Incremental cost (£) ICER (£)
gFOBT 18.6403 231 NA NA NA
OC-Sensor 18.6427 243 0.0024 12.22 5125
No triage (referral straight
to colonoscopy)
18.6428 501 Dominated by HM-JACKarc
HM-JACKarc 18.6431 273 0.0005 30.04 61,322
NA, not applicable.
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TABLE 79 Lifetime results for intervention vs. comparator in the scenario that a proportion of patients receives a
second FIT/gFOBT: results for all of the strategies (probabilistic)
Incremental QALYs Incremental cost (£) ICER (£)
HM-JACKarc vs. gFOBT 0.0029 42.26 14,706
HM-JACKarc vs. no triage
(referral straight to colonoscopy)
0.0004 –227.80 HM-JACKarc dominates
OC-Sensor vs. gFOBT 0.0024 12.22 5125
OC-Sensor vs. no triage (referral
straight to colonoscopy)
–0.0001 –257.84 2,533,617
TABLE 80 Lifetime results for all of the strategies in the scenario that prevalence of CRC is asymmetric (deterministic)
QALYs Cost (£) Incremental QALYs Incremental cost (£) ICER (£)
gFOBT 18.6219 232 NA NA NA
OC-Sensor 18.6239 244 0.0020 12.14 6133
No triage (referral straight
to colonoscopy)
18.6239 504 Dominated by HM-JACKarc
HM-JACKarc 18.6242 275 0.0003 30.33 88,798
NA, not applicable.
TABLE 81 Lifetime results for intervention vs. comparator in the scenario that prevalence of CRC is asymmetric
(deterministic)
Incremental QALYs Incremental cost (£) ICER (£)
HM-JACKarc vs. gFOBT 0.0023 42 18,296
HM-JACKarc vs. no triage
(referral straight to colonoscopy)
0.0003 –229 HM-JACKarc dominates
OC-Sensor vs. gFOBT 0.0020 12 6133
OC-Sensor vs. no triage (referral
straight to colonoscopy)
–0.0001 –259 4,133,559
TABLE 82 Lifetime results for all of the strategies in the scenario that prevalence of CRC is asymmetric (probabilistic)
QALYs Cost (£) Incremental QALYs Incremental cost (£) ICER (£)
gFOBT 18.4512 246.83 NA NA NA
OC-Sensor 18.4554 261.06 0.0042 14.24 3354
No triage (referral straight
to colonoscopy)
18.4559 516.60 Dominated by HM-JACKarc
HM-JACKarc 18.4564 291.04 0.0009 29.98 32,276
NA, not applicable.
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TABLE 83 Lifetime results for all of the strategies in the scenario that prevalence of CRC is asymmetric (probabilistic)
Incremental QALYs Incremental cost (£) ICER (£)
HM-JACKarc vs. gFOBT 0.0052 44.22 8545
HM-JACKarc vs. no triage
(referral straight to colonoscopy)
0.0005 –225.56 HM-JACKarc dominates
OC-Sensor vs. gFOBT 0.0042 14.24 3354
OC-Sensor vs. no triage (referral
straight to colonoscopy)
–0.0004 –255.54 601,774
TABLE 84 Lifetime results all of the strategies in the scenario in which FOB Gold is included (deterministic)
QALYs Cost (£) Incremental QALYs Incremental cost (£) ICER (£)
gFOBT 18.6219 232.28 NA NA NA
FOB Gold 18.6238 262.72 Dominated by OC-Sensor
OC-Sensor 18.6239 244.42 0.0020 12.14 6133
No triage (referral straight
to colonoscopy)
18.6239 503.67 Dominated by HM-JACKarc
HM-JACKarc 18.6242 274.75 0.0003 30.33 88,798
NA, not applicable.
TABLE 85 Lifetime results intervention vs. comparator in scenario in which FOB Gold is included (deterministic)
Incremental QALYs Incremental cost (£) ICER (£)
HM-JACKarc vs. gFOBT 0.0023 42.47 18,296
HM-JACKarc vs. no triage
(referral straight to colonoscopy)
0.0003 –228.92 HM-JACKarc dominates
OC-Sensor vs. gFOBT 0.0020 12.14 6133
OC-Sensor vs. no triage (referral
straight to colonoscopy)
–0.0001 –259.25 4,133,559
FOB Gold vs. gFOBT 0.0019 30.44 15,720
FOB Gold vs. no triage (referral
straight to colonoscopy)
–0.0001 –240.95 2,273,829
TABLE 86 Lifetime results for all of the strategies in the scenario in which FOB Gold is included (probabilistic)
QALYs Cost (£) Incremental QALYs Incremental cost (£) ICER (£)
gFOBT 18.6424 230.92 NA NA NA
FOB Gold 18.6444 261.07 Dominated by OC-Sensor
OC-Sensor 18.6444 242.92 0.0020 12.00 6081
No triage (referral straight
to colonoscopy)
18.6445 500.69 Dominated by HM-JACKarc
HM-JACKarc 18.6446 272.94 0.0002 30.02 128,618
NA, not applicable.
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TABLE 87 Lifetime results for intervention vs. comparator in the scenario in which FOB Gold is included (probabilistic)
Incremental QALYs Incremental cost (£) ICER (£)
HM-JACKarc vs. gFOBT 0.0022 42.02 19,040
HM-JACKarc vs. no triage
(referral straight to colonoscopy)
0.0001 –227.75 HM-JACKarc dominates
OC-Sensor vs. gFOBT 0.0020 12.00 6081
OC-Sensor vs. no triage (referral
straight to colonoscopy)
–0.0001 –257.76 2,830,605
FOB Gold vs. gFOBT 0.0020 30.14 15,456
FOB Gold vs. no triage (referral
straight to colonoscopy)
–0.0001 –239.62 2,097,433
TABLE 88 Lifetime results for all of the strategies in the scenario with increased mortality due to colonoscopy
(deterministic)
QALYs Cost (£) Incremental QALYs Incremental cost (£) ICER (£)
No triage (referral straight
to colonoscopy)
18.6064 503.65 Dominated by gFOBT
gFOBT 18.6148 232.26
HM-JACKarc 18.6157 274.73 Dominated by OC-Sensor
OC-Sensor 18.6165 244.40 0.0017 12.14 7144
TABLE 89 Lifetime results for intervention vs. comparator in the scenario with increased mortality due to
colonoscopy: intervention vs. comparator (deterministic)
Incremental QALYs Incremental cost (£) ICER (£)
HM-JACKarc vs. gFOBT 0.0009 42.47 45,271
HM-JACKarc vs. no triage
(referral straight to colonoscopy)
0.0093 –228.92 HM-JACKarc dominates
OC-Sensor vs. gFOBT 0.0017 12.14 7144
OC-Sensor vs. no triage (referral
straight to colonoscopy)
0.0101 –259.25 OC-Sensor dominates
TABLE 90 Lifetime results for all of the strategies in the scenario with increased mortality due to colonoscopy
(probabilistic)
QALYs Cost (£) Incremental QALYs Incremental cost (£) ICER (£)
No triage (referral straight
to colonoscopy)
18.6258 500 Dominated by gFOBT
gFOBT 18.6343 230
HM-JACKarc 18.6350 272 Dominated by OC-Sensor
OC-Sensor 18.6359 243 0.0016 12.08 7535
DOI: 10.3310/hta21330 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 33
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Westwood et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
217
TABLE 91 Lifetime results for intervention vs. comparator in the scenario with increased mortality due to
colonoscopy (probabilistic)
Incremental QALYs Incremental cost (£) ICER (£)
HM-JACKarc vs. gFOBT 0.0007 42.05 58,563
HM-JACKarc vs. no triage
(referral straight to colonoscopy)
0.0092 –227.77 HM-JACKarc dominates
OC-Sensor vs. gFOBT 0.0016 12.08 7535
OC-Sensor vs. no triage (referral
straight to colonoscopy)
0.0101 –257.74 OC-Sensor dominates
TABLE 92 Lifetime results for all of the strategies in the scenario in which the diagnosis was delayed with 1 year
(deterministic)
QALYs Cost (£) Incremental QALYs Incremental cost (£) ICER (£)
gFOBT 18.6195 230.90 NA NA NA
OC-Sensor 18.6235 244.20 0.0040 13.30 3352
No triage (referral straight
to colonoscopy)
18.6239 503.67 Dominated by HM-JACKarc
HM-JACKarc 18.6242 274.75 0.0007 30.55 43,642
NA, not applicable.
TABLE 93 Lifetime results for intervention vs. comparator in the scenario in which the diagnosis was delayed with
1 year (deterministic)
Incremental QALYs Incremental cost (£) ICER (£)
HM-JACKarc vs. gFOBT 0.0047 43.85 9360
HM-JACKarc vs. no triage
(referral straight to colonoscopy)
0.0003 –228.92 HM-JACKarc dominates
OC-Sensor vs. gFOBT 0.0040 13.30 3352
OC-Sensor vs. no triage (referral
straight to colonoscopy)
–0.0004 –259.47 592,092
TABLE 94 Lifetime results for all of the strategies in the scenario in which the diagnosis was delayed with 1 year
(probabilistic)
QALYs Cost (£) Incremental QALYs Incremental cost (£) ICER (£)
gFOBT 18.6316 229.27 NA NA NA
OC-Sensor 18.6357 242.63 0.0040 13.37 3306
No triage (referral straight
to colonoscopy)
18.6361 500.61 Dominated by HM-JACKarc
HM-JACKarc 18.6363 272.76 0.0006 30.13 48,223
NA, not applicable.
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TABLE 95 Lifetime results for intervention vs. comparator in the scenario in which the diagnosis was delayed with
1 year (probabilistic)
Incremental QALYs Incremental cost (£) ICER (£)
HM-JACKarc vs. gFOBT 0.0047 43.50 9318
HM-JACKarc vs. no triage
(referral straight to colonoscopy)
0.0001 –227.85 HM-JACKarc dominates
OC-Sensor vs. gFOBT 0.0040 13.37 3306
OC-Sensor vs. no triage (referral
straight to colonoscopy)
–0.0005 –257.97 539,543
TABLE 96 Lifetime results for all of the strategies in the scenario that the FIT threshold was set to ≥ 20µg Hb/g
faeces (deterministic)
QALYs Cost (£) Incremental QALYs Incremental cost (£) ICER (£)
gFOBT 18.6219 232.28 NA NA NA
FOB Gold 18.6237 240.62 0.0018 8.34 4725
OC-Sensor 18.6238 241.83 0.0001 1.21 12,576
No triage (referral straight
to colonoscopy)
18.6239 503.67 0.0002 261.84 1,449,585
NA, not applicable.
TABLE 97 Lifetime results for intervention vs. comparator in the scenario that the FIT threshold was set to
≥ 20 µg Hb/g faeces (deterministic)
Incremental QALYs Incremental cost (£) ICER (£)
FOB Gold vs. gFOBT 0.0018 8.34 4725
FOB Gold vs. no triage (referral straight to colonoscopy) –0.0003 –263.05 950,102
OC-Sensor vs. gFOBT 0.0019 9.55 5131
OC-Sensor vs. no triage (referral straight to colonoscopy) –0.0002 –261.84 1,449,585
TABLE 98 Lifetime results for all of the strategies in the scenario that the FIT threshold was set to ≥ 20µg Hb/g
faeces (probabilistic)
QALYs Cost (£) Incremental QALYs Incremental cost (£) ICER (£)
gFOBT 18.6386 231.69 NA NA NA
OC-Sensor 18.6406 241.21 Dominated by FOB-Gold
FOB Gold 18.6406 240.01 0.0019 8.33 4283
No triage (referral straight
to colonoscopy)
18.6408 500.60 0.0002 260.59 1,365,199
NA, not applicable.
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TABLE 99 Lifetime results for intervention vs. comparator in the scenario that the FIT threshold was set to
≥ 20µg Hb/g faeces (probabilistic)
Incremental QALYs Incremental cost (£) ICER (£)
FOB Gold vs. gFOBT 0.0019 8.33 4283
FOB Gold vs. no triage (referral straight to colonoscopy) –0.0002 –260.59 1,365,199
OC-Sensor vs. gFOBT 0.0019 9.53 4962
OC-Sensor vs. no triage (referral straight to colonoscopy) –0.0002 –259.39 1,212,654
TABLE 100 Lifetime results for all of the strategies in the scenario for which accuracy data for faecal occult blood
testing are taken from Bjerregaard et al.93 (deterministic)
QALYs Cost (£) Incremental QALYs Incremental cost (£) ICER (£)
gFOBT 18.6230 258.97 Dominated by OC-Sensor
OC-Sensor 18.6239 244.42
No triage (referral straight
to colonoscopy)
18.6239 503.67 Dominated by HM-JACKarc
HM-JACKarc 18.6242 274.75 0.0003 30.33 88,798
TABLE 101 Lifetime results for intervention vs. comparator in the scenario for which accuracy data for faecal occult
blood testing are taken from Bjerregaard et al.93 (deterministic)
Incremental QALYs Incremental cost (£) ICER (£)
HM-JACKarc vs. gFOBT 0.0012 15.78 13,482
HM-JACKarc vs. no triage
(referral straight to colonoscopy)
0.0003 –228.92 HM-JACKarc dominates
OC-Sensor vs. gFOBT 0.0008 –14.55 OC-Sensor dominates
OC-Sensor vs. no triage (referral
straight to colonoscopy)
–0.0001 –259.25 4,133,559
TABLE 102 Lifetime results for all of the strategies in the scenario for which accuracy data for faecal occult blood
testing are taken from Bjerregaard et al.93 (probabilistic)
QALYs Cost (£) Incremental QALYs Incremental cost (£) ICER (£)
gFOBT 18.6432 257.38 Dominated by OC-Sensor
OC-Sensor 18.6440 242.90
No triage (referral straight
to colonoscopy)
18.6441 500.60 Dominated by HM-JACKarc
HM-JACKarc 18.6444 272.90 0.0003 30.00 88,544
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TABLE 103 Lifetime results for intervention vs. comparator in the scenario for which accuracy data for faecal occult
blood testing are taken from Bjerregaard et al.93 (probabilistic)
Incremental QALYs Incremental cost (£) ICER (£)
HM-JACKarc vs. gFOBT 0.0012 15.52 13,019
HM-JACKarc vs. no triage
(referral straight to colonoscopy)
0.0003 –227.70 HM-JACKarc dominates
OC-Sensor vs. gFOBT 0.0009 –14.48 OC-Sensor dominates
OC-Sensor vs. no triage (referral
straight to colonoscopy)
–0.0001 –257.70 3,119,555
TABLE 104 Lifetime results for all of the strategies in the scenario for which accuracy data for faecal occult blood
testing are taken from Niv and Sperber92 (deterministic)
QALYs Cost (£) Incremental QALYs Incremental cost (£) ICER (£)
gFOBT 18.6227 277.55 Dominated by OC-Sensor
OC-Sensor 18.6239 244.42
No triage (referral straight
to colonoscopy)
18.6239 503.67 Dominated by HM-JACKarc
HM-JACKarc 18.6242 274.75 0.0003 30.33 88,798
TABLE 105 Lifetime results for intervention vs. comparator in the scenario for which accuracy data for faecal occult
blood testing are taken from Niv and Sperber92 (deterministic)
Incremental QALYs Incremental cost (£) ICER (£)
HM-JACKarc vs. gFOBT 0.0015 –3 HM-JACKarc dominates
HM-JACKarc vs. no triage
(referral straight to colonoscopy)
0.0003 –229 HM-JACKarc dominates
OC-Sensor vs. gFOBT 0.0011 –33 OC-Sensor dominates
OC-Sensor vs. no triage (referral
straight to colonoscopy)
–0.0001 –259 4,133,559
TABLE 106 Lifetime results for all of the strategies in the scenario for which accuracy data for faecal occult blood
testing are taken from Niv and Sperber92 (probabilistic)
QALYs Cost (£) Incremental QALYs Incremental cost (£) ICER (£)
gFOBT 18.6425 275.67 Dominated by OC-Sensor
OC-Sensor 18.6436 242.63
No triage (referral straight
to colonoscopy)
18.6436 500.60 Dominated by HM-JACKarc
HM-JACKarc 18.6439 272.69 0.0004 30.05 83,261
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TABLE 107 Lifetime results for intervention vs. comparator in the scenario for which accuracy data for faecal occult
blood testing are taken from Niv and Sperber92 (probabilistic)
Incremental QALYs Incremental cost (£) ICER (£)
HM-JACKarc vs. gFOBT 0.0014 –2.99 HM-JACKarc dominates
HM-JACKarc vs. no triage
(referral straight to colonoscopy)
0.0003 –227.91 HM-JACKarc dominates
OC-Sensor vs. gFOBT 0.0010 –33.04 OC-Sensor dominates
OC-Sensor vs. no triage (referral
straight to colonoscopy)
–0.0001 –257.96 3,117,361
TABLE 108 Lifetime results for all of the strategies in the scenario for which the distribution of the Dukes’ stages is
based on Cubiella et al.55 (deterministic)
QALYs Cost (£) Incremental QALYs Incremental cost (£) ICER (£)
gFOBT 18.6215 232.02 NA NA NA
No triage (referral straight
to colonoscopy)
18.6231 503.16 Dominated by OC-Sensor
OC-Sensor 18.6231 243.95 0.0016 11.93 7454
HM-JACKarc 18.6234 274.24 0.0003 30.29 110,838
NA, not applicable.
TABLE 109 Lifetime results for intervention vs. comparator in the scenario for which the distribution of the Dukes’
stages is based on Cubiella et al.55 (deterministic)
Incremental QALYs Incremental cost (£) ICER (£)
HM-JACKarc vs. gFOBT 0.0019 42 22,319
HM-JACKarc vs. no triage
(referral straight to colonoscopy)
0.0003 –229 HM-JACKarc dominates
OC-Sensor vs. gFOBT 0.0016 12 7370
OC-Sensor vs. no triage (referral
straight to colonoscopy)
0.0000 –259 OC-Sensor dominates
TABLE 110 Lifetime results for all of the strategies in the scenario for which the distribution of the Dukes’ stages is
based on Cubiella et al.55 (probabilistic)
QALYs Cost (£) Incremental QALYs Incremental cost (£) ICER (£)
OC-Sensor 18.6355 242.48 0.0018 11.94 6499
No triage (referral straight
to colonoscopy)
18.6355 500.11 Dominated by HM-JACKarc
HM-JACKarc 18.6357 272.41 0.0002 29.93 183,714
OC-Sensor 18.6355 242.48 0.0018 11.94 6499
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TABLE 111 Lifetime results for intervention vs. comparator in the scenario for which the distribution of the Dukes’
stages is based on Cubiella et al.55 (probabilistic)
Incremental QALYs Incremental cost (£) ICER (£)
HM-JACKarc vs. gFOBT 0.0020 41.88 20,934
HM-JACKarc vs. no triage
(referral straight to colonoscopy)
0.0002 –227.70 HM-JACKarc dominates
OC-Sensor vs. gFOBT 0.0018 11.94 6499
OC-Sensor vs. no triage (referral
straight to colonoscopy)
–0.0000 –257.64 64,414,134
TABLE 112 Lifetime results for all of the strategies in the scenario for which the distribution of the Dukes’ stages is
based on expert opinion (deterministic)
QALYs Cost (£) Incremental QALYs Incremental cost (£) ICER (£)
gFOBT 18.6227 232.71 NA NA NA
OC-Sensor 18.6254 245.21 0.0027 12.50 4655
No triage (referral straight
to colonoscopy)
18.6256 504.53 Dominated by HM-JACKarc
HM-JACKarc 18.6259 275.61 0.0005 30.40 60,798
NA, not applicable.
TABLE 113 Lifetime results for all intervention vs. comparator in the scenario for which the distribution of the
Dukes’ stages is based on expert opinion (deterministic)
Incremental QALYs Incremental cost (£) ICER (£)
HM-JACKarc vs. gFOBT 0.0032 42.90 13,574
HM-JACKarc vs. no triage
(referral straight to colonoscopy)
0.0003 –228.92 HM-JACKarc dominates
OC-Sensor vs. gFOBT 0.0027 12.50 OC-Sensor dominates
OC-Sensor vs. no triage (referral
straight to colonoscopy)
–0.0002 –259.32 1,322,872
TABLE 114 Lifetime results for all of the strategies in the scenario for which the distribution of the Dukes’ stages is
based on expert opinion (probabilistic)
QALYs Cost (£) Incremental QALYs Incremental cost (£) ICER (£)
gFOBT 18.6424 230.92 NA NA NA
OC-Sensor 18.6455 243.30 0.0031 12.38 3984
No triage (referral straight
to colonoscopy)
18.6457 501.46 Dominated by HM-JACKarc
HM-JACKarc 18.6461 273.34 0.0006 30.04 50,961
NA, not applicable.
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TABLE 115 Lifetime results for intervention vs. comparator in the scenario for which the distribution of the Dukes’
stages is based on expert opinion (probabilistic)
Incremental QALYs Incremental cost (£) ICER (£)
HM-JACKarc vs. gFOBT 0.0037 42.42 11,476
HM-JACKarc vs. no triage
(referral straight to colonoscopy)
0.0004 –228.12 HM-JACKarc dominates
OC-Sensor vs. gFOBT 0.0031 12.38 3984
OC-Sensor vs. no triage (referral
straight to colonoscopy)
–0.0002 –258.16 1,081,160
TABLE 116 Lifetime results: scenario with no adverse events associated to colonoscopy – results for all of the
strategies (deterministic)
QALYs Cost (£) Incremental QALYs Incremental cost (£) ICER (£)
gFOBT 18.6221 230.97
OC-Sensor 18.6241 243.06 0.002 12.09 6081
No triage (referral straight
to colonoscopy)
18.6245 500.49 Dominated by HM-JACKarc
HM-JACKarc 18.6245 273.19 0.0004 30.13 80,244
TABLE 117 Lifetime results: scenario with no adverse events associated to colonoscopy – intervention vs. comparator
(deterministic)
Incremental QALYs Incremental cost (£) ICER (£)
HM-JACKarc vs. gFOBT 0.0024 42.23 17,862
HM-JACKarc vs. no triage
(referral straight to colonoscopy)
0.0000 –227.30 Dominated by HM-JACKarc
OC-Sensor vs. gFOBT 0.0020 12.09 6081
OC-Sensor vs. no triage (referral
straight to colonoscopy)
–0.0004 –257.43 685,532
TABLE 118 Lifetime results: scenario with no adverse events associated to colonoscopy – results for all of the
strategies (probabilistic)
QALYs Cost (£) Incremental QALYs Incremental cost (£) ICER (£)
gFOBT 18.6431 229.66
OC-Sensor 18.6453 241.61 0.0022 11.96 5406
HM-JACKarc 18.6457 271.48 0.0004 29.87 81,573
No triage (referral straight
to colonoscopy)
18.6457 497.00 0.0000 225.52 9,135,836
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TABLE 119 Lifetime results: scenario with no adverse events associated to colonoscopy – intervention vs. comparator
(probabilistic)
Incremental QALYs Incremental cost (£) ICER (£)
HM-JACKarc vs. gFOBT 0.0026 41.82 16,224.64
HM-JACKarc vs. no triage
(referral straight to colonoscopy)
–0.00002 –225.52 9,135,836.87
OC-Sensor vs. gFOBT 0.0022 11.96 5406.14
OC-Sensor vs. no triage (referral
straight to colonoscopy)
–0.0004 –255.39 653,493.58
TABLE 120 Lifetime results: scenario without CRC progression – results for all of the strategies (deterministic)
QALYs Cost (£) Incremental QALYs Incremental cost (£) ICER (£)
gFOBT 18.701 263.92
OC-Sensor 18.711 279.10 0.0101 15.18 1508
No triage (referral straight
to colonoscopy)
18.713 538.93 Dominated by HM-JACKarc
HM-JACKarc 18.713 310.01 0.0019 30.9054 16,528
TABLE 121 Lifetime results: scenario without CRC progression – intervention vs. comparator (deterministic)
Incremental QALYs Incremental cost (£) ICER (£)
HM-JACKarc vs. gFOBT 0.0119 46.09 3859
HM-JACKarc vs. no triage
(referral straight to colonoscopy)
0.0003 –228.92 HM-JACKarc dominates
OC-Sensor vs. gFOBT 0.0101 15.18 1508
OC-Sensor vs. no triage (referral
straight to colonoscopy)
–0.0016 –259.83 163,305
TABLE 122 Lifetime results: scenario without CRC progression – results for all of the strategies (probabilistic)
QALYs Cost (£) Incremental QALYs Incremental cost (£) ICER (£)
gFOBT 18.7191 262.22
OC-Sensor 18.7291 277.18 0.0101 14.96 1485
HM-JACKarc 18.7307 307.57 0.0015 30.39 19,790
No triage (referral straight
to colonoscopy)
18.7307 535.84 0.0001 228.27 4,171,882
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TABLE 123 Lifetime results: scenario without CRC progression: intervention vs. comparator (probabilistic)
Incremental QALYs Incremental cost (£) ICER (£)
HM-JACKarc vs. gFOBT 0.0116 45.36 3907
HM-JACKarc vs. no triage
(referral straight to colonoscopy)
–0.0001 –228.27 4,171,882
OC-Sensor vs. gFOBT 0.0101 14.96 1485
OC-Sensor vs. no triage (referral
straight to colonoscopy)
–0.0016 –258.66 162,620
TABLE 124 Lifetime results: scenario for which all patients referred to colonoscopy as opposed to CTC – results for
all of the strategies (deterministic)
QALYs Cost (£) Incremental QALYs Incremental cost (£) ICER (£)
gFOBT 18.6219 243.73
OC-Sensor 18.6239 256.31 0.002 12.58 6352
No triage (referral straight
to colonoscopy)
18.6239 531.40 Dominated by HM-JACKarc
HM-JACKarc 18.6242 288.36 0.0003 32.05 93,832
TABLE 125 Lifetime results: scenario for which all patients referred to colonoscopy as opposed to CTC –
intervention vs. comparator (deterministic)
Incremental QALYs Incremental cost (£) ICER (£)
HM-JACKarc vs. gFOBT 0.0023 44.63 19,224
HM-JACKarc vs. no triage
(referral straight to colonoscopy)
0.0003 –243.05 HM-JACKarc dominates
OC-Sensor vs. gFOBT 0.0020 12.58 6352
OC-Sensor vs. no triage (referral
straight to colonoscopy)
–0.0001 –275.10 4,386,188
TABLE 126 Lifetime results: scenario all patients referred to colonoscopy as opposed to CTC – results for all of the
strategies (probabilistic)
QALYs Cost (£) Incremental QALYs Incremental cost (£) ICER (£)
gFOBT 18.6390 243.13
OC-Sensor 18.6410 255.60 0.0020 12.46 6158
No triage (referral straight
to colonoscopy)
18.6411 527.98 Dominated by HM-JACKarc
HM-JACKarc 18.6412 286.99 0.00 31.39 156,950
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TABLE 127 Lifetime results: scenario all patients referred to colonoscopy as opposed to CTC – intervention vs.
comparator (probabilistic)
Incremental QALYs Incremental cost (£) ICER (£)
HM-JACKarc vs. gFOBT 0.0023 43.86 19,406
HM-JACKarc vs. no triage
(referral straight to colonoscopy)
0.0003 –243.05 HM-JACKarc dominates
OC-Sensor vs. gFOBT 0.0020 12.46 6159
OC-Sensor vs. no triage (referral
straight to colonoscopy)
–0.0001 –272.39 3,859,404
TABLE 128 Lifetime results: scenario for OC threshold – results for all of the strategies (deterministic)
QALYs Cost (£) Incremental QALYs Incremental cost (£) ICER (£)
gFOBT 18.6219 232.28
No triage (referral straight
to colonoscopy)
18.6239 503.67 Dominated by OC-Sensor
OC-Sensor 18.6241 375.40 0.0022 143.12 65,055
TABLE 129 Lifetime results: scenario for OC threshold – intervention vs. comparator (deterministic)
Incremental QALYs Incremental cost (£) ICER (£)
OC-Sensor vs. gFOBT 0.0022 143.12 65,191.91
OC-Sensor vs. no triage (referral
straight to colonoscopy)
0.0002 –128.27 OC-Sensor dominates
TABLE 130 Lifetime results: scenario for OC threshold – results for all of the strategies (probabilistic)
QALYs Cost (£) Incremental QALYs Incremental cost (£) ICER (£)
gFOBT 18.6384 232.10
No triage (referral straight
to colonoscopy)
18.6404 500.63 Dominated by OC-Sensor
OC-Sensor 18.6406 373.75 0.0022 141.65 64,386
TABLE 131 Lifetime results: scenario for OC threshold – intervention vs. comparator (probabilistic)
Incremental QALYs Incremental cost (£) ICER (£)
OC-Sensor vs. gFOBT 0.0022 141.65 65,696
OC-Sensor vs. no triage (referral
straight to colonoscopy)
0.0002 –126.88 OC-Sensor dominates
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TABLE 132 Lifetime results: scenario double probability of persisting in symptoms after negative test result –
results for all of the strategies (deterministic)
QALYs Cost (£) Incremental QALYs Incremental cost (£) ICER (£)
gFOBT 18.6217 381.09
OC-Sensor 18.6237 389.26 0.002 8.17 4118
No triage (referral straight
to colonoscopy)
18.6239 503.67 Dominated by HM-JACKarc
HM-JACKarc 18.6241 403.87 0.0004 14.61 36,534
TABLE 133 Lifetime results: scenario double probability of persisting in symptoms after negative test result –
intervention vs. comparator (deterministic)
Incremental QALYs Incremental cost (£) ICER (£)
HM-JACKarc vs. gFOBT 0.0023 22.78 9729
HM-JACKarc vs. no triage
(referral straight to colonoscopy)
0.0001 –99.80 Dominated by HM-JACKarc
OC-Sensor vs. gFOBT 0.0020 8.17 4118
OC-Sensor vs. no triage (referral
straight to colonoscopy)
–0.0002 –114.42 536,359
TABLE 134 Lifetime results: scenario double probability of persisting in symptoms after negative test result –
results for all of the strategies (probabilistic)
QALYs Cost (£) Incremental QALYs Incremental cost (£) ICER (£)
gFOBT 18.6416 379.39
OC-Sensor 18.6437 387.44 0.0021 8.05 3793
No triage (referral straight
to colonoscopy)
18.6439 500.60 Dominated by HM-JACKarc
HM-JACKarc 18.6440 401.82 0.0003 14.38 47,933
TABLE 135 Lifetime results: scenario double probability of persisting in symptoms after negative test result –
intervention vs. comparator (probabilistic)
Incremental QALYs Incremental cost (£) ICER (£)
HM-JACKarc vs. gFOBT 0.0024 22.43 9421
HM-JACKarc vs. no triage
(referral straight to colonoscopy)
0.0000 –98.78 HM-JACKarc dominates
OC-Sensor vs. gFOBT 0.0021 8.05 3794
OC-Sensor vs. no triage (referral
straight to colonoscopy)
–0.0002 –113.16 508,628
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TABLE 136 Lifetime results: scenario half probability of persisting in symptoms after negative test result – results
for all of the strategies (deterministic)
QALYs Cost (£) Incremental QALYs Incremental cost (£) ICER (£)
gFOBT 18.6220 157.88
No triage (referral straight
to colonoscopy)
18.6239 503.67 Dominated by OC-Sensor
OC-Sensor 18.6239 172.01 0.002 14.13 7143
HM-JACKarc 18.6243 210.19 0.0003 38.19 114,546
TABLE 137 Lifetime results: scenario half probability of persisting in symptoms after negative test result –
intervention vs. comparator (deterministic)
Incremental QALYs Incremental cost (£) ICER (£)
HM-JACKarc vs. gFOBT 0.0023 52.32 22,637
HM-JACKarc vs. no triage
(referral straight to colonoscopy)
0.0003 –293.48 HM-JACKarc dominates
OC-Sensor vs. gFOBT 0.0020 14.13 7143
OC-Sensor vs. no triage (referral
straight to colonoscopy)
0.00001 –331.67 OC-Sensor dominates
TABLE 138 Lifetime results: scenario half probability of persisting in symptoms after negative test result – results
for all of the strategies (probabilistic)
QALYs Cost (£) Incremental QALYs Incremental cost (£) ICER (£)
gFOBT 18.6427 156.42
OC-Sensor 18.6445 170.45 0.0018 14.04 7697
No triage (referral straight
to colonoscopy)
18.6446 500.60 Dominated by HM-JACKarc
HM-JACKarc 18.6449 208.24 0.0004 37.79 94,475
TABLE 139 Lifetime results: scenario half probability of persisting in symptoms after negative test result –
intervention vs. comparator (probabilistic)
Incremental QALYs Incremental cost (£) ICER (£)
HM-JACKarc vs. gFOBT 0.0022 51.82 23,340
HM-JACKarc vs. no triage
(referral straight to colonoscopy)
0.0003 –292.36 HM-JACKarc dominates
OC-Sensor vs. gFOBT 0.0018 14.04 7697
OC-Sensor vs. no triage (referral
straight to colonoscopy)
–0.0001 –330.15 5,370,520
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TABLE 140 Lifetime results: prevalence 3% – results for all of the strategies (deterministic)
QALYs Cost (£) Incremental QALYs Incremental cost (£) ICER (£)
gFOBT 18.3672 253.88
OC-Sensor 18.3712 269.06 0.0040 15.19 3829
No triage (referral straight
to colonoscopy)
18.3716 524.89 Dominated by HM-JACKarc
HM-JACKarc 18.3719 299.55 0.0007 30.49 42,517
TABLE 141 Lifetime results: prevalence 3% – intervention vs. comparator (deterministic)
Incremental QALYs Incremental cost (£) ICER (£)
HM-JACKarc vs. gFOBT 0.0047 45.68 9754
HM-JACKarc vs. no triage
(referral straight to
colonoscopy)
0.0003 –225.34 HM-JACKarc dominates
OC-Sensor vs. gFOBT 0.004 15.19 3829
OC-Sensor vs. no triage
(referral straight to
colonoscopy)
–0.0004 –255.83 578,092
TABLE 142 Lifetime results: prevalence 3% – results for all of the strategies (probabilistic)
QALYs Cost (£) Incremental QALYs Incremental cost (£) ICER (£)
gFOBT 18.3886 252.18
OC-Sensor 18.3934 267.17 0.0048 14.99 3137
No triage (referral straight
to colonoscopy)
18.3939 521.86 Dominated by HM-JACKarc
HM-JACKarc 18.3944 297.15 0.001 30 29,980
TABLE 143 Lifetime results: prevalence 3% – intervention vs. comparator (probabilistic)
Incremental QALYs Incremental cost (£) ICER (£)
HM-JACKarc vs. gFOBT 0.0058 44.97 7773
HM-JACKarc vs. no triage
(referral straight to colonoscopy)
0.0005 –224.71 HM-JACKarc dominates
OC-Sensor vs. gFOBT 0.0048 14.99 3137
OC-Sensor vs. no triage (referral
straight to colonoscopy)
–0.0005 –254.69 491,877
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TABLE 144 Lifetime results: prevalence 5.4% – results for all of the strategies (deterministic)
QALYs Cost (£) Incremental QALYs Incremental cost (£) ICER (£)
gFOBT 17.9597 288.43
OC-Sensor 17.9668 308.48 0.0071 20.06 2808
No triage (referral straight
to colonoscopy)
17.9679 558.85 Dominated by HM-JACKarc
HM-JACKarc 17.9681 339.23 0.0013 30.75 23,327
TABLE 145 Lifetime results: prevalence 5.4% – intervention vs. comparator (deterministic)
Incremental QALYs Incremental cost (£) ICER (£)
HM-JACKarc vs. gFOBT 0.0085 50.80 6004
HM-JACKarc vs. no triage
(referral straight to colonoscopy)
0.0003 –219.62 HM-JACKarc dominates
OC-Sensor vs. gFOBT 0.0071 20.06 2808
OC-Sensor vs. no triage (referral
straight to colonoscopy)
–0.0011 –250.36 238,380
TABLE 146 Lifetime results: prevalence 5.4% – results for all of the strategies (probabilistic)
QALYs Cost (£) Incremental QALYs Incremental cost (£) ICER (£)
gFOBT 17.9840 286.88
OC-Sensor 17.9926 306.63 0.0086 19.75 2304
No triage (referral straight
to colonoscopy)
17.9937 555.87 Dominated by HM-JACKarc
HM-JACKarc 17.9943 336.60 0.0017 29.97 17,629
TABLE 147 Lifetime results: prevalence 5.4% – intervention vs. comparator (probabilistic)
Incremental QALYs Incremental cost (£) ICER (£)
HM-JACKarc vs. gFOBT 0.0104 49.72 4798
HM-JACKarc vs. no triage
(referral straight to colonoscopy)
0.0006 –219.28 HM-JACKarc dominates
OC-Sensor vs. gFOBT 0.0086 19.75 2304
OC-Sensor vs. no triage (referral
straight to colonoscopy)
–0.0012 –249.25 210,923
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Appendix 12 National Institute for Health and
Care Excellence guidance relevant to colorectal cancer
Published National Institute for Health and Care Excellence guidance
Aflibercept in Combination with Irinotecan and Fluorouracil-based Therapy for Treating Metastatic
Colorectal Cancer that has Progressed Following Prior Oxaliplatin-based Chemotherapy. NICE technology
appraisal guidance TA307; March 2014. URL: www.nice.org.uk/guidance/ta307 (accessed 9 August 2016).
Bevacizumab and Cetuximab for the Treatment of Metastatic Colorectal Cancer. NICE technology appraisal
guidance TA118; January 2007. URL: www.nice.org.uk/guidance/ta118 (accessed 9 August 2016).
Bevacizumab in Combination with Oxaliplatin and either Fluorouracil plus Folinic Acid or Capecitabine for the
Treatment of Metastatic Colorectal Cancer. NICE technology appraisal guidance TA212; December 2010.
URL: www.nice.org.uk/guidance/ta212 (accessed 9 August 2016).
Capecitabine and Oxaliplatin in the Adjuvant Treatment of Stage III (Dukes’s C) Colon Cancer. NICE
technology appraisal guidance TA100; April 2006. URL: www.nice.org.uk/guidance/ta100 (accessed
9 August 2016).
Cetuximab and Panitumumab for Previously Untreated Metastatic Colorectal Cancer. NICE technology
appraisal guidance TA439; March 2017. URL: www.nice.org.uk/guidance/ta439 (accessed 9 August 2016).
Cetuximab for the First-line Treatment of Metastatic Colorectal Cancer. NICE technology appraisal guidance
TA176; August 2009. URL: www.nice.org.uk/guidance/ta176 (accessed 9 August 2016).
Cetuximab, Bevacizumab and Panitumumab for the Treatment of Metastatic Colorectal Cancer after
First-line Chemotherapy: Cetuximab (monotherapy or combination chemotherapy), Bevacizumab (in
combination with non-oxaliplatin chemotherapy) and Panitumumab (monotherapy) for the Treatment of
Metastatic Colorectal Cancer after first-line Chemotherapy. Review of technology appraisal guidance
TA150 and part review of technology appraisal guidance TA118. NICE technology appraisal guidance
TA242; January 2012. URL: www.nice.org.uk/guidance/ta242 (accessed 9 August 2016).
Colorectal Cancer Prevention: Colonoscopic Surveillance in Adults with Ulcerative Colitis, Crohn’s Disease or
Adenomas. NICE clinical guideline CG118; March 2011. URL: www.nice.org.uk/guidance/cg118 (accessed
9 August 2016). Date for review: February 2019.
Colorectal Cancer: Diagnosis and Management. NICE clinical guideline CG131; November 2011, updated
December 2014. URL: www.nice.org.uk/guidance/cg131 (accessed 9 August 2016). Date for review:
February 2016.
Combined Endoscopic and Laparoscopic Removal of Colonic Polyps. NICE interventional procedure
guidance IPG503; September 2014. URL: www.nice.org.uk/guidance/ipg503 (accessed 9 August 2016).
Computed Tomographic Colonography (Virtual Colonoscopy). NICE interventional procedure guidance
IPG129; June 2005. URL: www.nice.org.uk/guidance/ipg129 (accessed 9 August 2016).
Cytoreduction Surgery followed by Hyperthermic Intraoperative Peritoneal Chemotherapy for Peritoneal
Carcinomatosis. NICE interventional procedure guidance IPG331; February 2010. URL: www.nice.org.uk/
guidance/ipg331 (accessed 9 August 2016).
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Endoscopic Submucosal Dissection of Lower Gastrointestinal Lesions. NICE interventional procedure
guidance IPG335; March 2010. URL: www.nice.org.uk/guidance/ipg335 (accessed 9 August 2016).
Fluorouracil chemotherapy: The My5-FU Assay for Guiding Dose Adjustment. NICE diagnostic guidance
DG16; December 2014. URL: www.nice.org.uk/guidance/dg16 (accessed 9 August 2016).
Guidance on the Use of Capecitabine and Tegafur with Uracil for Metastatic Colorectal Cancer. NICE
technology appraisal guidance TA61; May 2003. URL: www.nice.org.uk/guidance/ta61 (accessed
9 August 2016).
Improving Outcomes in Colorectal Cancer. NICE guidance on cancer services CSG5; June 2004.
URL: www.nice.org.uk/guidance/csg5 (accessed 9 August 2016). To be updated by the update of the
guideline on colorectal cancer (NICE guideline CG131).
Laparoscopic Surgery for Colorectal Cancer. NICE technology appraisal guidance TA105; August 2006.
URL: www.nice.org.uk/guidance/ta105 (accessed 9 August 2016).
Preoperative High Dose Rate Brachytherapy for Rectal Cancer. NICE interventional procedure guidance
IPG531; August 2015. URL: www.nice.org.uk/guidance/ipg531 (accessed 9 August 2016).
Radiofrequency Ablation for Colorectal Liver Metastases. NICE interventional procedure guidance IPG327;
December 2009. URL: www.nice.org.uk/guidance/ipg327 (accessed 9 August 2016).
Selective Internal Radiation Therapy for Non-resectable Colorectal Metastases in the Liver. NICE
interventional procedure guidance IPG401; July 2011, updated May 2013. URL: www.nice.org.uk/
guidance/ipg401 (accessed 9 August 2016).
Suspected Cancer: Recognition and Referral. NICE guideline NG12; June 2015. URL: www.nice.org.uk/
guidance/ng12 (accessed 9 August 2016).
Transanal Total Mesorectal Excision of the Rectum. NICE interventional procedure guidance IPG514;
March 2015. URL: www.nice.org.uk/guidance/ipg514 (accessed 9 August 2016).
Wireless Capsule Endoscopy for Investigation of the Small Bowel. NICE interventional procedure guidance
IPG101; 2004. URL: www.nice.org.uk/guidance/ipg101 (accessed 9 August 2016).
National Institute for Health and Care Excellence guidance
under development
Colon Cancer (adjuvant) – Irinotecan [ID379]. NICE technology appraisal guidance. URL: www.nice.org.uk/
guidance/indevelopment/gid-tag380 (accessed 9 August 2016). Expected publication date: TBC.
Low-energy Contact X-ray Brachytherapy (the Papillon Technique) for Early-stage Rectal Cancer. NICE
interventional procedure guidance IPG532; September 2015. URL: www.nice.org.uk/guidance/
indevelopment/gid-ip1234 (accessed 9 August 2016).
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